---
document_datetime: 2024-08-01 11:28:12
document_pages: 293
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/tizveni-epar-public-assessment-report_en.pdf
document_name: tizveni-epar-public-assessment-report_en.pdf
version: success
processing_time: 437.6079374
conversion_datetime: 2025-12-28 15:44:47.981124
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 February 2024 EMA/116407/2024 Committee for Medicinal Products for Human Use (CHMP)

Assessment report Tizveni International non-proprietary name: Tislelizumab Procedure No. EMEA/H/C/005542/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................7                                                      |
|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7        |                                                                                                      |
| 1.2. Information relating to orphan market exclusivity.....................................................7                 |                                                                                                      |
| 1.2.1. Similarity..........................................................................................................7 |                                                                                                      |
| 1.3. Applicant's request(s) for consideration                                                                                | ...................................................................8                                 |
| 1.3.1. New active substance status                                                                                           | ...............................................................................8                     |
| 1.4. Scientific advice                                                                                                       | ...................................................................................................8 |
| 1.5. Steps taken for the assessment of the product.........................................................8                 |                                                                                                      |
| 2. Scientific discussion                                                                                                     | ..............................................................................10 authorised          |
| 2.1. Problem statement                                                                                                       | .............................................................................................10      |
| 2.1.1. Disease or condition.........................................................................................10       |                                                                                                      |
| 2.1.2. Epidemiology                                                                                                          | ..................................................................................................10 |
| 2.1.3. Biologic features..............................................................................................10     |                                                                                                      |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                  | ............................................10                                                       |
| 2.1.5. Management...................................................................................................11       |                                                                                                      |
| 2.2. About the product                                                                                                       | ..............................................................................................12     |
| 2.3. Type of application and aspects on development longer                                                                   | ....................................................15                                               |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................15 |
| 2.4.1. Introduction....................................................................................................15    |                                                                                                      |
| 2.4.2. Active Substance.............................................................................................15       |                                                                                                      |
| 2.4.3. Finished Medicinal Product ................................................................................21         |                                                                                                      |
| 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological no                                              | aspects.......25                                                                                     |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects product                                            | ......................25                                                                             |
| 2.4.6. Recommendations for future quality development................................................26                      |                                                                                                      |
| 2.4.7. Introduction....................................................................................................26    |                                                                                                      |
| 2.4.8. Pharmacology .................................................................................................26      |                                                                                                      |
| 2.4.9. Pharmacokinetics.............................................................................................27       |                                                                                                      |
| 2.4.10. Toxicology ....................................................................................................28    |                                                                                                      |
| 2.4.11. Ecotoxicity/environmental risk assessment                                                                            | .......................................................29                                            |
| 2.4.12. Discussion on non-clinical aspects....................................................................29             |                                                                                                      |
| 2.4.13. Conclusion on the non-clinical aspects..............................................................31               |                                                                                                      |
| 2.5. Clinical aspect....................................................................................................32   |                                                                                                      |
| 2.5.1. Introduction....................................................................................................32    |                                                                                                      |
| 2.5.2. Clinical pharmacology                                                                                                 | ......................................................................................34             |
| 2.5.3. Discussion on clinical pharmacology...................................................................79 Medicinal    |                                                                                                      |
| 2.5.4. Conclusions on clinical pharmacology                                                                                  | .................................................................84                                  |
| 2.5.5. Clinical efficacy                                                                                                     | ...............................................................................................85    |
| 2.5.6. Discussion on clinical efficacy..........................................................................             | 214                                                                                                  |
| 2.5.7. Conclusions on the clinical efficacy...................................................................               | 225                                                                                                  |
| 2.5.8. Clinical safety................................................................................................       | 225                                                                                                  |
| 2.5.9. Discussion on clinical safety                                                                                         | ............................................................................ 274                     |
| 2.5.10. Conclusions on the clinical safety ...................................................................               | 280                                                                                                  |
| 2.6. Risk Management Plan                                                                                                    | ...................................................................................... 280           |

<div style=\"page-break-after: always\"></div>

| 2.7. Pharmacovigilance............................................................................................ 281                |
|---------------------------------------------------------------------------------------------------------------------------------------|
| 2.8. Product information .......................................................................................... 282               |
| 3. Benefit-Risk Balance............................................................................283                                |
| 3.1. Therapeutic Context ......................................................................................... 283                |
| 3.1.1. Disease or condition....................................................................................... 283                |
| 3.1.2. Available therapies and unmet medical need..................................................... 283                            |
| 3.1.3. Main clinical studies ....................................................................................... 284              |
| 3.2. Favourable effects ............................................................................................ 284              |
| 3.3. Uncertainties and limitations about favourable effects ........................................... 285                           |
| 3.4. Unfavourable effect .......................................................................................... 285               |
| 3.5. Uncertainties and limitations about unfavourable effects ....................................... 286                             |
| 3.6. Effects Table.................................................................................................... 287            |
| 3.7. Benefit-risk assessment and discussion............................................................... 290                        |
| 3.7.1. Importance of favourable and unfavourable effects............................................ 290                              |
| 3.7.2. Balance of benefits and risks........................................................................... 290                   |
| 3.8. Conclusions ..................................................................................................... 291 authorised |
| 4. Recommendations...............................................................................292                                  |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

Anti-drug antibodies

ADCC

Antibody-dependent cellular cytotoxicity

ADCP

Antibody-dependent cellular phagocytosis

ADME

Absorption, distribution, metabolism and excretion

AET

Analytical evaluation threshold

AEX

Anion exchange chromatography

APG

Acidic peak group

AUC

Area under the curve

BICN-PB

Boehringer Ingelheim Biopharmaceuticals (Lishizhen Road) China Boehringer Ingelheim Biopharmaceuticals (Halei Road) China Boehringer Ingelheim Pharma Germany Basic peak group Corrective action and preventive action Container closure integrity testing Container closure system Cluster of differentiation, such as CD274, CD279, CD3 and etc. Complement-dependent cytotoxicity Cation exchange chromatography Colony forming unit Capillary gel electrophoresis Current good manufacturing practice Committee for Evaluation of Human Medicinal Products Chinese hamster ovary Chinese Pharmacopoeia Clearance Maximum (plasma or tissue) concentration Critical process parameter Capillary zone electrophoresis Deoxyribonucleic acid Extracellular domain Electrocardiogram Enzyme-linked immunosorbent assay European Medicines Agency End-of-production cell bank European Pharmacopoeia Endotoxin unit European Union Ethylene-vinyl acetate Antigen-binding fragment Medicinal product no longer authorised

Biolab BICN

BIP Biberach

BPG

CAPA

CCIT

CCS

CD

CDC

CEX

CFU

CGE

cGMP

CHMP

CHO

ChP

CL

Cmax

CPP

CZE

DNA

ECD

ECG

ELISA

EMA

EOPCB

EP

EU

EU

EVA

Fab

FACS

Fluorescence activated cell sorting

Fc

Fragment crystallizable region (typically, of immunoglobulin G)

FcγR

Fc gamma receptor

FDA

Food and Drug Administration

FMEA

Failure modes and effect analysis

FMP

Final manufacturing process

G/P

Growth and production

GLP

Good laboratory practice

HC

Heavy chain

<div style=\"page-break-after: always\"></div>

<!-- image -->

HCB

Host Cell bank

HCP

Host cell protein

HMW

High molecular weight

HPSEC

Size-exclusion chromatography using high-performance liquid chromatography

IC50

Inhibitory concentration 50%

ICH

International Council For Harmonization Of Technical Requirements For

Pharmaceuticals For Human Use

IFN- γ

Interferon-gamma

IgG4

Immunoglobulin G4

IL

Interleukin, such as IL-2, IL-6, and more International non-proprietary name In-process control Intravenously Japanese Pharmacopoeia Dissociation constant Kindos Pharmaceuticals Co., Ltd., Chengdu Constant for off-rate Key process parameter Limulus amebocyte lysate Light chain Low endotoxin recovery Limit of in vitro cell age Low molecular weight Marketing authorisation application Master cell bank Murine granulocyte-macrophage colony-stimulation Master host cell bank Major objection Mechanism of action Main peak N-acetylneuraminic acid N-glycolylneuraminic acid Normal operating range Non-small cell lung cancer Nephelometric turbidity unit Overall concern Optical density Organization for Economic Cooperation and Development Original manufacturing process Post-approval change management protocol Proven acceptable range Medicinal product no longer authorised

INN

IPC

IV

JP

KD

Kindos

Koff

KPP

LAL

LC

LER

LIVCA

LMW

MAA

MCB

mGM-CSF

MHCB

MO

MOA

MP

NANA

NGNA

NOR

NSCLC

NTU

OC

OD

OECD

OMP

PACMP

PAR

PBMC

Peripheral blood mononuclear cell

PD-1

Programmed cell death protein 1

PDE

Permitted daily exposure

PD-L1

Programmed -death ligand-1

PD-L2

Programmed-death ligand-2

PE

Polyethylene

PES

Polyethersulfone

Ph. Eur.

European Pharmacopoeia

pI

Isoelectric pH

PK PP PPQ PRS PVC QA QbD RH RRF RS SCB SCID SPR SUB TGI TK TSE USAN USP UV VCD WCB WRS WT

Pharmacokinetic

Process parameter

Process performance qualification

Primary reference standard

Polyvinyl chloride

Quality attribute

Quality by design

QW                             Every week

Q2W                           Every 2 week

<div style=\"page-break-after: always\"></div>

<!-- image -->

Q3W                           Every 3 week Relative humidity Risk-ranking and filtering Reference standard Safety cell bank Severe combined immunodeficiency (mouse) Surface plasmon resonance Single-use bioreactor Tumour growth inhibition Toxicokinetic Transmissible spongiform encephalopathy United States adopted name United States Pharmacopoeia Ultraviolet Viable cell density Working cell bank Working reference standard wild-type Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novartis Europharm Limited submitted on 3 March 2022 an application for marketing authorisation to the European Medicines Agency (EMA) for Tizveni, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indication:

Tizveni in combination with pemetrexed and platinum -containing chemotherapy is indicated for the first -line treatment of locally advanced or metastatic non -squamous non -small cell lung cancer in adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive mutation. Tizveni in combination with carboplatin and either paclitaxel or nab -paclitaxel is indicated for the first -line treatment of locally advanced or metastatic squamous non -small cell lung cancer in adults. Tizveni as monotherapy is indicated for the treatment of locally advanced or metastatic non -small cell lung cancer after prior chemotherapy in adults. During the procedure, the applicant has changed from Novartis Europharm Limited to Beigene Ireland limited. Relevant documents for the change of applicant have been provided, validated and agreed. Legal basis, dossier content The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). Information on paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0142/2019 on the granting of a (product-specific) waiver. 1.2. Information relating to orphan market exclusivity 1.2.1. Similarity Medicinal product no longer authorised

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.3. Applicant's request(s) for consideration

## 1.3.1. New active substance status

The applicant requested the active substance Tislelizumab contained in the above medicinal product to be considered as a new active substance, as the applicant claimed that it was not a constituent of a medicinal product previously authorised within the European Union.

## 1.4. Scientific advice

| The application was received by the EMA on                                                                                                                                                                                                                                                                                  | 3 March 2022                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| The procedure started on                                                                                                                                                                                                                                                                                                    | 24 March 2022                       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on no                                                                                                                                                                                                                             | 13 June 2022                        |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on product                                                                                                                                                                                                                        | 27 June 2022                        |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                                                                                                                                                     | 21 July 2022                        |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                                                                                                                                                         | 25 January 2023                     |
| The following GMP and GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product: Medicinal                                                                                                                                   |                                     |
| GCP inspections were requested and conducted at one investigator site in Turkey between 29 August to 2 September 2022, the sponsor site in the USA, between 9 and 17 November 2022 and two investigator sites in China between 6 and 17 November 2023. The outcome of the inspections carried out was issued on:            | 20 January 2023 and 04 January 2024 |
| A GMP inspection at Boehringer Ingelheim Biopharmaceuticals (China) Ltd., 1090 Halei Road, Pilot Free Trade Zone, Shanghai, 201203, China for Drug Substance and Drug Product manufacturing and testing, Drug Product Primary packaging, between 13-17 March 2023. The outcome of the inspection carried out was issued on: | 08 May 2023                         |

<!-- image -->

The applicant did not seek scientific advice from the CHMP. 1.5. Steps taken for the assessment of the product The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Jan Mueller-Berghaus Co-Rapporteur:  Aaron Sosa Mejia The Rapporteur appointed by the PRAC was: PRAC Rapporteur: Bianca Mulder Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                      | 10 March 2023               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                             | 16 March 2023               |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                            | 30 March 2023               |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                      | 16 January 2024             |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on             | 24 March 2023               |
| The CHMP, in light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Tizveni on: | 22 February 2024 authorised |
| Furthermore, the CHMP adopted a report on new active substance (NAS) status of the active substance contained in the medicinal product                                               | 22 February 2024            |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

The initially claimed therapeutic indication was : ' Tislelizumab as monotherapy is indicated for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy in adults.

Tislelizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.

Tislelizumab in combination with pemetrexed and platinum- containing chemotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations .'

2.1.1. Disease or condition Lung cancer is the second most common cancer worldwide (after breast cancer) and is associated with the highest cancer mortality. As per GLOBOCAN data in 2020, there were approximately 2.2 million new cases and 1.8 million deaths (Sung et al 2021). Based on the estimates from GLOBOCAN 2020, the age-adjusted incidence rate (IR) of lung cancer in 2020 was 33.1 per 100000 in the United States of America (US) and was 29.4 per 100000 in 2020 in Europe (Ferlay et al 2020). The leading cause of lung cancer is smoking in both men and women, irrespective of geographic region. Emerging economies vary widely in smoking practices and cancer incidence but commonly also harbour risks from environmental exposures (Barta et al 2019). Non-small cell lung cancer (NSCLC) accounts for 80%-85% of all lung cancers (Bareschino et al 2011) and based on this assumption, the estimated incidence of NSCLC in Europe is approximately 25.0 per 100000 and was 28.1 per 100000 in USA (Goldstraw et al 2016). The main histological subtypes are adenocarcinoma (40%), squamous cell carcinoma (25-30%), and large cell carcinoma (10-15%) (National Cancer Institute 2017). Lung cancer is often diagnosed at an advanced stage, resulting in a poor prognosis; the 5-year OS rate for patients with advanced NSCLC ranges from 19% in patients with Stage IIIB to 6% with Stage IV disease (Goldstraw et al 2016). 2.1.2. Epidemiology The highest incidence rates of lung cancer in males are observed in Micronesia/Polynesia, Eastern and Southern Europe, and Eastern and Western Asia, and among women in North America, Northern and Western Europe, Micronesia/Polynesia, and Australia/New Zealand (Sung et al 2021). In the US, according to SEER-18 data (2017), the incidence of NSCLC was 37.5 per 100,000 (42.4 per 100,000 in men and 33.8 per 100,000 in women), and the 5-year survival overall was 26.4% (21.9% in men and 31.3% in women) (Ganti et al 2021). In Europe, the age-standardised incidence rate of all lung cancers is 63.5 per 100,000 (97.6 per 100,000 among men and 38.3 per 100,000 among women) (Dyba et al 2021). 2.1.3. Biologic features Medicinal product no longer authorised

Non-small cell lung cancer (NSCLC) is the predominant subtype, accounting for approximately 85% of all cases. NSCLC can be divided into two major histologic types: non-squamous and squamous cell carcinoma. Non-squamous histology accounts for more than half of all NSCLC, whereas squamous histology accounts for approximately 30% (Brambilla et al, 2014 and Schrump DS et al. NSCLC; Principles and Practice of Oncology. 9th Edition. 2011) in Europe.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

More than half of the patients are diagnosed at an advanced stage of disease, which directly contributes to poor survival, as expressed by an untreated median OS of 4 months and a metastatic 5-

<div style=\"page-break-after: always\"></div>

year survival rate of &lt;5% (Lindsey A. et al, 2016). Poor prognostic factors for survival in patients with NSCLC include advanced stage of disease at the time of initial diagnosis, poor performance status (PS), and a history of unintentional weight loss. More than half of the patients with NSCLC are diagnosed with distant metastatic disease, which directly contributes to poor survival prospects.

## 2.1.5. Management

Over the past decade, there have been considerable advances in the management of NSCLC. Improved understanding of the biology and molecular subtypes of NSCLC has led to development of a number of biomarker-directed therapies for patients with metastatic disease, including drugs targeting EGFR mutations, ALK rearrangements, and other molecular aberrations. These therapies have improved OS for patients with metastatic NSCLC with an oncogenic driver (Arbour and Riely 2019). For patients with metastatic NSCLC with no actionable oncogenic driver (notably without EGFR mutations and ALK rearrangements), the development of immune checkpoint inhibitors (ICIs) has transformed the care, providing a survival benefit when administered as monotherapy following disease progression on platinum-based chemotherapy (Borghaei et al 2015, Brahmer et al 2015, Herbst et al 2016, Rittmeyer et al 2017) or when administered with or without chemotherapy in the first-line setting (Borghaei et al 2017, Gandhi et al 2018, Paz-Ares et al 2018, Socinski et al 2018, West et al 2019, Jotte et al 2020, Nishio et al 2021, Paz-Ares et al 2021).

Before ICI therapy became available as the first-line treatment for advanced or metastatic NSCLC, platinum-based doublet therapy was the recommended treatment option in patients with no actionable oncogenic driver and an ECOG performance status of 0 to 2. Pemetrexed use is restricted to nonsquamous cell carcinoma in first- (or later-) line of treatment in advanced disease, and is preferred to gemcitabine- or docetaxel-based combinations in nonsquamous NSCLC (Planchard et al 2018).

Second-/third-line treatment options for advanced or metastatic NSCLC without oncogenic driver mutations Before ICI therapy was available, there were 2 established chemotherapeutic agents available globally for the treatment of locally advanced or metastatic NSCLC with no actionable oncogenic driver after prior chemotherapy: docetaxel for patients with either nonsquamous or squamous NSCLC and pemetrexed for patients with nonsquamous NSCLC who did not receive pemetrexed as first-line treatment (Planchard et al 2018, Ettinger et al 2019). Erlotinib can also be considered for patients who cannot receive cytotoxic chemotherapy due to poor performance status (Tarceva USPI 2010, Planchard et al 2018). Overall, the therapeutic benefit of these further lines of treatment has been restricted by limited improvements in survival, low response rates, and significant toxicities (Stinchcombe and Socinski 2008, Al-Farsi and Ellis 2014, Nadler et al 2018). PD-1/PD-L1 ICIs were first approved beginning in 2015 for patients with second- or later-line locally advanced or metastatic NSCLC lacking sensitizing EGFR or ALK mutations, and over time, access has expanded globally from early approvals in the US and EU (Novello et al 2016, Ettinger et al 2019). As access in other parts of the world arrived later, docetaxel remained a commonly used standard treatment option for both squamous and nonsquamous NSCLC in the second- and third-line treatment settings until recently. Presently, pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are approved in the EU for the second-line treatment of metastatic NSCLC (Keytruda SmPC 2021, Opdivo SmPC 2021, Tecentriq SmPC 2021). First-line treatment options for advanced or metastatic NSCLC without oncogenic driver mutations Medicinal product no longer authorised

The approval of ICIs has now been extended to first-line treatment therapy for NSCLC with no actionable oncogenic driver, either as monotherapy or in combination with chemotherapy (Reck et al 2016, Paz-Ares et al 2018, Mok et al 2019). Pembrolizumab in combination with platinum and pemetrexed has since become a new standard of care for patients with first-line nonsquamous NSCLC,

<div style=\"page-break-after: always\"></div>

irrespective of PD-L1 status (Gandhi et al 2018). ICI monotherapy has been approved for patients with PDL1 positive expression (≥50%) and, in some countries, the approval was also extended to the patients with tumour PDL1 expression ≥1% (Reck et al 2016, Mok et al 2019, Keytruda SmPC 2021).

Similarly, in the first-line squamous NSCLC setting, pembrolizumab has been approved as first-line treatment therapy for squamous NSCLC, either as monotherapy for the 'PD -L1 high' (≥50%) population (and also for the population with PDL1 ≥1% in the US) (Re ck et al 2016) or in combination with chemotherapy irrespective of PD-L1 expression (Paz-Ares et al 2018). More recently, nivolumab/ipilimumab with platinum-doublet chemotherapy has been approved as first-line treatment for NSCLC irrespective of histology, and nivolumab/ipilimumab combination therapy alone was approved in tumours expressing PDL1 ≥1% (Opdivo SmPC 2021). Other ICIs approved for treatment in the first-line setting include atezolizumab and cemiplimab as monotherapy for first-line treatment of NSCLC whose tumours have high PD-L1 expression irrespective of histology, and atezolizumab as firstline treatment of metastatic nonsquamous NSCLC with no EGFR or ALK genomic tumour aberrations in combination with bevacizumab, paclitaxel, and carboplatin as well as with paclitaxel protein-bound and carboplatin (Tecentriq SmPC 2021, Libtayo SmPC 2021).

- locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or

2.2. About the product Tislelizumab is a humanised IgG4 variant monoclonal antibody that binds to the T-cell surface receptor programmed cell death protein 1 (PD-1) with high specificity and affinity (KD = 0.15 nM). It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling. As such, upregulation of PD-1 ligands occurs in some tumours and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumours, which is counteracted by the administration of PD-1 inhibitors like tislelizumab. The antibody does not bind to Fc gamma receptors and C1q and therefore does not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. Tislelizumab belongs to the therapeutic subgroup L01 (antineoplastic agents) of the Anatomical Therapeutic Chemical Classification System. The approved indication is: Tizveni in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PDL1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: · locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or · metastatic NSCLC. Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the firstline treatment of adult patients with squamous non-small cell lung cancer who have: Medicinal product no longer authorised

- metastatic NSCLC.

Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.

Tislelizumab concentrate for solution for infusion is formulated in vials of 10 mL containing 100 mg tislelizumab. Tislelizumab treatment must be initiated and supervised by physicians experienced in the

<div style=\"page-break-after: always\"></div>

treatment of cancer. The recommended dose of tislelizumab is 200 mg administered by intravenous infusion once every 3 weeks. Tislelizumab treatment should be continued until disease progression or unacceptable toxicity. No dose reductions of Tizveni as monotherapy are recommended. Tizveni should be withheld or discontinued as described in Table below. Detailed guidelines for the management of immune-related adverse reactions are described in section 4.4.

Table 1. Recommended treatment modifications for Tizveni

<!-- image -->

| Immune-related adverse reaction            | Severity 1                                                  | Tizveni treatment modification                                                                                                                                                                                          |
|--------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | Grade 2                                                     | Withhold 2,3                                                                                                                                                                                                            |
| Pneumonitis                                | Recurrent grade 2; grade 3 or 4                             | Permanently discontinue 3                                                                                                                                                                                               |
|                                            | ALT or AST >3 to 8 x ULN or total bilirubin >1.5 to 3 x ULN | Withhold 2,3                                                                                                                                                                                                            |
| Hepatitis                                  | ALT or AST >8 x ULN or total bilirubin >3 x ULN             | Permanently discontinue 3                                                                                                                                                                                               |
| Rash                                       | Grade 3                                                     | Withhold 2,3                                                                                                                                                                                                            |
|                                            | Grade 4                                                     | Permanently discontinue 3 Withhold 2,3                                                                                                                                                                                  |
| Severe cutaneous adverse reactions (SCARs) | Suspected SCARs, including SJS or TEN                       | For suspected SJS or TEN, do not resume unless SJS/TEN has been ruled out in consultation with appropriate specialist(s). authorised                                                                                    |
|                                            | Confirmed SCARs, including longer                           | Permanently discontinue                                                                                                                                                                                                 |
|                                            | SJS or TEN                                                  |                                                                                                                                                                                                                         |
| Colitis                                    | Grade 2 or 3 Recurrent grade 3; grade 4                     | Withold 2,3 Permanently discontinue 3                                                                                                                                                                                   |
| Myositis/rhabdomyolysis                    | Grade 2 or 3 grade 4 no                                     | Withhold 2,3 Permanently discontinue 3                                                                                                                                                                                  |
|                                            | Recurrent grade 3; Grade 2, 3 or 4 product                  | Hypothyroidism may be managed with replacement therapy without treatment                                                                                                                                                |
| Hypothyroidism                             | Grade 3 or 4                                                | interruption. Withhold 2 For grade 3 or 4 that has improved to grade ≤2 and is controlled with anti-thyroid therapy, if indicated continuation of Tizveni may be                                                        |
| Hyperthyroidism Medicinal                  | Grade 2                                                     | Consider withholding treatment until controlled by HRT.                                                                                                                                                                 |
| Adrenal insufficiency                      | Grade 3 or                                                  | Withhold 3 For grade 3 or 4 that has improved to grade ≤2 and is controlled with HRT, if indicated continuation of Tizveni may be considered after corticosteroid taper. Otherwise, treatment should be discontinued. 3 |
|                                            | 4                                                           |                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                                                                                                                                                                                                                                           | Grade 2                                                                                                                                                                                                                                                                                                   | Consider withholding treatment until controlled by HRT.                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypophysitis                                                                                                                                                                                                                                                                                              | Grade 3 or 4                                                                                                                                                                                                                                                                                              | Withhold 2,3 For grade 3 or 4 that has improved to grade ≤2 and is controlled with HRT, if indicated continuation of Tizveni may be considered after corticosteroid taper. Otherwise, treatment should be discontinued. 3                                                                                 |
| Type 1 diabetes mellitus                                                                                                                                                                                                                                                                                  | Type 1 diabetes mellitus associated with grade ≥3 hyperglycaemia (glucose >250 mg/dl or >13.9 mmol/l) or associated with ketoacidosis                                                                                                                                                                     | Withhold For grade 3 or 4 that has improved to grade ≤2 with insulin therapy, if indicated continuation of Tizveni may be considered once metabolic control is achieved. Otherwise, treatment should be discontinued. authorised                                                                          |
| Nephritis with renal dysfunction                                                                                                                                                                                                                                                                          | Grade 2 (creatinine >1.5 to 3 x baseline or >1.5 to 3 x ULN) Grade 3 (creatinine >3 x                                                                                                                                                                                                                     | Withhold 2,3                                                                                                                                                                                                                                                                                              |
| Nephritis with renal dysfunction                                                                                                                                                                                                                                                                          | baseline or >3 to 6 x ULN) or grade 4 (creatinine >6 x ULN) Permanently discontinue 3 longer                                                                                                                                                                                                              | baseline or >3 to 6 x ULN) or grade 4 (creatinine >6 x ULN) Permanently discontinue 3 longer                                                                                                                                                                                                              |
| Myocarditis                                                                                                                                                                                                                                                                                               | Grade 2, 3 or 4                                                                                                                                                                                                                                                                                           | Permanently discontinue 3                                                                                                                                                                                                                                                                                 |
| Neurological toxicities                                                                                                                                                                                                                                                                                   | Grade 2                                                                                                                                                                                                                                                                                                   | Withhold 2,3 3                                                                                                                                                                                                                                                                                            |
| Pancreatitis                                                                                                                                                                                                                                                                                              | Grade 3 or 4 Grade 3 pancreatitis or grade 3 or 4 serum amylase or lipase levels increased (>2 x ULN) no                                                                                                                                                                                                  | Permanently discontinue Withhold 2,3                                                                                                                                                                                                                                                                      |
| Pancreatitis                                                                                                                                                                                                                                                                                              | Grade 4                                                                                                                                                                                                                                                                                                   | Permanently discontinue 3 2,3                                                                                                                                                                                                                                                                             |
| Other immune-related adverse reactions                                                                                                                                                                                                                                                                    | Grade 3 Recurrent grade 3; grade 4 product                                                                                                                                                                                                                                                                | Withhold Permanently discontinue 3                                                                                                                                                                                                                                                                        |
| Other adverse drug reactions                                                                                                                                                                                                                                                                              | Other adverse drug reactions                                                                                                                                                                                                                                                                              | Other adverse drug reactions                                                                                                                                                                                                                                                                              |
| Infusion-related reactions                                                                                                                                                                                                                                                                                | Grade 1                                                                                                                                                                                                                                                                                                   | Consider pre-medication for prophylaxis of subsequent infusion reactions. Slow the rate of infusion by 50%.                                                                                                                                                                                               |
| Infusion-related reactions                                                                                                                                                                                                                                                                                | Grade 2                                                                                                                                                                                                                                                                                                   | Interrupt infusion. Resume infusion if resolved or decreased to grade 1, and slow rate of infusion by 50%.                                                                                                                                                                                                |
| Infusion-related reactions                                                                                                                                                                                                                                                                                | Grade 3 or                                                                                                                                                                                                                                                                                                | Permanently discontinue                                                                                                                                                                                                                                                                                   |
| 4 ALT = alanine aminotransferase, AST = aspartate aminotransferase, HRT= hormone replacement therapy, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit normal 1 Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria Medicinal | 4 ALT = alanine aminotransferase, AST = aspartate aminotransferase, HRT= hormone replacement therapy, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit normal 1 Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria Medicinal | 4 ALT = alanine aminotransferase, AST = aspartate aminotransferase, HRT= hormone replacement therapy, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit normal 1 Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria Medicinal |

<div style=\"page-break-after: always\"></div>

## 2.3. Type of application and aspects on development

The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC, as amended complete and independent application.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as concentrate for solution for infusion containing 100 mg/10 mL of tislelizumab as active substance. Other ingredients are: sodium citrate dihydrate, citric acid monohydrate, L-histidine hydrochloride monohydrate, L-histidine, trehalose dihydrate, polysorbate 20 and water for injections. The product is available in a 20 mL type 1 glass vial, with a grey chlorobutyl stopper with FluroTec coating and seal cap with a flip-off button. The product is available in unit packs containing 1 vial and in multipacks containing 2 (2 x 1) vials. 2.4.2. Active Substance 2.4.2.1. General Information Tislelizumab is a Fc engineered humanised immunoglobulin G4 (IgG4) variant monoclonal antibody produced in recombinant Chinese Hamster Ovary (CHO) cells. The antibody binds to the programmed cell death protein 1 (PD-1) receptor on the T-cell surface, preventing interaction with PD-1 ligands PDL1 and PD-L2, thereby blocking PD-1-mediated inhibitory signalling. Tislelizumab consists of two heterodimers, each composed of a heavy and a light polypeptide chain. The amino acid sequences of the light chain (LC) and heavy chain (HC) in tislelizumab are shown in Figure 1. The theoretical molecular weight calculated from the amino acid sequence is 144,080 Dalton. Tislelizumab is composed of 1318 amino acid residues, 445 in the HC and 214 in the LC. Each HC contains one N-glycosylation site at asparagine 295. Post-translational modifications concern the Ntermini with a N-term pyroglutamate, or Pyr-Q, and the C-termini with a C-term lysine clipped, -K, as well as a glycosylation at the conserved Fc glycosylation site. Due to the modulations in the Fc region, tislelizumab does not bind to Fc gamma receptors and C1q. Therefore, it does not include antibodydependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and/or complement-dependent cytotoxicity (CDC). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 1: Primary structure of tislelizumab The physicochemical properties of tislelizumab active substance are provided in the dossier. The general information is considered sufficient. 2.4.2.2. Manufacture, process controls and characterisation The active substance is manufactured, tested and released in accordance with good manufacturing practice (GMP). The site responsible for the manufacture of the active substance is Boehringer Ingelheim Biopharmaceuticals (China) Ltd., 1090 Halei Road Pilot Free Trade Zone, 201203 Shanghai, China. During the procedure, a major objection (MO) was raised for the lack of proof of EU GMP compliance for several of the active substance manufacturing sites. Following remote inspection and/or agreement to conduct a post-approval inspection at the concerned sites from the responsible supervisory authorities, EU GMP compliance for the active substance manufacturing sites has been confirmed. Description of manufacturing process and process controls Medicinal product no longer authorised 91

The overall active substance manufacturing process is adequately presented in the dossier. The tislelizumab active substance is expressed in the CHO cell expression system. The manufacturing process is divided into cell culture/harvest (upstream) and purification (downstream) steps.

To initiate the tislelizumab cell culture process, working cell bank (WCB) is thawed and cells are cultivated under controlled conditions. After vial thaw, a series of sequential passages are performed to expand and scale-up the tislelizumab cell culture before being finally transferred into the production bioreactor.

<div style=\"page-break-after: always\"></div>

During the harvest unit operation, cells and cell debris are separated from the cell culture fluid of the production bioreactor containing tislelizumab active substance to provide harvested cell culture fluid for purification.

The purification of the active substance starts with a Protein A affinity chromatography to remove process-related impurities. Viral reduction follows during a virus inactivation and pH adjustment step. Turbidities are removed by depth filtration subsequently. Process-related impurities are removed further by several other chromatography techniques. Virus filtration is conducted as a second orthogonal method specifically dedicated for viral clearance that provides additional assurance of viral safety by the physical removal of potential adventitious viruses by size. After ultrafiltration and diafiltration during tangential flow filtration, the tislelizumab active substance is supplemented with spike buffer and formulation buffer to achieve the target product concentration and excipient composition.

Lastly, the filtration and storage unit operation include filtration of the active substance into a mixing bag with subsequent transfer into bags for long-term storage. The container closure system (CCS) for tislelizumab active substance is a single-use pre-sterilised bag that complies with the compendial requirements. Sufficient details on the CCS, including materials, dimensions and technical drawings are provided in the dossier. Adequate definition of a batch of tislelizumab active substance is included in the dossier. Reprocessing is claimed for several manufacturing steps and the proposed approach is considered acceptable. An extractables assessment was performed based on extractables study data to identify potential leachables present in both tislelizumab active substance and finished product manufacturing processes, which may adversely affect patient safety. Polymeric materials used throughout the manufacturing processes were assessed by review of associated extractables data available for each material. The leachable study results, by all analyses, detected no elemental impurities with a concentration greater than or equal to the corresponding Permitted Daily Exposure (PDE) limits and no organic compounds with a concentration greater than or equal to the corresponding Analytical Evaluation Threshold (AET) limits. Therefore, the leachables study supports the conclusion that potential leachables present in the tislelizumab active substance/finished product manufacturing processes and/or in the active substance CCS pose no risk to patient safety. Overall, the active substance manufacturing process has been adequately described and the in-process controls (IPCs) are indicated for each step, with adequately justified acceptance criteria. It is mentioned that a deviation procedure, which includes an investigation, is followed when any normal operating range (NOR) or proven acceptable range (PAR) limits for process parameters (PP) are exceeded or when excursions for critical (CPP), key (KPP) and non-key (non-KPP) process parameters occur. This approach is endorsed. In conclusion, the active substance manufacturing process is considered acceptable. Control of materials Medicinal product no longer authorised

Sufficient information on raw materials has been submitted by the applicant. Raw materials and reagents for the manufacture of tislelizumab active substance are commercial or prepared from commercially available materials and are qualified. Compendial raw materials comply with their respective monographs. None of the raw materials of the manufacturing process are of animal or human origin. The composition of media for cell banking, growth and production, feed is provided and process parameters for media preparation are indicated.

<div style=\"page-break-after: always\"></div>

Tislelizumab is expressed in CHO cells. Sufficient information regarding cell line development has been presented in the dossier. Master cell bank (MCB), working cell bank (WCB) and end-of-production cell banks (EOPCBs) were tested for identity, sterility, mycoplasma, endogenous and adventitious viruses.

The limit of in vitro cell age (LIVCA) has been established for the tislelizumab production cell line in accordance with ICH Q5B.

## Control of critical steps and intermediates

A comprehensive overview of critical in-process controls and critical in-process tests performed throughout the tislelizumab active substance manufacturing process is given. Acceptable information has been provided on the control system in place to monitor and control the active substance manufacturing process with regard to critical, as well as non-critical operational parameters and inprocess tests. Actions taken if limits are exceeded are specified. The critical manufacturing controls are supported by process characterisation studies, additional supportive studies and manufacturing experience. Hold time CPPs through both harvest and purification processes are established and considered acceptable. Process validation Process validation follows a master validation plan to control consistent and robust quality of the active substance. A three-stage approach to validation was followed: Stage 1 - Process Design, Stage 2 Process Performance Qualification (PPQ) and Stage 3 - Continued Process Verification. Process characterisation studies and scale down models were conducted to support the commercial manufacturing process control strategy and to ensure robust process performance and consistent product quality. Quality attributes (QA) are established and the criticality of each quality attribute is assessed with respect to impact on biological activity, pharmacokinetics, pharmacodynamics, and immunogenicity and safety, which are directly linked to product efficacy and safety. Impact of non-conformities to the product quality or to the validation execution was assessed and corrective and preventive actions (CAPAs) were initiated as appropriate. Results of the process performance qualification (PPQ) demonstrated that the tislelizumab manufacturing process is consistently capable of producing product meeting predefined criteria for each PPQ batch, including repeatability and consistency of all PPQ batches manufactured. Reprocessing, hold times and resin reuse are validated within supporting validation studies. In conclusion, the active substance manufacturing process is adequately validated. Manufacturing process development The commercial active substance manufacturing process was developed in parallel with the clinical development program. Several important changes have been introduced during the development of the manufacturing process. These include changes to manufacturing site, scale and to the process itself. Medicinal product no longer authorised

The tislelizumab final manufacturing process (FMP) is the process intended for commercial manufacturing and was the only source of active substance used in the pivotal study for the Marketing Authorisation Application (MAA).

Comparability studies were performed at every major stage of development to assure product quality and performance. The comparability assessment showed no impact to purity and potency. All active substance batches met the predetermined comparability criteria. The additional characterisation confirmed the consistent higher-order structure and biophysical properties. Slight differences in glycosylation were observed, which were attributed to variability in the cell culture medium used.

<div style=\"page-break-after: always\"></div>

Despite these differences, no changes in functional attributes were correlated to an increase or decrease of specific glycan forms or charge variant groups. Therefore, tislelizumab manufacturing process was demonstrated to be comparable throughout development.

## Characterisation

Structure, physicochemical characteristics and biological properties of tislelizumab were elucidated by release tests and additional characterisation assays. The analytical results are consistent with the proposed structure.

During the assessment, the applicant was requested to tighten the acceptance criteria for several quality attributes (bacterial endotoxin and biological activity). Additionally, inclusion of a quantitative acceptance criteria for glycan content was requested. A recommendation to monitor the glycan content, until a sufficient number of active substance batches is manufactured to document manufacturing process consistency and determine if the quantitative control of glycan content for tislelizumab release testing is required, has been given (Recommendation).

Primary, secondary and higher order structure has been thoroughly characterised applying various orthogonal methods, revealing that the active substance has the expected structure of a human IgG4type antibody. Furthermore, heterogeneity of the active substance was adequately characterised by analysing size and charge variants, glycosylation and other product-related substances and impurities. Biological characterisation of tislelizumab indicates that this antibody has a high affinity for human PD1 and binds to the extracellular domain of PD-1, as well as to the native PD-1 expressed on cell surface, in a dose-dependent manner. Binding activities of tislelizumab to Fc gamma receptors and C1q protein were analysed and results show that tislelizumab does not bind to different Fc gamma receptors and has little or no binding to C1q. ADCC and CDC activity of tislelizumab was characterised by cell-based assays and neither ADCC, nor CDC activity were detected, as expected for IgG4 construct. Process-related impurities comprise of impurities originating from the cell substrates, cell culture and purification processing. During process characterisation studies and process validation campaigns, sufficient clearance of certain process-related impurities was shown. Based on the provided data, it is acceptable that tests for these impurities are not included as in-process controls or in the tislelizumab active substance release specification. In summary, the characterisation data presented are considered appropriate for this type of molecule. 2.4.2.3. Specification The release and stability specification for tislelizumab active substance are set based on regulatory guidelines, analytical capability, process capability and clinical experience. The tislelizumab release/stability specification includes general tests, test for identity, purity and impurity tests for product-related impurities, test for process-related impurities, test for protein content, biological activity, as well as tests for safety parameters. Medicinal product no longer authorised

Overall, the parameters included in the active substance release and shelf-life specification are found adequate to control the quality of tislelizumab.

<div style=\"page-break-after: always\"></div>

## Analytical methods

Method descriptions for all non-compendial analytical procedures are provided and validations are performed according to ICH Q2(R1). The compendial methods have been verified to demonstrate the suitability for the intended purpose. The biological activity of tislelizumab is determined by a cell-based assay, measuring the ability of the active substance to block PD-1 receptor from engaging with the target ligand PD-L1.

## Batch analysis

Batch analysis data of the active substance were provided, cover early-stage batches produced by the original manufacturing process and late-stage batches produced by the final manufacturing process. All batch analysis data were in line with the acceptance criteria that applied at the time of testing. The results for batch release demonstrate a high level of batch-to-batch consistency. Reference materials A 2-tiered reference standard (RS) system has been established with a primary reference standard (PRS) and a working reference standard (WRS). The information provided is found sufficient and the extent of the qualification of the standards is adequate. Future WRS will be prepared form representative commercial active substance batches. A detailed protocol for the characterisation and qualification of future WRS has been provided, including sufficient description of potency assignment. Requalification protocols for the PRS and WRS have been included and are found acceptable. 2.4.2.4. Stability The proposed shelf-life for the tislelizumab active substance is 24 months in the defined CCS and at the proposed long-term storage condition. The active substance stability program is conducted according to ICH Q1A (R2) and ICH Q5C. Primary data are derived from PPQ batches and from additional representative clinical batches, manufactured at the proposed commercial site. All primary stability batches were manufactured using the final manufacturing process and the CCS used is representative of the commercial container closure. In addition to data from the primary stability studies, data from supportive stability batches manufactured using the original manufacturing process are also provided. Medicinal product no longer authorised

In summary, the stability data demonstrate that the active substance is stable at the recommended long-term storage condition for all attributes tested, supporting the proposed shelf-life of 24 months. All stability data remain within the clinical specifications in place at the time of testing, indicating that there have been no significant changes in terms of potency, quality or purity of the active substance when stored at the long-term condition. No change has been observed relative to the initial time point and the results meet the acceptance criteria for all analytical procedures applied. In addition, data from stability studies conducted under accelerated and stressed conditions are also included in the dossier and results are adequately discussed.

Additionally, forced degradation studies were performed to further characterise the active substance and to build knowledge around specific molecular degradation pathways and resilience of the molecule under various stressed conditions. The results obtained demonstrate that selected analytical methods are stability indicating.

<div style=\"page-break-after: always\"></div>

The applicant commits to conduct and complete the ongoing long-term stability studies of the primary batches, which includes stability studies for process validation batches, according to the stability protocols. This approach is endorsed.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product is presented as a 10 mL concentrate for solution for infusion in a 20 mL vial, consisting of 10 mg/mL tislelizumab formulated in citrate, histidine, trehalose, polysorbate 20. The concentrate is a clear to slightly opalescent, colourless to slightly yellowish solution, that contains no preservative and is intended for intravenous infusion as single use only. Acceptable description of the finished product composition has been provided. All excipients are of Ph. Eur. compendial grade and specifications for the excipients have been provided, including additional testing of polysorbate 20 and trehalose dihydrate for residual solvents. No novel excipients and no excipients of human or animal origin are used in the finished product formulation. Compatibility between the excipients and the tislelizumab active substance is considered demonstrated by the longterm stability data. The primary packaging is a Type I glass vial, with a grey chlorobutyl stopper with FluroTec-coating and secured with aluminium flip-off seal caps. The finished product CCS complies with compendial requirements. Suitability of the CCS is supported by the chemical resistance of the selected components, container closure integrity testing (CCIT) and stability data. In addition, extractable and leachables studies were performed, in line with ICH Q3D guideline. The extractables study identified no extractables requiring further investigation. The leachables study results indicate that all elemental analyses were below the PDE and all organic compounds were below the AET, with the exception of two substances of interest. However, as both compounds were detected at levels well below the safety threshold, no further toxicology evaluation was needed. In summary, test results support the conclusion that the selected CCS is compatible with the finished product and adequate for the intended use of the product throughout the shelf-life. The commercial formulation of the finished product was established in formulation screening and robustness studies. The objective of the finished product formulation development program was to develop a formulation sufficiently stable and robust for manufacturing, storage, transportation and administration of tislelizumab by intravenous infusion. There have been no changes in the formulation of tislelizumab finished product between the toxicology batches used for nonclinical safety studies, clinical batches and the planned commercial batches. Medicinal product no longer authorised

Over the course of manufacturing process development, the manufacturing process has undergone several changes as appropriate for each development stage. These changes were primarily associated with the transfer to the commercial manufacturing site, process scale-up and change of the CCS. Process characterisation, process transfer and comparability studies were conducted to support the commercial manufacturing process control strategy and to ensure robust process performance and consistent finished product quality.

The clinical dose of 200 mg is delivered using two 100 mg vials via intravenous administration with a 0.22 µm filter, upon dilution with saline solution. Compatibility with representative infusion bags, infusion lines and in-line filter has been investigated in-use stability studies and results demonstrate that the diluted tislelizumab injection solution is stable for 24 hours at refrigerated conditions (2°C to 8°C), as well as 4 hours at 25°C ± 2°C, when in contact with clinically representative plastics. Further

<div style=\"page-break-after: always\"></div>

studies demonstrate that no microbial proliferation occurred in spiked 0.9% saline bags for 48 hours at the refrigerated conditions (2°C to 8°C) and for 8 hours at room temperature conditions (25°C ± 2°C). The proposed in-use period and storage conditions stated in the SmPC are therefore supported.

## 2.4.3.2. Manufacture of the product and process controls

The manufacture, control, packaging and release of tislelizumab finished product is performed, in accordance with GMP. The sites responsible for the batch release of the finished product are: Novartis Farmacéutica, S.A., Gran Via de les Corts Catalanes, 764, 08013 Barcelona, Spain and Novartis Pharma GmbH, Roonstrasse 25, 90429 Nuremberg, Germany.

Taken together, the finished product manufacturing process is considered validated and it has been demonstrated that the process is capable of producing a product of intended quality in a reproducible manner.

During the procedure, a major objection (MO) was raised for the lack of proof of EU GMP compliance for several of the finished product manufacturing sites. The MO was resolved, reference is made to the active substance section. The tislelizumab finished product manufacturing process consists of the following unit operations: thawing, bioburden reduction filtration and pooling, sterile filtration, filling and stoppering, capping and visual inspection. The finished product manufacturing process includes no additional formulation steps, hence all physicochemical and biological properties of the finished product are the same as those for the active substance. Controls for CPPs and IPCs (including microbiologic contamination control) with process limits and acceptance criteria are established for the finished product manufacturing process to ensure consistent process performance and product quality. Hold times for thawing and pooled active substance have been adequately defined. A three-stage approach to validation of the finished product manufacturing process was followed: Stage 1 - Process Design, Stage 2 - Process Performance Qualification (PPQ) and Stage 3 - Continued Process Verification. The predefined PPQ requirement of the finished product batches was determined based on platform experience, process development knowledge and manufacturing history. PPQ batches are subject to increased scrutiny of process performance and extended sampling and testing, and encompass all unit operations of the finished product manufacturing process. The PPQ campaign was performed under cGMP conditions, with defined targets and/or ranges for process parameters equivalent to the NORs. All CPPs and KPPs were assessed per PPQ protocol. All process parameters were within all NORs and all outputs met all process validation limits and acceptance criteria. As a consequence, all validated ranges or limits are implemented as the commercial process NORs, PARs and IPCs process limits or IPC acceptance criteria. The consistency and reproducibility of the intermediate hold times were successfully validated during the PPQ campaign with the demonstration that the intermediate hold validation batches met all predefined validation criteria. Medicinal product no longer authorised

Results of shipping qualification for non-simulated shipment over a worst-case distance of the bulk finished product between China and a site in the US and back to China for testing have been further provided. It is concluded that there is no adverse effect on the tislelizumab finished product. The same conclusion results upon risk assessment of the second shipping configuration and associated shipment of bulk finished product from China to a secondary packaging site in Switzerland.

<div style=\"page-break-after: always\"></div>

## 2.4.3.3. Product specification

The release and shelf-life specification includes general tests, test for protein content, test for identity, purity and impurity tests for product-related impurities and heterogeneity, biological activity, as well as tests for safety parameters. Polysorbate 20 content is tested at both release and stability. Further, container closure integrity is tested during stability.

The general approach for selection of the attributes included in the finished product release and stability specification is based on clinical safety, efficacy, and pharmacokinetic analysis, statistical analysis of release and stability data and historical understanding of the finished product performance/formulation robustness studies. Further, compendial requirements are considered. Overall, the selection of specification attributes and setting of the acceptance criteria are in line with ICH Q6B and are found adequate to control the quality of the tislelizumab finished product. However, similar to the active substance specification, some adjustments/tightening of the acceptance criteria for biological activity, visible particles and bacterial endotoxin were performed upon request.

No additional process or product-related impurities are introduced or expected to form as a result of the finished product manufacturing. Therefore, finished product impurities are expected to be the same as those described in the active substance section. A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed, considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report - Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impuritie s in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary. In addition, the risk of extractable, leachables and elemental impurities is found sufficiently addressed and no additional controls are necessary, as stated in the active substance section. Analytical methods The finished product is tested using both compendial and non-compendial methods. Many of the methods used to test the finished product are equivalent to the methods used to test the active substance, since there is no compositional difference between the active substance and the finished product with respect to protein concentration or formulation. The only non-compendial method which is unique to finished product is determination of polysorbate 20 content, for which appropriate validation data in accordance with ICH guidelines have been provided. The applicant has declared that a new method employing a demasking procedure coupled with endotoxin determination is currently under development. Therefore, the applicant is recommended to communicate the outcome of method evaluation to the authority immediately upon finalisation (to be submitted as a Recommendation). Medicinal product no longer authorised

## Batch analysis

The data for all tislelizumab finished product batches used during clinical development and manufactured at the commercial manufacturing facility, demonstrate that all batches met the specifications in place at the time of release, are comparable across production sites and scales and confirm consistency of the manufacturing process.

## Reference materials

Reference is made to the corresponding active substance section.

<div style=\"page-break-after: always\"></div>

## 2.4.3.4. Stability of the product

The applicant claims a shelf-life for the finished product of 36 months when stored at 2°C to 8°C in the defined CCS.

Stability results for tislelizumab finished product stored under recommended long-term conditions (5°C ± 3°C) and under accelerated conditions (25°C ± 2°C, 60% ± 5% RH) are provided. Primary stability data are derived from finished product PPQ batches and from representative clinical finished product batches, all batches being manufactured at the commercial site and packaged in the CCS. Data from supportive stability clinical batches are also provided. All the primary and supportive stability finished product batches have the same formulation composition and protein concentration.

A photostability study was conducted in line with ICH Q1B and data obtained show no significant impact on the finished product quality after exposure to light. Nevertheless, the SmPC statement 'Store in the original carton in order to protect from light' is kept as a precaution due to optimal storage. This approach is considered acceptable. As discussed in the Pharmaceutical Development section, in-use stability of the diluted finished product solution has been demonstrated for 24 hours at 2°C to 8°C. The 24 hours include storage of the diluted solution under refrigeration (2°C to 8°C) for no more than 20 hours, time required for returning to room temperature (25°C or below) and time to complete the infusion within 4 hours. In summary, the stability data demonstrate that the tislelizumab finished product is stable at the recommended long-term storage condition of 2°C to 8°C, as mentioned in the SmPC, supporting the proposed shelf-life of 36 months. The applicant commits to conduct and complete the ongoing stability studies, which includes stability studies for process validation batches, according to the stability protocols. This approach is endorsed. 2.4.3.5. Post approval change management protocol(s) Two post-approval change management protocols (PACMPs) are included in Module 3.2.R of the dossier. The protocols concern: 1. Introduction of an additional active substance manufacturing and testing site. 2. Introduction of an additional finished product manufacturing site, as well as introduction of two additional finished product testing sites. Overall, the strategies provided in both PACMPs are considered adequate. Provided that the PACMPs are fulfilled and successfully implemented, it is agreed that the changes can be accepted. 2.4.3.6. Adventitious agents Transmissible spongiform encephalopathy (TSE) compliance Medicinal product no longer authorised

No animal-derived or human-derived components were used in the manufacture of the MCB and WCB. No animal-derived or human-derived components were used during cell line development and generation of the MCB. None of the raw materials used during manufacturing of active substance or finished product are of animal or human origin. No human or animal-derived excipients are used at formulation of the finished product. One animal-derived material, sheep-wool -derived cholesterol, was used in the development of the MHCB, which was transfected to generate MCB, for which a TSE Certificate was provided.

<div style=\"page-break-after: always\"></div>

In summary, compliance with ' Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3)' requirement has been demonstrated.

## Virus safety

The antibody is produced in a cell culture medium, free of animal or human-derived components. MCB and WCB and cells from end of production have been sufficiently tested for adventitious and endogenous viruses. The tests demonstrate the absence of viral contaminants. Only retrovirus-like particles have been detected, which is expected for this type of cells. A retroviral risk assessment demonstrated an excess reduction capacity for retroviral particles within manufacturing process. The presence of retroviral particles is therefore justified. The purification process includes four steps, including virus filtration, which all have been validated for their virus removal capacity of enveloped and non-enveloped viruses.

Overall, sufficient virus inactivation/removal capacity has been demonstrated. 2.4.3.7. GMO Not applicable. 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use. The applicant has applied QbD principles in the development of the active substance and/or finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the active substance, nor for the finished product. One major objection was raising during the assessment for the lack of valid EU GMP certificates for active substance and finished product sites, which has been adequately addressed by the end of the procedure. At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the benefit/risk ratio of the product, which pertain to the: 1) requirement to continue monitoring the glycan content at the active substance level until a sufficient number of batches has been manufactured to document manufacturing process consistency and 2) requirement to update the dossier with an optimised endotoxin test procedure once validation of the new procedure is finalised. These points are put forward and agreed as recommendations for future quality development. Medicinal product no longer authorised

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The Applicant proposes to monitor glycan content through a continued process verification protocol in which glycan content can be quantitatively monitored in all commercially manufactured active substance lots for the first year of manufacture, and trending analysis performed to ensure levels are not drifting or changing in a meaningful manner over time. A determination can then be made after the first year as to whether continued quantitative control of glycan content for active substance release testing is required. This approach is supported, provided that a sufficient number of active substance batches is manufactured to document manufacturing process consistency. The Applicant is recommended to follow this approach and submit a suitable variation application when sufficient data is available to support discontinued quantitative control of glycan content for active substance release testing.

<!-- image -->

The Applicant performed a wide panel of in vitro studies to characterise tislelizumab binding to its target PD.1 and its subsequent whished effect (i.e. re-activation of immune response). From the results shown, tislelizumab seems to specifically bind to PD-1 (and to cynomolgus PD-1, but not to murine PD-1) with KD in the order of 0.1-0.2 nM. EC50 values were calculated with different methods and in different experimental settings (e.g. ELISA and FACS) and they were in low nM order. Competition with PD-L1 and PD-L2 molecules was also tested with IC50 values of approximatively 0.5nM. Functional assays showed variable activity but with IC50 or EC50 again in low nM order (0.41.5 nM).

2. For the determination of bacterial endotoxin, low endotoxin recovery (LER) was observed in the finished product. The Applicant has declared that a new method employing a demasking procedure coupled with endotoxin determination is currently under development. The Applicant is recommended to communicate the outcome of method evaluation to the authorities immediately upon finalisation. Non-clinical aspects 2.4.7. Introduction Tislelizumab is a humanised IgG4 variant antibody derived from a murine hybridoma clone. The proposed mode of action consists in binding to the check-point molecule PD-1, blocking its signal transduction and consequently enhancing immune cell functions, possibly leading to inhibition of tumour growth in vivo. Tislelizumab has been mutated in the Fc region, in order to minimise the binding to Fc gamma receptors. Non-clinical studies are based on the requirements of the ICH S6 and S9 guidelines; therefore, a reduced package of studies was submitted. 2.4.8. Pharmacology 2.4.8.1. Primary pharmacodynamic studies Medicinal product no longer authorised

The activity of tislelizumab was investigated in several in vivo experiments. The experiments include also allogeneic xenograft models of epidermoid carcinoma, colon and lung cancers. In all studies

<div style=\"page-break-after: always\"></div>

presented, treatment with tislelizumab (10mg/kg, i.p QW or less) showed a decrease in tumour growth compared to controls. Although, animal survival was not an endpoint, in most of the studies tumour regression (not always long lasting) could be observed in some animals (Reports: R01-vivo-127 and 125 colon cancers). Of note, tumour inoculation had only marginal effect on animal weight and no significant difference could be noted between treated animals and controls.

## 2.4.8.2. Secondary pharmacodynamic studies

Since tislelizumab contains mutations to reduce Fc effector functions, several experiments were performed to verify a reduced binding to FcγRs and lack of ADCC and CDC activity.

Toxicokinetics: In the single dose study in monkeys, tislelizumab Cmax and AUC increased slightly more than dose-proportionally. T ½ ranged from 7-11 days, approximatively. In the 13-week repeat-dose study in monkeys, tislelizumab Cmax and AUC increased approximatively dose proportional at day 1. Slight accumulation between d1, d29 and d71 could be seen in the mid and high dose groups in male animals. The presence of ADA may have affected Cmax and AUC especially in the low dose group and potentially AUC for the mid and high-dose groups, nevertheless exposure was still present in the majority of the animals. Of note, results of the nAb assay indicate that the ADA were neutralising. Serum exposure in male and female monkeys was generally comparable after a single dose on Day 1 across the two IV dose groups. Serum exposure to tislelizumab in female monkeys was generally lower compared with those measured for male monkeys after repeated once every two weeks IV bolus doses on Day 71 across the two IV dose groups.

Dahan et al. 2015 report that Fcγ receptor engagement augments the anti -tumour activity of anti-PDL1 antibodies (Abs), but compromises the anti-tumour activity of anti-PD-1 Abs. These findings provide rationale for Fc engineering of these Abs to optimise anti-tumour efficacy. Lack of binding of tislelizumab to FcγR as compared to pembrolizumab and nivolumab was demonstrated in vitro. These interactions between anti-PD-1 antibodies with competent Fc have shown to significantly reduce their therapeutic efficacy for cancer treatment, likely due to the killing of T cells by antibody-mediated effector functions (such as ADCC). 2.4.8.3. Safety pharmacology programme Safety pharmacology parameters were assessed during the toxicology studies, please refer to the Toxicology section. 2.4.8.4. Pharmacodynamic drug interactions No pharmacodynamic drug interactions studies were submitted as part of this application. 2.4.9. Pharmacokinetics The PK behaviour of tislelizumab was investigated after single or repeat intravenous infusion administration to cynomolgus monkeys. The study P14-057-YD included three groups with single dose administrations of 3/10/30 mg/kg tislelizumab and one group with repeat-dose administration of tislelizumab 10mg/kg once weekly for four weeks with a total of five doses. There was no control group in this study. In the single dose groups, Cmax and exposure increased approximatively doseproportional. In the repeat-dose group, some accumulation could be noticed between d1 and d289, at least in male animals. Slight differences in PK parameters between female and male animals were observed. ADA were detected in the vast majority of the animals with possible impact on tislelizumab concentration. Medicinal product no longer authorised

Overall, PK parameters were compatible with the ones expected for monoclonal antibodies.

<div style=\"page-break-after: always\"></div>

## Distribution

No specific tissue-cross reactivity with tislelizumab was noted in cynomolgus monkey or human tissues. (study Nos O14-057-2ZJ and O14-057-1ZJ). A Retrogenix assay, was also performed, please refer to the section 'other toxicity studies' .

No animal studies have been conducted to assess the impact of tislelizumab on milk production or its presence in breast milk.

## Metabolism and excretion

No metabolism and excretion studies were performed. Pharmacokinetic drug interactions As there is minimal involvement of the cytochrome P450 system in the metabolism of monoclonal antibodies it is endorsed that no in vitro drug interaction studies with tislelizumab are conducted. 2.4.10. Toxicology 2.4.10.1. Single dose toxicity The Applicant performed a single-dose toxicology study in mice (m14-057-jd), where 0/30/100 mg/kg tislelizumab was administered IV once to 10 female and 10 male animal/group and followed by a 28day recovery period. Only a limited set of parameters was analysed: clinical observations, body weight, food consumption, upon necropsy: macroscopic evaluation (gross findings), the Applicant did not observe any sign of toxicity. Of note, no TK analysis performed so the exposure not known in this study. Importantly, the mouse is not the relevant animal species, since tislelizumab does not bind to murine PD-1. Moreover, the Applicant performed a single-dose toxicology study in monkeys (p14-057-jd), where 0/10/30/100 mg/kg tislelizumab was administered IV once to one female and one male animal/group and followed by a 28-day recovery period. The Applicant did not observe any sign of toxicity and set the MTD at 100mg/kg. ADA were detected in about 50% of the animals. 2.4.10.2. Repeat dose toxicity The Applicant performed a repeat-dose toxicology study in monkeys (p14-057-cd), where 0/3/10/30 mg/kg tislelizumab was administered IV once biweekly for 13 weeks to 6 animals/sex/group followed by a 6-week recovery period (the first 4 monkeys/sex/group were euthanised after 13-week of dosing on Day 91 and the remaining 2 monkeys/sex/group were euthanised on Day 133) following a 6-week recovery period. The Applicant did not observe any sign of toxicity and set the NOAEL at 30 mg/kg. Safety pharmacology parameters were incorporated in the toxicology studies and no effects were noted on parameters evaluating respiratory, neural or cardiovascular system. Importantly, the outcome of the triggered GLP inspection was negative. Results of an additional repeat-dose toxicity study in cynomolgus monkeys were submitted during the procedure. Doses of 0/30/60 mg/kg tislelizumab was administered IV once every two weeks for 13 weeks to 3 animals/sex/group or as two single doses (14 days apart to 3 males only) via subcutaneous injection (SQ). No sign of toxicity was observed at 30mg/kg, which was confirmed to be the NOAEL. However, in the 60 mg/kg IV group, a female had to be euthanised early at day 31. The causes were possibly attributed to immunogenicity. Medicinal product no longer authorised

## 2.4.10.3. Genotoxicity

No genotoxicity studies were performed as part of this application.

## 2.4.10.4. Carcinogenicity

No carcinogenicity studies were performed as part of this application.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.4.10.5. Reproductive and developmental toxicity

No dedicated in vivo studies reproductive and developmental toxicity studies were submitted as part of this application The applicant submitted a literature review on the effects of PD-1/PD-L1 on embryofoetal toxicity. The risk-assessment highlighted the important role of the PD-1/PD-L1 axes in pregnancy and foetal loss. Tislelizumab may cause foetal harm, increase rates of abortion or stillbirth or altering the normal immune response in foetuses if administered to a pregnant woman, which is acknowledged. Moreover, the effects of PD-1/PD-L1 on prenatal and postnatal development, including maternal function, suggest that inhibition of PD-1/PD-L1 pathway during pregnancy may cause or potentiate autoimmune diseases in infants. Examination of reproductive organs was performed during the 13-week repeat dose study, where no findings were reported.

A justification for not performing an environmental risk assessment was provided. As tislelizumab is a protein composed of natural amino acids, and proteins are expected to biodegrade in the environment and not pose a significant risk. Therefore, tislelizumab is exempt from preparation of an Environmental Risk Assessment as per the 'Guideline on the En vironmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00).

2.4.10.6. Toxicokinetic data 2.4.10.7. Local tolerance Local tolerance endpoints were included in the repeated dose toxicity study and no findings were reported. This is considered acceptable. 2.4.10.8. Other toxicity studies Other in vitro toxicity studies were performed in order to evaluate tislelizumab antigenicity, immunotoxicity and potential to induce cytokine release. The Applicant performed two tissue cross-reactivity studies on 30 human normal tissues (O14-0571ZJ) and 30 monkey normal tissues (O14-057-2ZJ). The GLP TCR studies submitted in the original application were not considered GLP compliant therefore the study results were replaced with Retrogenix assay. The Applicant performed a Retrogenix assay showing binding of tislelizumab to PD-1 on fixed and live human cells (HEK293 transfectants). The positive signals were further verified by FACS. Although for tislelizumab an Ab concentration much higher than the one of the positive control rituximab was used (20µg/ml versus 1µg/ml respectively), the signal appears to be strong and specific. The results of the Retrogenix assay identified a specific, although weak, off-target binding to TREML1, which was not sufficiently addressed in the current answer and the Applicant was asked to further investigate. In response, the Applicant provided an additional study investigating the potential binding of tislelizumab to TREML-1 via SPR. Two different assay formats were tested, one format had the antigen in solution (monovalent format) the other format had the antigen bound to the surface (avid format). None of the formats could confirm tislelizumab binding to TREML-1. Of note, the respective positive controls resulted in positive signals, as expected. Therefore, it is unlikely that VDT482 shows significant competition against the natural ligand of TREML1 and thus the weak interaction observed in the Retrogenix in vitro assay is not expected to have any physiological implication.' 2.4.11. Ecotoxicity/environmental risk assessment Medicinal product no longer authorised

## 2.4.12. Discussion on non-clinical aspects

Overall, the primary pharmacodynamic studies provided evidence that tislelizumab can bind to PD-1 receptor and can prevent the interaction with PD-1 ligands PD-L1 and PD-L2, avoiding PD-1-mediated

<div style=\"page-break-after: always\"></div>

inhibitory signalling. However, most experiments were performed in very artificial conditions showing binding to PD-1 transfectants, believed to have a very high target expression. Lack of binding of tislelizumab to FcγR as compared to pembrolizumab and ni volumab was demonstrated in vitro. These interactions between anti-PD-1 antibodies with competent Fc have shown to significantly reduce their therapeutic efficacy for cancer treatment, likely due to the killing of T cells by antibody-mediated effector functions (such as ADCC). However, how this would pan out in a disease animal model is not known. Therefore, a comparative study with nivolumab and pembrolizumab in an animal model to determine the lack of antibody effector function in vivo would have been supportive of the non-clinical proof of concept of tislelizumab. Therefore, more data on binding to unstimulated PBMCs (performed, but not shown) were requested. In vivo studies using murine xenograft tumour models and human PBMCs showed tislelizumab efficacy against several tumour cell lines.

The pharmacokinetics of tislelizumab were assessed in cynomolgus monkeys in a single-dose PK study and in the repeat-dose toxicity study after IV administration. This is appropriate as it reflects the clinical route of administration. ADA were detected in most of the animals and determined to be mostly neutralising. An impact on Cmax and AUC was evident especially in the low dose group and potentially also on AUC for the mid and high-dose group, nevertheless exposure was still present. Overall, these studies indicate that tislelizumab has pharmacokinetics typical for a mAb. The newly developed validation methods are considered fit for purpose and suitable to be used in support of the pivotal GLP toxicology study. As tislelizumab is expected to be degraded to small peptides and individual amino acids, the omission of metabolism and excretion studies is supported. As there is minimal involvement of the cytochrome P450 system in the metabolism of monoclonal antibodies it is endorsed that no in vitro drug interaction studies with tislelizumab are conducted. The toxicity of tislelizumab was evaluated in a single-dose toxicology study in mice (not relevant species) and in two studies in cynomolgus monkeys, the relevant species. The studies in monkeys were a single-dose toxicology study with tislelizumab IV up to 100 mg/kg, a first 13-week repeat-dose study with tislelizumab IV biweekly up to 30 mg/kg and an additional repeat-dose study, where 0/30/60 mg/kg tislelizumab was administered IV once every two weeks for 13 weeks to 3 animals/sex/group or as two single doses (14 days apart to 3 males only) via subcutaneous injection (SQ)+. In the first two studies, no signs of toxicity were observed. A MTD of 100mg/kg for the single dose study in monkeys and a no observed adverse effect level (NOAEL) at 30mg/kg for the repeat-dose study were set. In the additional repeat-dose study (Labcorp, USA) no sign of toxicity at 30mg/kg were observed, which was confirmed to be the NOAEL. However, in the 60 mg/kg IV group, a female has to be euthanised early at day 31. The causes were possibly attributed to immunogenicity.  ADA were detected in most of animals at low doses and in individual animals at mid and higher doses, however the exposure was maintained in almost all animals. In conclusion, in repeat-dose toxicology studies in cynomolgus monkeys with intravenous dose administration for 13 weeks at doses of 3, 10, 30 or 60 mg/kg every 2 weeks for 13 weeks (7 dose administrations), no apparent treatment-related toxicity or histopathological changes were observed at doses up to 30 mg/kg every 2 weeks, corresponding to 4.3 to 6.6 times the exposure in humans with the clinical dose of 200 mg. This is reflected in section 5.3 of the SmPC. Reproductive and developmental toxicity studies have not been conducted with tislelizumab. In line with ICH S9, omission of fertility/early embryonic development studies and of pre-/post-natal development studies is accepted. A weight of evidence approach, as outlined in ICH S6(R1) was applied to describe the potential risk of tislelizumab to human pregnancy, which is acceptable. Given the role of the PD-1/PD-L1 pathway in maintaining materno-fetal tolerance (in murine models of pregnancy, blockade of PD-1/PD-L1 signalling has been shown to disrupt tolerance to the foetus and to result in increased foetal loss, treatment with tislelizumab during pregnancy may lead to abortion or still births. Furthermore, tislelizumab is a monoclonal antibody and is expected to be present in breast milk. Because of the potential for serious Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

adverse drug reactions in breast-fed infants breastfeeding is not recommended during tislelizumab treatment and for at least 4 months after stopping treatment with tislelizumab.

This is reflected in section 4.6 of the SmPC.

No studies have been performed to assess the potential of tislelizumab for carcinogenicity or genotoxicity in line with ICH guideline S9 and ICH S6(R1).

Moreover, two tissue cross reactivity studies on cynomolgus and human normal tissues were performed, but their sensitivity was questioned. Therefore, a Retrogenix assay was performed in order to address the concerns. Results from this assay show binding to tislelizumab to PD-1 on fixed and live human cells (HEK293 transfectants). The positive signals were further verified by FACS. Although for tislelizumab an Ab concentration much higher than the one of the positive control Rituximab was used (20 µg/ml versus 1 µg/ml respectively), the signal appears to be strong and specific. These results, together with the data provided contributed to clear up the doubts about tislelizumab possible insufficient binding. However, the results of the Retrogenix assay identified a specific, although weak, off-target binding to TREML1, which needed to be further investigated. In response, an additional study investigating the potential binding of tislelizumab to TREML-1 via SPR was provided. Two different assay formats were tested, one format had the antigen in solution (monovalent format), the other format had the antigen bound to the surface (avid format). None of the formats could confirm tislelizumab binding to TREML-1. Of note, the respective positive controls resulted in positive signals, as expected. Therefore, in conclusion, it is unlikely that VDT482 shows significant competition against the natural ligand of TREML1 and thus the weak interaction observed in the Retrogenix in vitro assay is not expected to have any physiological implication. Importantly, the TCR and the first toxicological studies were performed in the facility of JOINN Laboratories (Beijing, China), which was not part of a compliance monitoring program of an EU monitoring authority and located in a non-OECD MAD country. A study-specific GLP inspection was triggered for studies P14-057-CD (13-week repeat-dose toxicity in monkeys), O14-057-2ZJ (TCR in monkey tissues) and O14-057-1ZJ (TCR in human tissues) A remote inspection was performed from 14/11/2022 to 18/11/2022. The final inspection report, dated 20/01/2023, indicated several critical and major findings and declared all the three studies as non OECD- GLP compliant. Several actions to mitigate the negative inspection outcome were proposed. A new in vivo 13-week repeat-dose toxicology study for tislelizumab in a GLP-compliant facility (Labcorp, USA) was initiated. Considering the new study results confirming the NOAEL at 30mg/kg, the results of additional tests confirming the specific binding of tislelizumab to PD-1, the wellknown target and that 'nonclinical toxicity studies in nonhuman primates have been poor in predicting clinical toxicities for antibodies mediating immune checkpoint blockade (Wang et al 2014)', the GLP inspections findings were considered solved. Several other in vitro toxicity studies were performed in order to evaluate tislelizumab antigenicity, immunotoxicity and potential to induce cytokine release. Beside the potential of tislelizumab to induce neutralising ADA and to possibly induce an enhanced recall response to the re-challenge antigen, no other toxicities were detected. Medicinal product no longer authorised

Regarding ecotoxicity, the active substance is a natural substance, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, tislelizumab is not expected to pose a risk to the environment.

## 2.4.13. Conclusion on the non-clinical aspects

Overall, the package of in vitro and in vivo non-clinical studies with tislelizumab is adequate and is supportive of market approval for Tizveni.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical aspect

## 2.5.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

<!-- image -->

| Study Status   | Study Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Treatments and target dose regimen                    | Patients randomised (N)      |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|------------------------------|
| 001 Completed  | Phase I, open-label, multiple-dose, dose- escalation and expansion study investigating the safety, tolerability, PK, and antitumour activity of tislelizumab in patients with advanced tumours, including NSCLC. Participating countries: Australia, New Zealand, South Korea, Taiwan, United States (27 centres) longer                                                                                                                                                                                                       | 0.5/2/5/10 mg/kg Q2W, 2/5 mg/kg Q3W, and 200 mg Q3W   | 451 enrolled (49 with NSCLC) |
| 102 Completed  | Phase I/II multicentre, open-label, study in Chinese patients with advanced solid tumours. The Phase I portion assessed safety, tolerability, PK characteristics, preliminary antitumour activity, and determined the MTD and/or RP2D of tislelizumab. The Phase II portion was conducted as an indication-expansion study to further assess the safety, PK, and preliminary efficacy in patients with malignant solid tumours, including cohorts in patients with NSCLC. Participating country: China (16 centres) product no | 200mg Q3W                                             | 300 enrolled (56 with NSCLC) |
| 303 Ongoing    | Phase III, randomised, open-label, multicentre study in adult patients with histologically confirmed, locally advanced or metastatic NSCLC (squamous or nonsquamous) who had disease progression during or after a platinum- containing regimen to investigate the efficacy and safety of tislelizumab compared with docetaxel. Participating countries: China, Bulgaria, Brazil, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, Turkey. Medicinal                                                                  | Tislelizumab 200 mg iv Q3W Docetaxel 75 mg/m 2 iv Q3W | 535 270 Total: 805           |
| 307            | Phase III, multicentre, randomised, open- label study to compare the efficacy and Arm                                                                                                                                                                                                                                                                                                                                                                                                                                          | T+PC                                                  | T+PC: 120                    |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Ongoing safety of tislelizumab combined with paclitaxel plus carboplatin or nabpaclitaxel plus carboplatin vs. paclitaxel plus carboplatin alone as first-line treatment for untreated advanced squamous NSCLC.

Participating country:

China

Tislelizumab 200 mg iv D1 Q3W Paclitaxel 175 mg/m 2  D1 Q3W Carboplatin AUC 5 D1 Q3W (Paclitaxel and carboplatin administered 4-6 cycles)

Arm T+nPC

Tislelizumab 200 mg iv D1 Q3W

Nab-paclitaxel 100 mg/m 2  D1, 8,

15 Q3W

Carboplatin AUC 5 D1 Q3W (Nab-paclitaxel and carboplatin administered 4-6 cycles)

Arm PC* Paclitaxel 175 mg/m 2  D1 Q3W Carboplatin AUC 5 D1 Q3W (Paclitaxel and carboplatin administered 4-6 cycles) *Optional crossover to receive tislelizumab 200 mg iv upon disease progression. Phase III, multicentre, randomised study to investigate the efficacy and safety of tislelizumab combined with platinumpemetrexed vs. platinum-pemetrexed alone as first-line treatment for patients with Stage IIIB or IV nonsquamous NSCLC. Participating country: Induction Phase: Arm T+PP Pemetrexed 500 mg/m 2 (Chemotherapy administered 4-6 cycles Q3W) Arm PP Pemetrexed 500 mg/m 2 (Chemotherapy administered 4-6 cycles q3w) Maintenance Phase: Tislelizumab 200 mg iv D1 Q3W Pemetrexed 500 mg/m 2  Q3W Arm PP* Pemetrexed 500 mg/m 2  Q3W Medicinal product no longer authorised

T+nPC: 119

PC: 121

Total: 360

304 Ongoing

China

Tislelizumab 200 mg iv D1 Q3W

Cisplatin 75 mg/m 2  or carboplatin

AUC 5

Cisplatin 75 mg/m 2  or carboplatin

AUC 5

Arm T+PP

*Optional crossover to receive tislelizumab 200 mg iv upon disease progression.

T+PP: 223

PP: 111

Total:334

<div style=\"page-break-after: always\"></div>

## 2.5.2. Clinical pharmacology

## 2.6.2.1   Pharmacokinetics

Clinical studies that contributed to the characterisation of the clinical pharmacology properties of tislelizumab are presented in Table 2. Dose ranges from 0.5 to 10 mg/kg Q2W, 2 and 5 mg/kg Q3W, and 200 mg Q3W, all administered as intravenous infusions over 30 to 60 minutes were studied. Sparse PK samples were collected in Phase I, II, and III studies that tested the recommended dose of 200 mg Q3W. PK data from the studies presented in Table 2 were also used in the popPK analysis and to characterise ER relationships.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

The number of patients by age group for the 12 studies of the PopPK dataset is provided in the table below. Table 3: Number of patients by age group in the 12 studies included in the PopPK dataset Analytical methods Two quantitative indirect enzyme immunoassay methods were validated and used for measurement of tislelizumab in human serum. The first analytical laboratory method in serum was developed and fully validated at Australia CPR Pharma Service (VAL136). This method was then transferred to Covance and fully validated at their Shanghai laboratory (8354-363). In addition, a formal cross-validation has been performed to verify that PK data obtained at different laboratories (method VAL136 and method 8354363) are reliable and comparable. A validated antidrug antibody (ADA) electro-chemiluminescent (ECL) immunoassay utilizing the Meso Scale Discovery (MSD) technology was used for determination of anti-tislelizumab antibodies in human serum from clinical studies. Detection of ADAs was performed in 3 steps: a screening assay; a confirmation assay and a titration assay to estimate the level of antibody in confirmed positive samples. A validated competitive ECL ligand-binding assay utilizing MSD technology was applied for detection of neutralizing antibodies (NAbs) to tislelizumab. Medicinal product no longer authorised

## PK data analysis

In the early studies (BGB-A317-001 and BGB-A317-102), PK parameters were derived using standard noncompartmental methods with WinNonlin Professional or SAS.

In addition, a popPK model was developed from the full PK analysis dataset consisting of 12 studies (Studies 001, 102, 203, 204, 205, 206, 208, 209, 302, 303, 304, and 307, see Table 4) to quantitatively describe the PK properties of tislelizumab and identify sources of interindividual variability.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Region       | Study No.    | Tite                                                                                                                                                                                                              | Phase   | Dose Regimen                                                      | Planned N   |
|--------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------|-------------|
| Global       | BGB-A317-001 | Safety.Phamcokinetics andAntirmorActivitiesoftheani-PD-1 MonoclonalAntibodyBGB-A317n A Phase lA/1B.OpenLabel Multiple Dose,Dose Escalation and Expansion Study to Investigate the Subjects with Advanced Tumors   | la/lb   | 2mgkgor5mg/kgQ3w: 0.5mg/kg.2mgkg.5 mg/kg.or10mgkgQ2W: and200mgO3w | 451         |
| China        | BGB-A317-102 | Activities ofAnti-PD-1 Monoclonal Antbody BGB-A317in ChinesePatients withAdvanced Solid Tumors                                                                                                                    | 12      | 200 mgQ3W                                                         | 300         |
| China        | BGB-A317-203 | ASingleAMuticenterPhase2StudyofBGB-A317asMonotherapyinRelapsedorRefactory Classical Hodgkin Lympboma                                                                                                              | 2       | 200mgQ3W                                                          | 70          |
| China/ Korea | BGB-A317-204 | Locally Advanced or Metastatic Urothelial Bladder Cancer A Single-AnmMulticenter Phase 2 Study of BGB-A317 in Patients with Previously Treated PD-L1+                                                             | 2       | 200mgQ3W                                                          | 113         |
| China        | BGB-A317-205 | Activity ofthe ant-PD.1Monoclonal Annbody BGB-A317inCombinationwithChemotherapyasFirst- LineTreatment in Adults with InoperableLocallyAdvanced orMetastaticEsophagealGastic,or Gastroesophageal Jumction Carcinom | 2       | 200mgQ3W                                                          | 30          |
|              |              | and Pharmacokinetics of the anti-PD.1 Monoclonal Annbody BGB-A317 in Combination with                                                                                                                             | 2       |                                                                   |             |

Table 4: Summary of studies included in the PopPK analysis

<!-- image -->

A 3-compartment model with first order elimination from the central compartment, and redistribution into the peripheral compartments best characterised tislelizumab PK following IV administration. Medicinal product no longer authorised

Parameter estimates for the final PopPK model for tislelizumab are presented in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5: Summary of final population PK parameters

<!-- image -->

|    | authorised   |
|----|--------------|
|    | longer       |
| no |              |

The general goodness-of-fit plots of the final PopPK model are shown in Figure 7 and Figure 8, where a good agreement between the predicted concentrations and the observed concentrations was observed and no apparent bias was observed in the residuals plots over time and across predicted concentrations.

In Amendment 1 to the popPK report, discrepancies regarding the baseline body weight of two subjects from BGB-A317-302 study were corrected and PK parameters were re-estimated using the final PopPK model and the updated PopPK dataset with corrected weights. The estimated PK parameters using updated dataset were almost identical to those reported in the original PopPK report, with some minor differences in second decimal place. Evaluation and Qualification of popPK model The final PopPK model was evaluated with multiple model qualification/validation methods, including goodness-of-fit (GOF) plots, prediction-corrected visual predictive check (pcVPC), numerical predictive check (NPC), bootstrap, and shrinkage assessments. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 3: Predicted versus observed concentration for the final PopPK model Medicinal product no longer authorised relationshipbetween2variables.

Figure 4: Residual diagnostic plots for the final PopPK model

The ability of the final popPK model to reproduce the distribution of the tislelizumab concentration data over time was evaluated using pcVPC based on 1000 simulated replicates of the original dataset. The pcVPC plots showed that the observed median, 2.5th and 97.5th %tiles of the concentration-time profiles were generally contained within the simulation-based 95% confidence intervals for the corresponding model predicted median and 2.5th and 97.5 th  %tiles. These results suggest that the

<div style=\"page-break-after: always\"></div>

final popPK model adequately predicted the central tendency and variability of the serum tislelizumab concentrations following IV administration.

<!-- image -->

Figure 5: Prediction-corrected visual predictive check of tislelizumab serum concentration time profiles across all studies Absorption In study 001, noncompartmental PK analysis revealed a Cmax after the first dose of tislelizumab (200 mg Q3W) of 76.1 µg/mL. In Cycle 4 or Cycle 5, Cmax was determined to be 89.5 µg/mL. In study 102, Cmax in Cycle 1 and Cycle 5 was determined to be 66.5 µg/mL and 126 µg/mL, respectively. The estimate for steady-state Cmax derived by population PK analysis was 110 μg/mL. 100% bioavailability is expected as tislelizumab is administered by iv infusion. Distribution Noncompartmental analysis: Medicinal product no longer authorised

In study 102, geometric mean VSS (Cycle 5) was determined to be 4.04 L.

## Population PK analysis:

The steady-state volume of distribution is 6.42 L. Vc, V2, and V3 were estimated to be 3.05 L, 1.27 L, and 2.10 L, respectively.

<div style=\"page-break-after: always\"></div>

## Elimination

Noncompartmental analysis:

After 200 mg intravenous tislelizumab dosing, mean CL determined in Cycle 1 and Cycle 5 of study 001 were 0.186 and 0.242 L/day. The apparent terminal t½ estimated in Cycle 1 and Cycle 5 was 15.9 days and 14.9 days, respectively.

In study 102, clearance values determined in Cycle 1 and Cycle 5 after dosing with 200 mg tislelizumab Q3W were 0.233 and 0.186 L/day, respectively. The apparent half-lives (t½ values) estimated in Cycle 1 and Cycle 5 were 12.9 and 16.6 days, respectively.

Population PK analysis: The geometric mean elimination half-life was estimated to be 23.8 days. Clearance was estimated to be 0.153 L/day. Tislelizumab as monoclonal antibody is metabolised by protein catabolism via the reticuloendothelial system or target-mediated disposition. Due to its large molecular size, renal excretion of intact tislelizumab is unlikely. Dose proportionality and time dependencies In study 001, drug exposure (Cmax and AUC0-14d) increased in a dose-proportional manner from 0.5 mg/kg to 10 mg/kg both after the first dose administration and at Cycle 4/5, corresponding to steady state. The accumulation indices in study 001 were 1.21 and 1.60 determined by the ratio of steady-state and first dose of Cmax and AUC0-tau, respectively. In study 102, the accumulation index ranged between 1.87 and 2.13 determined by PK exposures (ratio of steady-state and first dose of AUC0-tau, Cmax, and predose Ctrough). Referring to the population PK analysis, the accumulation ratios are 2.14, 1.62, and 2.49 for AUCss, Cmax,ss and Cmin,ss. PK in target population Study BGB-A317-303 (Study 303) A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGBA317 (Anti-PD-1 Antibody) Compared With Docetaxel in Patients with Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen. A total of 534 patients received tislelizumab at a dose of 200 mg administered intravenously Q3W. Study treatment continued until disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first. Medicinal product no longer authorised

As of the data cutoff date, geometric means of predose (Cycle 1, 2, 5, 9, and 17) and postdose (Cycle 1 and 5) serum concentrations after the intravenous doses of tislelizumab 200 mg Q3W, summarised by study cycles up to Cycle 17, are presented in Table 6. A total of 532 patients were included in the PK data analysis set.

<div style=\"page-break-after: always\"></div>

Table 6. Summary of tislelizumab serum concentrations in study 303 (PK analysis set)

|         | Tislelizumabconcentrations(μg/mL)   | Tislelizumabconcentrations(μg/mL)   |
|---------|-------------------------------------|-------------------------------------|
| Visit   | Predose (Cmin) GM (GCV%)            | Postdose(Cmax) GM (GCV%)            |
| Cycle 1 | NCa (n=519)                         | 68.4 (27.3%) (n=517)                |
| Cycle 2 | 16.0 (36.9%) (n=493)                | NA                                  |
| Cycle 5 | 33.8(38.3%) (n= 329)                | 100.8(27.5%) (n=329)                |
| Cycle 9 | 40.7 (48.0%) (n=224)                | NA                                  |

Study BGB-A317-304 (Study 304) A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus PlatinumPemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV NonSquamous Non-Small Cell Lung Cancer. Study 304 is an ongoing, open-label, multicentre, randomised Phase III study designed to compare the efficacy and safety of tislelizumab combined with platinum (cisplatin or carboplatin) and pemetrexed versus platinum (cisplatin or carboplatin) and pemetrexed alone as first-line treatment in patients who have Stage IIIB or IV non-squamous NSCLC, whereby the choice of platinum (cisplatin or carboplatin) was at the investigator's discretion. As of the data cutoff date, total of 334 patients were random ised of which 222 patients received 200 mg of tislelizumab in combination with pemetrexed and platinum. Pharmacokinetic data were available for a total of 222 patients (1185 samples with 961 observed values and 224 below the limit of quantification samples) following treatment with tislelizumab 200 mg every 3 weeks administered as an iv infusion over 30 to 60 minutes (60 minutes for the first dose; if well-tolerated, 30 minutes for the rest of doses). The exclusion percentage for tislelizumab was 3.71% (44/1185 samples). As of the data cutoff date, the mean (± standard deviation), Ctrough (predose), and Cmax (postdose) following the iv doses of tislelizumab 200 mg every 3 weeks up to Cycle 17, were presented in Table 7. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | TislelizumabConcentrations(μg/mL)   | TislelizumabConcentrations(μg/mL)   |
|-----------|-------------------------------------|-------------------------------------|
| Timepoint | Cycle                               | T+PP                                |
| Pre-Dose  | Cycle1                              | NCa(n=219)                          |
|           | Cycle 2                             | 16.4±5.75(n=202)                    |
|           | Cycle5                              | 38.2±14.39(n=162）                   |
|           | Cycle9                              | 47.8±17.46(n=107)                   |
|           | Cycle 17                            | 61.3±19.85(n=18)                    |

Table 7: Summary of tislelizumab serum concentration (mean Plus/Minus standard deviation) (PK analysis set)

<!-- image -->

<!-- image -->

Study BGB-A317-307 (Study 307) Study 307 is an ongoing open-label, randomised, multicentre Phase III study designed to compare the efficacy and safety of tislelizumab combined with carboplatin and either paclitaxel (Arm T+PC) or nabpaclitaxel (Arm T+nPC) versus paclitaxel plus carboplatin alone (Arm PC) as first-line treatment in patients with untreated Stage IIIB or IV squamous NSCLC. As of the data cutoff date, total of 360 patients were randomised of which 120 patients received 200 mg of tislelizumab in combination with paclitaxel and 118 patients received 200 mg of tislelizumab in combination with nab-paclitaxel. Pharmacokinetic data were available for a total of 238 patients (1222 samples with 983 observed values and 239 below the limit of quantification samples) following treatment with tislelizumab 200 mg every 3 weeks administered as an intravenous infusion over 30 to 60 minutes (60 minutes for the first dose; if well-tolerated, 30 minutes for the rest of doses). As of the data cutoff date, the mean (±SD) Ctrough (predose) and Cmax (postdose) following the intravenous doses of tislelizumab 200 mg every 3 weeks, stratified by treatment cohorts up to Cycle 17, were presented in the below table. Table 8: Summary of tislelizumab serum concentration (mean +/- standard deviation) (PK analysis set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## PK in special populations

In the population PK model, baseline body weight, albumin level, tumour size of solid tumours, ADA status (treatment-emergent ADA), and tumour type were identified as significant covariates on CL. Baseline body weight, sex, and age were identified as significant covariates on Vc.

<!-- image -->

Medicinal product no longer authorised

Figure 6: Sensitivity analysis plot comparing the effect of covariates on tislelizumab steady state exposure (AUCss, Cmaxss and Cminss)

## Impaired renal function

Renal function was not identified as a significant covariate. No dedicated studies of tislelizumab have been conducted in patients with renal impairment. In the population PK analyses of tislelizumab, no clinically relevant differences in the clearance of tislelizumab were found between patients with mild

<div style=\"page-break-after: always\"></div>

renal impairment (CLCr 60 to 89 ml/min, n = 1 046) or moderate renal impairment (CLCr 30 to 59 ml/min, n = 320) and patients with normal renal function (CLCr ≥90 ml/min, n = 1 223) ( Figure 7).

<!-- image -->

Figure 7: Steady-state tislelizumab exposure by renal function Impaired hepatic function No dedicated studies of tislelizumab have been conducted in patients with hepatic impairment. The liver function laboratory tests (AST, ALT, or total bilirubin) were not found to be significant covariates on tislelizumab PK in the popPK analysis. The mean simulated exposures (AUCss, Cmax,ss and Cmin,ss) in mild, moderate, or severe hepatic impairment were up to 8.71% lower, 15.4% lower, and 9.12% lower, respectively, compared with those of  subjects with normal hepatic function. Comparing popPK model-predicted exposures between different impairment groups, no clinically relevant effect of hepatic function was noticeable on the PK of tislelizumab. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 8: Steady-state tislelizumab exposure by hepatic function Gender Gender was found to be a significant covariate on the Vc (volume of distribution in the central compartment). The typical Vc estimate was 11% lower for female than male patients. The geometric mean of simulated exposures (AUCss, Cmax,ss and Cmin,ss) in female subjects was 14.7% to 19.0% higher compared with those of male subjects. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 9: Simulated steady-state exposures of tislelizumab by gender following 200mg and Q3W dosing Race The popPK analysis showed that race was not a significant covariate on the PK parameters (CL and Vc) of tislelizumab and had no clinical relevance on tislelizumab PK exposure. Subsequent simulations indicated that overall range of tislelizumab exposure after 200 mg Q3W is largely overlapped between the Asian and white patients, as shown below. The simulated geometric mean exposures (AUCss, Cmax,ss, and Cmin,ss) of the Asian patient population (the majority of Asian patients are Chinese) from 12 studies were approximately 12% to 21% higher than those of white patients. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 10: Simulated steady-state exposures of tislelizumab by race following 200mg Q3W dosing Weight Body weight was identified as a significant covariate on the CL and Vc of tislelizumab in the final PopPK model. Increased body weight was associated with increased CL and Vc values. Therefore, subjects with higher body weight are predicted to have lower exposure. The geometric mean simulated exposures (AUCss, Cmax,ss and Cmin,ss) in the lowest and highest quartile of body weight were up to 14.5% higher and 17.3% lower, respectively, compared with those of the overall population. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 11: Simulated steady-state exposures of tislelizumab by body weight quartiles following 200mg and Q3W dosing Because body weight was identified as a significant covariate on clearance, simulations were performed to compare the exposure produced with the 200 mg Q3W flat dose regimen with those produced with a hypothetical 3 mg/kg Q3W body weight based dose to further understand the effect of body-weight distribution on dosing. The overall difference in geometric means of all summary exposure measures between the two dosing scenarios was &lt;4%, with similar variability (% CV) (Table 9). Although predicted exposures were higher in patients with lower body weight receiving the flat dosing regimen, the median and 90% prediction intervals of tislelizumab summary exposures across the body weight range was maintained well within the range of 2 -5 mg/kg Q3W (therapeutic range established in FIH study 001), and well below the corresponding median exposures observed with tislelizumab 10 mg/kg Q2W, the clinically established highest, safe and tolerable dose. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 9: Comparison of summary of exposures between flat and body weight-based dosing regimens

| Summary exposure   | 3mg/kgQ3W             | 3mg/kgQ3W         | 200mgQ3W            | 200mgQ3W         |
|--------------------|-----------------------|-------------------|---------------------|------------------|
| Summary exposure   | GeometricMIean (% CV) | Mledian [P05,P95] | GeometricMean (% C) | Median [P05,P95] |
| AUC1 (μg*day/mL)   | 583 (20.7)            | 584[418,818]      | 601 (17.7)          | 601[446,799]     |
| Cmax1 (μg/mL)      | 65.8 (18.9)           | 65.4[49.0,89.4]   | 67.8 (18.1)         | 67.3[51.1,92.1]  |

<!-- image -->

<!-- image -->

|         | no   |
|---------|------|
| product |      |

Additionally, the predicted steady state exposures stratified by body weight quartiles are presented in Table below. The geometric mean simulated exposures (AUCss, Cmax,ss and Cmin,ss) in the lowest or highest quartile of body weight were up to 14.5% higher and 17.3% lower, respectively, compared with those of the overall population. Table 10: Comparison of the predicted steady-state exposures in patients stratified by body weight quartiles Further data were provided demonstrating that observed concentrations and the medians across various dose levels are in a similar range between patients with BW &lt; 89 kg and ≥ 89 kg (p95 of body weight). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 12: Observed tislelizumab concentrations stratified by dose and body weight groups (PopPK dataset) Further, PopPK-predicted tislelizumab exposure metrics (AUC, Cmax, Cmin, and Cavg) after 200 mg Q3W at dose 1 and steady-state in patients with 2L ESCC (Study 302) and NSCLC (Studies 303, 304, and 307) are shown in Figure 2-5 and Figure 2-6. These figures further show the overlapping exposure in patients with BW &lt; 89 kg and BW &gt; 89 kg, suggesting that BW is not the only covariate that affects tislelizumab PK. Other factors, such as baseline albumin level, tumour size, ADA status, tumour type, gender, and age, also contribute to the difference in PK. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Geometric mean (%CV) of simulated steady-state exposure metrics of tislelizumab at 200 mg Q3W for all patients in the PopPK dataset comparing BW &lt; 89 kg and BW ≥ 89 kg.

<div style=\"page-break-after: always\"></div>

Table 11: Geometric mean (%CV) of simulated steady-state exposure metrics of tislelizumab at 200 mg Q3W

| Characteristics        | BW<89kg         | BW≥89kg         |
|------------------------|-----------------|-----------------|
| No. of subjects, N (%) | 2463 (94.9)     | 133 (5.1)       |
| Cmin,ss (μg/mL)        | 40.67 (37.05)   | 30.34 (40.12)   |
| Cmax,ss (μg/mL)        | 110.03 (21.4)   | 88.43 (19.6)    |
| AUC,ss (μg*day/mL)     | 1270.49 (27.32) | 1002.57 (28.11) |
| CL (L/day)             | 0.15 (28.06)    | 0.2 (28.52)     |

<!-- image -->

Elderly Baseline age was identified as a significant covariate on the Vc of tislelizumab in the final popPK model. The estimates of Vc at 10th and 90th percentile of age distribution (45 to 71-year-old) were within 3% of the typical estimate of Vc at median age of 60. The predicted steady-state exposures after 200 mg Q3W dosing for subjects stratified by age groups are presented in Figure below. Medicinal product no longer authorised

Abbreviations:AUCs,areaundertheserumconcentration-imecurve atsteady-state;CL,clearance; Cmin.ss,minimumserumconcentrationatsteady-state;PK,pharmacokinetic(s).

Notes:Thesteady-state exposures(Cmin.ss andAuCss) of tislelizumabwere computed foreach patient. AUC, was calculated as dose/CL. Cmin.ss was calculated as the minimum concentration on the 21st dayafterthe10thconsecutivedosesoftislelizumab200mgQ3W[PopPKReport-Section5.5and Section 5.6].

Thedashedredhorizontallinerepresentsthemeanoftheoverallpopulation.

Figure 15: simulated steady-state exposures of tislelizumab by age group after 200 mg Q3W dosing

<div style=\"page-break-after: always\"></div>

## Children

Tislelizumab has no study conducted in paediatric subjects.

In the presentation of variability in special populations, the Applicant notes in several instances that \"These differences were small relative to the overall variability of exposures and are not considered clinically significant\". The variability values were obtained by taking the largest differences between the 5th and 95th percentile exposures in the overall population compared to the typical individual, which are ~ 55.8%, 47.3%, and 70.8% for AUC,ss, Cmax,ss, and Cmin,ss, respectively. Based on the data provided, it is agreed that the variability in the special populations is small compared to the overall variability.

<!-- image -->

Impact of ADA on PK In the Phase III Studies 302, 303, 304, and 307, patients who tested positive for treatment-emergent ADA had slightly lower trough tislelizumab concentrations as compared to patients who were ADA negative. However, the serum concentrations in the treatment-emergent ADA-positive patients were within the range observed in ADA-negative patients. The effect of immunogenicity (ADA) on PK was further evaluated by treatment-emergent ADA status in the popPK model. The subject-level ADA status was identified as a significant covariate on the CL of tislelizumab in the final PopPK model, where ADA positive status was associated with a slightly increased CL compared with ADA negative status. The predicted steady state exposures following 200 mg Q3W dosing stratified by ADA are presented below. The geometric mean simulated exposures (AUCss, Cmax,ss and Cmin,ss) in ADA positive subjects were up to 20.5% lower compared with those of in ADA negative subjects (Table below). Table 12: Geometric mean (%CV) simulated steady state exposure of tislelizumab by ADA status following 200mg Q3W dosing Medicinal product no longer authorised

%difference from the geometric mean simulated exposures of the ADA negative subjects in the overall a. population.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 16: Simulated steady state exposure of tislelizumab by ADA following 200mg Q3W dosing Pharmacokinetic interaction studies No formal drug-drug interaction studies have been conducted with tislelizumab. The drug interaction potential of tislelizumab is expected to be low based on the nature of therapeutic antibody drugs and the knowledge on antibodies of the same class of PD-1 checkpoint inhibitors. Population PK analysis: Single or combination therapy was not tested during the PopPK covariate model development because multiple chemotherapeutic combination regimens were included in many tumour types (i.e. NPC, GC, EC, and NSCLC) and studies (i.e. 205, 206, 304, 307, and 309). The impact of combination therapy on the covariate-adjusted tislelizumab PK parameters (CL and Vc) were evaluated in post hoc analysis based on the final model are illustrated in Figure 17 . The result suggested a significant correlation (p &lt; 0.0001) between the covariate-adjusted CL and therapy. In order to evaluate the impact of therapy on tislelizumab exposure, the predicted steady state exposures following 200 mg Q3W dosing were summarised and plotted by therapy ( Table 13 and Figure 18 ). The mean simulated exposures (AUCss, Cmax,ss and Cmin,ss) in subjects with combination therapy were up to 8.79% higher compared with those of  subjects with monotherapy in the overall population. These differences were very small relative to the overall variability of exposures and are not considered clinically significant. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

pvalue&lt;0.0001(n=2586)

pvalue=0.245(n=2586)

Race

<!-- image -->

Figure 17: Impact of therapy on the covariate-adjusted tislelizumab CL and Vc based on the final PopPK model Table 13: Geometric mean (%CV) simulated steady state exposure of tislelizumab by therapy following 200mg Q3W dosing Medicinal product no longer authorised

|           | product no   |
|-----------|--------------|
| Medicinal |              |
| Medicinal |              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Immunogenicity

Figure 18: Simulated steady state exposure of tislelizumab by therapy following 200 mg Q3W dosing 2.6.2.2 Pharmacodynamics Throughout the clinical studies, no specific pharmacodynamic endpoints were investigated. Exposure-response (E-R) analyses were performed to understand the relationships between PK and efficacy, as well as safety parameters. These analyses support the proposed dosing regimen of 200 mg Q3W. The immunogenicity profile of tislelizumab and its impact on PK, safety, and efficacy in the NSCLC population has been characterised. Mechanism of action Tislelizumab is a humanised IgG4 variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1 with high specificity and affinity (KD = 0.15 nM). It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling, and enhancing the functional activity in T-cells in in vitro cell-based assays. Tislelizumab does not bind to Fc gamma receptors and C1q and therefore does not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. Medicinal product no longer authorised

Immunogenicity data are available from 10 clinical studies of tislelizumab administered as a monotherapy (Studies 001, 102, 203, 204, 208, 302, and 303) or in combination with chemotherapy (Studies 206, 304, and 307) in patients with different tumour types.

Monitoring of antidrug antibodies (ADA) to tislelizumab and titre determination for confirmed positive ADA samples has been performed. Neutralizing antibodies (NAbs) were evaluated in the confirmed positive ADA samples.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Tislelizumab monotherapy

Among 1424 evaluable patients treated with tislelizumab 200 mg Q3W as monotherapy, 232 (16.3%) had treatment-emergent ADA, of which 224 (15.7%) had treatment-induced ADA, and 8 (0.6%) had treatment-boosted ADA, and 11 (0.6%) had neutralizing antibodies (Table below).

## Tislelizumab combination therapy

Among 492 evaluable patients treated with tislelizumab 200 mg Q3W in combination with platinumcontaining chemotherapy (Studies 206, 304, and 307), 118 (24.0%) had treatment-emergent ADA, of whom 114 (23.2%) had treatment-induced ADA and 4 (0.8%) had treatment-boosted ADA, and 7 (1.4%) had NAb (Table 14). Transient ADA (14.8%) were more common than persistent ADA (8.3%), although this may reflect the limited sampling schedule in these studies (predose of Cycles 1, 2, 5, 9, and 17).

<!-- image -->

Higher ADA incidence rates were observed in White vs. Asian patients (21.0% vs. 14.3%) and also in Europe/North America vs. Asia (24.4% vs. 15.2%), although exposure-response analyses revealed that the difference in ADA incidence rates between White and Asian patients is not associated with altered clinical efficacy and safety.

Table 14: ADA incidence by dose regimen -Studies 001, 102, 203, 204, 206, 208, 302, 303, 304 and 307 (ADA evaluable patients) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Onset and duration

The onset and duration of treatment-induced, persistent, and transient ADA were comparable across the studies. Most patients with treatment-induced ADA, persistent or transient, developed the ADA by the second dose (Cycle 2 Day 1; Study Day 22 ± 4 days) and before the third dose of the Q3W regimen ( Table 15 ).

Table 15: Onset and duration (days) of treatment induced ADA -Studies 001, 102, 203, 204, 208, 302, 303, 304 and 307 (ADA evaluable patients)

| Treatment-inducedADA   | PersistentADA   | TransientADA   | TransientADA   |
|------------------------|-----------------|----------------|----------------|

<!-- image -->

Median titre levels The median titre levels generally fluctuated between 10 and 100 over time. Higher titres ≥1000 were observed in some patients in Studies 304 and 307 at isolated timelines during treatment with tislelizumab in combination with chemotherapy. Individual titre values for most patients did not increase over the course of the studies. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Impact of ADA on clinical efficacy

| authorised   | authorised   | authorised   |
|--------------|--------------|--------------|
| longer       | longer       | longer       |
|              | no           |              |

<!-- image -->

Table 16: Clinical response endpoints after tislelizumab treatment by ADA status in all patients -Studies 001, 102, 203, 204, 208, 302, 303, 304 and 307 (ADA evaluable patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<!-- image -->

Figure 19: Progression free survival by ADA status after tislelizumab monotherapy  - Study 302 (ADA evaluable patients) Figure 20: Progression free survival by ADA status after tislelizumab monotherapy  - Study 303 (ADA evaluable patients) Medicinal product no longer authorised

Source:[Study304IARMemo-AppendixFigure20] ADApositive=patientswithtreatment-emergentADA

Figure 21: Progression free survival by ADA status after tislelizumab + permetrexed + cisplatin or carboplatin- Study 304 (ADA evaluable patients)

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 22: Progression free survival by ADA status after tislelizumab + paclitaxel or Nabpaclitaxel + carboplatin  - Study 307 (ADA evaluable patients) Medicinal product no longer authorised

Figure 23: Overall survival by ADA status after tislelizumab monotherapy  - Study 302 (ADA evaluable patients)

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 24: Overall survival by ADA status after tislelizumab monotherapy  - Study 303 (ADA evaluable patients) Medicinal product no longer authorised

Figure 25: Overall survival by ADA status after tislelizumab + pemetrexed + cisplatin or carboplatin- Study 304 (ADA evaluable patients)

<div style=\"page-break-after: always\"></div>

## T+PC arm

Figure 26: Overall survival by ADA status after tislelizumab + paclitaxel or Nab paclitaxel + carboplatin- Study 307 (ADA evaluable patients)

<!-- image -->

To further estimate the causal treatment effects on survival in subgroups defined based on a postbaseline variable, the principal stratum strategy was applied to the primary endpoint of OS in Studies 302 and 303, and PFS in Studies 304 and 307. Comparable survival benefits favouring tislelizumab

<div style=\"page-break-after: always\"></div>

arm compared to the adjusted control arm were observed in both ADA-positive and ADA-negative subgroups of the Phase III studies, confirming the lack of causal impact of ADA on survival (data not shown).

The impact of transient versus persistent ADA response as well as Nab positivity on evaluated efficacy parameters were investigated (data not shown).

## Impact of ADA on safety

Overall, the incidence of immune-mediated AEs and AESIs (comprising immune-mediated AEs and infusion-related reactions) were comparable between patients who developed ADA and those who tested negative for ADA. AEs causing treatment discontinuation or dose modification also showed no notable differences by ADA status. There was no apparent relationship between AEs and ADA titres in ADA-positive patients, with most AEs occurring in patients with low titres &lt;40 or &lt;80.

<!-- image -->

A higher incidence of Grade ≥ 3 AEs in treatment -emergent ADA-positive patients compared with ADAnegative patients was observed in all studies, with the exception of Study 307 which showed similar incidence of Grade ≥ 3 AEs in the two ADA subgroups. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|         | no   |
|---------|------|
| product |      |

Table 17: Treatment-emergent adverse events by ADA status -Studies 001, 102, 203, 204, 208, 302, 303, 304 and 307 (ADA evaluable patients)

<!-- image -->

The imbalance in Grade ≥ 3 AEs observed between the ADA subgroups was driven mainly by Grade 3 AEs, of which the majority in both ADA subgroups were considered not related to study treatment. Across all Phase III studies, the Grade ≥ 3 events had no impact on the continuation of tislelizumab as confirmed by the comparable rates of AEs leading to discontinuation between the ADA subgroups. In general, there was no obvious temporal association between Grade ≥ 3 AEs and ADA onset (although limited by sparse ADA sampling), no correlation between toxicity grade and ADA titre, and no clinically relevant relationships between tislelizumab exposure and safety endpoints. Importantly, immunemediated AEs and infusion-related reactions, which may be potentially attributable to ADA, showed no differences between treatment-emergent ADA positive and ADA-negative patients.

<div style=\"page-break-after: always\"></div>

Upon request, treatment-emergent AEs by ADA status in a pooled dataset for patients treated with tislelizumab monotherapy at a dose of 200 mg Q3W and pooled for the combination therapy studies were provided separately for immunemediated AEs, IRRs, Grade ≥ 3 AEs, SAEs, and AEs causing treatment discontinuation/dose modification. The ADA-positive and ADA-negative groups had comparable rates of immune-mediated AEs, IRRs, AEs causing treatment discontinuation and AEs causing dose modification, while the ADA-pos itive group showed higher rates of Grade ≥ 3 AEs (50.9% vs. 39.3% for monotherapy and 85.6% vs. 78.2% for combination therapy) and SAEs (37.1% vs. 29.7% for monotherapy and 45.9% vs. 38.2% for combination therapy).

## Grade ≥ 3 AEs in monotherapy studies

- Metabolism and nutrition disorders (9.9% vs. 6.7%), with small differences seen in decreased appetite (2.7% vs. 1.2%) and hypokalaemia (2.7% vs. 0.9%).

In the pooled monotherapy studies, the following SOCs showed numerical differences &gt;2% between the treatment-emergent ADA-positive and ADA-negative groups: Investigations SOC (12.9% vs. 10.3%), with PTs that were generally low and comparable between the ADA-positive and ADA-negative groups. · Metabolism and nutrition disorders (11.6% vs. 7.3%), with small differences of 1-2% between ADA-positive and ADA-negative groups in PTs of hyponatraemia (4.3% vs. 2.0%) and hypokalaemia (2.6% vs. 1.3%). · Blood and lymphatic system disorders (9.9% vs. 5.3%), with small differences of 1-3% in anaemia (7.8% vs. 4.2%) and thrombocytopenia (1.3% vs. 0%). · Gastrointestinal disorders (9.1% vs. 5.7%), with no single PT driving this difference. · General disorders and administrative site conditions (6.5% vs. 3.9%), with no single PT driving this difference. · Hepatobiliary disorders (4.7% vs. 2.1%), with PTs that occurred at very low and comparable rates (≤0.9% in either ADA group). Grade ≥ 3 AEs in combination therapy studies In the pooled combination therapy studies, the following SOCs showed numerical differences &gt;2% between the treatment-emergent ADA-positive and ADA-negative: · Blood and lymphatic system disorders (53.2% vs. 44.2%), mainly driven by anaemia (21.6% vs. 13.0%), leukopenia (18.9% vs. 14.8%) and thrombocytopenia (13.5% vs. 9.7%), and febrile neutropenia (4.5% vs. 1.8%). These haematological events are common with chemotherapy and the majority of such events were considered related to the chemotherapy rather than to tislelizumab [Study 304-Table 14.3.1.2.5.3], [Study 307- Table 14.3.1-2.5.3]. · Infections and infestations (15.3% vs. 8.2%), mainly due to pneumonia (9.0% vs. 3.9%). In the overall populations of the NSCLC studies, Grade ≥3 pneumonia occurred with comparable rates between tislelizumab + chemotherapy and chemotherapy arms [Study 304-Table 14.3.12.4.2], [Study 307-Table 14.3.1.2.4.2]. · Respiratory, thoracic, and mediastinal disorders (10.8% vs. 8.2%), with a small difference seen in haemoptysis (3.6% vs. 1.2%). Medicinal product no longer authorised

- General disorders and administration site conditions (4.5% vs. 2.4%), with a small difference seen in malaise (2.7% vs. 0.3%).

## SAEs in monotherapy studies

In the pooled monotherapy studies, the following SOCs showed numerical differences &gt;2% between the treatment-emergent ADA-positive and ADA-negative groups:

<div style=\"page-break-after: always\"></div>

- Gastrointestinal disorders (9.1% vs. 4.5%), with differences in dysphagia (2.2% vs. 0.5%) and diarrhoea (1.3% vs. 0.1%). All other PTs occurred in ≤ 1% of patients in either group.
- Hepatobiliary disorders (3.9% vs. 1.8%), with PTs that occurred at very low and comparable rates (≤0.9% in either ADA group).

## SAEs in combination therapy studies

In the pooled combination therapy studies, the following SOCs showed numerical differences &gt;2% between the treatment-emergent ADA-positive and ADA-negative groups:

## Exposure-efficacy analysis:

· Respiratory, thoracic, and mediastinal disorders (17.1% vs. 11.2%), driven primarily by pneumonitis (8.1% vs. 5.2%) and haemoptysis (5.4% vs. 1.2%). Pneumonitis is a known imAE of immune checkpoint inhibitors (Wu et al 2017) and was more common in the tislelizumab + chemotherapy arm vs. chemotherapy arm in the NSCLC studies: 5.9% T+PP vs. 0.9% PP [Study 304-Table 27], and 2.5% T+PC, 1.7% T+nPC vs. 0% PC [Study 307-Table 25]. · Infections and infestations (12.6% vs. 7.9%), driven by pneumonia (9.0% vs. 5.5%). In the overall populations of the NSCLC studies, the incidence of serious pneumonia was comparable between tislelizumab + chemotherapy and chemotherapy arms [Study 304- Table 27], [Study 307-Table 25]. · Blood and lymphatic system disorders (10.8% vs. 4.8%), with differences in thrombocytopenia (4.5% vs. 1.5%) and anaemia (3.6% vs. 0.3%). · General disorders and administration site conditions (6.3% vs. 3.3%) due mainly to malaise (1.8% vs. 0%). · Cardiac disorders (3.6% vs. 0.9%), with all PTs occurring as single events (≤0.9% in either ADA group). · Skin and connective tissue disorders (2.7% vs. 0.6%) due mainly to rash (1.8% vs. 0%). · Hepatobiliary disorders which were more common in the ADA-negative group (2.1%) than in the ADA-positive group (0%). Most SOCs and PTs of SAEs listed above are not known to be mediated by ADA. On the other hand, ADA-related immune complexes have been shown to induce release of inflammatory cytokines and complement activation, leading to inflammation and breakdown of self-tolerance (Krishna and Nadler 2016). While it is unclear what role, if any, ADA may play in the pathogenesis of imAEs such as pneumonitis, the incidence of pneumonitis in tislelizumab studies in NSCLC is similar to those reported for other PD-1/PD-L1 inhibitors, including nivolumab and atezolizumab which have comparable or higher ADA incidences as tislelizumab (Wu et al 2017, Rittmeyer et al 2017). The majority of the 18 patients with NAb (0.8% of 2277 ADA evaluable patients; Table 14) across the 10 clinical studies did not experience immune-mediated AEs or AESIs, and none had hypersensitivity AEs. Exposure-response analyses Medicinal product no longer authorised

The exposure-efficacy relationship was explored for each of the pivotal studies (303, 304 and 307) using various endpoints, such as BOR, PFS, and OS.

The relationship between exposure and BOR was first illustrated descriptively for Studies 303, 304, and 307 by providing summary statistics of popPK predicted Cavg,ss and covariates of interest by response status. Logistic regression was then used to further evaluate the relationship between exposure and the probability of response (i.e., BOR being CR or PR), separately for each study, and identify significant covariates.

<div style=\"page-break-after: always\"></div>

Similarly, OS and PFS were first illustrated by Kaplan-Meier survival curves, stratified by quartiles of tislelizumab exposure (Cavg,ss) and covariates of interest. A Cox regression model was then used to further characterise the relationship between exposure and PFS and OS and identify significant covariates.

## Results

For all efficacy endpoints (BOR, PFS, and OS) analysed, there appears to be a positive trend between these efficacy endpoints and exposure within the range of exposure at 200 mg Q3W, which was the only dose evaluated in all three studies. As shown in Figure below, in general, higher exposure seems to be associated with higher probability of OS in 2/3L, and PFS in 1L SQ and NSQ NSCLC population at a given time, respectively.

<!-- image -->

Furthermore, results from Cox regression models (Table 18, Table 19 and Table 20) also suggest that the risk of death or risk of disease progression decreases with an increase in exposure for 2/3L, 1L SQ and 1L NSQ NSCLC population, respectively. In addition, significant covariates were identified based on the covariate search. As shown in Table 18, baseline LDH, PD-L1 status, weight and disease stage were statistically significant covariates on OS in 2/3L NSCLC. Specifically, subjects with lower LDH, higher PD-L1 expression, locally advanced carcinoma and higher body weight seem to have lower risk of death. Similarly, as shown in Table 19 and Table 20, baseline weight and PD-L1 status were identified as significant covariates in 1L SQ and NSQ, respectively. Subjects with higher baseline weight, or higher PD-L1 expression tend to have lower risk of disease progression in 1L SQ and NSQ, respectively. However, the present analysis, in which only one dose level of 200 mg Q3W was evaluated, has important limitations. For example, the positive exposure efficacy relationship in BOR observed at the 200 mg Q3W dose was not consistent with the flat exposure response relationship on BOR observed at 200 mg Q3W and 5 mg/kg Q3W, in the previous exposure response analysis based on earlier phase data on patients with NSCLC [BGB-A317-CP-009]. In fact, this inconsistency in exposure response relationship between a given dose level and across different dose levels was not uncommon in anti-PD1 drugs. For instance, in both pembrolizumab and nivolumab, within a given dose level, a similar positive relationship was observed between exposure and efficacy endpoints (Agrawal et al 2016, Feng et al 2017, Turner et al 2018), while a flat dose response relationship was observed across multiple doses. This inconsistency suggests that the within dose difference in efficacy across exposure quartile were likely due to factors other than exposure. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 27: Kaplan-Meier curves of OS stratified by quartiles of Cavg,ss -2L NSCLC (2LPK -Efficacy set) Table 18: Summary of Cox model parameters for OS -2L NSCLC (2LPK- Efficacy set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| product   |
|-----------|

Figure 28 Kaplan-Meier curves of PSF stratified by Cavg,ss -1L NSCLC (1LSQPK - Efficacy set) Table 19: Summary of Cox model parameters for PFS -1L SQ NSCLC (1LSQPK- Efficacy set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

The exposure-safety relationship was explored using various endpoints, such as immune-mediated TEAEs, infusion-related reactions (IRRs), TEAEs with CTCAE Grade &gt; 3, TEAEs leading to treatment discontinuation, and TEAEs leading to dose modification(s). The relationship between exposure and safety endpoints was first explored descriptively by providing summary statistics and boxplots of popPK predicted Cmax,ss by event status (patient experienced at least one AE, yes/no). In addition, logistic regression analysis was performed to evaluate the relationship between exposure and the probability of at least one such safety event.

Figure 29: Kaplan-Meier curves of PFS stratified by Cavg,ss -1L NSQ NSCLC (1LNSQPK -Efficacy set) Table 20: Summary of Cox model parameters for PFS -1L NSQ NSCLC (1LNSQPK- Efficacy set) Exposure-safety analysis: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

While steady-state Cmax is a common PK metric used in ER safety analysis, the conclusion would remain the same using other PK metrics, such as Cavg,ss and Cmin,ss, since all these PK metrics are highly correlated.

## Results

To support the indication of tislelizumab as second (or third-) line treatment for patients with locally advanced or metastatic NSCLC, the analyses were conducted separately on Study 303 and on the monotherapy pool comprising studies with various solid tumour types across a wide range of doses (0.5 -10 mg/kg Q2W, 2-5 mg/kg Q3W including 200 mg Q3W). As shown in Figure 3-11 and Figure 312, the tislelizumab exposure was similar between subjects with or without any immune related TEAEs, or TEAEs with CTCAE Grade &gt; 3, respectively, based on data from Study 303. This observation was further supported by results from logistic regression (Figures below), in which an increase in tislelizumab exposure was not associated with an increased risk of immune-mediated TEAEs or TEAEs with CTCAE Grade &gt; 3. In fact, for all safety endpoints analysed based on data from Study 303 and the monotherapy pool, both the descriptive summary and the logistic regression suggest no clinically relevant association between exposure and increased probability of safety events. In addition, these analyses indicated that exposure metrics were comparable between Asians and Whites with or without safety events. These same analyses and endpoints were also conducted on the combination pool to support the 1L indication in squamous and non-squamous NSCLC population. As shown in Figure 3-15 and Figure 316, the tislelizumab exposure was similar between subjects with or without any immune related TEAEs, or TEAEs with CTCAE grade &gt; 3, respectively, based on data from 1L combination pool. Consistent with the observed data, logistic regression analyses also suggest that an increase in exposure does not lead to increased probability of immune-mediated TEAEs or TEAEs with CTCAE grade &gt; 3. Moreover, for all other safety endpoints analysed based on 1L combination pool, both the descriptive statistics and the logistic regression suggest no association between tislelizumab exposure and probability of safety events. Medicinal product no longer authorised

<!-- image -->

Symbols are the popPK predicted exposure matrices.The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xlQR from the box. The grey horizontal line represents the median valueofoverallset.

Figure 30: Boxplot of popPK predicted Cmax,ss by- immune mediated TEAE status , Study 303 only 2LPK-Safety set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 31: Probability of immune-mediated TEAE vs. exposure, Study 303 only (2LPK -safety set) Medicinal product no longer authorised

Symbols are the popPK predicted exposure matrices. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xlQR from the box. The grey horizontal line represents the median value of overall set.

Figure 32: Boxplot of popPK predicted Cmax,ss by TEAEs with CTCAE grade greater than or equal to 3 status , Study 303 only (2LPK -safety set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 33: Probability of TEAEs with CTCAE grade greater than or equal to 3 vs. exposure, Study 303 only (2LPK -safety set) Medicinal product no longer authorised

/CVDT482C1/mas/mas\\_2/model/pgm\\_001/PopPK/ER\\_Safety\\_NSCLC/MT-46551-ER\\_NSCLC/Safety\\_SAE/Task01\\_ER\\_SAE.R /CVDT482C1/mas/mas\\_2/model/pgm\\_001/PopPK/ER\\_Safety\\_NSCLC/MT-46551-ER\\_NSCLC/Safety\\_SAE/Boxplot\\_PKmetrics\\_TESAE\\_303.png

Figure 34: Boxplot of PopPK predicted Cmax,ss vs. occurrence of TESAES, Study 303

Symbols are the PopPK predicted exposure matrices. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xIQR from the box. The grey horizontal line represents the median value of overall set.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 35: Probability of TESAEs vs. PopPK predicted Cmax,ss, Study 303 Model is log(p/(1-p)) = intercept + log PopPK predicted Cmax,ss, where p is the probability of TESAEs. The blue shade area represents the 95% CI of the logistic regression model estimation, and the black line in the middle of the shaded area represents the median prediction. The dots are the observed proportions at the median PopPK predicted Cmax,ss within each quartile, and the range represents the 95% CIs for these are based on the ClopperPearson method. The three vertical grey line represents the 25th, 50th and 75th percentile of the PopPK predicted Cmax,ss. Medicinal product no longer authorised

Symbols arethepopPKpredictedexposurematrices.Themedianisrepresentedbythehorizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xlQR from the box. The grey horizontal line represents the median valueofoverallset.

Figure 36: Boxplot of popPK predicted Cmax,ss by immune-mediated TEAE status (1LPK -Safety set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 37: Probability of immune-mediated TEAE vs exposure, combination therapy pool (1LPK -Safety set) Medicinal product no longer authorised

SymbolsarethepopPKpredictedexposurematrices.Themedianisrepresentedbythehorizontal blacklineinthemiddleofeachbox.Thelowerandupperendsoftheboxplotrepresentthe25thand 75thpercentile（thelowerandupperquartiles,respectively).Thebarsextendtothemostextremedata pointwhichisnomorethan1.5xlQRfromthebox.Thegreyhorizontal linerepresentsthemedian valueofoverallset.

Figure 38: Boxplot of PopPK predicted Cmax, ss by TEAEs with CTCAE grade greater than or equal to 3 status (1LPK safety set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 39. Probability of TEAEs with CTCAE grade greater than or equal to 3 vs exposure, combination therapy pool (1LPK safety set) Medicinal product no longer authorised

CVDT482C1/mas/mas

/CVDT482C1/mas/mas\\_2/model/pgm\\_001/PopPK/ER\\_Safety\\_NSCLC/MT-46551-ER\\_NSCLC/Safety\\_SAE/Boxplot\\_PKmetrics\\_TESAE\\_combo\\_pool.png

Symbols are the PopPK predicted exposure matrices. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xIQR from the box. The grey horizontal line represents the median value of overall set.

Figure 40: Boxplot of PopPK predicted Cmax,ss vs. occurrence of TESAEs, combination therapy pool

<div style=\"page-break-after: always\"></div>

<!-- image -->

For determination of anti-drug antibodies (ADA) to tislelizumab, an electro-chemiluminescent (ECL) immunoassay method using the Meso Scale Discovery (technology) was developed and validated (8354-373). A standard 3-tiered approach was applied, comprising a screening assay followed by confirmation of ADA status and determination of ADA titre. Assay sensitivity was determined to be 21.7 ng/mL relative to surrogate ADA and drug tolerance was 200 μg/mL in the presence of 100 ng/mL of surrogate ADA. Two different antibodies (mAb and pAb) were used as positive controls during the ADA assay validation in order to provide a complete characterisation of assay parameters. The mAb PC ('reference antibody 1') was used for the whole method validation (to prepare positive control samples used in the whole method validation process and validation samples, except for the drug tolerance

Model is log(p/(1-p)) = intercept + log PopPK predicted Cmax,ss, where p is the probability of TESAEs. The blue shade area represents the 95% CI of the logistic regression model estimation, and the black line in the middle of the shaded area represents the median prediction. The dots are the observed proportions at the median PopPK predicted Cmax,ss within each quartile, and the range represents the 95% CIs for these are based on the Clopper-Pearson method. The three vertical grey line represents the 25th, 50th and 75th percentile of the PopPK predicted Cmax,ss. Figure 41: Probability of TESAEs vs. PopPK predicted Cmax,ss, combination therapy pool 2.5.3. Discussion on clinical pharmacology Pharmacokinetics The clinical pharmacology package of tislelizumab comprised 12 clinical studies contributing to the characterisation of tislelizumab pharmacokinetics (2596 patients). Doses ranging from 0.5 to 10 mg/kg Q2W, 2 and 5 mg/kg Q3W, and 200 mg Q3W, all administered as intravenous infusions over 30 to 60 minutes, were investigated. The proposed dosing regimen for tislelizumab is 200 mg administered IV once every 3 weeks. Analytical methods For the quantitation of tislelizumab concentrations, a quantitative indirect ELISA method was developed and validated. A formal cross-validation has been performed to verify that PK data obtained at different laboratories (method VAL136 and method 8354-363) are reliable and comparable. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

samples), while the pAb PC ('reference antibody 2') was used only in the drug tolerance evaluations (to prepare drug tolerance samples). This is considered to be acceptable.

A competitive ECL ligand-binding assay utilizing MSD technology to detect neutralizing antibodies (NAbs) to tislelizumab was also developed and validated (8369-215). The NAb assay sensitivity was 173 ng/mL. Drug tolerance was 100 μg/mL and 10 µg/mL in the presence of 1000 ng/mL and 500 ng/mL of surrogate NAb in the serum which is considered too low for adequate detection of NAbs in a relevant number of study samples with tislelizumab concentrations &gt;10µg/mL. Thus, confirmed ADAs against tislelizumab might be not correctly classified as neutralizing. No Hook effect and no interference with PD-1 concentrations up to 4000 pg/mL was observed. Selectivity of the assay was not demonstrated in disease state matrix. However, to test the selectivity, additional experiments were performed in pre-dose samples from clinical studies 302 and 303. Therefore, 10 samples for each patient population were analysed in the NAb assay unspiked as well as spiked with LPC and HPC concentration of the positive control. The results of the additional experiments currently provided were in accordance with the acceptance criteria of the EU guidance and are considered acceptable. Data and information from the additional experiments to further confirm the selectivity of the NAb assay, were included in the amended bioanalytical data reports for studies BGB-A317-302 and BGB-A317-303.

Population PK model The final population PK model was a 3-compartment model with first order elimination. The dataset consisted of 14,473 observed serum concentrations from 2,596 subjects enrolled in 12 clinical studies of tislelizumab. In the PopPK model dataset, there are 52 BLQ samples, approximately 0.36% of the total 14525 samples, which were excluded from the analysis. Due to the small percentage of BLQ data, exclusion of these data is not considered to affect the overall conclusions of the PopPK analysis and is thus considered to be acceptable. In addition, 11 PK samples, which were outside the proven stability timeframe, were included in the population PK dataset. However, these 11 PK samples are not considered to have a significant impact on the population PK modelling and parameter estimation because the number of samples (11) is very small compared to the entire dataset and only accounted for 0.076% of the total number of population PK data points. In addition, these data points do not have extreme values nor are they outside the range of samples that were within the proven stability timeframe. In the final PopPK model, WT, age, sex, ALB, TUMSZ, TUMTP, and ADA were identified as statistically significant covariates on the PK of tislelizumab, while covariate sensitivity analysis showed that body weight was the most influential covariate on tislelizumab exposure. This is in line with what has been described for other monoclonal antibodies in the past. Goodness-of-fit (GOF) and prediction-corrected visual predictive check (VPC) plots showed good agreement between the observed and the simulated exposure supporting the structural model. However, more details on the included population regarding to BW were required to ensure that the data are representative of the EU population. Although, with the proposed 200 mg Q3W dosing regimen, the observed exposure and the simulated overall exposure (AUC) at steady state were lower in patients with BW ≥89 kg than in patients with BW &lt; 89 kg, this difference is not considered clinically meaningful, based on the new data provided. Medicinal product no longer authorised

Referring to the presented pcVPC plots by treatment regimen, model-fit for the Q2W treatment regimen is slightly worse, as a tendency towards slight underprediction of observed values is shown. Still, the final popPK model is considered to provide acceptable estimations of tislelizumab exposure for the relevant dose of this application.

No exposure differences (simulated) were observed based on tumour subtype.

Incidence of ADAs and NAbs were low and seem to have a lowering effect on exposure. Even the mean exposure was lower than the mean for ADA negatives, all ADA/Nab positive data were within the range

<div style=\"page-break-after: always\"></div>

of data points of ADA negatives, thus the effect is not considered clinically relevant. The submitted Pop PK model can adequately describe the PK of tislelizumab in patients with NSLC and other cancer types/subtypes included in the analysis.

## ADME

Tislelizumab is presently intended to be solely administered via the IV route, which implies that the drug will be 100% bioavailable. Cmax ranged between 89.5 µg/mL and 126 µg/mL. Central volume of distribution and clearance of tislelizumab estimated by population PK analysis was 3.05 L and be 0.153 L/day, respectively. These values correspond to typical values described for V and CL of monoclonal antibodies in the past.

## Dose proportionality and time dependency

No time-varying CL has been observed for tislelizumab, which was concluded from the investigation of an empirical model of time-varying clearance that did not improve model fit of the initial base model. This is considered somewhat unexpected, given that other checkpoint inhibitors currently approved which target PD-1/PD-L1 have all been described to exhibit time-varying CL (decrease in CL when tumour burden declines and disease state improves, presumably due to TMDD). In line with this, tumour size was determined to be a significant covariate affecting tislelizumab CL (lower tumour size resulted in decreased CL and higher AUC, large tumour size resulted in increased CL and decreased AUC). Although most published popPK models for other checkpoint inhibitors exhibited time varying CL, based on the currently updated information provided, it appears that the time-varying clearance of tislelizumab has no strong meaningful impact on the PK characteristics of tislelizumab. Both assessed popPK models with or without time-varying clearance appear to be largely comparable in the PK metrics (e.g. geometric mean of AUC, Cmax and Cmin after dose 1 or at steady state (ss)). Therefore, the current approach and conclusion of a 3-compartment model without time-varying CL appears to be valid and appropriate based on the currently provided data. The estimate for the terminal half-life of tislelizumab derived from population PK analysis (which is also stated in the SmPC) differs from the result obtained for t1/2 in noncompartmental analyses (i.e. study 001 and study 102). However, it was clarified that the terminal half-life (t1/2) of tislelizumab from the PopPK model was derived from the PK concentration time profiles for the original 2596 patients (from 12 studies), that were simulated following 200 mg Q3W IV for 17 doses. The steady state t1/2 was then estimated by non-compartmental analyses (NCA) based on the simulated concentration time profile from day 336 to day 347. However, the observed post-treatment PK concentration samples for NCA were limited (n = 5 for study 001 and n=10 for study 102 at the flat dose level of 200 mg Q3W) and the variability in study 001 for the apparent terminal half-life at a flat dose 200 mg Q3W was quite high (127%). In addition, the applicant clarified that the Q2W and Q3W dosing intervals in study 001 and Q3W intervals in Study 102 limited the sampling time windows for PK profiles after the first dose, therefore were not sufficient to robustly characterise the t1/2 of tislelizumab using NCA. The approach of using the estimated terminal half-life of tislelizumab derived from the population PK analysis based on sparse samples from a large patient population pooled from all studies with evaluable PK data, is considered acceptable. Medicinal product no longer authorised

PK of tislelizumab was shown to be linear and dose-proportional at dosing regimens of 0.5 mg/kg to 10 mg/kg once every 2 or 3 weeks and 200 mg Q3W. Steady-state accumulation ratio of tislelizumab PK exposure is approximately 2-fold.

No dose adjustment is needed for patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to make dosing recommendations for this population.

<div style=\"page-break-after: always\"></div>

No dose adjustment is needed for patients with mild or moderate hepatic impairment. Data from patients with severe hepatic impairment are too limited to make dosing recommendations for this population.

## Variability

Inter-individual variability with regard to PK parameters of tislelizumab was moderate, e.g. the popPKderived estimate of inter-individual variability for tislelizumab CL was 26.3%. Higher inter-individual variability (74.7%, and 99.9%) was observed for V2 and V3.

The variability values were obtained by taking the largest differences between the 5 th  and 95 th percentile exposures in the overall population compared to the typical individual, which are ~ 55.8%, 47.3%, and 70.8% for AUC,ss, Cmax,ss, and Cmin,ss, respectively. Exposure in patient population In study 001, PK of tislelizumab at dose levels ranging from 0.5 mg/kg -10 mg/kg Q2W or Q3W was assessed by noncompartmental analysis. PK was determined after the first dose and in Cycle 4 (for Q2W regimen) or Cycle 5 (for Q3W regimen), corresponding to steady state. However, PK at steady state (Cycle 4 or Cycle 5) was derived from a rather limited number of patients (at 200 mg flat dose Q3W, 5 patients have contributed to PK results), therefore, reliability of those data is considered questionable. Geometric means of AUC0-21d, Cycle 1, and AUC0-inf, Cycle 1, were 644 and 1075 μg·day/mL, respectively. At steady state (Cycle 4 or Cycle 5), geometric mean AUC0 -tau was 825 μg·day/mL. In the Phase 1 part of study 101, further noncompartmental PK analyses were performed for tislelizumab dosed at 200 mg Q3W. The number of patients after the first dose (Cycle 1) and after multiple dosing at Cycle 5 was 20 patients and 12 patients, respectively. Overall, PK results were similar to those obtained in study 001. The geometric means of AUC0-tau in Cycle 1 and Cycle 5 were 582 and 1073 μg·day/mL, respectively. After doses of tislelizumab at 200 mg once every 3 weeks, the geometric mean of AUCss was estimated by population PK analysis to be 1283 μg·day/mL. The estimate is similar to results for AUCtau at Cycle 4 or Cycle 5 derived by noncompartmental PK analyses in studies 001 and 102. No meaningful discrepancies resulted from re-analysis of the population PK model as described in popPK report amendment 1. Special populations Medicinal product no longer authorised

In the population PK model, baseline body weight, albumin level, tumour size of solid tumours, ADA status (treatment-emergent ADA), and tumour type were identified as significant covariates on CL. Baseline body weight, sex, and age were identified as significant covariates on Vc. However, simulated mean exposure differences observed in patients with impaired renal or hepatic function, different gender, different race (Asian vs. White), different body weight, and in the elderly were rather small compared to the overall variability of tislelizumab exposure and thus currently not deemed clinically relevant. Conclusively, no dose adjustment of tislelizumab is currently deemed necessary for any special populations.

The number of patients with severe renal impairment (n=5) was too low to make any valid conclusions, whether the increase in tislelizumab exposure in patients with severe renal impairment (50.5% higher as compared to subjects with normal renal function) resulted in any clinically relevant impact on efficacy or safety parameters. However, as for other mAbs, there is no mechanistic rationale for an increase in exposure with reduced renal function. Results are likely to be confounded by other baseline characteristics, such as lower body weight. Based on currently available information it is not

<div style=\"page-break-after: always\"></div>

suggested that the observed increase in tislelizumab exposure in patients with severe renal impairment (50.5% higher as compared to subjects with normal renal function) resulted in any clinically relevant impact on efficacy or safety parameter, however no dosing recommendations can be made for these patients (see sections 4.2 and 5.2 of the SmPC).

Tislelizumab has no study conducted in paediatric subjects.

In the population PK analyses of tislelizumab, no clinically relevant differences in the clearance of tislelizumab were found between patients with mild hepatic impairment (bilirubin ≤ ULN and AST &gt;ULN or bilirubin &gt;1.0 to 1.5 x ULN and any AST, n = 396) or moderate hepatic impairment (bilirubin &gt;1.5 to 3 x ULN and any AST; n = 12), compared to patients with normal hepatic function (bilirubin ≤ ULN and AST = ULN, n = 2 182) No dose adjustment is needed for patients with mild or moderate renal impairment (see sections 4.2 and 5.2 of the SmPC). Based on the limited number of patients with severe hepatic impairment (bilirubin &gt;3 x ULN and any AST, n = 2), the effect of severe hepatic impairment on the pharmacokinetics of tislelizumab is unknown and no dosing recommendations for this population can be made.

The weight is similar in the different hepatic function groups and therefore not a potential confounder of the influence of hepatic impairment on tislelizumab PK. The use of AST, ALT, or total bilirubin as markers of metabolic liver function is questioned but will not be further pursued since tislelizumab is a monoclonal antibody for which the elimination is not expected to depend on the hepatic function. Interactions The impact of combination therapy on the covariate-adjusted tislelizumab PK parameters (CL and Vc) were evaluated in post hoc analysis based on the final popPK model. Again, accounting for the overall variability of exposures, differences were not considered clinically significant, which is agreed. Pharmacodynamics No specific pharmacodynamic parameters were investigated in the clinical development program for tislelizumab. Immunogenicity Immunogenicity was analysed in 10 clinical studies of tislelizumab administered either as monotherapy (Studies 001, 102, 203, 204, 208, 302, and 303) or in combination with chemotherapy (Studies 206, 304, and 307) in patients with different tumour types. Anti-drug antibodies were determined by screening and confirmatory assays, followed by the analysis of ADA titre. Of 1 916 antidrug antibodies (ADA)-evaluable patients treated at the recommended dose of 200 mg once every 3 weeks, 18.3% of patients tested positive for treatment-emergent ADA, and neutralising antibodies (NAbs) were detected in 0.9% of patients. Population pharmacokinetic analysis showed that ADA status was a statistically significant covariate on clearance; however, the presence of treatmentemergent ADA against tislelizumab appears to have no clinically relevant impact on pharmacokinetics or efficacy. Medicinal product no longer authorised

Among ADA-evaluable patients, the following rates of adverse events (AEs) have been observed for the ADA-positive population compared to the ADAnegative population, respectively: grade ≥3 AEs 50.9% vs. 39.3%, serious adverse events (SAEs) 37.1% vs. 29.7%, AEs leading to treatment discontinuation 10.8% vs. 10.2%: (for monotherapy); grade ≥ 3 AEs 85.6% vs. 78.2%, SAEs 45.9% vs. 38.2%, AEs leading to treatment withdrawal 13.5% vs. 13.3% (for combination therapy). Patients who developed treatment-emergent ADAs tended to have overall poorer health and disease characteristics at baseline which can confound the interpretation of the safety analysis. Available data do not allow firm conclusions to be drawn on possible patterns of adverse drug reactions.

<div style=\"page-break-after: always\"></div>

## Exposure-response analyses

## Exposure-efficacy analyses

In the first-line SQ NSCLC population, a positive correlation between tislelizumab exposure (Cavg,ss) and the evaluated efficacy endpoints (BOR, PFS, and OS) was observed. In addition to exposure, baseline weight was another significant covariate identified in the analyses of PFS and OS.

In the first-line NSQ NSCLC population, a positive correlation between tislelizumab exposure (Cavg,ss) and the evaluated efficacy endpoints (BOR, PFS, and OS) was observed. In addition to exposure, PDL1 status was identified as significant covariate in the analyses of BOR and PFS.

In the overall NSCLC population (studies 001, 102, 303 including data on 5 mg/kg Q3W and 200 mg Q3W dosing groups), a positive correlation between tislelizumab exposure (Cavg,ss) and the evaluated efficacy endpoints (BOR, PFS, and OS) was observed (for results see section 3.3.2.1.1.)  Several baseline characteristics were identified as significant covariates. The positive ER efficacy relationship was less pronounced when using Cavg,dose1 as compared to that with Cavg,ss. The main limitation of these analyses is that only one dose level was tested in studies 303, 304 and 307. The phenomenon of E-R confounding has been broadly observed for monoclonal antibody cancer therapies (including immune checkpoint inhibitors) and is believed to relate to cancer cachexia and/or inflammation causing more rapid protein turnover and thus mAb catabolism in patients with poor prognosis. Hence, in the present analyses, the observed tislelizumab E-R relationship seen with 200 mg Q3W dose for BOR, OS, and PFS was likely a result of increased tislelizumab clearance in patients with poorer prognosis rather than a true exposure effect on the drug efficacy. Moreover, the flat exposure response relationship observed based on the earlier phase data of 200 mg and 5 mg/kg Q3W suggested that 200 mg Q3W might already reach the plateau, achieving maximum efficacy. Exposure-safety analyses The exposure-safety relationship for tislelizumab in NSCLC was explored using various endpoints, such as immune-mediated TEAEs, IRR, TEAEs with CTCAE grade &gt; 3, TEAEs leading to treatment discontinuation and TEAEs leading to dose modification(s) and treatment-emergent SAEs. The exposure metric was based on steady-state Cmax predicted by the population PK model. Analyses were conducted separately on Study 303 and on the monotherapy pool comprising studies with various solid tumour types. In all safety endpoints analysed (except for IRR on the monotherapy pool), logistic regression models suggest no statistically significant relationship between the probability of safety events and exposure within the range of dose levels investigated. For the analysis of IRR based on the data from the monotherapy pool, while the relationship between the probability of an event and exposure was statistically significant, the increase in the probability of having an IRR was from 3.27% at the median of the 1st exposure quartile to 5.5 % at the median of the 4th exposure quartile. Hence, this minor increase in the safety risk was not considered clinically relevant, which is agreed. In addition, the analysis based on the monotherapy pool data indicated that exposure metrics were comparable between Asians and Whites with or without safety events. Overall, based on these analyses, there was no evidence of higher tislelizumab exposure leading to increased safety risks in the population analysed. Medicinal product no longer authorised

## 2.5.4. Conclusions on clinical pharmacology

Overall, pharmacokinetics and pharmacodynamics, i.e. immunogenicity and exposure-response relationships, of tislelizumab have been adequately characterised.

<div style=\"page-break-after: always\"></div>

## 2.5.5. Clinical efficacy

## 2.5.5.1. Dose response studies

The recommended dose of tislelizumab is 200 mg administered as an intravenous (IV) infusion once every 3 weeks (Q3W) until disease progression or unacceptable toxicity.

## Study 001

Phase IA of Study 001 was designed to establish the recommended Phase II dose in patients with advanced tumours. Phase IA was also designed to determine the maximum tolerated dose (MTD) for tislelizumab, although no MTD was established in the study.

Four dose levels were investigated during dose escalation in Phase 1A Part 1: 0.5, 2.0, 5.0, and 10 mg/kg Q2W. After clearance of the dose-limiting toxicity (DLT) period, two dosing schedules 2 mg/kg and 5 mg/kg, Q2W and Q3W were further evaluated during schedule expansion in Phase 1A Part 2. Phase 1A Part 3 comprised the fixed dose exploration with the 200 mg Q3W dose. Study results: · Rates of treatment-related adverse events (AEs) and serious adverse events observed in patients receiving 2 mg/kg and 5 mg/kg either administered as Q2W or Q3W were comparable. · Confirmed overall response rates (ORRs) in patients treated with tislelizumab 2 mg/kg and 5 mg/kg Q2W were 10% (2 of 20) and 15% (3 of 20), respectively, and ORRs were 38% (8 of 21) and 15% (3 of 20) for patients treated at 2 mg/kg and 5 mg/kg Q3W, respectively. · Dose proportional increases in Cmax and AUC were observed across a range of 0.5 mg/kg to 10 mg/kg. No correlation was found between clearance and body weight. The steady-state geometric mean elimination half-life was calculated to be about 23.8 days based on popPK analysis, and steady state trough concentrations were similar across the Phase 1B indication arms suggesting a lack of a disease effect on PK. . · Pharmacokinetic data from patients who were administered 200 mg Q3W showed that tislelizumab concentrations after the first 200 mg dose were within the range of concentrations observed from the 2 mg/kg and 5 mg/kg doses . Exposure-response analysis in patients with solid tumours The purpose of this analysis was to analyse the exposure-response (E-R) relationships for tislelizumab efficacy and safety endpoints using data collected in the studies BGB-A317-001, BGB-A317-102, BGBA317-203 and BGB-A317-204. The distribution of different dose regimens used in each study is displayed in Table 21. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 21: Summary of dose regimens

| Dose Regimen   | BGB-A317-001a (N=450)   | BGB-A317-102b (N=300)   | BGB-A317-203 (N=70)   | BGB-A317-204 (N=112)   | Overall (N=932)   |
|----------------|-------------------------|-------------------------|-----------------------|------------------------|-------------------|
| 0.5 mg/kg Q2W  | 3 (0.7%)                |                         |                       |                        | 3 (0.3%)          |
| 10 mg/kg Q2W   | 7 (1.6%)                |                         |                       |                        | 7 (0.8%)          |
| 2 mg/kg Q2W    | 26 (5.8%)               |                         |                       |                        | 26 (2.8%)         |
| 2 mg/kg Q3W    | 21 (4.7%)               |                         |                       |                        | 21 (2.3%)         |

The E-R logistic regression models for ORR in patients with solid tumours against tislelizumab Cavg,dose1 were developed using combined data in all solid tumour types in studies BGB-A317-001, BGB-A317-102 and BGB-A317-204. Table 22: The model building process for ORR Table 23: Summary of logistic model parameters for ORR in patients with solid tumours Medicinal product no longer authorised a. b. C.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 42: Logistic regression of probability of ORR versus tislelizumab exposure in patients with solid tumours Table 24: PopPK predicted Cavg,ss by confirmed responders status -2L NSCLC (2LPKEfficacy set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 43: Boxplot for popPK predicted Cavg,ss by confirmed responder status -2L NSCLC (2LPK-Efficacy set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Logistic regression was further used to evaluate the relationship between exposure and confirmed BOR.

<!-- image -->

Figure 44: Logistic regression of probability of confirmed BOR being CR/PR vs. popPK predicted Cavg,ss -2L NSCLC (2LPK-Efficacy set) Table 25: Probability estimates of confirmed BOR being CR/PR vs. popPK predicted Cavg,ss -2L NSCLC (2LPK-Efficacy set) Medicinal product no longer authorised

The slope (coefficient of log (Cavg,ss)) of the relationship between the probability of confirmed BOR being CR/PR and the log of popPK predicted Cavg,ss was positive.

Based on covariate selection analysis, 'PD -L1 expression' and 'sex' were identified as significant covariates and were therefore incorporated into the final model.

In addition, the relationship between exposure and AEs was evaluated by building logistic regression models and plotting data by tumour type for imAEs (Figure 45) and AESIs (Figure 46).

<div style=\"page-break-after: always\"></div>

Figure 45: Probability of selected AEs vs tislelizumab exposure in subjects with advanced tumours Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

The safety and efficacy of the 200 mg Q3W tislelizumab dose was further verified in Study 102 in patients with multiple malignancies, and has been used in all the subsequent tislelizumab clinical studies. Thus, no additional dose selection studies or analyses were performed for the present application.

## Figure 46: Probability of immune-mediated AEs vs tislelizumab exposure in subjects by tumour type Medicinal product no longer authorised

## Exposure-response analyses for the overall NSCLC population

The applicant provided E-R analyses of efficacy for the overall NSCLC population by developing a model that includes studies 001, 102 and 303.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 47: Logistic regression of BOR on PopPK predicted Cavg,ss (base model) -2L NSCLC patients from studies 001, 102 and 303 Medicinal product no longer authorised

Figure 48. Kaplan-Meier OS curves stratified by Cavg,ss quartiles, 2L NSCLC patients from studies 001, 102 and 303

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 49 : Kaplan-Meier PFS curves stratified by Cavg,ss, 2L NSCLC patients from studies 001, 102 and 303 With these analyses a positive relationship between exposure and efficacy response was determined. To adjust for baseline characteristics and the potential confounding effect of CL, stepwise covariate search based on AIC was conducted on baseline characteristics and the base model. As a result, in addition to CL and Cavg,dose1, several other baseline covariates were retained in the final model. While the association between Cavg,dose1 and efficacy outcomes was statistically significant in the base model, after adjusting for CL and other baseline covariates, the association between Cavg,dose1 and efficacy outcome was no longer statistically significant in the final model. For reasons of simplifying dosing and administration, the 200 mg once every 3 weeks dose was chosen as recommended dose because this dose resulted in tislelizumab concentrations largely overlapping with concentrations observed with the 2 mg/kg and 5 mg/kg dose levels. Ultimately, the toxicokinetic profile of tislelizumab was characterised in preceding preclinical studies in monkeys. Tislelizumab exposure in monkey serum at the NOAEL of 30 mg/kg Q2W was approximately 5- to 8-fold higher than those in patients receiving the studied human dose of 200 mg Q3W. Main studies Summary of the main studies supporting the 3 indications within this application, described in the sections below: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Clinical efficacy of tislelizumab monotherapy as 2L+ treatment of NSCLC                                 | Clinical efficacy of tislelizumab monotherapy as 2L+ treatment of NSCLC                                 |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Main study                                                                                              | Study 303                                                                                               |
| Supportive study(ies)                                                                                   | Study 001 (dose response), Study 102                                                                    |
| Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of squamous NSCLC    | Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of squamous NSCLC    |
| Main study                                                                                              | Study 307                                                                                               |
| Supportive study(ies)                                                                                   | Study 206 (squamous NSCLC cohort)                                                                       |
| Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of nonsquamous NSCLC | Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of nonsquamous NSCLC |
| Main study                                                                                              | Study 304                                                                                               |
| Supportive study(ies)                                                                                   | Study 206 (nonsquamous NSCLC cohort)                                                                    |

<!-- image -->

2.5.5.2. Clinical efficacy of tislelizumab monotherapy as 2L+ treatment of NSCLC Main study Study 303 (BGB-A317-303): A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen Study 303 is an ongoing Phase III, randomised, open-label, parallel-group multicentre study designed to evaluate the efficacy and safety of tislelizumab in adult patients with histologically confirmed, locally advanced or metastatic (squamous or non-squamous) NSCLC who had progressed during or after a prior platinum-containing regimen. The proportion of PD-L1-negative patients (defined as &lt; 25% of tumour cells (TC) with PDL1 membrane staining via the Ventana SP263 assay) was capped at ≤ 60% of patients in the study. Patients were randomised in a 2:1 ratio to receive either tislelizumab or docetaxel treatment. Randomisation was stratified by histology (squamous vs. non-squamous), line of therapy (second- vs. third-line), and PDL1 expression (&lt; 25% TC vs. ≥ 25% TC). Medicinal product no longer authorised

Figure 50: Study design (Study 303)

<div style=\"page-break-after: always\"></div>

## Methods

## · Study Participants

Key inclusion criteria included:

1. Histologically confirmed disease which was currently locally advanced or metastatic NSCLC of either squamous or non-squamous histology.
2. With disease progression during or following treatment with at least one platinum-containing regimen.

· Patients who received prior neoadjuvant or adjuvant chemotherapy but progressed within 6 months after the last dose were eligible provided the target lesion(s) had not been previously treated with local therapy (radiation) or the target lesion(s) within the field of local therapy had subsequently progressed as defined per RECIST v1.1. · Note: No more than 2 prior lines of syste mic chemotherapy for advanced or metastatic disease -Chemotherapy regimens were counted on the basis of interval disease progression and not the number of agents or switches in agents (e.g., a first-line therapy that consisted of several cycles of a platinum doublet and subsequent maintenance therapy that introduced or was switched to a new chemotherapy agent without interval disease progression was all considered one chemotherapy regimen). -Adjuvant/neoadjuvant chemotherapy or chemoradiation counted as a prior chemotherapy regimen if ≤ 6 months had elapsed between the last dose and the date of recurrence. Combined treatment with chemotherapy and radiation constitutes a single regimen; surgery was not considered a regimen. · Anti -EGFR treatment with disease progression as the treatment outcome was counted as a line of therapy. · Anticancer agents used for pleurodesis were not counted as a line of therapy. 3. Patients were able to provide archival/fresh tumour tissues (FFPE blocks or approximately 11 [at least 5] freshly cut unstained FFPE slides) for biomarker analysis to assess PD-L1 expression and provided sufficient tissue, including TMB and GEP. 4. ECOG PS ≤ 1. Key exclusion criteria included: 1. Received prior docetaxel treatment for metastatic disease or prior immune checkpoint inhibitor therapies targeting PD-1, PD-L1, or CTLA-4. Medicinal product no longer authorised

2. Diagnosed with NSCLC that harbours EGFR sensitizing or driver mutation or ALK gene translocation.

· Patients with a known ALK fusion oncogene were excluded. Patients (non -squamous or squamous histology) with unknown ALK fusion oncogene status were not required to be tested at screening given that testing for ALK fusion was not considered standard in the squamous type patient population and a low frequency in non-squamous type.

3. Patients with toxicities (as a result of prior anticancer therapy including radiation) which had not recovered to baseline or stabilised, except for AEs not constituting a likely safety risk (including but not limited to alopecia, rash, pigmentation, specific laboratory abnormalities, etc). Received

<div style=\"page-break-after: always\"></div>

chemotherapy, immunotherapy (e.g., interleukin, interferon, thymosin), or investigational agent used to control cancer ≤ 28 days (or ≤ 5 half-lives, whichever was shorter) prior to randomisation.

4. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc.
5. Patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline.
6. Clinically significant pericardial effusion.

7. Active leptomeningeal disease or uncontrolled, untreated brain metastasis: · Patients with a history of treated and, at the time of screening, asymptomatic central nervous system (CNS) metastases were eligible, provided they met all the following: -Brain imaging at screening showed no evidence of interim progression. -Had measurable disease outside the CNS, only supratentorial metastases allowed. -No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose were allowed. -No stereotactic radiation or whole-brain radiation within 14 days prior to randomisation. · Patients with new asymptomatic CNS metastases detected at the screening scan had to receive radiation therapy and/or surgery for CNS metastases. -Following treatment, these patients could then be eligible, provided all other criteria, including those for patients with a history of brain metastases, were met. 8. Malignancy other than NSCLC. · Any active malignancy ≤ 2 years before randomisation except for the specific cancer under investigation in this study with the exception of those with a negligible risk of metastasis or death, such as localised and adequately treated malignancies (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast). 9. Requiring systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of randomisation. · A brief course (≤ 7 days) of corticosteroids for prophylaxis ( e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) was permitted. · Adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent was permitted in the absence of active autoimmune disease. Medicinal product no longer authorised

- Topical, ocular, intra -articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) were permitted.
10. Active autoimmune diseases or history of autoimmune diseases that may relapse were excluded. Patients with the following autoimmune diseases were allowed: controlled type 1 diabetes, hypothyroidism managed with hormone replacement therapy only, controlled celiac disease, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or diseases not expected to recur in the absence of external triggering factors.
11. Any of the following cardiovascular criteria:

<div style=\"page-break-after: always\"></div>

a. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 28 days before random isation.

b. Symptomatic pulmonary embolism ≤ 28 days before random isation.

c. Acute myocardial infarction ≤ 6 months prior to random isation.

d. Heart failure of New York Heart Association Classification III or IV ≤ 6 months prior to randomisation.

12. Prior allogeneic stem cell transplantation or organ transplantation.

## · Treatments

ORR was defined as the proportion of patients who had a CR or PR as assessed by the investigator per RECIST v1.1 in the ITT and PD-L1-Positive Analysis Set. Patients without any postbaseline assessment were considered non-responders. Patients without measurable disease at baseline were also considered as non-responders. The difference in ORR between arms was evaluated using the CochranMantel-Haenszel (CMH) chi-square test with the actual stratification factors as strata.

Tislelizumab 200 mg was administered by IV infusion on Day 1 of each 21-day cycle (once every 3 weeks). The initial infusion (Cycle 1 Day 1) was delivered over 60 minutes. If this was well tolerated, then the subsequent infusions were administered over 30 minutes, which was the shortest time period permissible for infusion. Tislelizumab was not concurrently administered with any other drug. Tislelizumab was given until disease progression assessed by the investigator per RECIST v1.1, unacceptable toxicity, or withdrawal of informed consent, whichever occurs first. Docetaxel 75 mg/m 2 was administered as an IV infusion over 1 hour once every 3 weeks until disease progression, intolerable toxicity, or withdrawal of consent. Additional premedications were administered as per standard practice. Tumour assessments were conducted every 9 weeks for 52 weeks after randomisation and continued every 12 weeks thereafter. Survival status was followed every 3 months after discontinuation of the study treatment. · Objectives Assess the efficacy and safety of tislelizumab as monotherapy for the treatment in 2L (or 3L) of NSCLC. · Outcomes/endpoints Primary Efficacy Endpoint Overall Survival OS was defined as the time from the date of randomisation to the date of death due to any cause in the ITT and PD-L1-Positive Analysis Sets. Secondary Efficacy Endpoints Objective Response Rate Medicinal product no longer authorised

The two-sided 95% CIs for the odds ratio and the difference in ORR were calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm. In addition, the number and percentage of patients for each of the BOR categories were presented. A waterfall plot of best percent change in sum of target lesion diameters from baseline was provided by treatment arm. The patients in each arm were ordered by the percentage, and patients with the largest percentage were presented on the right.

<div style=\"page-break-after: always\"></div>

## Progression-Free Survival

PFS was defined as the time from randomisation to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first, in the ITT and PD-L1-Positive Analysis Sets. The actual tumour assessment visit date was used to calculate PFS. The PFS censoring rules were specified in the Statistical Analysis Plan. Similar methodology except for sensitivity analyses used to evaluate OS was applied to the analysis of PFS.

## Duration of Response

Duration of response (DoR) was defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first, in the ITT and PDL1-Positive Analysis Sets. Only the subset of patients who showed a CR or PR were to be included in the DoR analysis. Data for patients who were alive and who had not experienced disease progression at the time of analysis were censored at the date of the last tumour assessment. If no tumour assessments were performed after the date of the first occurrence of the objective response (CR or PR), DoR was censored at the date of the first occurrence of the objective response. Median DoR and corresponding 95% CIs were estimated using the Kaplan-Meier methodology for each treatment arm. Comparisons of DoR between treatment arms was made using the log-rank test. Health-Related Quality of Life Analysis method: the three patient-reported outcomes used for measuring HRQoL included QLQ-C30 (measuring core cancer) and its lung cancer module QLQ-LC13. Also, EQ-5D-5L was used for measuring general health status. Exploratory Efficacy Endpoints Disease Control Rate per the Investigator DCR was defined as the proportion of patients with objective response (CR or PR), non-CR/non-PD, or stable disease maintained for ≥ 9 weeks (with allowable visit window) using RECIST v1.1. DCR per the investigator was analysed. Similar methodologies for the analysis of ORR were applied. Clinical Benefit Rate per the Investigator CBR was defined as the proportion of patients who had CR, PR, non-CR/non-PD, and stable disease that is ≥ 24 weeks in duration per RECIST v1.1. CBR per the investigator was analysed. Similar methodologies for the analysis of ORR were applied. Time to Response per the Investigator Medicinal product no longer authorised

Time to response per the investigator was defined for patients with an objective response as determined by the investigator as the time from randomisation to the first occurrence of a CR or PR as assessed by the investigator using RECIST v1.1. Only the subset of patients who showed a CR or PR was included in the time to response analysis. Time to response was summarised for descriptive purposes. The mean, SD, median, and range of time to response were provided.

## Time to First Subsequent Anticancer Systemic Therapy

Time to first subsequent anticancer systemic therapy was defined for patients with the use of subsequent anticancer systemic therapy as the time from end of study treatment to first dose of subsequent anticancer systemic therapy. The mean, SD, median, and range of time to first subsequent anticancer systemic therapy were provided.

<div style=\"page-break-after: always\"></div>

## Subsequent Anticancer Therapy

Subsequent anticancer therapy was summarised by percentage, category and Preferred Term (PT) in the ITT and PD-L1-Positive Analysis Sets for each treatment arm.

## PD-L1 Expression as a Predictive Biomarker for Response

Distribution of PD-L1 expression was examined in the ITT Analysis Set. Association between PD-L1 expression (not restricted to the prespecified cutoff level of 25%) and tislelizumab treatment effect over docetaxel (OS, ORR, PFS, DoR, DCR, CBR) was explored.

The PD-L1 expression status was planned to be closely monitored and enrolment of patients whose tumours are PD-L1 negative was planned to be stopped as necessary through IWRT upon reaching ~60%, that is to ensure that the percentage of PD-L1 positive patients is no less than 40% of the ITT Analysis Set. The capping of PD-L1 negative patients to ~60% was planned to be implemented in both ITT-CAP and ITT-ROW independently.

· Sample size The original sample size calculation (i.e., approximately 640 patients in China and Asia Pacific region) was based on the number of events required to demonstrate the OS superiority of Arm A to Arm B in ITT-CAP and ITT-CAP patients with PD-L1 positive tumours. The sample size has been increased to include an additional 160 patients from ROW (rest of the world), hence a total of approximately 800 patients were planned to be recruited into the trial. Six hundred and forty patients in ITT-CAP were planned to be enrolled over a 16-month period at a constant enrolment rate and randomised in a 2:1 ratio to Arms A and B. The enrolment of 160 patients in ITT-ROW was expected to start approximately 8 months after that for the ITT-CAP and to last about 12 months. The median OS was assumed as 10 months in Arm B. An interim analysis was planned when approximately 426 deaths in the ITT Analysis Set have been observed, which represents 76% of the planned number of events (i.e. 560 events) in the ITT Analysis Set for the final analysis. There was an approximately 87% power to detect an OS HR (Arm A/Arm B) of 0.75 with a one-sided type I error of 0.02 in the ITT. A Hwang-ShihDeCani spending function with γ parameter of -2 based on the information fraction in the ITT Analysis Set was used in setting up the upper (efficacy) boundary. The stopping boundaries in Table 27 (below) were planned to be updated based on the actual death events observed in the ITT Analysis Set at the interim and final analyses. The superiority test of OS in the PD-L1 positive Analysis Set were planned to be performed only in the final analysis. Two hundred and seven deaths in the ITT patients with PD-L1 positive tumours were planned to be required to have an approximately 86% power to detect an OS HR of 0.60 with a onesided type I error of 0.007. Assuming the prevalence of PD-L1 positivity is 40% in the ITT Analysis Set, it was planned that it would take approximately 31.0 months to accumulate the required approximately 207 events in approximately 320 patients with PD-L1 positive tumours in the ITT Analysis Set. Medicinal product no longer authorised

The sample size and power considerations are acceptable, assumptions were well justified at the time of planning.

An interim analysis was planned when approximately 426 deaths in the ITT Analysis Set had been observed; however, the interim analysis was conducted after 441 events.

A capping of PD-L1 negative patients was planned to ensure that the percentage of PD-L1 positive patients was no less than 40% of the ITT Analysis Set. Capping was triggered for the Rest of the World

<div style=\"page-break-after: always\"></div>

population. After triggering this cap, 33 ROW patients were randomised, among whom 31 were PD-L1 ≥25%. 131 ROW patients had been already enrolled. A total of 16 patients were screen failures due to the cap.

In amendment 1, the sample size has been increased to enrol an additional 160 patients from ROW.

## · Randomisation and Blinding (masking)

Patients were planned to be randomised in a 2:1 ratio to receive tislelizumab or docetaxel, using the IWRT system for this study by permuted block stratified randomisation. According to the original study protocol, the randomisation was stratified according to the following factors: histology (squamous versus non-squamous), line of therapy (2 versus 3) and PD-L1 expression level on tumour cell membrane (&lt;25% versus ≥25%). The PD -L1 expression status was planned to be measured by immunohistochemistry (IHC) assay in a central laboratory and using the Ventana PD-L1 (SP263) antibody. To mitigate the risk of obtaining skewed PD-L1 distribution toward low expression due to competing trials enrolling only patients whose tumour PD-L1 expression is high, adjustment to enrolment was planned to be made by capping the PD-L1 negative and low population to ~60% of ITT. This was planned to be accomplished through the Interactive Web Response Technology (IWRT) system, when necessary. This study was open-label. · Statistical methods Analysis Sets The ITT population was planned to include all randomised patients and to analyse all patients according to their randomised treatment arms. It was planned to be the primary analysis population for the efficacy analysis. The ITT Analysis Sets was planned to be summarised for both the China and Asia Pacific (ITT-CAP) Analysis Set and the rest of world (ITT-ROW) Analysis Set. According to the original protocol, the Per Protocol (PP) population was planned to include all randomised patients who received at least one dose of the assigned study drug and had no major protocol deviations. Major protocol deviations were planned to be determined and documented before the database lock for the primary analysis. The PD-L1 positive population (&gt;=25% TCs) was planned to include all randomised patients whose tumours were PD-L1 positive and to analyse all patients according to their randomised treatment arms. It was planned to be the dual primary analysis population for efficacy analysis. Safety Analysis Set was planned to include all patients who received at least one dose of study drug. It was planned to be the population for the safety analyses. The PK Analysis Set was planned to include patients who contributed at least one quantifiable postdose PK sample. The ADA Analysis Set was planned to include all patients who have received at least 1 dose of tislelizumab for whom non-missing baseline ADA and at least 1 non-missing postbaseline ADA results are available. Medicinal product no longer authorised

## Primary and secondary endpoints

The primary endpoint of the trial was OS - defined as the time from the date of randomisation to the date of death due to any cause in the ITT and PD-L1 positive Analysis Set.

Secondary endpoints included in the multiple testing procedure were:

- ORR -defined as the proportion of patients in the ITT and PD-L1 positive Analysis Set who had a CR or PR as assessed by the investigator per RECIST v1.1.

<div style=\"page-break-after: always\"></div>

- DoR -defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator per RECIST v1.1, or death from any cause, whichever comes first, in the ITT and PD-L1 positive Analysis Set.
- PFS -defined as the time from the date of randomisation to the date of the first objectively documented tumour progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first, in the ITT and PD-L1 positive Analysis Set.
- HRQoL -measured using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) and Core 30 (EORTC QLQ-C30), and European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) scale.

Analysis primary endpoints OS was planned to be compared between tislelizumab (Arm A) and docetaxel (Arm B) in the ITT analysis set in a stratified log-rank test using a significance level of 0.02 (one-sided). The null hypothesis planned to be tested was: H0: OS in Arm A = OS in Arm B against the alternative hypothesis: Ha: OS in Arm A ≠ OS in Arm B This was planned to be the primary analysis once the targeted numbers of deaths would be reached in the ITT Analysis Set. The p-value from stratified log-rank test was planned to be presented using stratification factors (histology (squamous versus non-squamous), line of therapy (2 versus 3) and PDL1 expression level on tumour cell membrane (&lt;25% versus ≥25%)). The median OS and the cumulative probability of OS at every 6 months were planned to be calculated for each treatment arm and presented with two-sided 95% CIs. Kaplan-Meier survival probabilities for each arm were planned to be plotted over time. The hazard ratio between tislelizumab and docetaxel (HR A/B) and its 95% CI were planned to be estimated using a Cox proportional hazard model with treatment arm as a factor and stratified by the actual value of the stratification factors. The hypothesis testing of OS in the PD-L1 positive Analysis Set was planned to be carried out at a significance level of 0.007. If the OS hypothesis in the ITT Analysis Set could be rejected, its corresponding α would be shifted to the testing in the PD -L1 positive Analysis Set (i.e., a total α of 0.025). Similar statistical methods as described above were planned to be applied with histology and line of therapy as strata in the stratified analyses. Supplementary Analyses for Primary Endpoint In order to evaluate the robustness of the OS results, several sensitivity analyses were planned and further described in the Statistical Analysis Plan (SAP). The sensitivity analysis 1 was planned to be the same as the primary analysis except that it was planned to be based on the stratification factors using the values from Interactive Response Technology, by which patients were randomised. Medicinal product no longer authorised

The sensitivity analysis 2 was planned to be the same as the primary analysis except that it was planned to use Rank Preserving Structural Failure Time Model (RPSFTM) to adjust survival estimates in the presence of arm B patients receiving any subsequent immunotherapy after discontinuation of docetaxel.

The sensitivity analysis 3 was planned to be the same as the primary analysis except that a patient was planned to be censored at the date last known to be alive before his/her COVID-19 related drug administration protocol deviation.

<div style=\"page-break-after: always\"></div>

When there are over 10% ITT patients who had critical protocol deviations, the sensitivity analysis 4 in the PP analysis set was planned to be implemented in the same way as the primary analysis.

## Analysis Secondary Endpoints

The statistical significance of the difference in ORR between arms in the ITT Analysis Set was planned to be evaluated using the Cochran-Mantel-Haenszel chi-square test with the actual stratification factors as strata. The two-sided 95% CIs for the odds ratio and the difference in ORR was planned to be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm.

<!-- image -->

Progression-free survival was planned to be compared between the 2 arms in the ITT Analysis Set using a stratified log-rank test using actual stratification factors as strata. The median PFS and the cumulative probability of PFS at every 3 months were planned be calculated for each treatment arm and presented with two-sided 95% CIs. PFS was planned be estimated using the Kaplan-Meier method. The PFS censoring rule were planned to follow the 'FDA Guidance for Industry 2007'. The actual tumour assessment visit date was planned to be used to calculate PFS. Data for patients without disease progression or death at the time of analysis were planned to be censored at the time of the last valid tumour assessment. Data for patients who start to receive new anticancer therapy or are lost to follow-up were planned to be censored at the last valid tumour assessment date prior to the introduction of new therapy or lost to follow-up. Patients who had a clinical determination of progression were planned to undergo a CT/MRI, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient could be confirmed, the date of the CT/MRI scan would get considered as the progression date for that patient. The DoR was planned to be analysed similarly as the PFS. It was planned to be summarised within responders. Efficacy outcomes (i.e., ORR, DoR, and PFS) in the PD-L1 positive Analysis Set were planned to be summarised similarly. European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire (EORTC QLQ-LC13 and EORTC QLQ-C30) and EQ-5D-5L post baseline scores were planned to be compared between the 2 treatment arms, using a mixed model with baseline score and time since the randomisation as covariates. Significant interaction between treatment and time since randomisation or quadratic term of time since randomisation (p-value&lt;0.05) were planned to also be included in the final model. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 26: Censoring rules for primary analysis of PFS per RECIST version 1.1 (Study 303)

| authorised   |
|--------------|

Multiplicity The overall type I error was planned to be strongly controlled at a onesided α of 0.025 within the two dual primary hypotheses and 4 secondary efficacy hypotheses. An α of 0.02 and 0.007 was planned to be initially assigned to the primary hypothesis testing in the ITT and PD-L1 positive Analysis Sets, resp ectively. The α allocation accounts for the positive correlation between the test statistics in the 2 Analysis Sets (i.e., PD-L1 positive is a subset of the ITT Analysis Set). The overall type I error was controlled at 0.025 when at least 30% of the deaths in the ITT Analysis Set were from the PD-L1 positive subset. The α of 0.007 in the PD -L1 testing was planned to be adjusted downwards if the final observed percentage was lower. At the final analysis, it was planned to test the OS hypothesis first in the ITT Analysis Set. If the hypothesis in the ITT Analysis Set could be rejected, it was planned to pass the unused α on to the OS hypothesis test in PD -L1 positive Analysis Set; followed by the second efficacy hypothesis testing in the sequential order of ORR in the PD-L1 positive Analysis Set, DoR in the PD-L1 positive Analysis Set, PFS in the PD-L1 positive Analysis Set, PFS in the ITT Analysis Set, ORR in the ITT Analysis Set, DoR in the ITT Analysis Set, lung cancer symptom scale measured by QLQ-LC13 and QLQ-C30 global health status/QoL in the ITT and PD-L1 Analysis Sets. Otherwise, if the OS hypothesis in the ITT Analysis Set could not be rejected, the hypothesis testing would be carried out sequentially only in the PD-L1 positive Analysis Set for OS, ORR, DoR, PFS, lung cancer symptom scale measured by QLQ-LC13 and QLQC30 global health status/QoL scale at α of 0.007. The testing was planned to be continued until the first non-significant outcome occurs, following the methodology of Glimm et al (2010). Interim Analyses Medicinal product no longer authorised

An interim analysis for OS in the ITT Analysis Set was planned to be performed by an independent statistician external to BeiGene and when approximately 426 deaths (76% of the target number of 560 deaths) among the 2 treatment arms were observed in the ITT Analysis Set. It was estimated that it would take approximately 23.1 months to observe 426 events. The final analysis of OS was planned to take place after 560 deaths were observed in the ITT Analysis Set and 207 deaths were observed in its subgroup of patients with PD-L1 positive tumours. Thus, the predefined number of deaths in the ITT Analysis Set would trigger the interim and final analyses. The information fraction used in α spending function was planned to be based on the observed number of deaths in the ITT Analysis Set at the

<div style=\"page-break-after: always\"></div>

corresponding time points. With Protocol Amendment 3, a Hwang-Shih-DeCani (HSD) spending function with γ parameter of -2 was planned to be used in setting up the upper (efficacy) boundary. Initially, a HSD spending function with γ = -4 was defined. In Protocol Amendment 1 this was modified to a HSD with γ = -0.7. . Stopping boundaries (p-value and Z score) of superiority test for OS at the interim and final analyses in the ITT Analysis Set, as well as OS at the final analysis in the PD-L1 positive Analysis Set are shown in Table 27. The boundaries for hypothesis testing in OS were planned to be updated according to the actual numbers of death events in the interim and final analyses, using the pre-specified α spending function.

The IDMC was advised to make the recommendation of stopping the trial early for efficacy only when the early stopping boundaries for efficacy were crossed in the ITT Analysis Set.

<!-- image -->

<!-- image -->

Table 27: Stopping boundaries (p-value and Z score) and approximate HR threshold of interim and final analyses of OS (Study 303) Subgroup Analyses To determine if the treatment effect was consistent across various subgroups, the HR estimates of OS and its 95% CI were planned to be estimated and plotted within each category of the following variables: PDL1 expression in TC (≥25% TC versus &lt;25% TC) in the ITT Analysis Set, histology (squamous versus nonsquamous), line of therapy (2 versus 3), age (≤65 versus &gt;65 years), gender (Female versus Male), ECOG PS (0 versus 1), smoking status and region (CAP versus ROW). Approximately 160 patients were planned to be randomised in the ITT-ROW from countries outside of China and Asia Pacific region, which consisted of the 20% of the ITT Analysis Set. With the additional region, it was possible to evaluate the treatment effect of tislelizumab in a broader population, as well as its consistency between Asian and Caucasian populations. Subgroup analysis in the ITT-ROW were planned for descriptive purpose only due to the small sample size. Selected efficacy and safety variables were planned to be summarised in the ITT-ROW as subgroup analysis using similar methodologies discussed earlier. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Results

## · Participant flow

<!-- image -->

<!-- image -->

· Recruitment This ongoing study is currently being conducted in 109 study centres. Patients were enrolled in China, Brazil, Bulgaria, Lithuania, Mexico, New Zealand, Poland, Russia, Slovakia, and Turkey. The dominating enrolling country was China with a total of 651 subjects. The most common reasons for screen failure were Exclusion 11 (active leptomeningeal disease or uncontrolled, untreated brain metastasis/134 patients, 18.4%), Inclusion 5 (Patients must be able to provide archival/fresh tumour tissues for biomarker analysis to assess PD-L1 expression and, provided sufficient tissue, including TMB, and gene expression profiling (GEP), 132 patients, 18.1%), and Exclusion 23 (Underlying medical conditions, 84 patients, 11.5%). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Conduct of the study

Table 28: Summary of protocol amendments (Study 303)

<!-- image -->

|           | authorised   |           |
|-----------|--------------|-----------|
|           | no longer    |           |
|           | product      |           |
| Medicinal | Medicinal    | Medicinal |

<div style=\"page-break-after: always\"></div>

## · Baseline data

Table 29: Demographics and baseline characteristics (ITT analysis set) (Study 303) (DCO: 15JUL2021)

<!-- image -->

|           |         | longer   |
|-----------|---------|----------|
|           | no      |          |
|           | product |          |
| Medicinal |         |          |

Data Source: ADSL ADBASE ADCM ADTRSUM. Data cutoff: 15JUL2021. Data extraction: 22OCT2021.

<div style=\"page-break-after: always\"></div>

Table 30: Disease history (ITT analysis set) (Study 303) (DCO: 15JUL2021)

<!-- image -->

|           |    | longer   |
|-----------|----|----------|
|           | no |          |
| product   |    |          |
| Medicinal |    |          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |    | longer   |
|-----------|----|----------|
|           | no |          |
| product   |    |          |
| Medicinal |    |          |

Data Source: ADSL ADBASE ADCM ADTRSUM. Data cutoff: 15JUL2021. Data extraction: 22OCT2021.

For patients with any prior anticancer treatment, percentages were based on N; for others, percentages were based on the number of patients with any prior anticancer treatment.

<div style=\"page-break-after: always\"></div>

- a  Patients with missing baseline PD-L1 expression were the patients scored with unqualified samples

(n=1). Eight NSQ patients had their EGFR mutation status updated from unknown to wild type, which was due to sites updating the EGFR wild-type result confirmed by non-tissue-based to tissue-based method. In total, there was 1 NSQ patient who did not have a tissue-based EGFR wild-type result and had only a blood-based EGFR wild-type result.

- c Study Entry date referred to randomization date in this study.
- d A patient was counted only once within each category, but may be counted in multiple categories.

## · Numbers analysed

All 805 patients who were randomised to the study were included in the ITT Analysis Set.

<!-- image -->

<!-- image -->

Table 31: Analysis sets (Study 303) (DCO: 15JUL2021) · Outcomes and estimation Primary endpoint: dual primary (OS) Overall Survival in the ITT analysis The interim analysis of Study 303 (DCO 10 Aug 2020) had a median follow-up of 11.7 months (13.3 and 9.7 for Tislelizumab and Docetaxel arms, respectively). A statistically significant improvement in OS was observed in the ITT population. Results favoured the tislelizumab arm (HR = 0.64; 95% CI: 0.53, 0.78; p &lt; 0.0001). Median OS was 17.2 months for the tislelizumab arm and 11.9 months for the docetaxel arm. The final analysis (DCO 15 July 2021) had a median follow-up of 14.2 months (16.0 and 10.7 for Tislelizumab and Docetaxel arms, respectively). Results of the final analysis are provided below: Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 32: Analysis of overall survival (ITT analysis set) (Study 303) (DCO: 15JUL2021)

|                                    | Tislelizumab (N=535)   | Docetaxel (N=270)   |
|------------------------------------|------------------------|---------------------|
| Overall Survival                   |                        |                     |
| Death, n (%)                       | 365 (68.2)             | 206 (76.3)          |
| Censored, n (%)                    | 170 (31.8)             | 64 (23.7)           |
| Ongoing in the Study               | 153 (28.6)             | 45 (16.7)           |
| Withdrawal by Subject              | 6 (1.1)                | 16 (5.9)            |
| Lost to Follow-up                  | 10 (1.9)               | 2 (0.7)             |
| Study Discontinuation Due to Other | 1 (0.2)                | 1 (0.4)             |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 51: Kaplan-Meier plot of overall survival (ITT analysis set) (Study 303) (DCO: 15JUL2021) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Overall Survival in PD-L1-Positive Analysis Set ( &gt;25% PD-L1 positivity )

Table 33: Analysis of overall survival (PD-L1-positive analysis set, (&gt;25% PD-L1 positivity)) (Study 303) (DCO:15JUL2021)

| longer   |
|----------|

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Secondary endpoints: PFS, ORR, DoR, HRQoL

Progression-Free Survival

| longer   |
|----------|

Table 34: Analysis of progression-free survival per RECIST version 1.1 by investigator (ITT analysis set) (Study 303) (DCO: 15JUL2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 52: Kaplan-Meier plot of progression-free survival per RECIST version 1.1 by investigator (ITT analysis set) (Study 303) (DCO: 15JUL2021) In the PD-L1 Positive Analysis Set, the median PFS was 6.5 months (95% CI: 6.24, 8.28 months) and 2.5 months (95% CI: 2.10, 4.11 months) for the tislelizumab arm and Docetaxel arm, respectively, as estimated using the Kaplan-Meier method, with a stratified HR of 0.38 (95% CI: 0.285, 0.494), indicating a 62% reduction in the risk of experiencing a PFS event for patients in the Tislelizumab arm. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Objective Response Rate

Table 35: Analysis of disease response per RECIST version 1.1 by investigator (ITT analysis set), unconfirmed responses (Study 303) (DCO: 15JUL2021)

| authorised   |
|--------------|
| longer       |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 36: Analysis of disease response per RECIST version 1.1 by investigator (ITT analysis set), confirmed responses (Study 303) (DCO: 15JUL2021)

|                                               | Tislelizumab (N=535) n (%)   | Docetaxel (N=270) n (%)   |
|-----------------------------------------------|------------------------------|---------------------------|
| Best Overall Response with confirmation,n (%) |                              |                           |
| CR (Complete Response)                        | 9 (1.7)                      | 1 (0.4)                   |
| PR (Partial Response)                         | 103 (19.3)                   | 9 (3.3)                   |
| SD (Stable Disease)                           | 166 (31.0)                   | 100 (37.0)                |

In the PD-L1 Positive Analysis Set, the unconfirmed ORR in the tislelizumab arm (37.4% [95% CI: 31.13, 44.09]) was higher than the ORR in the docetaxel arm (7.0% [95% CI: 3.05, 13.25]) (with pvalue &lt; 0.0001). Meanwhile, a numerically higher ORR of 37.4% (85 patients) in the tislelizumab arm was observed in the PD-L1 Positive Analysis Set compared with 22.6% (121 patients) in the ITT Analysis Set. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Duration of Response

Table 37: Analysis of duration of response (unconfirmed) per RECIST version 1.1 by investigator (ITT analysis set) (Study 303) (DCO: 15JUL2021)

| authorised   |
|--------------|

| Medicinal   |
|-------------|

In the PD-L1 Positive Analysis Set, the median DoR in the tislelizumab arm (11.9 [95% CI: 8.31, 19.85]) was higher than the median DoR in the docetaxel arm (4.2 [95% CI: 0.56, 6.05]). Table 38: Analysis of duration of response (confirmed) per RECIST version 1.1 by investigator (ITT analysis set) (Study 303) (DCO: 15JUL2021) Medicinal product no longer authorised

DataSource:ADSLADTTE.Data cutoff:15JUL2021.Data extraction:22OCT2021.

Percentageswerebased on number ofresponders.

Duration of response analysis includedpatientswith objective response.

Medianfollow-uptimewasestimated bythereverseKaplan-Meiermethod.

Event freerateswere estimated byKaplan-Meiermethodwith95%CIs estimated usingtheGreenwood'sformula.

Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

Stratified by stratification factors: histology (squamous versus non-squamous), lines of therapy (second versus third), and PD-L1 expression (&gt;25% TC versus &lt;25% TC).

<div style=\"page-break-after: always\"></div>

## Health-Related Quality of Life

Compliance rates for all the 3 questionnaires were similar in both treatment arms, with highest compliance rates of &gt; 98% to 100% for QLQ-C30 and QLQ-LC13 and 78% to 100% for EQ-5D-5L in the HRQoL Analysis Set.

In the tislelizumab arm, there was a trend towards improvement in HRQoL as measured by QLQ-C30 GHS/QoL (LS mean difference up to Cycle 12 was 2.44 (95% CI: 4.050, 0.837), and in QLQ-LC13 coughing and dyspnoea compared to the docetaxel arm. The time to deterioration (TTD) for QLQ-C30 GHS/QoL and for the index score of the QLQ-LC13 was not reached in either treatment arm.

· Ancillary analyses Sensitivity Analysis for OS To test the robustness of the OS data, sensitivity analyses were performed as predefined in the statistical analysis plan at the interim analysis (DCO 10 Aug 2020). Sensitivity Analysis 1 The sensitivity analysis 1 was the same as the primary analysis except that it was based on the stratification factors using the values from IRT, by which patients were randomised. Sensitivity Analysis 1 showed consistent results with those from the primary OS analysis for the ITT Analysis Set, with a stratified HR of 0.64 (95% CI: 0.529, 0.781) Sensitivity Analysis 2 The sensitivity analysis 2 used RPSFTM to adjust survival estimates in the presence of patients in the docetaxel arm receiving any subsequent immunotherapy after discontinuation of docetaxel. As of the data cutoff date, 53 patients (19.6%) in the docetaxel arm received subsequent immunotherapy. The stratified HR was 0.58 (95% CI: 0.457, 0.736). Sensitivity Analysis 3 Sensitivity Analysis 3 was conducted to evaluate the impact of the COVID-19 pandemic for the primary analysis. It was the same as the primary analysis except that patients were censored at the date last known to be alive before his/her COVID-19 related drug administration protocol deviation (70 patients in total). The resulting stratified HR was 0.67 (95% CI: 0.548, 0.809) Sensitivity Analysis 4 In total, 61 patients (7.6%) in the ITT Analysis Set had critical protocol deviations and were excluded from the PP Analysis Set. Sensitivity Analysis 4 conducted in the PP Analysis Set showed a stratified HR of 0.62 (95% CI: 0.506, 0.757). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Subgroup Analysis

Table 39: Subgroup analysis: forest plot of OS (ITT analysis set) (Study 303) (DCO 15JUL2021)

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 40: Subgroup analysis: forest plot of PFS per RECIST 1.1 by investigator (ITT analysis set) (Study 303) (DCO 15JUL2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Overall Survival in PD-L1-Negative Analysis Set (&lt;25% PD-L1 positivity)

|                       | Tislelizumab (N=307)   | Docetaxel (N=152)   |
|-----------------------|------------------------|---------------------|
| Overall Survival      |                        |                     |
| Death, n (%)          | 223 (72.6)             | 117 (77.0)          |
| Censored, n (%)       | 84 (27.4)              | 35 (23.0)           |
| Ongoing in the Study  | 73 (23.8)              | 26 (17.1)           |
| Withdrawal by Subject | 3 (1.0)                | 7 (4.6)             |
| Lost to Follow-up     | 7 (2.3)                | 1 (0.7)             |

Table 41: Analysis of overall survival (PD-L1-negative analysis set, (&lt;25% PD-L1 positivity)) (Study 303) (DCO: 15JUL2021) -exploratory analysis

|                  | Objective Response n (%) (95% CI)   | Rate          |                |
|------------------|-------------------------------------|---------------|----------------|
|                  | Tislelizumab                        | Docetaxel     | Total          |
| Smoking status   | product                             |               |                |
| Former (n=492)   | 61/323 (18.9)                       | 5/169 (3.0)   | 66/492 (13.4)  |
|                  | (14.76, 23.59)                      | (0.97, 6.77)  | (10.53, 16.75) |
| Current (n=69)   | 13/50 (26.0)                        | 2/19 (10.5)   | 15/69 (21.7)   |
|                  | (14.63, 40.34)                      | (1.30, 33.14) | (12.71, 33.31) |
| Never (n=244)    | 33/162 (20.4)                       | 3/82 (3.7)    | 36/244 (14.8)  |
| Medicinal        | (14.46, 27.40)                      | (0.76, 10.32) | (10.55, 19.84) |
| Gender           |                                     |               |                |
| Male (n=622)     | 90/416 (21.6)                       | 7/206 (3.4)   | 97/622 (15.6)  |
|                  | (17.77, 25.91)                      | (1.38, 6.88)  | (12.83, 18.69) |
| Female (n=183)   | 17/119 (14.3)                       | 3/64 (4.7)    | 20/183 (10.9)  |
|                  | (8.55, 21.88)                       | (0.98, 13.09) | (6.80, 16.37)  |
| Brain metastasis |                                     |               |                |
| Yes (n=57)       | 9/39 (23.1)                         | 0/18 (0.0)    | 9/57 (15.8)    |
|                  | (11.13, 39.33)                      | (0.00, 18.53) | (7.48, 27.87)  |
| No (n=748)       | 98/496 (19.8)                       | 10/252 (4.0)  | 108/748 (14.4) |
|                  | (16.34, 23.54)                      | (1.92, 7.18)  | (12.00, 17.16) |
| PD-L1 TC <25%    |                                     |               |                |
| Yes              | 32/307 (10.4)                       | 6/152 (3.9)   | 38/459 (8.3)   |
|                  | (7.24, 14.40)                       | (1.46, 8.39)  | (5.93, 11.19)  |

Objective Response Rate by smoking status, gender and brain metastases Table 42: Analysis of confirmed objective response rate per RECIST version 1.1 by Investigator by smoking status, gender, and brain metastasis (ITT analysis set) (Study 303) (DCO 15JUL2021) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the 2L/3L (as monotherapy) NSCLC indication of the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 43: Summary of efficacy for BGB-A317-303 (Study 303)

<!-- image -->

| Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of BGB-A317 (anti-PD1 antibody) compared with docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen   | Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of BGB-A317 (anti-PD1 antibody) compared with docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen   | Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of BGB-A317 (anti-PD1 antibody) compared with docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                    | BGB-A317-303; EudraCT number 2018-000245-39, RATIONALE 303                                                                                                                                                                                                          | BGB-A317-303; EudraCT number 2018-000245-39, RATIONALE 303                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                              | Phase III, multicentre, randomised (2:1), open-label study comparing tislelizumab monotherapy versus docetaxel                                                                                                                                                      | Phase III, multicentre, randomised (2:1), open-label study comparing tislelizumab monotherapy versus docetaxel                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                              | Duration of main phase:                                                                                                                                                                                                                                             | 30-Nov-2017 - Ongoing (data cut-off for interim analysis: 10-Aug-2020; final analysis: 15-July-2021) The interim and final analyses were conducted when the predefined death events had been observed for the efficacy and safety evaluations. Results for the final analysis are presented in this submission. The study will continue until the last patient has died, becomes lost to follow-up, or withdraws from study, or until Sponsor decides to terminate the study. authorised |
| Design                                                                                                                                                                                                                                                              | Duration of Run-in phase:                                                                                                                                                                                                                                           | Not applicable longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                                                                                                                                              | Duration of Extension phase:                                                                                                                                                                                                                                        | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hypothesis                                                                                                                                                                                                                                                          | Superiority no                                                                                                                                                                                                                                                      | Superiority no                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                                                   | Tislelizumab                                                                                                                                                                                                                                                        | 200 mg IV Q3W / n = 535                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                   | Docetaxel                                                                                                                                                                                                                                                           | 75 mg/m 2 IV Q3W / n = 270                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Endpoints and definitions                                                                                                                                                                                                                                           | Primary endpoint OS product                                                                                                                                                                                                                                         | Time from the date of randomisation to the date of death due to any cause in the ITT and PD-L1 positive analysis set (defined as ≥25% of tumour cells with PD-L1 membrane staining via Ventana SP263 assay)                                                                                                                                                                                                                                                                              |
| Endpoints and definitions                                                                                                                                                                                                                                           | Secondary endpoint PFS                                                                                                                                                                                                                                              | Time from the date of randomisation to the date of the first objectively documented tumour progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first, in the ITT and PD-L1 positive analysis set                                                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                                                           | Secondary endpoint ORR Medicinal                                                                                                                                                                                                                                    | Proportion of patients who had a CR or PR as assessed by the investigator per RECIST v1.1 in the ITT and PD-L1-Positive Analysis                                                                                                                                                                                                                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                           | Secondary endpoint DOR                                                                                                                                                                                                                                              | Time from the first occurrence of a documented objective response to the time of relapse, as determined by the investigator per RECIST v1.1, or death from any cause, whichever comes first, in the ITT and PD-L1 positive analysis set                                                                                                                                                                                                                                                  |
| Data cutoff                                                                                                                                                                                                                                                         | 15-July-2021 (final analysis data cut-off date)                                                                                                                                                                                                                     | 15-July-2021 (final analysis data cut-off date)                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Results and Analysis                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis description                                      | Primary endpoint analysis - OS in ITT and PD-L1 positive subgroup                                                                                                                                                                                       | Primary endpoint analysis - OS in ITT and PD-L1 positive subgroup                                                                                                                                                                                       | Primary endpoint analysis - OS in ITT and PD-L1 positive subgroup                                                                                                                                                                                       |
|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description            | ITT and PD-L1 positive analysis set Time point: As of the data cut-off date of 15-July-2021, a total of 571 death events had occurred in the ITT Analysis Set, reaching the preplanned number of events in the final analysis for the primary endpoint. | ITT and PD-L1 positive analysis set Time point: As of the data cut-off date of 15-July-2021, a total of 571 death events had occurred in the ITT Analysis Set, reaching the preplanned number of events in the final analysis for the primary endpoint. | ITT and PD-L1 positive analysis set Time point: As of the data cut-off date of 15-July-2021, a total of 571 death events had occurred in the ITT Analysis Set, reaching the preplanned number of events in the final analysis for the primary endpoint. |
| Descriptive statistics and estimate variability           | Treatment group                                                                                                                                                                                                                                         | Tislelizumab                                                                                                                                                                                                                                            | Docetaxel                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability           | ITT                                                                                                                                                                                                                                                     | ITT                                                                                                                                                                                                                                                     | ITT                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability           | Number of patients                                                                                                                                                                                                                                      | 535                                                                                                                                                                                                                                                     | 270                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability           | mOS (months)                                                                                                                                                                                                                                            | 16.9                                                                                                                                                                                                                                                    | 11.9                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability           | 95% CI                                                                                                                                                                                                                                                  | 15.24, 19.09                                                                                                                                                                                                                                            | 9.63, 13.54                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability           | PD-L1 ≥ 25% authorised                                                                                                                                                                                                                                  | PD-L1 ≥ 25% authorised                                                                                                                                                                                                                                  | PD-L1 ≥ 25% authorised                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability           | Number of patients                                                                                                                                                                                                                                      | 227                                                                                                                                                                                                                                                     | 115                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability           | mOS (months)                                                                                                                                                                                                                                            | 19.3                                                                                                                                                                                                                                                    | 11.5                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability           | 95% CI                                                                                                                                                                                                                                                  | 16.5, 22.6                                                                                                                                                                                                                                              | 8.2, 13.5                                                                                                                                                                                                                                               |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                       | Tislelizumab vs. docetaxel                                                                                                                                                                                                                              |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                                      | 0.66                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                  | 0.56, 0.79                                                                                                                                                                                                                                              |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | p-value                                                                                                                                                                                                                                                 | <0.0001                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                            | PD- L1 ≥ 25%                                                                                                                                                                                                                                            | Comparison groups longer                                                                                                                                                                                                                                | Tislelizumab vs. docetaxel                                                                                                                                                                                                                              |
| Effect estimate per comparison                            | PD- L1 ≥ 25%                                                                                                                                                                                                                                            | HR                                                                                                                                                                                                                                                      | 0.53                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                            | PD- L1 ≥ 25%                                                                                                                                                                                                                                            | 95% CI no                                                                                                                                                                                                                                               | 0.41, 0.70                                                                                                                                                                                                                                              |
| Notes                                                     | Not applicable.                                                                                                                                                                                                                                         | Not applicable.                                                                                                                                                                                                                                         | Not applicable.                                                                                                                                                                                                                                         |
| Analysis description                                      | Secondary endpoint analysis - PFS in ITT and PD-L1 positive subgroup                                                                                                                                                                                    | Secondary endpoint analysis - PFS in ITT and PD-L1 positive subgroup                                                                                                                                                                                    | Secondary endpoint analysis - PFS in ITT and PD-L1 positive subgroup                                                                                                                                                                                    |
| Analysis population and time point description            | ITT and PD-L1 positive analysis set product                                                                                                                                                                                                             | ITT and PD-L1 positive analysis set product                                                                                                                                                                                                             | ITT and PD-L1 positive analysis set product                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability Medicinal | Treatment group                                                                                                                                                                                                                                         | Tislelizumab                                                                                                                                                                                                                                            | Docetaxel                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability Medicinal | Number of patients                                                                                                                                                                                                                                      | 535                                                                                                                                                                                                                                                     | 270                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability Medicinal | mPFS (months)                                                                                                                                                                                                                                           | 4.2                                                                                                                                                                                                                                                     | 2.6                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability Medicinal | 95% CI                                                                                                                                                                                                                                                  | 3.88, 5.52                                                                                                                                                                                                                                              | 2.17, 3.78                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability Medicinal | PD-L1 ≥ 25%                                                                                                                                                                                                                                             | PD-L1 ≥ 25%                                                                                                                                                                                                                                             | PD-L1 ≥ 25%                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability Medicinal | Number of patients                                                                                                                                                                                                                                      | 227                                                                                                                                                                                                                                                     | 116                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability Medicinal | mPFS (months)                                                                                                                                                                                                                                           | 6.5                                                                                                                                                                                                                                                     | 2.5                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability Medicinal | 95% CI                                                                                                                                                                                                                                                  | 6.24, 8.28                                                                                                                                                                                                                                              | 2.10, 4.11                                                                                                                                                                                                                                              |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                       | Tislelizumab vs. docetaxel                                                                                                                                                                                                                              |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | HR                                                                                                                                                                                                                                                      | 0.63                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                            | ITT                                                                                                                                                                                                                                                     | 95% CI                                                                                                                                                                                                                                                  | 0.53, 0.75                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                 | PD- L1 ≥ 25%                                                                                       | Comparison groups                                                                                  | Tislelizumab vs. docetaxel                                                                         |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                 |                                                                                                    | HR                                                                                                 | 0.38                                                                                               |
|                                                 |                                                                                                    | 95% CI                                                                                             | 0.29, 0.49                                                                                         |
| Notes                                           | Not applicable.                                                                                    | Not applicable.                                                                                    | Not applicable.                                                                                    |
| Analysis description                            | Secondary endpoint analysis - ORR in ITT and PD-L1 positive subgroup                               | Secondary endpoint analysis - ORR in ITT and PD-L1 positive subgroup                               | Secondary endpoint analysis - ORR in ITT and PD-L1 positive subgroup                               |
| Analysis population and time point description  | ITT and PD-L1 positive analysis set                                                                | ITT and PD-L1 positive analysis set                                                                | ITT and PD-L1 positive analysis set                                                                |
| Descriptive statistics and estimate variability | Treatment group                                                                                    | Tislelizumab                                                                                       | Docetaxel                                                                                          |
| Descriptive statistics and estimate variability | ITT                                                                                                | ITT                                                                                                | ITT                                                                                                |
| Descriptive statistics and estimate variability | Number of patients                                                                                 | 535                                                                                                | 270                                                                                                |
| Descriptive statistics and estimate variability | ORR CR+PR (%)                                                                                      | 112 (20.9)                                                                                         | 10 (3.7)                                                                                           |
| Descriptive statistics and estimate variability | 95% CI                                                                                             | 17.56, 24.63                                                                                       | 1.79, 6.71                                                                                         |
| Descriptive statistics and estimate variability | PD-L1 ≥ 25% authorised                                                                             | PD-L1 ≥ 25% authorised                                                                             | PD-L1 ≥ 25% authorised                                                                             |
| Descriptive statistics and estimate variability | ORR CR+PR (%)                                                                                      | 34.4                                                                                               | 7.0                                                                                                |
| Descriptive statistics and estimate variability | 95% CI                                                                                             | 31.13, 44.09                                                                                       | 3.05, 13.25                                                                                        |
| Notes                                           | Not applicable.                                                                                    |                                                                                                    |                                                                                                    |
| Analysis description                            | Secondary endpoint analysis - DOR (Unconfirmed Response) in ITT and PD-L1 positive subgroup longer | Secondary endpoint analysis - DOR (Unconfirmed Response) in ITT and PD-L1 positive subgroup longer | Secondary endpoint analysis - DOR (Unconfirmed Response) in ITT and PD-L1 positive subgroup longer |
| Analysis population and time point description  | ITT and PD-L1 positive analysis set no                                                             | ITT and PD-L1 positive analysis set no                                                             | ITT and PD-L1 positive analysis set no                                                             |
| Descriptive statistics and estimate variability | Treatment group                                                                                    | Tislelizumab                                                                                       | Docetaxel                                                                                          |
| Descriptive statistics and estimate variability | ITT product                                                                                        | ITT product                                                                                        | ITT product                                                                                        |
| Descriptive statistics and estimate variability | Number of patients                                                                                 | 535                                                                                                | 270                                                                                                |
| Descriptive statistics and estimate variability | mDOR (months)                                                                                      | 13.5                                                                                               | 6.0                                                                                                |
| Descriptive statistics and estimate variability | 95% CI                                                                                             | 8.54, 19.58                                                                                        | 2.10, 7.16                                                                                         |
| Descriptive statistics and estimate variability | PD-L1 ≥ 25%                                                                                        | PD-L1 ≥ 25%                                                                                        | PD-L1 ≥ 25%                                                                                        |
| Descriptive statistics and estimate variability | Number of patients                                                                                 | 227                                                                                                | 116                                                                                                |
| Descriptive statistics and estimate variability | mDOR (months)                                                                                      | 11.9                                                                                               | 4.2                                                                                                |
| Descriptive statistics and estimate variability | 95% CI                                                                                             | 8.31, 19.85                                                                                        | 0.56, 6.05                                                                                         |
| Notes Medicinal                                 | Not applicable.                                                                                    | Not applicable.                                                                                    | Not applicable.                                                                                    |

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Table 44: Analysis of OS, PFS and confirmed ORR by age group (Study 303) (DCO: 15JUL2021)

|                                 | <65years                                                               | <65years            | 65-<75years           | 65-<75years         | >=75 years           | >=75 years          |
|---------------------------------|------------------------------------------------------------------------|---------------------|-----------------------|---------------------|----------------------|---------------------|
|                                 | Tislelizumab (N =364)                                                  | Docetaxel (N = 180) | Tislelizumab (N =156) | Docetaxel (N = 79)  | Tislelizumab (N =15) | Docetaxel (N = 11)  |
| Overallsurvival(month)          |                                                                        |                     |                       |                     |                      |                     |
| Median (95% CI)                 | 17.6 (15.41,20.57)11.5 (9.63,13.54)17.2 (13.44,23.69)13.1 (7.49,16.56) |                     |                       |                     | 7.5 (3.48, NE)       | 7.0 (2.73, NE)      |
| Stratified HR(95% CI)           | 0.59 (0.463, 0.748)                                                    | 0.59 (0.463, 0.748) | 0.67 (0.461, 0.974)   | 0.67 (0.461, 0.974) | 0.91 (0.289, 2.879)  | 0.91 (0.289, 2.879) |
| Progression-FreeSurvival(month) |                                                                        |                     |                       |                     |                      |                     |
| Median (95% CI)                 | 4.0 (2.76, 4.24)                                                       | 2.3 (2.10, 3.78)    | 6.0 (4.14, 7.75)      | 3.7 (2.23, 4.21)    | 3.5 (2.04, 8.31)     | 3.8 (2.10, 8.38)    |
|                                 |                                                                        |                     |                       |                     |                      | 0 (0.0)             |
|                                 |                                                                        |                     |                       |                     |                      | (0.00, 28.49)       |

| Medicinal   |
|-------------|

In vitro biomarker test for patient selection for efficacy Assay used: VENTANA PD-L1 (SP263) Analytical Performance Cut-off TC25% Sensitivity and Specificity Analytical sensitivity and specificity of the VENTANA PD-L1 (SP263) CDx Assay is assessed by immunoreactivity testing on various normal and neoplastic tissues. The normal tissues were evaluated for the presence of any specific epithelial membrane staining. Neoplastic tissues were evaluated for tumour cell membrane staining and tumour-associated immune cell staining. Repeatability and Intermediate Precision Table 45: Repeatability and intermediate precision study of VENTANA PD-L1 (SP263) CDx assay on NSCLC tissue specimens -25% TC cutoff Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 46: Lot-to-lot reproducibility agreement rates across NSCLC tissue specimens at 25% TC cutoff

| Lotto Lot Reproducibility   | PositivePercent Agreement (95%CI)**   | NegativePercent Agreement (95%CI)**   | OverallPercent Agreement (95%CI)**   |
|-----------------------------|---------------------------------------|---------------------------------------|--------------------------------------|
| Average of all three        | 99.2%                                 | 97.5%                                 | 98.4%                                |
| lot-to-lotcomparisons       | (97.0-99.8)                           | (94.7-98.9)                           | (96.8-99.2)                          |

| longer   |
|----------|

Inter-and Intra-Reader Precision Studies Table 47: Between and within reader precision of VENTANA PD-L1 (SP263) CDx Assay staining of NSCLC -25% TC cutoff Clinical Performance Tumour specimens from eligible patients were prospectively tested for PD-L1 expression by a central laboratory. The study enrolled all eligible patients whose tissue was evaluable for expression testing, regardless of PD-L1 expression status. The PD-L1 expression status remained blinded to BeiGene, patients, and investigators and only open to the Independent Data Monitoring Committee (IDMC). Determination of the 25% cutoff for the PD-L1 expression level was chosen based on: (1) durvalumab studies in late-line NSCLC using the same PD-L1 kits with SP263 (Planchard et al 2016, Garassino et al 2017), and (2) NSCLC cohort data from Study 001 with tislelizumab. Both the durvalumab studies and Study 001 for tislelizumab suggest that patients with PDL1 ≥ 25% had better clinical efficacy than PD -L1 &lt; 25%. As such, the 25% PD L1 expression level was prespecified in the protocol to assess PD-L1 positive/negative status in Study 303. The 25% cutoff selection cannot be followed. The Applicant explained that data from published durvalumab studies (performed with the same assay) were considered.  The cut-off was further validated in Study001 where PDL1 ≥25% was determined as the most optimal cutoff based on statistical parameters relative to clinical response, as well as improved ORR and DCR. Medicinal product no longer authorised

To mitigate the risk of obtaining skewed PD-L1 distribution toward low expression due to competing studies enrolling only patients whose tumour PD-L1 expression was high, an adjustment to the enrolment was made by capping the PD-L1 negative and low population to ~60% of the ITT population. This was accomplished through the IWRT system such that the percentage of PD-L1 positive (≥ 25%) patients was no less than 40% of the ITT population (based on the reported prevalence of PD-L1 positivity of ~40% in the NSCLC population (Rebelatto et al 2016, Antonia et al

<div style=\"page-break-after: always\"></div>

2017)). Capping was triggered towards the end of enrolment; thus, the impact could be low on the patient population selection in this study.

The percentage of PD-L1 high (60% of the study population) in the durvalumab study differs largely from the values tested in Study 303 (42%) which could be due to competing studies enrolling only patients whose tumour PD-L1 expression was high, as the applicant stated. This could, however, also indicate a low concordance between the data from durvalumab VENTANA PD-L1 (SP263) and data generated in this study. This issue is not further pursued, one should nevertheless take into consideration that PD-L1 expression data represent another uncertainty to the question of the external validity of the trial.

<!-- image -->

<!-- image -->

Analysis performed across trials (pooled analyses and meta-analysis) Not applicable. Supportive study(ies) Study 001 Study 001 was a Phase I open-label multiple dose study consisting of a Phase IA dose escalation and dose-finding component to establish the MTD, if any, and RP2D(s) followed by a Phase IB component to investigate the safety, tolerability, PK, and antitumour activity of tislelizumab in patients with advanced tumours including NSCLC. Phase IA consisted of 3 parts. Part 1 was a multicentre, open-label, multiple-dose, dose-escalation, FIH study. Part 2 evaluated the safety and PK of 2 dosing schedules, once every 2 weeks vs. once every 3 weeks at selected doses. Part 3 evaluated the safety and PK of tislelizumab at a flat dose that did not exceed the exposure as determined in Part 1. Part 2 and Part 3 also evaluated preliminary efficacy. Phase IB was a multicentre, open-label, multiple-dose (repeated dosing), multiple-arm, indication expansion study. The various arms of the study examined the potential efficacy, safety, and tolerability of tislelizumab in patients with cancer who had previously failed standard of care therapies. The patients with NSCLC (n = 49) were treated at 5 mg/kg dose in Q3W dosing schedule. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 53: Study design FIH study (Study 001) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| no longer   |
|-------------|

Table 48: Summary of treatment response by investigator (Study 001, phase 1B) (safety analysis set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 49: Tumour response by PD-L1 expression status (Study 001) (safety analysis set)

| OverallResponseCategory    | GC (N=54)     | EC (N=54)     | HCC (N =50)   | oC (N =51)    | NSCLC (N = 49)   | TNBC (N =21)   | CRC (N=21)    | HNSCC (N =20)   | UBC (N = 17)   | CC (N=18)     | RCC (N=16)     |
|----------------------------|---------------|---------------|---------------|---------------|------------------|----------------|---------------|-----------------|----------------|---------------|----------------|
| Overal1 ORR [1] (CR, PR)   |               |               |               |               |                  |                |               |                 |                |               |                |
| n (%)                      | 7 (13.0)      | 6 (11.1)      | 6 (12.0)      | 5 (9.8)       | 6 (12.2)         | 0 (0.0)        | 3 (14.3)      | 3 (15.0)        | 5 (29.4)       | 0 (0.0)       | 5 (31.3)       |
| (Exact 95% CI)             | (5.37, 24.90) | (4.19, 22.63) | (4.53, 24.31) | (3.26, 21.41) | (4.63, 24.77)    | (0.00, 16.11)  | (3.05, 36.34) | (3.21, 37.89)   | (10.31, 55.96) | (0.00, 18.53) | (11.02, 58.66) |
| PD-L1ExpressionPositive[2] | 23            | 33            | 26            | 22            | 16               | 13             | 6             | 5               | 9              | 7             | 6              |
| n(%) [3]                   | 4 (17.4)      | 4 (12.1)      | 6 (23.1)      | 3 (13.6)      | 3 (18.8)         | 0 (0.0)        | 2 (33.3)      | 1 (20.0)        | 3 (33.3)       | 0 (0.0)       | 2 (33.3)       |
| (Exact 95% CI)             | (4.95, 38.78) | (3.40, 28.20) | (8.97, 43.65) | (2.91, 34.91) | (4.05, 45.65)    | (0.00, 24.71)  | (4.33, 77.72) | (0.51, 71.64)   | (7.49, 70.07)  | (0.00, 40.96) | (4.33, 77.72)  |
|                            |               |               |               |               |                  |                |               |                 |                |               | 9              |
|                            |               |               |               |               |                  |                |               |                 |                |               | 1              |

<!-- image -->

b The duration of the first cycle for the first 20 patients was 21 days, and DLT assessment was conducted in this period; the duration of the first cycle for the remaining 48 patients was 28 days, which was performed for the PK analyses of the products derived from 2 manufacturing processes and scales (500L-FMP versus 2000L-FMP).

Study 102 Study 102 was a two-phase, non-randomised, Phase 1/2 study of tislelizumab monotherapy in Chinese patients with advanced solid tumours. The Phase 1 part of Study 102 was a multicentre and open-label study for the verification of tislelizumab dosing regimen identified in Study 001. a Fresh tumour biopsy samples (optional) were collected within 42 days prior to the first dose of study drug if patients had no archival tumour tissue samples. Other screening assessments were completed within 28 days prior to the first dose of the study drug. Medicinal product no longer authorised

## Figure 54: Flow chart for Phase 1 (Study 102)

The Phase 2 of Study 102 was conducted as an indication-expansion study with the 200mg Q3W tislelizumab dose among the following 11 arms of indications to further assess the preliminary efficacy, safety, and PK of tislelizumab in Chinese patients with multiple malignant solid tumours. For the purpose of this submission, only data from the NSCLC arm is discussed in this report.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Figure 55: Flow chart for Phase 2 (Study 102)

<!-- image -->

The tumours evaluated include NSCLC; gastric cancer (GC); melanoma; oesophageal cancer; renal cell carcinoma (RCC); urothelial carcinoma (UC); microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) colorectal cancer; triple-negative breast cancer, head and neck squamous cell carcinoma, small cell neuroendocrine carcinoma or other tumours with known MSI-H or dMMR; nasopharyngeal carcinoma (NPC); and hepatocellular carcinoma including mixed hepatocellular and cholangiocellular carcinoma. a Tumour samples and blood samples for detecting MSI or tumour samples for detecting MMR mutation status were collected during prescreening period (≤ 8 weeks prior to screening period) from patients to be enrolled in arm 8 when their MSI/MMR mutation status was unknown. b Fresh tumour biopsy samples were collected within 42 days prior to the first dosing if patients had no archival tumour tissue samples. Other screening assessments were completed within 28 days prior to the first dose of the study drug. Objective response rate was a primary endpoint of the Phase 2 stage. There was no formal statistical testing for the efficacy endpoints; the efficacy analyses were descriptive only. Response was based on Investigators' judgment according to RECIST v1.1. OS was also collected. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | no      |
|-----------|---------|
|           | product |
| Medicinal |         |

Table 50: Baseline characteristics NSCLC population (Study 102)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 51: Analysis of confirmed disease response per RECIST v1.1 (Study 102)

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

Among 56 patients with NSCLC, 33 (58.9%) patients had died as of the final data cutoff date. The median OS was 22.1 months (95% CI: 10.1 to 33.5). The cumulative probability of OS at 12 and 24 months was 0.6 (95% CI: 0.4 to 0.7) and 0.5 (95% CI: 0.4 to 0.6), respectively. Medicinal product no longer authorised

Figure 56: Kaplan-Meier plot of overall survival (Study 102) (safety analysis set)

PD -L1 expression on tumour cell membranes was assessed by the central laboratory using the VENTANA PD -L1 (SP263) assay. PDL1 positivity was defined as ≥10% of tumour cells with PD -L1 membrane staining at any intensity. Response was observed regardless of PD-L1 expression levels. Of

<div style=\"page-break-after: always\"></div>

the 56 patients, there were 24 patients (42.9%) with PD-L1-positive NSCLC, 31 patients (55.4%) with PD-L1-negative NSCLC, and 1 patient (1.8%) with PD-L1 status unknown. ORR was 16.7% and 19.4% for patients with PD-L1-positive NSCLC and patients with PD-L1-negative NSCLC, respectively. The median OS was 22.1 months (95% CI: 11.0 to 28.5) for patients with PD-L1-positive NSCLC and 28.1 months (95% CI: 7.3 to NE) for patients with PD-L1-negative NSCLC, with a median survival follow-up time of 31.4 months (95% CI: 26.8 to 34.2).

## 2.5.5.3. Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of squamous NSCLC

<!-- image -->

<!-- image -->

Main study Study 307 (BGB-A317-307): A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer Study 307 is a Phase III, 3-arm, open-label, randomised, multicentre study, conducted solely in China, designed to evaluate the efficacy and safety of tislelizumab in combination with carboplatin plus either paclitaxel (Arm T+PC) or nab-paclitaxel (Arm T+nPC) vs. paclitaxel plus carboplatin alone (Arm PC) as first-line treatment in 360 patients with Stage IIIB or IV squamous NSCLC. The study design schema is depicted below. The enrolment period was from 30-July-2018 to 13-Jun-2019. Figure 57: Study design (Study 307) Medicinal product no longer authorised

## Methods

## · Study Participants

Key inclusion criteria included:

1. 18 to 75 years old on the day of signing the informed consent form (ICF)
2. Histologically confirmed, locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) squamous NSCLC

<div style=\"page-break-after: always\"></div>

a. Patients with tumours of mixed non-small cell histology (squamous and non-squamous) were eligible if the major histological component appeared to be squamous.

3. Patients must have been able to provide fresh or archival tumour tissues (formalin-fixed paraffinembedded blocks or approximately 15 [≥ 6] freshly cut unstained formalin -fixed paraffinembedded slides) with an associated pathological report (squamous). In the absence of sufficient archival tumour tissues, a fresh biopsy of a tumour lesion at baseline was mandatory. PD-L1 expression was assessed centrally.
4. ECOG PS ≤ 1

5. Patients must have had ≥ 1 measurable lesion as defined per RECIST v1.1. 6. Must have been treatment-naive for locally advanced or metastatic squamous NSCLC. a. Patients who had received prior neoadjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a diseasefree interval of ≥ 6 months from the last dose of chemotherapy and/or r adiotherapy prior to randomisation. Key exclusion criteria included: 1. Diagnosed with NSCLC that harbours an EGFR -sensitizing mutation or ALK gene translocation 2. Received any approved systemic anticancer therapy, including hormonal therapy within 28 days prior to initiation of study treatment 3. Treatment with systemic immune-stimulatory agents (including but not limited to interferons, interleukin 2, and tumour necrosis factor) within 4 weeks or 5 half-lives of the drug, whichever was longer, prior to randomisation (prior treatment with cancer vaccines was allowed) 4. Active leptomeningeal disease or uncontrolled, untreated brain metastasis a. Patients with a history of treated and, at the time of screening, asymptomatic CNS metastases were eligible, provided they met all the following: i. Brain imaging at screening showed no evidence of interim progression ii. Had measurable disease outside the CNS, only supratentorial metastases allowed iii. No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed iv. No stereotactic radiation or whole-brain radiation within 14 days prior to randomisation b. Patients with new asymptomatic CNS metastases detected at the screening scan must have received radiation therapy and/or surgery for CNS metastases. Medicinal product no longer authorised

- i. Following treatment, these patients may have then been eligible, provided all other criteria, including those for patients with a history of brain metastases, were met.
5. Any major surgical procedure requiring general anaesthesia ≤ 28 days before random isation
6. Any active malignancy ≤ 2 years before randomisation, except for the specific cancer under investigation in this study and any locally recurring cancer that had been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)

<div style=\"page-break-after: always\"></div>

7. Active autoimmune diseases or history of autoimmune diseases that may have relapsed Note: Patients with the following diseases were not excluded and may have proceeded to further screening:
- a. Controlled Type I diabetes
- b. Hypothyroidism (provided it was managed with hormone replacement therapy only)
- c. Controlled celiac disease
- d. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia)
- e. Any other disease that was not expected to recur in the absence of external triggering factor

8. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before randomisation · Treatments Tislelizumab Tislelizumab 200 mg was administered on Day 1 of each 3-week cycle, by intravenous infusion through an intravenous line containing a sterile, nonpyrogenic, low-protein-binding 0.2 or 0.22 micron in-line or add-on filter. The initial infusion (Day 1 of Cycle 1) was delivered over 60 minutes; if it was well-tolerated, subsequent infusions were to be administered over 30 minutes, which was the shortest period permissible for infusion. Tislelizumab must not have been concurrently administered with any other drug. As a routine precaution, after infusion of tislelizumab on Day 1 of Cycle 1 and Cycle 2, patients were monitored for ≥ 1 hour afterward in an area with resuscitation equipment and emergency agents. From Cycle 3 onward, a monitoring period of ≥ 30 minutes was required in an area with resuscitation equipment and emergency agents. Chemotherapy Paclitaxel 175 mg/m 2 was administered as an intravenous infusion over 3 hours on Day 1 of each cycle, for 4 to 6 cycles . In addition, all patients received the appropriate premedications as per the local approved label and standard practice. Nab-paclitaxel 100 mg/m2 was administered as an intravenous infusion over 30 minutes on Day 1, Day 8, and Day 15 of each cycle for 4 to 6 cycles . All patients received the appropriate premedications as per the local approved label and standard practice. Carboplatin given at AUC 5 mg/mL/min was administered as an intravenous infusion over 15 minutes on Day 1 of each cycle, for 4 to 6 cycles immediately after paclitaxel or nab-paclitaxel. Additional premedications were administered as per standard practice. Medicinal product no longer authorised

When clinically feasible, premedication with steroids was limited due to their immunomodulatory effects.

<div style=\"page-break-after: always\"></div>

Table 52: Treatments (Study 307)

<!-- image -->

| Study drug         | Dose               | Frequencyof administration   | Routeof administration   |
|--------------------|--------------------|------------------------------|--------------------------|
| Tislelizumab|200mg | Tislelizumab|200mg | D1ofeachcycle                | Intravenous              |
| Paclitaxel         | 175mg/m²           | Daylofeachcycle              | Intravenous              |
| Nab- paclitaxel    | 100mg/m²           | D1.D8.and D15of eachcycle    | Intravenous              |

To compare PFS as assessed by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or nab-paclitaxel + carboplatin and paclitaxel + carboplatin alone in the ITT Analysis Set.

Abbreviations: AUC, area under the plasma or serum concentration-time curve Note: Treatment of paclitaxel or nabpaclitaxel was determined at randomisation. Chemotherapy was administered on a 3-week cycle. Tumour assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks for the remainder of the first year, then every 12 weeks until disease progression. · Objectives Assess the efficacy and safety of tislelizumab in combination with chemotherapy as 1L treatment of squamous NSCLC. · Outcomes/endpoints Primary Efficacy Endpoint Progression Free Survival (per IRC) To compare the PFS as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in an Intent-to-Treat (ITT) Analysis Set between tislelizumab either combined with paclitaxel + carboplatin (Arm A) or combined with nab-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin alone (Arm C) in patients with untreated Stage IIIB or Stage IV (as classified according to American Joint Committee Cancer 7th Edition of Cancer Staging Manual) squamous NSCLC. Secondary Efficacy Endpoints Overall Survival To compare OS between tislelizumab combined with paclitaxel + carboplatin or nab-paclitaxel + carboplatin and paclitaxel + carboplatin alone in the ITT Analysis Set. Progression Free Survival (per investigator) Medicinal product no longer authorised

## Objective Response Rate (per IRC and per investigator)

To compare ORR as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or nab-paclitaxel + carboplatin and paclitaxel + carboplatin alone.

<div style=\"page-break-after: always\"></div>

## Duration of Response (per IRC and per investigator)

To compare DOR as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or carboplatin + nab-paclitaxel and paclitaxel + carboplatin alone.

## Health-related Quality of Life

To compare HRQoL between tislelizumab combined with paclitaxel + carboplatin or nab-paclitaxel + carboplatin an paclitaxel + carboplatin alone.

Others To evaluate the safety and tolerability of tislelizumab combined with paclitaxel + carboplatin or nabpaclitaxel + carboplatin compared with paclitaxel + carboplatin alone. To evaluate the correlation between PD-L1 expression levels by immunohistochemistry and antitumour activity of tislelizumab combined with paclitaxel + carboplatin or nab-paclitaxel + carboplatin. · Sample size The sample size calculation was based on the number of PFS events required to demonstrate the PFS superiority of Arm A or Arm B to Arm C in the ITT Analysis Set, respectively. Exponential distribution was assumed for PFS. Estimates of the number of events required to demonstrate efficacy with regards to PFS were based on the following assumptions: 1. A one-sided α of 0.025 and 80% power to detect a HR of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months, in the PFS of A versus C comparison. 2. A one-sided α of 0.025 and 80% power to detect a HR of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months, in the PFS of B versus C comparison. 3. One planned interim analysis for both A versus C and B versus C comparisons when ~75% of the targeted PFS events have occurred, with Lan-DeMets O'Brien-Fleming approximation spending function. 4. Dropout rate of 5% per 12 months in PFS evaluation With these assumptions, a total of approximately 173 PFS events were planned to be required for each primary comparison of Arm A versus Arm C or Arm B versus Arm C at final analysis for PFS. Assuming 342 patients were to be enrolled and randomised at a 1:1:1 ratio over a 11.5-month period at a steady-state enrolment rate of 40 patients per month and enrolment ramp up duration of six month, i.e., enrolment rate of 10 patients per month from study Month 0 to Month 2, 20 patients per month from Month 2 to Month 4, 30 patients per month from Month 4 to Month 6, and 40 patients per month afterwards. Medicinal product no longer authorised

## · Randomisation and Blinding (masking)

Patients were planned to be randomised at a 1:1:1 ratio in one of the three arms by using the IRT system for this study by permuted block stratified randomisation with stratification factors of Stage (IIIB versus IV) and PDL1 expression in TC (≥ 50% TC ve rsus 1% - 49% TC versus &lt; 1% TC).

This study was open-label.

<div style=\"page-break-after: always\"></div>

## · Statistical methods

## Analysis Sets

The ITT Analysis Set was planned to include all randomised patients. Patients were planned to be analysed according to their randomised treatment arms. This was planned to be the primary analysis set for efficacy analysis.

The Safety Analysis Set was planned to include all patients who received ≥ 1 dose of study drug; it was planned to be the analysis set for the safety analyses.

The PK Analysis Set was planned to include all patients who receive ≥ 1 dose of tislelizumab per the protocol, for whom any postdose PK data were available. Primary Endpoint The primary endpoint PFS per the IRC was defined as the time from randomisation to the first documented disease progression as assessed by the IRC with the use of RECIST v1.1, or death from any cause, whichever occurred first. The actual tumour assessment visit date was planned to be used to calculate PFS. Data for patients without disease progression or death at the time of analysis were planned to be censored at the time of the last valid tumour assessment. Data for patients without postbaseline tumour assessment were planned to be censored at the time of randomisation. Data for patients who started to receive new anticancer therapy or were lost to follow-up were planned to be censored at the last valid tumour assessment date prior to the introduction of new therapy or loss to follow-up. Patients who had a clinical determination of progression were planned to undergo a CT/MRI, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient was confirmed, the date of the CT/MRI scan was planned to be considered as the progression date for that patient. PFS per the IRC was planned to be compared between tislelizumab combined with paclitaxel + carboplatin (Arm A) and paclitaxel + carboplatin (Arm C), and between tislelizumab combined with nab-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin (Arm C), using stratified log-rank test methodology. The two primary hypothesis tests were formed as follows: One-sided testing of PFS superiority of Arm A to Arm C: The null hypothesis to be tested is: H0: PFS in Arm A ≤ PFS in Arm C Against the alternative hypothesis: Ha: PFS in Arm A &gt; PFS in Arm C One-sided testing of PFS superiority of Arm B to Arm C: The null hypothesis to be tested is: H0: PFS in Arm B ≤ PFS in Arm C Against the alternative hypothesis: Ha: PFS in Arm B &gt; PFS in Arm C Medicinal product no longer authorised

The p-values from a stratified log-rank test were planned to be presented using stratification factors with actual values as recorded in the EDC at randomisation. The median PFS was planned to be calculated for each treatment arm and presented with two-sided 95% CIs. Kaplan-Meier survival probabilities for each arm were planned to be plotted over time. The HR for PFS for each comparison (i.e., Arm A versus Arm C, Arm B versus Arm C) were planned to be estimated using a stratified Cox regression model, with treatment arm as a factor and stratified by the actual value of the stratification factors as recorded in eCRF (electronic case report form). The 95% CI for the HR were planned to be provided. Unstratified analysis were planned to also be presented.

<div style=\"page-break-after: always\"></div>

## Secondary Endpoints

## Overall Survival

OS was defined as the time from randomisation to death from any cause. Data for patients who were not reported as having died at the time of analysis were planned to be censored at the date last known to be alive. Data for patients without postbaseline information were planned be censored at the date of randomisation. Similar methodology used to evaluate PFS per the IRC were planned to be applied to OS analysis.

## Progression-Free Survival per Investigator

Summary statistics (mean, standard deviation, median, and range) of the post-baseline scores and changes from baseline were planned to be reported for the EORTC questionnaires (QLQ-C30 and QLQLC13). Line charts depicting the mean changes (and standard errors) over time from the baseline assessment were planned to be provided for each treatment arm. The proportion of patients showing clinically meaningful changes in selected items and subscales at each assessment time point were planned to be calculated. Completion and compliance rates were planned to be summarised at each time point by treatment arm. Only patients in the ITT Analysis Set with a non-missing baseline assessment and at least one in-study non-missing post-baseline assessment were planned to be included in the analyses.

PFS per the investigator is defined as the time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined per RECIST v1.1 in the ITT Analysis Set. Similar methodology used to evaluate PFS per the IRC were planned to be applied to analysis of PFS per the investigator. Objective Response Rate per the IRC and per the Investigator ORR per the IRC resp. per the investigator (confirmation not required according to RECIST v1.1) was planned to be defined as the proportion of patients who had a CR or PR as assessed by the IRC resp. per the investigator per RECIST v1.1 in all randomised patients with measurable disease at baseline. Patients without any postbaseline assessment were planned to be considered non-responders. The difference in ORR per the IRC and per the investigator between Arm A versus Arm C and Arm B versus Arm C in the ITT Analysis Set were planned to be evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with the actual stratification factors as strata. The two-sided 95% CIs for the odds ratio and the difference in ORR were planned to be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm. Duration of Response per the IRC and per the Investigator DOR per the IRC resp. per the Investigator is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the IRC resp. as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who are alive and who have not experienced disease progression at the time of analysis were planned to be censored at the date of the last tumour assessment. If no tumour assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR was planned to be censored at the date of the first occurrence of the objective response. DOR per the IRC as well as per the Investigator was planned to be estimated using Kaplan-Meier methodology. Comparisons between treatment arms were planned to be made using the stratified and unstratified log-rank test for descriptive purposes only. Health-Related Quality of Life Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## PD-L1 Expression as a Predictive Biomarker for Response

Distribution of PD-L1 expression in TC were planned to be examined in the ITT Analysis Set. Association between PD-L1 expression and tislelizumab treatment effect over control (PFS, OS, ORR, DOR, DCR) were planned to be explored.

## Multiplicity

The overall Type I error for primary endpoint PFS per IRC that compared between Arm A versus Arm C or Arm B versus Arm C at the interim and final analyses was planned to be strongly controlled at an alpha of 0.025 by using sequential testing procedure. Hypothesis testing for the primary endpoint of PFS (Arm A vs C followed by Arm B vs C) was planned to be carried out sequentially, each at a onesided alpha of 0.025, until the first non-rejection. The alpha allocation algorithm is described below:

<!-- image -->

The interim and final analyses timing and stopping boundaries for PFS are summarised in Table 53 below. The times and boundaries for the interim and final analysis were based on protocol-defined enrolment and PFS assumptions. They were planned to be updated according to the actual PFS events included at the interim and final analyses using Lan-DeMets spending function.

Figure 58: Type I error control scheme (Study 307) Interim Analyses One interim efficacy analysis of PFS was planned in each comparison performed in the ITT Analysis Set. For the PFS endpoint, the interim efficacy analysis was planned to be performed after approximately 130 PFS events (75% of the target number of approximately 173 PFS events) would have been observed in each comparison of A versus C or B versus C. It was estimated that it would take approximately 17 months to accumulate the required number of PFS events. The final analysis for PFS was planned to be performed after approximately 173 PFS events have been observed and it was estimated that this would occur at approximately 24 months after the first patient was randomised. An independent statistical review was planned to be conducted to determine if the required number of events had occurred in two arms of A vs C or B vs. C. If the time of observing the targeted number of events in each comparison was different from each other, the analysis could be separate. The interim boundary was based on Lan-DeMets O'Brien-Fleming approximation spending function. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                  |                 | Expected time (months)   | Testingboundary   | Testingboundary                |
|------------------|-----------------|--------------------------|-------------------|--------------------------------|
| Type of analysis | Numberof events |                          | p-value boundary  | Approx. hazard ratio threshold |
| Interim analysis | 130             | 16.7                     | 0.0097            | 0.6637                         |
| Final analysis   | 173             | 23.8                     | 0.0221            | 0.7364                         |

Table 53: Analysis timing and stopping boundaries for PFS in each of the primary testing at one-sided α=0.025 (Study 307)

<!-- image -->

Subgroup Analyses Subgroup analysis of primary endpoint of PFS per the IRC were planned to be conducted to determine whether the treatment effect is consistent across various subgroups, and the HR estimates of PFS and its 95% CI were planned to be estimated and plotted within each category of the following variables: PDL1 expression in TC (≥ 50% TC versus 1% to 49% TC versus &lt; 1% TC), Stage (IIIB versus IV), age (≤ 65 versus &gt; 65 years), gender (female versus male), ECOG PS (0 versus 1), and smoking status (former versus current versus never). Results Medicinal product no longer authorised

Table 54: Patient disposition and reasons for discontinuation (ITT analysis set) (Study 307) (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

|    |        | authorised   |
|----|--------|--------------|
|    | longer |              |
| no |        |              |

· Recruitment This study is ongoing (start date 20-Jul-2018). Patients were enrolled in 43 centres in China. Median follow up time at final analysis (DCO: 30 September 2020): 16.7 month. · Conduct of the study Amendment 1.0 (dated 27 April 2018) · Updated NCI -CTCAE version from v4.03 to v5.0 Medicinal product no longer authorised

- Updated the frequency for tumour assessments
- Updated the reasons for patients to discontinue the study treatment or discontinue study
- Clarified the guidance regarding dose modifications for tislelizumab and chemotherapy
- Added 'total CK and creatine kinase cardiac muscle isoenzyme' to laboratory assessments
- Clarified the visits and the frequency to assess irAEs and concomitant medications during safety follow-up

<div style=\"page-break-after: always\"></div>

- Updated contents of interim analysis and sample size consideration by adjusting O'Brien -Fleming boundary per Center for Drug Evaluation comments
- Changed the frequency for the data review by IDMC from 'every 4 months' to 'every 6 months'
- Added the diagnostic tests and treatment for myocarditis/myositis (irAE evaluation and management) according to FDA requirements
- Replaced the Chronic Kidney Disease Epidemiology Collaboration (CKD -EPI) equation in Appendix 7 with more commonly used formula (Cockcroft-Gault Formula and Calvert Formula)

Amendment 1.0 Addendum 1 (dated 22 May 2018) · Added details for serum CK and creatine kinase cardiac muscle isoenzyme testing · Updated the diagnostic tests and treatment for myocarditis (irAE evaluation and management) Amendment 2.0 (dated 14 December 2018) · Clarified the criteria for squamous NSCLC staging in the primary objective · Updated the inclusion criteria to allow patients with unevaluable PD -L1 status to participate in this study · Added prophylaxis antiviral therapy for patients with inactive HBsAg, treated and stable hepatitis B (HBV DNA &lt; 500 IU/mL) to permitted concomitant medications · Added the guidance on pulmonary function assessment · Clarified the safety assessment schedule for patients who crossed over to tislelizumab monotherapy · Incorporated the changes made in addendum to protocol amendment 1.0 and updated the information regarding serum CK and creatine kinase cardiac muscle isoenzyme testing Amendment 3.0 (dated 16 August 2019) · Updated the statistical method to control overall Type I error for hypothesis tests of PFS in each comparison of Arm A versus Arm C or Arm B versus Arm C · Changed HR assumption of PFS from 0.6 to 0.65, and increased the number of PFS events at both interim and final analyses · Changed the method for HRQoL analysis from model -based method to descriptive method · Updated the tumour assessments for treatment beyond progression and for crossover · Added biomarker sample collection procedure for patients who cross over to tislelizumab monotherapy · Updated the definition of study termination Medicinal product no longer authorised

## · Baseline data

<div style=\"page-break-after: always\"></div>

Table 55: Demographics and baseline characteristics (ITT analysis set) (Study 307) (DCO: 30SEP2020)

<!-- image -->

Table 56: Disease characteristics (ITT analysis set) (Study 307) (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

| authorised   |
|--------------|

<!-- image -->

The efficacy results presented in this report are based on the interim analysis ( data cutoff 06 December 2019 , with a median follow-up time of 8.4 months) and final analysis of efficacy data ( data cutoff date of 30 September 2020 , with a median follow-up time of 16.7 months).

· Numbers analysed Table 57: Analysis sets (Study 307) (DCO: 30SEP2020) · Outcomes and estimation Medicinal product no longer authorised

As of the data cutoff date of 30 September 2020, a total of 245 PFS events per IRC across three arms were observed (166 in the comparison of Arm T+PC versus Arm PC and 165 in the comparison of Arm T+nPC versus Arm PC in the ITT Analysis Set).

## Primary Endpoint

Progression Free Survival

<div style=\"page-break-after: always\"></div>

Table 58: Analysis of progression-free survival per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 307); interim analysis (DCO: 06DEC2019)

| authorised   |
|--------------|

<!-- image -->

Medicinal product no longer authorised

Table 59: Analysis of progression-free survival per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|    |        | authorised   |
|----|--------|--------------|
|    | longer |              |
| no |        |              |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Arm T+PC versus Arm PC

Figure 59: Kaplan-Meier plots of progression-free survival per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

## Overall Survival

## Table 60: Analysis of overall survival (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<!-- image -->

<!-- image -->

| longer   |
|----------|
| no       |

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Overall Survival -Updated data

As the OS data were considered not mature, OS analyses based on the most recent data extraction with a data cutoff date of 15-July-2022, with a median study follow up of 20.5 months were provided during the assessment. At this cut-off date, the degree of maturity for OS for T+PC arm and T+nPC arm was 62.5% (75/120) and 70.6% (84/119) respectively and the fraction of cross over was app. 44 %.

<div style=\"page-break-after: always\"></div>

T+PC vs PC

<!-- image -->

T+nPC vs PC Figure 61: Kaplan-Meier plot of overall survival (ITT Analysis Set) (Study 307); Updated data (DCO: 15JUL2022) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Progression-Free Survival (per Investigator)

Table 61: Analysis of progression-free survival per RECIST version 1.1 by investigator (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Objective Response Rate (per IRC)

Table 62: Analysis of unconfirmed disease response per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

| authorised   |
|--------------|

<!-- image -->

Of note, only unconfirmed ORR results were prespecified. The Applicant provided post-hoc analysis of confirmed ORR (DCO 30 Sep 2020) results. Medicinal product no longer authorised

Table 63: Analysis of confirmed disease response per RECIST version 1.1 (efficacy analysis set) (Study 307) (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

|                                      | Study 307      | Study 307       | Study 307            |
|--------------------------------------|----------------|-----------------|----------------------|
|                                      | T+PC (N = 120) | T+nPC (N = 119) | PC (N = 121)         |
| Best Overall Response a , n (%)      |                |                 |                      |
| Complete Response                    | 7 (5.8)        | 6 (5.0)         | 1 (0.8)              |
| Partial Response                     | 67 (55.8)      | 68 (57.1)       | 44 (36.4)            |
| Stable Disease                       | 31 (25.8)      | 34 (28.6)       | 52 (43.0)            |
| Non-CR/Non-PD                        | 0 (0.0)        | 0 (0.0)         | 1 (0.8)              |
| Progressive Disease                  | 12 (10.0)      | 5 (4.2)         | 11 (9.1)             |
| Could not be Determined              | 3 (2.5)        | 6 (5.0)         | 12 (9.9)             |
| Objective Response Rate (ORR), n (%) | 74 (61.7)      | 74 (62.2)       | 45 (37.2) authorised |
| 95% CI                               | (52.4, 70.4)   | (52.8, 70.9)    | (28.6, 46.4)         |
| Disease Control Rate, n (%)          | 105 (87.5)     | 108 (90.8)      | 98 (81.0)            |
| 95% CI                               | (80.2, 92.8)   | (84.1, 95.3)    | (72.9, 87.6)         |
| Clinical Benefit Rate b , n (%)      | 100 (83.3)     | 102 (85.7)      | 87 (71.9)            |
| 95% CI                               | (75.4, 89.5)   | (78.1, 91.5)    | (63.0, 79.7)         |
| Clinical Benefit Rate c , n (%)      | 86 (71.7)      | 86 (72.3)       | 57 (47.1)            |
| 95% CI                               | (62.7, 79.5)   | (63.3, 80.1)    | (38.0, 56.4)         |

<!-- image -->

a  confirmed CR or PR is required in 307. b  Included patients with BOR in CR or PR or ≥12 weeks SD. c  Included patients with BOR in CR or PR or ≥24 weeks SD. Best overall response of could not be determined include patients who had post-baseline tumour assessment, none of which were evaluable; or patients who had no post-baseline tumour assessment, and non-CR/non-PD was due to no measurable target lesion per IRC. Results were summarised based on data as assessed by independent review committee for study 307. Objective Response Rate was the proportion of Patients who achieved CR or PR using RECIST version 1.1. Disease Control Rate was the proportion of Patients who achieved CR, PR, non-CR/non-PD or SD using RECIST version 1.1. Medicinal product no longer authorised

Objective Response Rate (per Investigator)

Table 64: Analysis of unconfirmed disease response per RECIST version 1.1 by investigator (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

|                                           | T+PC (N =120)   | T+nPC (N = 119)   | PC (N =121)   |
|-------------------------------------------|-----------------|-------------------|---------------|
| Best Overall Response -unconfirmed, n (%) |                 |                   |               |
| Complete Response                         | 1 (0.8)         | 0 (0.0)           | 0 (0.0)       |
| Partial Response                          | 83 (69.2)       | 93 (78.2)         | 60 (49.6)     |
| Stable Disease                            | 27 (22.5)       | 17 (14.3)         | 45 (37.2)     |
| Progressive Disease                       | 4 (3.3)         | 2 (1.7)           | 5 (4.1)       |
| Not Evaluable                             | 2 (1.7)         | 1 (0.8)           | 0 (0.0)       |
| Missing                                   | 3 (2.5)         | 6 (5.0)           | 11 (9.1)      |

<!-- image -->

Medicinal product no longer authorised

Duration of Response (by IRC)

Table 65: Analysis of duration of response based on unconfirmed responses per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<div style=\"page-break-after: always\"></div>

|                             | T+PC (N =120)     | T+nPC (N = 119)   | PC (N = 121)     |
|-----------------------------|-------------------|-------------------|------------------|
| NumberofResponders          | 89                | 88                | 58               |
| Duration of Response        |                   |                   |                  |
| Events, n (%)               | 53 (59.6)         | 56 (63.6)         | 44 (75.9)        |
| Progressive Disease         | 50 (56.2)         | 54 (61.4)         | 43 (74.1)        |
| Death                       | 3 (3.4)           | 2 (2.3)           | 1 (1.7)          |
| Censored, n (%)             | 36 (40.4)         | 32 (36.4)         | 14 (24.1)        |
| Duration ofResponse(months) |                   |                   |                  |
| Median (95% CI)             | 8.4 (5.03, 15.80) | 8.6 (7.13, 12.48) | 4.3 (2.86, 5.42) |

|           | product   |
|-----------|-----------|
| Medicinal |           |

Duration of Response (per Investigator) Table 66: Analysis of duration of response based on unconfirmed responses per RECIST version 1.1 by investigator (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020) Medicinal product no longer authorised

Abbreviations: NE,not estimable; PC, Paclitaxel+Carboplatin; T+PC, Tislelizumab+Paclitaxel+Carboplatin; T+nPC

Tislelizumab+nab-Paclitaxel+Carboplatin.

Percentages were based on number of responders. Duration of response analysis included patients with objective response. Medians and other quartiles were estimated by Kaplan-Meier method with 95% Cls estimated using the method of Brookmeyer and Crowley. Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

## Health-Related Quality of Life

<div style=\"page-break-after: always\"></div>

Patients in Arm T+PC and Arm T+nPC had similar HRQoL outcomes to those in Arm PC as measured by the key PRO endpoint of EORTC QLQ-C30 GHS/QoL and in lung cancer-specific symptoms of coughing, chest pain and dyspnoea. The median time to deterioration (TTD) for QLQ-C30 GHS/QoL was not reached in all treatment arms; the median TTD for the composite of cough, chest pain, and dyspnoea scores in Arm T+PC reached only in Arm T+PC of 5.7 months (95% CI: 3.06, NE).

- Ancillary analyses

## Sensitivity analysis 1 for PFS

<!-- image -->

|           | longer   |    |
|-----------|----------|----|
|           | no       | no |
|           | product  |    |
| Medicinal |          |    |

Sensitivity Analysis 1 evaluated the impact of censoring the primary endpoint due to new anticancer treatment. This analysis was the same as the primary analysis with regards to the censoring rules except for the handling of new anticancer treatment. The PFS was derived regardless of the new anticancer treatment. Table 67: Censoring rules for primary and sensitivity analysis of PFS Per RECIST version 1.1 (Study 307) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 68: Analysis of progression-free survival per RECIST version 1.1 by independent review committee, comparison of primary analysis and sensitivity analysis (ITT Analysis Set) (Study 307); final analysis (DCO: 30SEP2020)

|                                  | Primary Analysis   | Primary Analysis   | Primary Analysis   | SensitivityAnalysis   | SensitivityAnalysis   | SensitivityAnalysis   |
|----------------------------------|--------------------|--------------------|--------------------|-----------------------|-----------------------|-----------------------|
|                                  | T+PC (N = 120)     | T+=PC (N = 119)    | PC (N = 121)       | T+PC (N = 120)        | T+=PC (N = 119)       | PC (N = 121)          |
| Progression-Free Survival        |                    |                    |                    |                       |                       |                       |
| Events, n (%)                    | 80 (66.7)          | 79 (66.4)          | 86 (71.1)          | 81 (67.5)             | 81 (68.1)             | 88 (72.7)             |
| Censored, n (%)                  | 40 (33.3)          | 40 (33.6)          | 35 (28.9)          | 39 (32.5)             | 38 (31.9)             | 33 (27.3)             |
| Stratified Hazard Ratio (95% CI) | 0.450              | 0.428              |                    | 0.497                 | 0.476                 |                       |

<!-- image -->

|           | longer   |
|-----------|----------|
|           | no       |
| product   |          |
| Medicinal |          |

Subgroup analysis of PFS assessed by IRC Medicinal product no longer authorised

←T+PC PC→

<div style=\"page-break-after: always\"></div>

## Arm T+nPC vs Arm PC

<!-- image -->

Figure 62: Subgroup analysis: forest plot of PFS per RECIST version 1.1 by independent review committee for arms T+PC and T+nPC vs PC (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Subgroup Analysis of OS

ArmT+PCversusArmPC

| Subgroup                          | No.ofEvents/ No.ofPatients   |    | Hazard Ratio for Overall Suvival orDeath(95%CI)   | Median OS (95%CI)           | Median OS in Treatment Arm (95%C)   | Median Os in Contiol Arm (95%CI)   |
|-----------------------------------|------------------------------|----|---------------------------------------------------|-----------------------------|-------------------------------------|------------------------------------|
| Overall                           | 100/241                      |    | 0.778(0.524,1.154)                                | 22.8(18.96,NE)              | 22.8(19.09,NE)                      | 20.2(15.97,NE)                     |
| Age <65years ≥65yeas Sex          | 66/166 34/75                 |    | 0.784(0.483,1.271) 0.755(0.381,1.495)             | NE（18.10,NE) 22.8(15.80,NE) | NE（18.10NE) 22.8(12.35,NE)          | 20.2(15.74,NE) 18.5(9.99,NE)       |
| Female ECOGPerformanceStatus Male | 8/23 92/218                  | 中  | 0.331(0.079,1.390) 0.847(0.562,1.278)             | NE(13.90,NE) 20.6（18.23,NE) | NE(15.15,NE) 22.8(18.10,NE)         | 19.0(2.69,NE) 20.2(15.97,NE)       |

<!-- image -->

Figure 63: Subgroup analysis: forest plot of OS (ITT Analysis Set) (Study 307); final analysis (DCO: 30SEP2020) Medicinal product no longer authorised

| no      |
|---------|
| product |

## Efficacy by PD-L1 Expression

## · PFS by PD-L1 Expression

Data cutoff date 15-July-2022, median study follow-up of 20.5 months. At this cut-off date, the maturity of the PFS data was 70.0% (84/120) and 72.3% (86/119) for the T+PC arm and T+nPC arm respectively.

<div style=\"page-break-after: always\"></div>

## T+pC vs PC: TC &lt; 1%

<!-- image -->

<div style=\"page-break-after: always\"></div>

## T+PC vS PC: TC &gt;= 50%

<!-- image -->

<div style=\"page-break-after: always\"></div>

## T+nPC Vs PC : TC 1%-49%

<!-- image -->

<!-- image -->

Figure 64: Kaplan-Meier plot of progression-free survival per RECIST version 1.1 by independent review committee by PD-L1 Expression (ITT analysis set) (Study 307); updated data (DCO: 15JUL2022) · OS by PD-L1 Expression Data cutoff date 15-July-2022, median study follow-up of 20.5 months. At this cut-off date, the maturity of the OS data for T+PC arm and T+nPC arm was 62.5% (75/120) and 70.6% (84/119) respectively and the fraction of cross over was 58.7%. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## T+PCVSPC:TC&lt;1%

<!-- image -->

<div style=\"page-break-after: always\"></div>

## T+PC vs PC: TC 1%-49%

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## T+nPC vs PC : TC 1%-49%

Figure 65: Kaplan-Meier plot of overall survival by PD-L1 expression (ITT analysis set) (Study 307); updated data (DCO: 15JUL2022) Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · ORR by PD-L1 Expression

<!-- image -->

<!-- image -->

<!-- image -->

No. of Response/ ORR (95% CI) Estimated Treatment

No. of Patients

33/42

Difference (95% CT)

78.6 (63.2, 89.7)

37/42

22/41

88.1 (74.4, 96.0)

53.7 (37.4, 69.3)

Figure 66: Objective response per RECIST version 1.1 by IRC by PD-L1 expression (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020) OS Supportive Analyses To assess the impact of in-study crossover on OS, a supportive analysis was conducted using RankPreserving Structural Failure Time Model (RPSFTM, Robins et al 1991). The stratified HRs were 0.630 (95% CI: 0.312, 1.272) for the comparison between Arm T+PC and Arm PC and 0.624 (95% CI: 0.196, 1.981) for the comparison between Arm T+nPC and Arm PC. In addition, a supportive analysis using a two-stage method (Latimer et al 2014) was also performed to estimate the in-study crossover effect on the post-progression survival (PPS) using data from patients who progressed per IRC assessment before any subsequent anticancer therapy in the control arm only. The stratified HRs based on the counterfactual survival time of patients in Arm PC who had crossed over to receive tislelizumab and the observed survival times in the rest of the patients were estimated as 0.572 (95% CI: 0.350, 0.934) for Arm T+PC versus Arm PC and 0.572 (95% CI: 0.344, 0.951) for Arm T+nPC versus Arm PC. Medicinal product no longer authorised

24.9 (5.2, 44.6)

34.4 (16.3, 52.6)

<div style=\"page-break-after: always\"></div>

Figure 67: Kaplan-Meier Plot of OVERALL SURVIVAL -Sensitivity ANALYSIS USING RANKPRESERVING STRUCTURAL FAILURE TIME MODEL (ITT ANALYSIS SET) (Study 307); FINAL ANALYSIS (DCO: 30SEP2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 68: Kaplan-Meier plot of overall survival -sensitivity analysis using two-stage model (ITT analysis set) (Study 307); final analysis (DCO: 30SEP2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the 1L (in combination with chemotherapy) squamous NSCLC indication of the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 69: Summary of efficacy for trial BGB-A317-307 (Study 307)

<!-- image -->

| Title: A Phase 3, multicenter, randomized open-label study to compare the efficacy and safety of tislelizumab (BGB A317, anti-PD1 antibody) combined with paclitaxel plus carboplatin or nab -paclitaxel plus carboplatin versus paclitaxel plus carboplatin alone as first-line treatment for untreated advanced squamous non-small cell lung cancer   | Title: A Phase 3, multicenter, randomized open-label study to compare the efficacy and safety of tislelizumab (BGB A317, anti-PD1 antibody) combined with paclitaxel plus carboplatin or nab -paclitaxel plus carboplatin versus paclitaxel plus carboplatin alone as first-line treatment for untreated advanced squamous non-small cell lung cancer   | Title: A Phase 3, multicenter, randomized open-label study to compare the efficacy and safety of tislelizumab (BGB A317, anti-PD1 antibody) combined with paclitaxel plus carboplatin or nab -paclitaxel plus carboplatin versus paclitaxel plus carboplatin alone as first-line treatment for untreated advanced squamous non-small cell lung cancer                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                        | BGB-A317-307, RATIONALE 307                                                                                                                                                                                                                                                                                                                             | BGB-A317-307, RATIONALE 307                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                                                                                                                                                  | Phase III, multicentre, randomised (1:1:1), open-label study comparing tislelizumab + paclitaxel + carboplatin or tislelizumab + nab-paclitaxel + carboplatin versus paclitaxel + carboplatin alone                                                                                                                                                     | Phase III, multicentre, randomised (1:1:1), open-label study comparing tislelizumab + paclitaxel + carboplatin or tislelizumab + nab-paclitaxel + carboplatin versus paclitaxel + carboplatin alone                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                                                       | 30-Jul-2018 - Ongoing ( data cut-off for final analysis: 30-Sep-2020 ) The interim and final analyses were conducted when the predefined PFS events had been observed for the efficacy and safety evaluations. The study met its primary objective of PFS at the interim analysis. Results for the final analysis are presented in this report. The study will continue until the last patient has disease progression, is lost to follow-up, or withdraws from study, or until study completion by Sponsor. Not applicable longer authorised |
| Hypothesis                                                                                                                                                                                                                                                                                                                                              | Superiority no                                                                                                                                                                                                                                                                                                                                          | Superiority no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Treatments groups                                                                                                                                                                                                                                                                                                                                       | Duration of Extension phase: Arm T+PC: Tislelizumab Paclitaxel Carboplatin product                                                                                                                                                                                                                                                                      | Not applicable n = 120 Tislelizumab 200 mg i.v. D1 + paclitaxel 175 mg/m 2 D1 + carboplatin AUC 5 D1 for 4-6 cycles followed by tislelizumab 200 mg Q3W                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                                                                                                                       | Arm T+nPC: Tislelizumab Nab-Paclitaxel Carboplatin Medicinal                                                                                                                                                                                                                                                                                            | n = 119 Tislelizumab 200 mg D1 +nab-paclitaxel 100 mg/m 2 D1, D8, and D15 + carboplatin AUC 5 D1 for 4-6 cycles followed by tislelizumab 200 mg Q3W                                                                                                                                                                                                                                                                                                                                                                                           |
| Treatments groups                                                                                                                                                                                                                                                                                                                                       | Arm PC: Paclitaxel Carboplatin                                                                                                                                                                                                                                                                                                                          | n = 121 Paclitaxel 175 mg/m 2 D1 and carboplatin AUC 5 D1 for 4-6 cycles                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Primary endpoint   | PFS as assessed by the IRC             | Time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1 in the ITT analysis set                                                           |
|-----------------------------|--------------------|----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Secondary endpoint | OS                                     | Time from the date of randomisation to the date of death due to any cause in the ITT analysis set                                                                                                                                                          |
| Endpoints and definitions   | Secondary endpoint | PFS as assessed by the investigator    | Time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined by the investigator per RECIST v1.1 in the ITT analysis set                                                |
| Endpoints and definitions   | Secondary endpoint | ORR as assessed by the IRC             | Proportion of patients who had complete response (CR) or partial response (PR) as assessed by the IRC per RECIST v1.1 in all randomised patients with measurable disease at baseline                                                                       |
| Endpoints and definitions   | Secondary endpoint | ORR as assessed by the investigator    | Proportion of patients who had CR or PR as determined by the investigator per RECIST v1.1 in all randomised patients with measurable disease at baseline authorised                                                                                        |
| Endpoints and definitions   | Secondary endpoint | DOR as assessed by the IRC             | Time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the IRC per RECIST v1.1 in all randomised patients with documented objective responses longer     |
| Endpoints and definitions   | Secondary endpoint | DOR as assessed by the investigator no | Time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as determined by the investigator per RECIST v1.1 in all randomised patients with documented objective responses |
| Database lock               | 30-Sep-2020 (data  | cut-off date)                          |                                                                                                                                                                                                                                                            |

Analysis description

Analysis population and time point description

Descriptive statistics and estimate variability

Effect estimate per comparison

Primary endpoint analysis

ITT analysis set

Treatment group

Number of patients mPFS (months)

95% CI

Comparison groups

HR

Results and Analysis Time point: after 245 PFS by IRC events Medicinal product no longer authorised

95% CI

PFS by IRC

Arm T+PC

120

7.7

6.74, 10.41

Arm T+PC vs      Arm

PC

0.450

0.326, 0.619

Arm T+nPC

119

9.6

7.39, 10.78

Arm T+nPC vs

Arm PC

0.428

0.308, 0.595

-

Arm PC

121

5.5

4.21, 5.59

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                          | p-value                                                                                                                                                                                                                                                                           | <0.0001                                                                                                                                                                                                                                                                           | <0.0001                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                   |
|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Notes                                                    | The primary endpoint was met, and statistical significance was achieved for the prespecified interim analysis (06-Dec-2019 data cut-off) in both PFS comparisons of Arm T+PC versus Arm PC and Arm T+nPC versus Arm PC. The P-value for 30-Sep-2020 data cut-off was descriptive. | The primary endpoint was met, and statistical significance was achieved for the prespecified interim analysis (06-Dec-2019 data cut-off) in both PFS comparisons of Arm T+PC versus Arm PC and Arm T+nPC versus Arm PC. The P-value for 30-Sep-2020 data cut-off was descriptive. | The primary endpoint was met, and statistical significance was achieved for the prespecified interim analysis (06-Dec-2019 data cut-off) in both PFS comparisons of Arm T+PC versus Arm PC and Arm T+nPC versus Arm PC. The P-value for 30-Sep-2020 data cut-off was descriptive. | The primary endpoint was met, and statistical significance was achieved for the prespecified interim analysis (06-Dec-2019 data cut-off) in both PFS comparisons of Arm T+PC versus Arm PC and Arm T+nPC versus Arm PC. The P-value for 30-Sep-2020 data cut-off was descriptive. |
| Analysis description                                     | Secondary endpoint analysis - OS                                                                                                                                                                                                                                                  | Secondary endpoint analysis - OS                                                                                                                                                                                                                                                  | Secondary endpoint analysis - OS                                                                                                                                                                                                                                                  | Secondary endpoint analysis - OS                                                                                                                                                                                                                                                  |
| Analysis population and time point description           | ITT analysis set authorised                                                                                                                                                                                                                                                       | ITT analysis set authorised                                                                                                                                                                                                                                                       | ITT analysis set authorised                                                                                                                                                                                                                                                       | ITT analysis set authorised                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability          | Treatment group                                                                                                                                                                                                                                                                   | Arm T+PC                                                                                                                                                                                                                                                                          | Arm T+nPC                                                                                                                                                                                                                                                                         | Arm PC                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability          | Number of patients                                                                                                                                                                                                                                                                | 120                                                                                                                                                                                                                                                                               | 119                                                                                                                                                                                                                                                                               | 121                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability          | mOS (months)                                                                                                                                                                                                                                                                      | 22.8                                                                                                                                                                                                                                                                              | NE                                                                                                                                                                                                                                                                                | 20.2                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability          | 95% CI                                                                                                                                                                                                                                                                            | 19.09, NE                                                                                                                                                                                                                                                                         | 18.56, NE                                                                                                                                                                                                                                                                         | 15.97, NE                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                           | Comparison groups                                                                                                                                                                                                                                                                 | Arm T+PC vs Arm PC                                                                                                                                                                                                                                                                | Arm T+nPC vs Arm PC                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                           | HR                                                                                                                                                                                                                                                                                | 0.678                                                                                                                                                                                                                                                                             | 0.752                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                           | 95% CI                                                                                                                                                                                                                                                                            | 0.455, 1.010 0.504,                                                                                                                                                                                                                                                               | 1.120                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                   |
| Notes                                                    | longer                                                                                                                                                                                                                                                                            | longer                                                                                                                                                                                                                                                                            | longer                                                                                                                                                                                                                                                                            | longer                                                                                                                                                                                                                                                                            |
| Analysis description                                     | Secondary endpoint analysis - PFS by investigator                                                                                                                                                                                                                                 | Secondary endpoint analysis - PFS by investigator                                                                                                                                                                                                                                 | Secondary endpoint analysis - PFS by investigator                                                                                                                                                                                                                                 | Secondary endpoint analysis - PFS by investigator                                                                                                                                                                                                                                 |
| Analysis population and time point description           | ITT analysis set                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability          | Treatment group                                                                                                                                                                                                                                                                   | Arm T+PC no                                                                                                                                                                                                                                                                       | Arm T+nPC                                                                                                                                                                                                                                                                         | Arm PC                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability          | Number of patients                                                                                                                                                                                                                                                                | 120                                                                                                                                                                                                                                                                               | 119                                                                                                                                                                                                                                                                               | 121                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability          | mPFS (months)                                                                                                                                                                                                                                                                     | 9.6                                                                                                                                                                                                                                                                               | 9.9                                                                                                                                                                                                                                                                               | 5.5                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability          | 95% CI                                                                                                                                                                                                                                                                            | 7.62, 11.76                                                                                                                                                                                                                                                                       | 8.57, 11.86                                                                                                                                                                                                                                                                       | 4.21, 5.65                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                           | product                                                                                                                                                                                                                                                                           | Arm T+PC vs Arm PC                                                                                                                                                                                                                                                                | Arm T+nPC vs Arm PC                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                           | HR                                                                                                                                                                                                                                                                                | 0.341                                                                                                                                                                                                                                                                             | 0.403                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                           | 95% CI                                                                                                                                                                                                                                                                            | 0.245, 0.473                                                                                                                                                                                                                                                                      | 0.289, 0.564                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                   |
| Notes                                                    | Not applicable                                                                                                                                                                                                                                                                    | Not applicable                                                                                                                                                                                                                                                                    | Not applicable                                                                                                                                                                                                                                                                    | Not applicable                                                                                                                                                                                                                                                                    |
| Analysis description                                     | Secondary endpoint analysis - ORR by IRC                                                                                                                                                                                                                                          | Secondary endpoint analysis - ORR by IRC                                                                                                                                                                                                                                          | Secondary endpoint analysis - ORR by IRC                                                                                                                                                                                                                                          | Secondary endpoint analysis - ORR by IRC                                                                                                                                                                                                                                          |
| Analysis population and time point description Medicinal | ITT analysis set                                                                                                                                                                                                                                                                  | ITT analysis set                                                                                                                                                                                                                                                                  | ITT analysis set                                                                                                                                                                                                                                                                  | ITT analysis set                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability          | Treatment group                                                                                                                                                                                                                                                                   | Arm T+PC                                                                                                                                                                                                                                                                          | Arm T+nPC                                                                                                                                                                                                                                                                         | Arm PC                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability          | Number of patients                                                                                                                                                                                                                                                                | 120                                                                                                                                                                                                                                                                               | 119                                                                                                                                                                                                                                                                               | 121                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability          | OOR, n (%)                                                                                                                                                                                                                                                                        | 89 (74.2)                                                                                                                                                                                                                                                                         | 88 (73.9)                                                                                                                                                                                                                                                                         | 58 (47.9)                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability          | 95% CI 8.54, 21.78 2.10, 7.16 95% CI                                                                                                                                                                                                                                              | 65.4, 81.7                                                                                                                                                                                                                                                                        | 65.1, 81.6                                                                                                                                                                                                                                                                        | 38.8, 57.2                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                           |                                                                                                                                                                                                                                                                                   | Arm T+PC vs Arm PC                                                                                                                                                                                                                                                                | Arm T+nPC vs Arm PC                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                   |
|                                                          | Odds ratio                                                                                                                                                                                                                                                                        | 3.36                                                                                                                                                                                                                                                                              | 3.16                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                 | 95% CI                                                    | 1.923, 5.881                                              | 1.819, 5.489                                              |                                                           |
|-------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Notes                                           | Not applicable                                            |                                                           |                                                           |                                                           |
| Analysis description                            | Secondary endpoint analysis - ORR by investigator         | Secondary endpoint analysis - ORR by investigator         | Secondary endpoint analysis - ORR by investigator         | Secondary endpoint analysis - ORR by investigator         |
| Analysis population and time point description  | ITT analysis set                                          |                                                           |                                                           |                                                           |
| Descriptive statistics and estimate variability | Treatment group                                           | Arm T+PC                                                  | Arm T+nPC                                                 | Arm PC                                                    |
| Descriptive statistics and estimate variability | Number of patients                                        | 120                                                       | 119                                                       | 121                                                       |
| Descriptive statistics and estimate variability | OOR, n (%)                                                | 84 (70.0)                                                 | 93 (78.2)                                                 | 60 (49.6)                                                 |
| Descriptive statistics and estimate variability | 95% CI 8.54, 21.78 95% CI                                 | 61.0, 78.0                                                | 69.6, 85.2                                                | 40.4, 58.8                                                |
| Effect estimate per comparison                  | 2.10, 7.16                                                | Arm T+PC vs Arm PC                                        | Arm T+nPC vs Arm PC authorised                            | Arm T+nPC vs Arm PC authorised                            |
|                                                 | Odds ratio                                                | 2.56                                                      | 3.60                                                      | 3.60                                                      |
|                                                 | 95% CI                                                    | 1.486, 4.410                                              | 2.052, 6.309                                              | 2.052, 6.309                                              |
| Notes                                           | Not applicable                                            | Not applicable                                            | Not applicable                                            | Not applicable                                            |
| Analysis description                            | Secondary endpoint analysis - DOR by IRC                  | Secondary endpoint analysis - DOR by IRC                  | Secondary endpoint analysis - DOR by IRC                  | Secondary endpoint analysis - DOR by IRC                  |
| Analysis population and time point description  | ITT analysis set longer                                   | ITT analysis set longer                                   | ITT analysis set longer                                   | ITT analysis set longer                                   |
| Descriptive statistics and estimate variability | Treatment group                                           | Arm T+PC                                                  | Arm T+nPC                                                 | Arm PC                                                    |
| Descriptive statistics and estimate variability | Number of patients                                        | 120                                                       | 119                                                       | 121                                                       |
| Descriptive statistics and estimate variability | mDoR (months)                                             | 8.4                                                       | 8.6                                                       | 4.3                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                    | 5.03, 15.80 no                                            | 7.13, 12.48                                               | 2.86, 5.42                                                |
| Notes                                           |                                                           |                                                           |                                                           |                                                           |
| Analysis description                            | Secondary endpoint analysis - DOR by investigator product | Secondary endpoint analysis - DOR by investigator product | Secondary endpoint analysis - DOR by investigator product | Secondary endpoint analysis - DOR by investigator product |
| Analysis population and time point description  | ITT analysis set                                          |                                                           |                                                           |                                                           |
| Descriptive statistics and estimate variability | Treatment group                                           | Arm T+PC                                                  | Arm T+nPC                                                 | Arm PC                                                    |
| Descriptive statistics and estimate variability | Number of patients                                        | 120                                                       | 119                                                       | 121                                                       |
| Descriptive statistics and estimate variability | mDoR (months)                                             | 10.6                                                      | 8.8                                                       | 4.8                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                    | 7.03, 21.75                                               | 8.05, 11.10                                               | 2.86, 6.11                                                |
| Notes                                           |                                                           |                                                           |                                                           |                                                           |

Only patients under 75 years were included, therefore no analysis on special populations were performed for Study 307.

## In vitro biomarker test for patient selection for efficacy

## Clinical Performance

Archival tumour tissue (formalin-fixed paraffinembedded or approximately 15 [≥ 6] unstained slides) was sent to central laboratory for central immunohistochemistry assessment of PD-L1 status. PD-L1

<div style=\"page-break-after: always\"></div>

status was characterised as PD-L1 membrane staining on TC via the Ventana SP263 assay. If the submitted tumour tissue was unevaluable for PD-L1 expression status, patients were included in the &lt; 1% TC group. Other exploratory predictive biomarkers, such as tumour mutation load, immune-related gene expression profiling, and tumour-infiltrating immune cells that are related to response or clinical benefit of tislelizumab may also have been evaluated. If no archival samples were available, a fresh tumour biopsy at baseline was required.

## Rationale cut-off selection:

PD-L1 expression was tested centrally, and results remained blinded to the investigators, the patients, and the Applicant. The 3 cutoff levels employed (&lt; 1% TC vs. 1%49% TC vs. ≥ 50% TC) were selected based on prevalence data from previous NSCLC studies with ICIs. For the 3 cutoff levels employed (&lt; 1% TC vs. 1%49% TC vs. ≥ 50% TC ) that were also  chosen for stratification, no analytical validation report was provided. Data provided so far only support the 25% cutoff.

The applicant presented a critical analysis of the clinical data from squamous NSCLC patients in Study 307 and squamous NSCLC cohort in Study 206. The results from the two studies were presented side by side.

Analysis performed across trials (pooled analyses and meta-analysis) Not applicable. Supportive study(ies) Study 206 Study 206 was a multi-cohort, open label Phase II study of tislelizumab in combination with standard platinum-containing doublet chemotherapy as first-line treatment in Chinese patients with locally advanced or metastatic lung cancer. Patients were enrolled into 1 of 4 cohorts according to their pathological/histological diagnosis of the primary disease. These include a non-squamous NSCLC cohort, 2 squamous NSCLC cohorts (A and B), and a SCLC cohort. The study includes a safety run-in stage and a dose-expansion stage. Tislelizumab was continually dosed Q3W for all cohorts until the patients were deemed not to be benefiting from therapy under investigators' discretion, intolerable toxicity, or withdrawal of consent. Doublet chemotherapy was given until the completion of 4 to 6 cycles (4 cycles for the non-squamous NSCLC cohort), disease progression assessed by RECIST v1.1, intolerable toxicity, or withdrawal of consent. At the cutoff date of 31-Dec-2019, end of study was reached with the database closed as the final data point of interest had been collected from the last patient. The median age of all patients was 61.0 years (range: 36 to 75 years), most patients were male (74.1%); 83.3% had a baseline ECOG performance status of 1. All of 16 patients (100%) in the nonsquamous cohort were negative for EGFR and ALK mutations. More than half of the patients (55.6%) had &lt;10% PD-L1 expression on tumour cells. Study 307 and Study 206 (squamous NSCLC cohort) Medicinal product no longer authorised

All analyses were based on the efficacy set from Study 307 (T+PC; N = 120) (T+nPC; N = 119) (PC; N=121) and from Study 206 including 21 patients (squamous NSCLC cohorts; T+PC; N=15 and T+GC*; N=6).  [*GC = cis/carboplatin + gemcitabine].

Efficacy endpoints include PFS, ORR, DCR, DOR, CBR, and OS. There were differences between Study 307 and 206 regarding the definition of these efficacy endpoints. In Study 307, efficacy endpoints were assessed by IRC, and CR/PR confirmation was not required, whereas in Study 206, efficacy endpoints

<div style=\"page-break-after: always\"></div>

are assessed by investigator and confirmed CR/PR was required. For completeness, confirmed CR/PR were also included for Study 307. Confirmation CR/PR is defined as two determinations of CR/PR at least four weeks apart before progression as per RECIST 1.1.

Table 70: Demographics and baseline characteristics -Studies 307 and 206 (Efficacy Analysis Set)

|           |         |        | authorised   |
|-----------|---------|--------|--------------|
|           |         | longer |              |
|           | no      |        |              |
|           | product |        |              |
| Medicinal |         |        |              |

## Efficacy analysis: PFS

<div style=\"page-break-after: always\"></div>

Table 71: Analysis of progression-free survival per RECIST v1.1 (Studies 307 and 206) (Efficacy Analysis Set)

|        | authorised   |
|--------|--------------|
| longer |              |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Efficacy analysis: Disease response

Table 72: Analysis of confirmed disease response per RECIST v1.1 (Studies 307 and 206) (Efficacy Analysis Set)

| authorised   |
|--------------|

a    Best overall response of could not be determined include patients who had post-baseline tumour assessment, none of which were evaluable; or patients who had no post-baseline tumour assessment, and non-CR/non-PD was due to no measurable target lesion per IRC. Results were summarised based on data as assessed by independent review committee for Study 307 and as assessed by investigator for study 206. Objective Response Rate was the proportion of Patients who achieved CR or PR using RECIST version 1.1. Disease Control Rate was the proportion of patients who achieved CR, PR, non-CR/non-PD or SD using RECIST version 1.1. b    Included patients with BOR in CR or PR or ≥12 weeks SD c    including those patients with BOR in CR or PR or SD ≥ 24 weeks SD 2.5.5.4. Clinical efficacy of tislelizumab in combination with chemotherapy as 1L treatment of non-squamous NSCLC Main study Study 304 (BGB-A317-304): Phase III Open Label First Line Therapy Study of Tislelizumab With Chemotherapy Versus Chemotherapy in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Study 304 is a Phase III, open-label, multicentre, randomised study, conducted solely in China, and designed to evaluate the efficacy and safety of tislelizumab in combination with platinum and pemetrexed vs. platinum and pemetrexed alone in chemotherapy-naive patients with Stage IIIB or IV non-squamous NSCLC. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

- AJCC staging system v7 radiotherapy Figure 69: Study design (Study 304) Methods · Study Participants Key inclusion criteria included: 1. 18 to 75 years old on the day of signing the ICF 2. Histologically confirmed, locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) non-squamous NSCLC. Patients with tumours of mixed non-small cell histology (squamous and non-squamous) were eligible if the major histological component appears to be non-squamous. 3. Patients must have been able to provide fresh or archival tumour tissues (FFPE blocks or approximately 15 [at least 6] freshly cut unstained FFPE slides) with an associated pathological report (non-squamous). Patients must have been able to provide documentation of wild-type EGFR reported by a tissue-based test. For patients without documented EGFR status, archival or fresh tumour tissues were required for EGFR mutation assessment prior to enrolment. In the absence of archival tumour tissues, a fresh biopsy of a tumour lesion at baseline was mandatory. PD-L1 expression was to be assessed centrally, and patients who had evaluable PD-L1 results are eligible. Medicinal product no longer authorised
4. ECOG performance status ≤ 1
5. Patients must had at least one measurable lesion as defined per RECIST v1.1.
6. Have had no prior systemic chemotherapy for advanced or metastatic NSCLC. Patients who had received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must had experienced a treatment-free interval of at least 6 months from the last dose of chemotherapy and/or radiotherapy prior to randomisation.

<div style=\"page-break-after: always\"></div>

## 7. Life expectancy ≥ 12 weeks

Key exclusion criteria included:

1. Diagnosed with NSCLC that harbours an EGFR -sensitizing mutation or ALK gene translocation
2. Any approved systemic anti-cancer therapy, including hormonal therapy, within 28 days prior to initiation of study treatment
3. Received prior treatment with EGFR inhibitors or ALK inhibitors
4. Received prior therapies targeting PD-1 or PD-L1
- a. controlled type I diabetes;

5. Treatment with systemic immune-stimulatory agents (including but not limited to interferons, interleukin IL-2, and tumour necrosis factor) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomisation (prior treatment with cancer vaccines is allowed) 6. Had received any Chinese herbal medicine or Chinese patent medicines used to control cancer within 14 days of randomisation 7. With history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc 8. Active leptomeningeal disease or uncontrolled, untreated brain metastasis · Patients with a history of treated and, at the time of screening, asymptomatic CNS metastases are eligible, provided they meet all the following: -Brain imaging at screening shows no evidence of interim progression -Have measurable disease outside the CNS, only supratentorial metastases allowed -No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed -No stereotactic radiation or whole-brain radiation within 14 days prior to randomisation · Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases. -Following treatment, these patients may then be eligible, provided all other criteria, including those for patients with a history of brain metastases, are met. 9. Any major surgical procedure ≤ 28 days before random isation 10. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before randomisation 11. Active autoimmune diseases that may have relapsed. Patients with the following diseases were not excluded and may have proceeded to further screening: Medicinal product no longer authorised

- b. hypothyroidism (provided that it was managed with hormone replacement therapy only);
- c. controlled celiac disease;
- d. skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia); and e) any other disease that was not expected to recur in the absence of external triggering factors.

<div style=\"page-break-after: always\"></div>

## · Treatments

## Tislelizumab

Tislelizumab 200 mg was administered on Day 1 of each 21-day cycle (every 3 weeks) by IV infusion through an IV line containing a sterile, nonpyrogenic, low-protein-binding 0.2 or 0.22 micron in-line or add-on filter.

The initial infusion (Cycle 1 Day 1) was delivered over 60 minutes; if it was well-tolerated, the subsequent infusions were administered over 30 minutes, which was the shortest period permissible for infusion. Tislelizumab was not to be concurrently administered with any other drug.

<!-- image -->

Tumour assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks for the second 6 months, then every 12 weeks.

As a routine precaution, after infusion of tislelizumab on Day 1 of Cycle 1 and Cycle 2, patients were monitored for ≥ 1 hour afterward in an area with resuscitation equipment and emergency agents. From Cycle 3 onwards, a ≥ 30 -minute monitoring period was required in an area with resuscitation equipment and emergency agents. Chemotherapy Pemetrexed administration was performed before cisplatin or carboplatin during the induction phase. Pemetrexed 500 mg/m2 was administered as an IV infusion over 10 minutes once every 3 weeks until disease progression or unacceptable toxicity. All patients received the appropriate supplementation of vitamin B12 and folic acid according to the approved product label and/or standard practice. In addition, all patients received the appropriate corticosteroid pre-medications as per the local approved label. Additional pre-medications were to be administered as per standard practice. Carboplatin area under the curve (AUC) 5 was administered as an IV infusion over 15 minutes once every 3 weeks for 4 to 6 cycles immediately after pemetrexed. Additional premedications were to be administered as per standard practice. Cisplatin 75 mg/m2 was administered as an IV infusion over 2 hours once every 3 weeks for 4 to 6 cycles. All patients received adequate hydration (including pre-treatment hydration) and diuretics. Urinary output &gt;2000 mL was maintained for 24 hours after the infusion. Table 73: Treatments (Study 304) Medicinal product no longer authorised

## · Objectives

Assess the efficacy and safety of tislelizumab in combination with chemotherapy as 1L treatment of non-squamous NSCLC.

## Primary Objective

- To compare the progression -free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in the Intent-to-Treat (ITT)

<div style=\"page-break-after: always\"></div>

Analysis Set between tislelizumab combined with platinum-pemetrexed and platinum-pemetrexed alone in chemotherapy-naive patients with Stage IIIB or Stage IV (as classified according to the American Joint Committee Cancer 7th Edition of Cancer Staging Manual) non-small cell lung cancer (NSCLC).

## Secondary Objectives

· To compare the overall response rate (ORR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with platinum-pemetrexed and platinum-pemetrexed alone.

•

· To compare the duration of response (DOR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with platinum-pemetrexed and platinum-pemetrexed alone. · To compare overall survival (OS) between tislelizumab combined with platinum -pemetrexed and platinum-pemetrexed alone in the ITT Analysis Set. · To compare PFS as assessed by the investigator per RECIST v1.1 between tislelizumab combined with platinum-pemetrexed and platinum-pemetrexed alone in the ITT Analysis Set. · To compare health -related quality of life (HRQoL) between tislelizumab combined with platinumpemetrexed and platinum-pemetrexed alone. · To evaluate the safety and tolerability of tislelizumab combined with platinum -pemetrexed compared with platinum-pemetrexed alone. · To evaluate the correlation between programmed death -ligand 1 (PD-L1) expression levels by immunohistochemistry (IHC) and antitumour activity of tislelizumab combined with platinumpemetrexed. Exploratory Objectives · To compare tumour assessment outcomes (e.g., disease control rate [DCR], time to response [TTR]) between tislelizumab combined with platinum-pemetrexed and platinum-pemetrexed alone as assessed by the investigator per RECIST v1.1. · To assess tumour and blood biomarkers of tislelizumab response, resistance, and patient prognosis. · To character ise the pharmacokinetics (PK) of tislelizumab when given in combination with platinumpemetrexed. · To assess host immunogenicity to tislelizumab. Outcomes/endpoints Primary Efficacy Endpoint Medicinal product no longer authorised

## · PFS as assessed by the IRC

the time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined by the IRC per RECIST v1.1 in an ITT Population.

## Secondary Efficacy Endpoints

- OS -the time from the date of randomisation to the date of death due to any cause in an ITT Population.

<div style=\"page-break-after: always\"></div>

- PFS as assessed by the investigator -the time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined by the investigator per RECIST v1.1 in an ITT Population.
- ORR as assessed by the IRC -the proportion of patients who had complete response (CR) or partial response (PR) as determined by the IRC per RECIST v1.1 in all randomised patients with measurable disease at baseline.
- ORR as assessed by the investigator -the proportion of patients who had CR or PR as determined by the investigator per RECIST v1.1 in all randomised patients with measurable disease at baseline.
- Assessments of immunogenicity of tislelizumab by determining the incidence of antidrug antibodies (ADAs).

· DOR as assessed by the IRC -the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as determined by the IRC per RECIST v1.1 in all randomised patients with documented objective responses. · DOR as assessed by the investigator -the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as determined by the investigator per RECIST v1.1 in all randomised patients with documented objective responses. · HRQoL -measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ LC13) and Core 30 (EORTC QLQ-C30) as presented in patient-reported outcomes · Incidence and severity of treatment -emergent AEs (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03. · PD-L1 expression by IHC as a predictive biomarker for response. Exploratory Endpoints · DCR the proportion of patients who had a complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator per RECIST v1.1. · TTR the time from randomisation to the first occurrence of a documented objective response as assessed by the investigator per RECIST v1.1. · Status of exploratory biomarkers, including but not limited to: PD -L1, tumour mutation burden (TMB), and immune-related gene expression profiling (GEP) in archival and/or freshly obtained tumour tissues and blood (or blood derivatives) obtained before, during, or after treatment with tislelizumab or at progression and the association with disease status and/or response to tislelizumab in combination with chemotherapy. · Summary of serum concentrations of tislelizumab. Medicinal product no longer authorised

## · Sample size

The sample size calculation was based on the number of events required to demonstrate the PFS superiority of Arm A to Arm B in the ITT analysis set. The estimates of the number of events required to demonstrate efficacy about PFS in the primary comparisons were based on the following assumptions:

1. Median PFS of 7 months in Arm B with exponential distribution assumption.

<div style=\"page-break-after: always\"></div>

2. At a one-sided α of 0.025, 85% power to detect an HR of 0.65, corresponding to an improvement in median PFS from 7 months to 10.8 months, in the ITT analysis set.

3. Randomisation ratio of 2:1.

4. One interim analysis of PFS planned in the ITT analysis set when approximately 71% of total PFS events occurred, with LanDeMets' approximation to O'Brien -Fleming boundary (O'Brien et al, 1979).

With these assumptions, a total of 215 PFS events were planned to be required for the ITT analysis set for the PFS final analysis. Assuming 320 patients were planned to be enrolled over an 8-month period at a constant enrolment rate, the PFS final analysis was planned to occur approximately 19.2 months after the first patient was randomised.

· Randomisation and Blinding (masking) Patients were planned to be randomised in a 2:1 ratio to either Arm A or Arm B using the IRT system for this study by permuted block stratified randomisation with stratification factors of Stage (IIIB versus IV) and PDL1 expression in TC (≥ 50% TC versus 1%-49% TC versus &lt; 1% TC). The stratified randomisation was planned to be produced, reviewed, and approved by an independent statistician. The trial is an open-label study. Due to the open-label design, access to the patient level clinical data in the EDC system was planned to be assigned to predefined study personnel only. Functions/persons with access to the EDC system were planned to be prohibited from using the EDC system to generate unnecessary listings/summaries that may introduce unwanted bias, or share such outputs from the EDC system with other functions/persons who do not have access to the EDC. In addition, the central imaging vendor was planned to perform the central imaging review without knowledge of treatment arm assignment. Although the study is open label, analyses or summaries generated by randomised treatment assignment and actual treatment received were planned to be limited and documented. To minimise the potential for assessment bias in the open-label Study 304 when comparing tislelizumab combined with platinum-pemetrexed versus platinum-pemetrexed alone, PFS evaluated by a blinded IRC per RECIST v1.1 was used as the primary endpoint of the study. · Statistical methods Analysis Sets The ITT Analysis Set was planned to include all randomised patients. Patients were planned to be analysed according to their randomised treatment arms. This was planned to be the primary analysis set for efficacy analysis. The Per-Protocol (PP) Analysis Set was planned to include randomised patients who received at least 1 dose of the assigned study drug and had no major protocol deviations. Major protocol deviations were planned to be determined and documented before the database lock for the primary analysis. The Safety Analysis Set was planned to include all randomised patients who received at least 1 dose of study drug; it was planned to be the population for the safety analyses. Medicinal product no longer authorised

<!-- image -->

The PK Analysis Set was planned to include all patients who received at least 1 dose of tislelizumab per the protocol, for whom any post-dose PK data were available.

The immunogenicity (ADA) Analysis Set was planned to include all patients who received at least 1 dose of tislelizumab for whom both baseline ADA and at least 1 post-baseline ADA results were available.

<div style=\"page-break-after: always\"></div>

## Primary Endpoint

The primary endpoint PFS per the IRC was defined as the time from randomisation to the first documented disease progression as assessed by the IRC with the use of RECIST v1.1, or death from any cause, whichever occurred first. The actual tumour assessment visit date was planned to be used to calculate PFS. Data for patients without disease progression or death at the time of analysis were planned to be censored at the time of the last valid tumour assessment. Data for patients without post-baseline tumour assessment were planned to be censored at the time of randomisation. Data for patients who started to receive new anticancer therapy or were lost to follow-up were planned to be censored at the last valid tumour assessment date prior to the introduction of new therapy or loss to follow-up. Patients who had a clinical determination of progression were planned to undergo a CT/MRI, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient was confirmed, the date of the CT/MRI scan was planned to be considered as the progression date for that patient.

PFS per the IRC was planned to be compared between tislelizumab with platinum-pemetrexed (Arm A) and platinum-pemetrexed alone (Arm B) in a stratified log-rank test at one-sided significance level α=0.025. The null hypothesis to be tested was: H0: PFS in Arm A ≤ PFS in Arm B Against the alternative hypothesis: Ha: PFS in Arm A &gt; PFS in Arm B The p-value from a stratified log-rank test was planned to be presented using stratification factors. The median PFS was planned to be calculated for each treatment arm and presented with two-sided 95% CIs. Kaplan-Meier survival probabilities for each arm were planned to be plotted over time. The hazard ratio (HR) between Arm A and Arm B and its 95% CI were planned to be estimated using a Cox proportional hazard model with treatment arm as a factor and stratified by the actual value of the stratification factors as recorded in the eCRF. Secondary Endpoints Overall Survival OS was defined as the time from randomisation to death from any cause. Data for patients who were not reported as having died at the time of analysis were planned to be censored at the date last known to be alive. Data for patients who did not have post-baseline information were planned to be censored at the date of randomisation. Similar methodology used to evaluate PFS per the IRC was planned to OS analysis. Progression-Free Survival per Investigator PFS per the investigator was defined as the time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined per RECIST v1.1 in an ITT analysis set. Similar methodology used to evaluate PFS per the IRC was planned to be applied to analysis of PFS per the investigator. Medicinal product no longer authorised

## Objective Response Rate per the IRC and per the Investigator

ORR per the IRC or per the Investigator, resp. (confirmation not required according to RECIST v1.1) was defined as the proportion of patients who had a CR or PR as assessed by the IRC per RECIST v1.1 resp. as determined by the investigator per RECIST v1.1 in ITT analysis set. Patients without any postbaseline assessment were planned to be considered non-responders. The difference in ORR per the IRC and in ORR per the Investigator between arms in the ITT analysis set were planned to be evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with the actual stratification factors as

<div style=\"page-break-after: always\"></div>

strata. The two-sided 95% CIs for the odds ratio and the difference in ORR per the IRC as well as in ORR per the Investigator were planned to be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm.

## Duration of Response per the IRC and per the Investigator

DOR per the IRC resp. DOR per the Investigator was defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the IRC using the RECIST v1.1 resp. as determined by the investigator using the RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who were alive and who had have not experienced disease progression at the time of analysis were planned to be censored at the date of the last tumour assessment. If no tumour assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR was planned to be censored at the date of the first occurrence of the objective response. DOR was planned to be estimated using Kaplan-Meier methodology. Comparisons between treatment arms were planned to be made using the stratified and unstratified log-rank test for descriptive purposes only.

One interim efficacy analysis of PFS performed in the ITT analysis set was planned. The interim efficacy analysis of PFS was planned to be performed when approximately 153 PFS events (71% of the targeted number of 215 PFS events) were observed in the ITT analysis set. It was estimated that it would take approximately 12.8 months to observe 153 PFS events. The interim boundary for PFS was based on the LanDeMets approximation to O'Brien -Fleming boundary. The interim and final analysis timing and stopping boundaries were summarised in Table 74, and the exact time of each analysis was planned to depend on actual number of events occurred.

Health-Related Quality of Life Summary statistics (mean, SD, median, and range) of the post-baseline scores were planned to be reported for the EORTC Quality of Life Cancer Questionnaire (EORTC QLQ-LC13 and EORTC QLQC30). The mean change of the scores from baseline (and 95% CI with use of the normal approximation) were also planned to be assessed. Line charts depicting the mean changes (and standard errors) over time from the baseline assessment were planned to be provided for each treatment arm. The proportion of patients showing clinically meaningful change in selected items and subscales at each assessment time point were planned to be calculated. Completion and compliance rates were planned to be summarised at each time point by treatment arm. Only patients with a non-missing baseline assessment and at least one in-study non-missing post-baseline assessment were planned to be included in the analyses. Summaries were planned be performed for the ITT analysis set only. PD-L1 Expression as a Predictive Biomarker for Response Distribution of PD-L1 expression in TC was planned to be examined in the ITT analysis set. Association between PD-L1 expression and tislelizumab treatment effect over control (PFS, OS, ORR, DOR, DCR) were planned to be explored. Restricted Mean survival times Upon request, the applicant provided restricted mean survival times to address potentially nonproportional hazards. PD-L1 was included for as a continuous variable. Results (RMST(Arm T+PP) RMST(Arm PP): 3.19 months (95% CI: 1.23, 5.15, p= 0.001)) provide reassurance. Interim Analyses Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 74: Analysis timing and stopping boundary for PFS in the ITT analysis set (overall onesided hypothesis testing at α = 0.025) (Study 304)

| Type of Analysis   | Time (Months)   | Number ofEvents   | TestingBoundary   | TestingBoundary      |
|--------------------|-----------------|-------------------|-------------------|----------------------|
|                    |                 |                   | P-valueBoundary   | Approx. HR Threshold |
| Interim analysis   | 12.8            | 153               | 0.0078            | 0.660                |
| Final analysis     | 19.2            | 215               | 0.0226            | 0.748                |

## Subgroup Analyses

Subgroup analysis of primary endpoint of PFS per the IRC were planned to be conducted to determine if the treatment effect is consistent across various subgroups, the HR estimates of PFS and its 95% CI were planned to be estimated and plotted within each category of the following variables: PD-L1 expression in TC  (≥ 50% TC versus 1% -49% TC versus &lt; 1% TC), Stage (IIIB versus IV), age (≤ 65 versus &gt; 65 years), gender (female versus male), ECOG PS (0 versus 1), and smoking status (Former versus Current versus Never). Results · Participant flow Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 75: Patient disposition and reasons for discontinuation (ITT analysis) (Study 304) (DCO: 26OCT2020)

|    | longer   |
|----|----------|
| no |          |

The main purpose of this protocol amendment was:

Data cutoff: 26Oct2020 Abbreviations: 304, A317-304; T+PP, Tislelizumab+Pemetrexed+Platinum; PP, Pemetrexed+Platinum. a Primary reason for treatment discontinuation referred to primary reason of study drug which discontinued last. c Study follow-up time was defined as the time from the randomisation date to date of death or end of study date (whichever occurs first) for patient discontinued from the study or the database cutoff date for ongoing patients. · Recruitment This ongoing study is being conducted in 47 study centres in China. Start date was 24-Jul-2018. Median follow-up time at final analysis (DCO: 26 October 2020): 16.1 months. · Conduct of the study Amendment 1.0 (dated 07 June 2018) Medicinal product no longer authorised

- To update the safety data and clinical PK data according to the latest tislelizumab IB 5.0 and protocol template.
- To update statistical analysis parts by adjusting O'Brien -Fleming boundary per CDE comments, and PFS interim analysis timing per PFS delayed effect.
- To update protocol language to align with the latest protocol template, including updates to risk and management of myocarditis/myositis

<div style=\"page-break-after: always\"></div>

## Amendment 2.0 (dated 24 January 2019)

The main purpose of this protocol amendment was:

- To clarify the operational details of serum creatinine kinase (CK) and creatinine kinase cardiac muscle isoenzyme (CK-MB) testing for close monitoring of myocarditis/myositis;
- To update myocarditis/myositis language (immune -related adverse event evaluation and management) according to FDA requirements;
- To update to allow subjects with PD -L1 unevaluated results to be included in this study;

<!-- image -->

· To update the procedures for select study assessments to allow for greater flexibility in keeping with clinical practice; · To revise the content for clarity and consistency to align with the latest updates to the tislelizumab protocol template, including updates to safety assessment. Note: Patients with PD-L1 unevaluated results were allowed to be included in this study with protocol amendment V2 Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## · Baseline data

Table 76: Demographics and baseline characteristics (ITT analysis set) (Study 304) (DCO: 26OCT2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 77: Disease characteristics (ITT analysis set) (Study 304) (DCO: 26OCT2020)

|    | longer   |
|----|----------|
| no |          |

· Numbers analysed Table 78: Analysis sets (Study 304) (DCO: 26OCT2020) Medicinal product no longer authorised

- Outcomes and estimation

## Primary Endpoint

## Progression free survival (by IRC)

At Interim Analysis (data cut-off date 23 Jan 2020), a total of 104 (46.6%) PFS events in Arm A and 54 (48.6%) in Arm B had occurred, with a median follow-up time of 9.8 months in the ITT Analysis Set.

<div style=\"page-break-after: always\"></div>

Table 79: Analysis of progression-free survival per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 304); interim analysis (DCO: 23JAN2020)

|                           | T+PP (N = 223)   | PP (N =111)   |
|---------------------------|------------------|---------------|
| Progression-Free Survival |                  |               |
| Events, n (%)             | 104 (46.6)       | 54 (48.6)     |
| Progressive Disease       | 96 (43.0)        | 49 (44.1)     |
| Death                     | 8 (3.6)          | 5 (4.5)       |

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

The final efficacy analysis was performed by the IRC after 201 PFS events (60.2% of 334 patients in the ITT Analysis Set) were observed on 26 October 2020, the data cutoff date. The median follow-up time at the final analysis was 16.1 months. In the following, efficacy results from the data cutoff 26 Oct 2020 at the final analysis are presented. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 80: Analysis of progression-free survival per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 304); final analysis (CO: 26OCT2020)

| longer authorised   |
|---------------------|

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | no   |
|-----------|------|
| product   |      |
| Medicinal |      |

Figure 70: Kaplan-Meier plot of progression-free survival per RECIST v1.1 by independent review committee (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Secondary Endpoints Overall Survival Table 81: Analysis of overall survival (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

Source: ADSL, ADTTE. Data cutoff: 26Oct2020. Data extraction: 23Feb2021.

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<!-- image -->

Figure 71: Kaplan-Meier plot of overall survival (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Overall Survival -Updated data Figure 72: Kaplan-Meier plot of overall survival (ITT analysis set) (Study 304); updated data (DCO: 15JUL2022) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Progression-Free Survival (by Investigator)

| authorised   |
|--------------|

Table 82: Analysis of progression-free survival per RECIST version 1.1 by investigator (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020)

|                                                | Study 304      | Study 304    |
|------------------------------------------------|----------------|--------------|
| product                                        | T+PP (N = 223) | PP (N = 111) |
| Best Overall Response a , n (%)                |                |              |
| Complete Response                              | 9 (4.0)        | 2 (1.8)      |
| Partial Response                               | 104 (46.6)     | 29 (26.1)    |
| Stable Disease                                 | 83 (37.2)      | 56 (50.5)    |
| Non-CR/Non-PD                                  | 3 (1.3)        | 3 (2.7)      |
| Progressive Disease                            | 15 (6.7)       | 14 (12.6)    |
| Could not be Determined                        | 9 (4.0)        | 7 (6.3)      |
| Objective Response Rate (ORR), n (%) Medicinal | 113 (50.7)     | 31 (27.9)    |
| 95% CI                                         | (43.9, 57.4)   | (19.8, 37.2) |
| Disease Control Rate, n (%)                    | 199 (89.2)     | 90 (81.1)    |
| 95% CI                                         | (84.4, 93.0)   | (72.5, 87.9) |
| Clinical Benefit Rate b , n (%)                | 184 (82.5)     | 80 (72.1)    |
| 95% CI                                         | (76.9, 87.3)   | (62.8, 80.2) |
| Clinical Benefit Rate c , n (%)                | 149 (66.8)     | 54 (48.6)    |
| 95% CI                                         | (60.2, 73.0)   | (39.0, 58.3) |

Abbreviations: T+PP, Tislelizumab+Pemetrexed+Platinum; PP, Pemetrexed+Platinum.

Objective Response Rate (by IRC) Table 83: Analysis of confirmed disease response per RECIST v1.1 by independent review committee (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) DCO: 26Oct2020 Medicinal product no longer authorised

Best overall response of could not be determined included patients who had post-baseline tumour assessment, none of which were evaluable; or patients who had no post-baseline tumour assessments due to death, withdrawal of consent, lost to follow-up or any other reasons, and non-CR/non-PD was due to no measurable target lesion per IRC. Results were summarised based on data as assessed by independent review committee. Objective Response Rate was the proportion of Patients who achieved CR or PR using

RECIST version 1.1. Disease Control Rate was the proportion of Patients who achieved CR, PR, non-CR/non-PD or SD using RECIST v1.1.

a Confirmed CR or PR is required.

b Included patients with BOR in CR or PR or ≥12 weeks SD.

c Included patients with BOR in CR or PR or ≥24 weeks SD.

<div style=\"page-break-after: always\"></div>

## Duration of Response (by IRC)

Table 84: Analysis of duration of response confirmed per RECIST v1.1 by independent review committee (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020)

|                               | Study 304           | PP (N = 111)        |
|-------------------------------|---------------------|---------------------|
|                               | T+PP (N = 223)      |                     |
| Number of Responders a        | 113                 | 31                  |
| Duration of Response          |                     |                     |
| Events, n (%)                 | 53 (46.9)           | 17 (54.8)           |
| Progressive Disease           | 48 (42.5)           | 16 (51.6)           |
| Death                         | 5 (4.4)             | 1 (3.2)             |
| Censored                      | 60 (53.1)           | 14 (45.2)           |
| Duration of Response (Months) |                     |                     |
| Median (95% CI)               | 14.5 (10.09, NE)    | 8.4 (5.95, 15.47)   |
| Q1 (95% CI)                   | 6.5 (4.99, 8.31)    | 5.9 (3.25, 7.00)    |
| Q3 (95% CI)                   | NE (NE, NE)         | 15.5 (8.48, NE)     |
| Event Free Rate at, %(95% CI) |                     |                     |
| 6 months                      | 78.5 (69.47, 85.19) | 63.8 (41.78, 79.35) |
| 12 months                     | 53.9 (43.63, 63.11) | 37.2 (18.32, 56.24) |
| 18 months                     | 42.0 (30.35, 53.17) | 20.7 (4.86, 43.97)  |
| 24 months                     | 42.0 (30.35, 53.17) | NE (NE, NE)         |

Death Censored Duration of Response (Months) Median (95% CI) Q1 (95% CI) Q3 (95% CI) Event Free Rate at, % (95% CI) 6 months 12 months 18 months 24 months DCO: 26Oct2020 for 304. Abbreviations:T+PP, Tislelizumab+Pemetrexed+Platinum; PP, Pemetrexed+Platinum; NE, not estimable. a Responders are defined as patients who achieved best overall response of confirmed CR or PR using RECIST version 1.1.Percentages were based on number of responders. Results were summarised based on data as assessed by independent review committee. Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley. Event free rates were estimated by KaplanMeier method with 95% CI estimated using the Greenwood's formula. Health-related Quality of Life The addition of tislelizumab to platinum-pemetrexed trended towards improvements in HRQoL compared to platinum-pemetrexed alone in patients with previously untreated stage IIIB or IV nonsquamous NSCLC. The difference in LS mean change scores at Cycle 5 for QLQ-C30 GHS/QoL was 3.9 (95% CI: -0.9, 8.7); however, the difference at Cycle 7 (5.7 [95% CI: 1.0, 10.5]) showed a trend towards higher scores for Arm T+PP. The difference in LS mean change scores at Cycle 5 for QLQ-LC13 chest pain was -3.2 (95% CI: -7.6, 1.2); however, the difference at Cycle 7 (-6.2 [95% CI: -10.8, 1.6]) showed a trend towards lower scores for Arm T+PP. The difference in LS mean change scores at Cycle 5 for QLQ-LC13 coughing was -2.2 (95% CI: - 7.4, 3.1); however, the difference at Cycle 7 (-5.9 [95% CI: -11.6, -0.1]) showed a trend towards lower scores for Arm T+PP. The median TTD for QLQC30 GHS/QoL was not reached in either treatment arms; the median TTD for the composite of cough, chest pain, and dyspnoea in the QLQ LC13 was 5.8 months (95% CI: 4.40, NE) in Arm T+PP and 4.3 months (95 %CI: 3.09, NE) in Arm PP. · Ancillary analyses Medicinal product no longer authorised

## Sensitivity Analyses for PFS

Sensitivity Analysis 1 evaluated the impact of censoring the primary endpoint due to new anticancer treatment. This analysis was the same as the primary analysis with regards to the censoring rules except for the handling of new anticancer treatment.  The PFS was derived regardless of the new anticancer treatment.

<div style=\"page-break-after: always\"></div>

Table 85: Analysis of progression-free survival per RECIST version 1.1 by independent review committee - comparison of primary analysis and sensitivity analysis (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020)

|                                    | Primary Analysis    | Primary Analysis   | Sensitivity Analysis 1            | Sensitivity Analysis 1   |
|------------------------------------|---------------------|--------------------|-----------------------------------|--------------------------|
|                                    | T+PP (IN = 223)     | PP ( = 111)        | T+PP (IN = 223)                   | PP (N = 111)             |
| StratifiedHazardRatio (95% CI) a,b | 0.632 (0.467,0.855) |                    | 0.625 (0.467,0.837)               |                          |
| Progression-FreeSurvival (months)  |                     |                    |                                   |                          |
| Median (95% CI)                    | 9.8 (8.94, 11.70)   |                    | 7.6 (5.55,8.02) 9.7 (8.90, 11.70) | 7.5 (5.39, 7.89)         |

<!-- image -->

<!-- image -->

An additional analysis was conducted to evaluate the impact of never smoking and baseline liver metastasis on the primary analysis. The stratified HR as estimated from the Cox model adjusted for never-smoking and baseline liver metastasis was 0.636 (95% CI: 0.468, 0.863). Table 86: Analysis of progression-free survival per RECIST version 1.1 by independent review committee -adjusting for smoking status and baseline liver metastasis (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

|           | no longer   |
|-----------|-------------|
| product   |             |
| Medicinal |             |

## Sensitivity Analyses for OS

As of the data cutoff date of 26 October 2020, 16 patients (7.2%) in Arm T+PP, and 56 patients (50.5%) in Arm PP had received subsequent immunotherapy, including 40 patients (36.0%) with instudy crossover. The median time from randomisation to crossover was 35.1 weeks and from end of study treatment to crossover was 2.6 weeks (minimum: 0.1 week).

To assess the impact of in-study crossover on OS, a supportive analysis was conducted using Rank-

<div style=\"page-break-after: always\"></div>

Preserving Structural Failure Time Model (RPSFTM, Robins, et al. 1991). The stratified HR from this analysis was 0.844 (95% CI: 0.479, 1.488).

In addition, a supportive analysis using two-stage method (Latimer, et al. 2014) was also performed to estimate the in-study crossover effect on post-progression survival (PPS) using data from patients who progressed per IRC assessment before any subsequent anti-cancer therapy in the control arm only. The stratified HR based on the counterfactual survival time in arm PP crossed-over patients and the observed survival times in the rest of the patients was estimated as 0.707 (95% CI: 0.468, 1.070).

<!-- image -->

<!-- image -->

Figure 73: Kaplan-Meier Plot of overall survival - sensitivity analysis using rank- preserving structural failure time model (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

Figure 74: Kaplan-Meier plot of overall survival - sensitivity analysis using two stage method (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses

## Subgroup Analysis of PFS Assessed by IRC

<!-- image -->

<!-- image -->

Figure 75: Subgroup analysis: forest plot of PFS per RECIST version 1.1 by independent review committee (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Subgroup Analysis of OS

<!-- image -->

| authorised   |
|--------------|

<!-- image -->

Figure 76: Subgroup analysis: forest plot of overall survival (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Efficacy by PD-L1 Expression

## PD-L1 &lt;1%

## PFS

<!-- image -->

<div style=\"page-break-after: always\"></div>

## PD-L1 1%-49%

## PFS

<!-- image -->

<div style=\"page-break-after: always\"></div>

## PD-L1 ≥ 50%

## PFS

<!-- image -->

Stratified Hazard Ratio (95% CI): 0.39 (0.22, 0.71)

Figure 77: Kaplan-Meier plot of PFS per RECIST version 1.1 by independent review committee and OS by PD-L1 expression (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020)

<div style=\"page-break-after: always\"></div>

## ORR by PD-L1 expression

T+PP

PP

PD-L1 Expression in TC ≥ 50%

<!-- image -->

| Endpoint   | Tislelizumab + Pemetrexed + Platinum (n = 74)   | Pemetrexed + Platinum (n = 36)   |
|------------|-------------------------------------------------|----------------------------------|
| ORR, n (%) | 52 (70.3)                                       | 11 (30.6)                        |
| 95% CI     | (58.5, 80.3)                                    | (16.3, 48.1)                     |
| CR, n (%)  | 7 (9.5)                                         | 0 (0.0)                          |
| PR, n (%)  | 45 (60.8)                                       | 11 (30.6)                        |

| Endpoint                     | Tislelizumab + Pemetrexed + Platinum (n = 74)   | Pemetrexed + Platinum (n = 36)   |
|------------------------------|-------------------------------------------------|----------------------------------|
| Median DoR (months) (95% CI) | NE (13.2, NE)                                   | 8.5 (3.3, NE)                    |

Figure 78: Objective response per RECIST version 1.1 by IRC by PD-L1 expression (ITT analysis set) (Study 304); final analysis (DCO: 26OCT2020) Table 87: Confirmed objective response, PD-L1 positive population (PD-L1 expression ≥50%) (Study 304) ; final analysis (DCO: 26OCT2020) DoR by PD-L1 expression Table 88: Duration of Response, PD-L1 positive population (PDL1 expression ≥50%) (Study 304) Final Analysis (DCO: 26OCT2020) Medicinal product no longer authorised

## OS Supportive Analyses

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the 1L (in combination with chemotherapy) nonsquamous NSCLC indication of the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 89: Summary of efficacy for trial BGB-A317-304 (Study 304)

<!-- image -->

| Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab (BGB-A317) (anti-PD1 antibody) combined with platinum-pemetrexed versus platinum-pemetrexed alone as first-line treatment for patients with stage IIIB or IV non-squamous non-small cell lung cancer   | Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab (BGB-A317) (anti-PD1 antibody) combined with platinum-pemetrexed versus platinum-pemetrexed alone as first-line treatment for patients with stage IIIB or IV non-squamous non-small cell lung cancer   | Title: A Phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab (BGB-A317) (anti-PD1 antibody) combined with platinum-pemetrexed versus platinum-pemetrexed alone as first-line treatment for patients with stage IIIB or IV non-squamous non-small cell lung cancer                                                                                                                                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                          | BGB-A317-304, RATIONALE 304                                                                                                                                                                                                                                                                                               | BGB-A317-304, RATIONALE 304                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                                                                                                                    | Phase III, multicentre, randomised (2:1), open-label study comparing tislelizumab + platinum-pemetrexed versus platinum-pemetrexed alone                                                                                                                                                                                  | Phase III, multicentre, randomised (2:1), open-label study comparing tislelizumab + platinum-pemetrexed versus platinum-pemetrexed alone                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                           | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                                                         | 24-Jul-2018 - Ongoing ( data cut- off for final analysis: 26-Oct- 2020 ) The interim and final analyses were conducted when the predefined PFS events had been observed for the efficacy and safety evaluations. The study met its primary objective of PFS at the interim analysis. Results for the final analysis are presented in this submission. The study will continue until the last patient has disease progression, is lost to follow-up, or withdraws from study, or until study completion by Sponsor. Not applicable longer authorised |
| Hypothesis                                                                                                                                                                                                                                                                                                                | Superiority no                                                                                                                                                                                                                                                                                                            | Superiority no                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                                                                         | Arm T+PP Tislelizumab Pemetrexed Carboplatin or cisplatin product                                                                                                                                                                                                                                                         | n = 223 Tislelizumab 200 mg i.v. + carboplatin AUC 5 OR cisplatin 75 mg/m 2 + pemetrexed 500 mg/m 2 Q3W for 4-6 cycles followed by tislelizumab 200 mg + pemetrexed 500 mg/m 2 Q3W                                                                                                                                                                                                                                                                                                                                                                  |
| Medicinal                                                                                                                                                                                                                                                                                                                 | Arm PP Pemetrexed Carboplatin or cisplatin                                                                                                                                                                                                                                                                                | n = 111 Carboplatin AUC 5 OR cisplatin 75 mg/m 2 + pemetrexed 500 mg/m 2 Q3W for 4-6 cycles followed by pemetrexed 500 mg/m 2 Q3W                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Endpoints and definitions          | Endpoints and definitions                                | Primary endpoint                                         | PFS as assessed by the IRC                               | PFS as assessed by the IRC                               | Time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1 in ITT analysis set                                                 |
|------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                    |                                                          | Secondary endpoint                                       | OS                                                       | OS                                                       | Time from the date of randomisation to the date of death due to any cause in ITT analysis set                                                                                                                                                |
|                                    |                                                          | Secondary endpoint                                       | PFS as assessed by the investigator                      | PFS as assessed by the investigator                      | Time from randomisation to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined by the investigator per RECIST v1.1 in ITT analysis set authorised                           |
|                                    |                                                          | Secondary endpoint                                       | ORR as assessed by the IRC no longer                     | ORR as assessed by the IRC no longer                     | Proportion of patients who had complete response (CR) or partial response (PR) as assessed by the IRC per RECIST v1.1 in ITT analysis                                                                                                        |
| Medicinal                          | Medicinal                                                | Secondary endpoint DOR as assessed by the IRC product    | Secondary endpoint DOR as assessed by the IRC product    | Secondary endpoint DOR as assessed by the IRC product    | set Time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the IRC per RECIST v1.1 in ITT analysis set with documented objective responses |
| Database lock                      | Database lock                                            | 26-Oct-2020 (data cut-off date)                          | 26-Oct-2020 (data cut-off date)                          | 26-Oct-2020 (data cut-off date)                          | 26-Oct-2020 (data cut-off date)                                                                                                                                                                                                              |
| Results and Analysis               | Results and Analysis                                     | Results and Analysis                                     | Results and Analysis                                     | Results and Analysis                                     | Results and Analysis                                                                                                                                                                                                                         |
| Analysis description               | Primary endpoint analysis - PFS by IRC                   | Primary endpoint analysis - PFS by IRC                   | Primary endpoint analysis - PFS by IRC                   | Primary endpoint analysis - PFS by IRC                   | Primary endpoint analysis - PFS by IRC                                                                                                                                                                                                       |
| Analysis population and time point | ITT analysis set Time point: after 201 PFS by IRC events | ITT analysis set Time point: after 201 PFS by IRC events | ITT analysis set Time point: after 201 PFS by IRC events | ITT analysis set Time point: after 201 PFS by IRC events | ITT analysis set Time point: after 201 PFS by IRC events                                                                                                                                                                                     |
| description Descriptive            | Treatment group                                          | Treatment group                                          | Treatment group                                          | Arm T+PP                                                 | Arm PP                                                                                                                                                                                                                                       |
| statistics and                     | Number of patients                                       | Number of patients                                       | Number of patients                                       | 223                                                      | 111                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| estimate variability                                                                           | mPFS (months)                                                                                        | 9.8                                                                                                  | 7.6                                                                                                  |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| estimate variability                                                                           | 95% CI                                                                                               | 8.94, 11.70                                                                                          | 5.55, 8.02                                                                                           |
| Effect estimate per comparison                                                                 |                                                                                                      | Comparison groups                                                                                    | Arm T+PP vs. Arm PP                                                                                  |
| Effect estimate per comparison                                                                 |                                                                                                      | HR                                                                                                   | 0.632                                                                                                |
| Effect estimate per comparison                                                                 |                                                                                                      | 95% CI                                                                                               | 0.467, 0.855                                                                                         |
| Effect estimate per comparison                                                                 |                                                                                                      | p-value                                                                                              | 0.0013                                                                                               |
| Notes                                                                                          | The primary endpoint was met, and statistical significance was achieved in the pre-specified interim | The primary endpoint was met, and statistical significance was achieved in the pre-specified interim | The primary endpoint was met, and statistical significance was achieved in the pre-specified interim |
| Analysis description                                                                           | Secondary endpoint analysis - OS                                                                     | Secondary endpoint analysis - OS                                                                     | Secondary endpoint analysis - OS                                                                     |
| Analysis population and time point                                                             | ITT authorised                                                                                       | ITT authorised                                                                                       | ITT authorised                                                                                       |
| description Descriptive statistics and estimate variability                                    | Treatment group                                                                                      | Arm T+PP                                                                                             | Arm PP                                                                                               |
| description Descriptive statistics and estimate variability                                    | Number of patients                                                                                   | 223                                                                                                  | 111                                                                                                  |
| description Descriptive statistics and estimate variability                                    | mOS (months)                                                                                         | 21.4                                                                                                 | 21.3                                                                                                 |
| description Descriptive statistics and estimate variability                                    | 95% CI                                                                                               | 17.68, NE                                                                                            | 15.64, NE                                                                                            |
| Effect estimate per comparison                                                                 | product no                                                                                           | Comparison groups longer                                                                             | Arm T+PP vs. Arm PP                                                                                  |
| Effect estimate per comparison                                                                 |                                                                                                      | HR                                                                                                   | 0.900                                                                                                |
| Effect estimate per comparison                                                                 |                                                                                                      | 95% CI                                                                                               | 0.631, 1.283                                                                                         |
| Notes                                                                                          |                                                                                                      |                                                                                                      |                                                                                                      |
| Analysis description                                                                           | Secondary endpoint analysis - PFS by investigator                                                    | Secondary endpoint analysis - PFS by investigator                                                    | Secondary endpoint analysis - PFS by investigator                                                    |
| Analysis population and time point description Descriptive statistics and estimate variability | ITT Treatment group Medicinal                                                                        | Arm T+PP                                                                                             | Arm PP                                                                                               |
| Analysis population and time point description Descriptive statistics and estimate variability | Number of patients                                                                                   | 223                                                                                                  | 111                                                                                                  |
| Analysis population and time point description Descriptive statistics and estimate variability | mPFS (months)                                                                                        | 9.7                                                                                                  | 5.6                                                                                                  |
| Analysis population and time point description Descriptive statistics and estimate variability | 95% CI                                                                                               | 7.66, 11.70                                                                                          | 4.80, 7.89                                                                                           |
| Effect estimate per comparison                                                                 |                                                                                                      | Comparison groups                                                                                    | Arm T+PP vs. Arm PP                                                                                  |
| Effect estimate per comparison                                                                 |                                                                                                      | HR                                                                                                   | 0.550                                                                                                |
| Effect estimate per comparison                                                                 |                                                                                                      | 95% CI                                                                                               | 0.415, 0.729                                                                                         |
| Notes                                                                                          |                                                                                                      |                                                                                                      |                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Analysis description                                      | Secondary endpoint analysis - ORR by IRC         | Secondary endpoint analysis - ORR by IRC         | Secondary endpoint analysis - ORR by IRC         |
|-----------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Analysis population and time point description            | ITT                                              | ITT                                              | ITT                                              |
| Descriptive statistics and estimate variability           | Treatment group                                  | Arm T+PP                                         | Arm PP                                           |
| Descriptive statistics and estimate variability           | Number of patients                               | 223                                              | 111                                              |
| Descriptive statistics and estimate variability           | ORR, n (%)                                       | 113 (50.7)                                       | 31 (27.9)                                        |
| Descriptive statistics and estimate variability           | 95% CI                                           | 43.9, 57.4                                       | 19.8, 37.2                                       |
| Notes                                                     |                                                  |                                                  |                                                  |
| Analysis description                                      | Secondary endpoint analysis - DOR by IRC         | Secondary endpoint analysis - DOR by IRC         | Secondary endpoint analysis - DOR by IRC         |
| Analysis population and time point description            | ITT longer authorised                            | ITT longer authorised                            | ITT longer authorised                            |
| Descriptive statistics and estimate variability           | Treatment group                                  | Arm T+PP                                         | Arm PP                                           |
| Descriptive statistics and estimate variability           | Number of patients                               | 223                                              | 111                                              |
| Descriptive statistics and estimate variability           | mDoR (months)                                    | 14.5                                             | 8.4                                              |
| Descriptive statistics and estimate variability           | 95% CI                                           | 10.09, NE                                        | 5.9 (3.25, 7.00)                                 |
| Analysis description                                      | Subgroup analysis - PFS by IRC (PD- L1 ≥ 50%) no | Subgroup analysis - PFS by IRC (PD- L1 ≥ 50%) no | Subgroup analysis - PFS by IRC (PD- L1 ≥ 50%) no |
| Analysis population and time point description            | PD- L1 ≥ 50% product                             | PD- L1 ≥ 50% product                             | PD- L1 ≥ 50% product                             |
| Descriptive statistics and estimate variability Medicinal | Treatment group                                  | Arm T+PP                                         | Arm PP                                           |
| Descriptive statistics and estimate variability Medicinal | Number of patients                               | 74                                               | 36                                               |
| Descriptive statistics and estimate variability Medicinal | mPFS (months)                                    | 14.6                                             | 4.6                                              |
| Descriptive statistics and estimate variability Medicinal | 95% CI                                           | 11.5, NE                                         | 3.5, 9.7                                         |
| Descriptive statistics and estimate variability Medicinal |                                                  | Comparison groups                                | Arm T+PP vs. Arm PP                              |
| Descriptive statistics and estimate variability Medicinal |                                                  | HR                                               | 0.31                                             |
| Descriptive statistics and estimate variability Medicinal |                                                  | 95% CI                                           | 0.18, 0.55                                       |
| Analysis description                                      | Subgroup analysis - OS by IRC (PD- L1 ≥ 50%)     | Subgroup analysis - OS by IRC (PD- L1 ≥ 50%)     | Subgroup analysis - OS by IRC (PD- L1 ≥ 50%)     |
| Analysis population and time point description            | PD- L1 ≥ 50%                                     | PD- L1 ≥ 50%                                     | PD- L1 ≥ 50%                                     |
| Analysis population and time point description            | Treatment group                                  | Arm T+PP                                         | Arm PP                                           |

<div style=\"page-break-after: always\"></div>

|       | Number of patients   | 74                | 36                  |
|-------|----------------------|-------------------|---------------------|
|       | mOS (months)         | NE                | 13.1                |
|       | 95% CI               | NE, NE            | 5.6, NE             |
|       |                      | Comparison groups | Arm T+PP vs. Arm PP |
|       |                      | HR                | 0.39                |
|       |                      | 95% CI            | 0.22, 0.71          |
| Notes |                      |                   |                     |

<!-- image -->

Clinical studies in special populations Not applicable. In vitro biomarker test for patient selection for efficacy Clinical Performance Archival tumour tissue (formalin-fixed paraffinembedded or approximately 15 [≥ 6] unstained slides) was sent to central laboratory for central immunohistochemistry assessment of PD-L1 status. PD-L1 status was characterised as PD-L1 membrane staining on TC via the Ventana SP263 assay. If the submitted tumour tissue was unevaluable for PD-L1 expression status, patients were included in the &lt; 1% TC group. Other exploratory predictive biomarkers, such as tumour mutation load, immune-related gene expression profiling, and tumour-infiltrating immune cells that are related to response or clinical benefit of tislelizumab may also have been evaluated. If no archival samples were available, a fresh tumour biopsy at baseline was required. Rationale cut-off selection: PD-L1 expression was tested centrally, and results remained blinded to the investigators, the patients, and the Applicant. The 3 cutoff levels employed (&lt; 1% TC vs. 1%49% TC vs. ≥ 50% TC) were selected based on prevalence data from previous NSCLC studies with ICIs. For the 3 cutoff levels employed (&lt; 1% TC vs. 1%49% TC vs. ≥ 50% TC ) that were also  chosen for stratification, no analytical validation report was provided. Data provided so far only support the 25% cutoff. Analysis performed across trials (pooled analyses and meta-analysis) Not applicable. Supportive study(ies) Medicinal product no longer authorised

## Study 206

Study 206 was a multi-cohort, open label Phase II study of tislelizumab in combination with standard platinum-containing doublet chemotherapy as first-line treatment in Chinese patients with locally advanced or metastatic lung cancer. Patients were enrolled into 1 of 4 cohorts according to their pathological/histological diagnosis of the primary disease. These include a nonsquamous NSCLC cohort, 2 squamous NSCLC cohorts (A and B), and a SCLC cohort. The study includes a safety run-in stage and a dose-expansion stage. Tislelizumab was continually dosed Q3W for all cohorts until the patients were deemed not to be benefiting from therapy under investigators' discretion, intolerable toxicity, or withdrawal of consent. Doublet chemotherapy was given until the completion of 4 to 6 cycles (4 cycles

<div style=\"page-break-after: always\"></div>

for the nonsquamous NSCLC cohort), disease progression assessed by RECIST v1.1, intolerable toxicity, or withdrawal of consent.

At the cutoff date of 31-Dec-2019, end of study was reached with the database closed as the final data point of interest had been collected from the last patient.

Table 90: Efficacy of tislelizumab combination therapy in patients with lung cancer (Study 206)

<!-- image -->

| authorised   |
|--------------|

In general, the applied inclusion and exclusion criteria selected an adequate population of patients with advanced or metastatic NSCLC eligible for 2 nd  line treatment, although the population may be considered somewhat selected due to exclusion of patients with ECOG PS ≥ 2, which could raise concerns about the external validity of the trial. Considering that patients included were required to have ECOG P S ≤1, the population represents a rather selected population accounting for the fact that there is evidence from literature that approx. 20% of NSCLC patients have ECOG PS 2-4 (Kawaguchi et al. Journal of Thoracic Oncology, 2010). Patients were enrolled regardless of their tumour PD-L1 expression level, which is considered acceptable.

2.5.6. Discussion on clinical efficacy Tislelizumab monotherapy as 2L+ treatment of NSCLC Design and conduct of clinical studies The application for approval of tislelizumab for the treatment of 2L+ NSCLC is based on the single open-label, randomised, controlled, pivotal Phase 3 study BGB-A317-303 (Study 303). The study was conducted in adult patients with histologically confirmed, locally advanced or metastatic (squamous or nonsquamous) NSCLC who had progressed during or after a prior platinum-containing regimen. Overall, the study design is endorsed. Stratification factors histology (squamous versus nonsquamous), line of therapy (2 versus 3) and PD-L1 expression level on tumour cell membrane (&lt;25% versus ≥25%) are endorsed. Medicinal product no longer authorised

Overall survival was selected as primary endpoint and is endorsed, as OS represents the most persuasive outcome -both from a clinical and methodological point of view -and is adequate, especially considering the prognosis of NSCLC patients having failed prior therapy. Other secondary efficacy endpoints (PFS, ORR, DOR, HRQoL) are standard in oncology trials and generally acceptable,

<div style=\"page-break-after: always\"></div>

although an independent central review of PFS, ORR and DOR instead of the sole assessment by investigator would have been more persuasive and thus preferred. Nevertheless, since OS was selected as primary endpoint, the lack of independent central assessment of imaging endpoints can be considered acceptable.

The methods are overall acceptable. The sample size and power considerations are acceptable, assumptions were well justified at the time of planning. The primary analysis by means of a stratified log-rank test is in principle supported. An interim analysis was planned when approximately 426 deaths in the ITT Analysis Set had been observed and was conducted after 441 events. This is incorporated in the alpha-spending approach and had no relevant impact on study conduct or results.

The alpha was split for the two dual primary hypotheses to control the overall type I error strongly at a one-sided alpha of 0.025. To account for the positive correlation between the test statistics in the 2 Analysis Sets (since the PD-L1 positive set is a subset of the ITT Analysis Set), it was planned to assign an alpha of 0.02 and 0.007 to the primary hypothesis testing (in contrast to a conservative 0.02 and 0.005 split) in the ITT and PD-L1 analysis set. The applicant provided a justification that under the global null hypothesis of no effect this approach would control type I error at the level of 0.025. It is not obvious how the properties would be in case an interaction between PD-L1 and treatment (i.e. null hypothesis in one subgroup and effect in the complementary subgroup), however given the results the assessors do not see any value in further discussion.

A 2:1 randomisation ratio is acceptable. The choice and number of strata are considered feasible and reasonable. The primary analysis set, comprising all randomised subjects, is endorsed. Adherence to the ITT principle is endorsed. However, no estimand was defined. The primary analysis by means of a stratified log-rank test is in principle supported. The hazard ratio was calculated using a Cox proportional hazard model with treatment arm as factor and stratified by the actual value of the stratification factors. The primary analysis was stratified for strata as recorded in the eCRF rather than the strata used for randomisation, which is not considered optimal. A sensitivity analysis based on the randomisation stratification factors showed consistent results. A sensitivity analysis  was planned using a Rank Preserving Structural Failure Time Model (RPSFTM) to adjust survival estimates in the presence of arm B patients receiving any subsequent immunotherapy after discontinuation of docetaxel. The model should be interpreted with care because the adjustment is based on an intercurrent event. Nonetheless results are overall consistent with the primary analysis, which provides reassurance. A onesided significance level of α=0.025 is acceptable, and the use of the proposed alpha spending approach to account for multiple analyses as well as the use of a hierarchical testing approach for sequential testing of the secondary endpoints in the final analysis in the ITT as well as the PD-L1 population is acceptable. The timing (and populations) for interim analyses and the alpha-spending approach was updated multiple times. Initially, a Hwang-ShihDeCani (HSD) spending function with γ = -4 was defin ed. In Protocol Amendment 1 this was modified to a HSD with γ = -0.7. Only in Protocol Amendment 3 (09 Mar 2020) the final HSD spending function with γ = -2 was defined. Given that the study was an open-label study this is considered potentially problematic. The rationale for these changes provided by the Applicant upon request (delayed treatment effect became apparent from results of other studies) was considered acceptable. Sensitivity analyses provided reassurance that there was no meaningful impact on the obtained results. Medicinal product no longer authorised

Censoring rules for OS are acceptable. However, for PFS the censoring rules warrant further discussion. Data for patients who start to receive new anticancer therapy or died/progressed after two or more missed visits were planned to be censored at the last valid tumour assessment date prior to

<div style=\"page-break-after: always\"></div>

the introduction of new anticancer therapy or were planned to censored at date of last adequate tumour assessment prior to the &gt;=2 missed tumour assessments. This is not in line with the (Appendix 1 to the) EMA guideline on the evaluation of anticancer medicinal products in man (EMA/CHMP/27994/2008/Rev.1). Upon request, the applicant has conducted the analysis applying the censoring strategy requested with respect to missing observation, treatment discontinuation and rescue medication preceding the death. The results of the requested analyses agree with those previously provided.

## Recruitment and conduct of the study

Study 303 recruited patients from 10 countries, including Asia and Europe. In the ITT Analysis Set, a total of 805 patients were randomised 2:1 to receive tislelizumab or docetaxel. More patients in the docetaxel arm as compared to the tislelizumab arm were randomised but not treated (4.4% vs. 0.2%) or withdrew from the study. The higher proportion of patients in the control group who were not treated at all or discontinued treatment early could have had an impact on the performance of the control arm. The proportion of patients with uncontrolled, untreated brain metastasis excluded could be reasonable, this refers also to the incidence of EGFR mutation. The applicant provided conservative sensitivity analyses addressing this imbalance which were supporting. At the data cutoff date of 15 July 2021, the median follow-up time was 16.0 months for the tislelizumab arm and 10.7 months for the docetaxel arm in the ITT Analysis Set. Baseline characteristics The study population included in Study 303 was predominantly male (77%) and had a median age of 61.0 years. The majority of patients were recruited at sites in Asia and thus, 80% of patients were Asian versus 17% being of White or Caucasian race. Tumour tissue (either archival tissue or fresh biopsy) was required for enrolment in this study. Patients with known EGFR/ALK mutations were excluded. Overall, there are no meaningful imbalances in patients' baseline characteristics among treatment arms. However, several points could question whether the enrolled population is representative of reallife EU patients (i.e. 55% male, 45% female, 10% never smoker, 70% non-squamous, Simeone et al. 2019). In Study 303, 30% of patients were never smokers, 54% non-squamous and only 22% were female, which is not considered representative. 80% of the patients were enrolled in China, which means the ethnicity, the standard of care and the histology differs largely from a Western European population. Medicinal product no longer authorised

It is noted that most patients (85%) included in Study 303 had received 1 prior anticancer therapy. Only 2 nd  and 3 rd  line patients are included. The indication statement did not include a restriction of administration of tislelizumab to patients having received 1 or 2 prior therapy in the past. As such, patients may also be treated with tislelizumab in even further lines of therapy. Although no data are available for patients with advanced or metastatic NSCLC in later lines of therapy, the extrapolation of study results is considered acceptable. 15% of patients included in Study 303 had locally advanced disease, the remaining patients had been diagnosed with metastatic disease at study entry. Conclusively, the inclusion of locally advanced disease stage in the indication wording is agreed.

## Efficacy data and additional analyses

The primary efficacy analysis demonstrated a statistically significant difference in OS with tislelizumab versus docetaxel. The stratified HR was 0.66 (95% CI: 0.56, 0.79). The median OS was 16.9 months (95% CI: 15.24, 19.09 months) and 11.9 months (95% CI: 9.63, 13.54 months) for the tislelizumab arm and docetaxel arm, respectively. The median follow-up time estimated by the reverse Kaplan-

<div style=\"page-break-after: always\"></div>

Meier method was 31.1 months (95% CI: 29.54, 31.64 months) for the tislelizumab arm and 27.9 months (95% CI: 26.38, 31.15 months) for the docetaxel arm in the ITT Analysis Set.

Benefit could be shown for investigator-assessed PFS in the ITT population (stratified HR = 0.63; 95% CI: 0.53, 0.75). The secondary endpoint of unconfirmed ORR , as assessed by the investigator per RECIST v1.1, showed a higher response rate for tislelizumab; 22.6 % vs. 7% of patients in the tislelizumab vs. docetaxel arm presented with objective response. A relatively high percentage of patients in the docetaxel arm (52 patients; 19.3%) with BOR 'could not be determined' is noted. Per definition, this included patients with no post-baseline tumour assessment by the data cutoff due to discontinuation (for any reason) or death without having any post-baseline tumour assessment. The number of patients with indeterminable response in the docetaxel arm is in line and can be explained by the number of patients randomised but not treated or withdrawn from study treatment (N = 41). The high proportion of missing values in the control arm is considered unfortunate. DOR analysis demonstrated that among patients with objective response (CR or PR, as assessed by the investigator per RECIST v1.1), responses were of longer duration for tislelizumab as compared to control (median DOR 13.5 months vs. 6.0 months). These results were consistent with the interim analysis results (DCO 10 Aug 2020). A median OS of 17 months for the tislelizumab arm in study 303 is considered outstanding, when compared with other PD-(L)-1 inhibitors in the 2L NSCLC indications. Median OS ranged from 9.23 months (Opdivo CA209017(squamous)) to 13.8 months (Tecentriq OAK). A longer median OS is also reported in the control arm. Difference in OS could be explained by a selected patient population with a more favourable prognosis as the effect of tislelizumab on the other endpoints does not seem to differ from the effect of other PD-(L)1 inhibitors (e.g. ORR). Efficacy in subgroups A statistically significant improvement in OS was observed in the PDL1 ≥25% analysis set favouring the tislelizumab arm (HR = 0.54; 95% CI: 0.41, 0.71) with median OS being 19.3 months for the tislelizumab arm and 11.7 months for the docetaxel arm. A notably lower OS advantage was observed for tislelizumab relative to docetaxel in the PD-L1 negative subset (PD-L1 &lt;25%), with a stratified HR of 0.79 (95% CI; 0.64, 0.99), and median OS estimates of 15.2 months (95% CI: 13.4, 17.6) for the tislelizumab arm vs. 12.3 months (95% CI: 9.3, 14.3) for the docetaxel arm. OS subgroup analyses showed a lower effect for never smokers, female patients and subjects with brain metastasis when compared to the effect of tislelizumab on the ITT population. Acknowledging the wide confidence intervals due to the limited number of events, the evidence does not allow to conclude on the lower benefit in these subgroups. No meaningful differences are observed based on histology. Subgroup analyses in subjects ≤65 and &gt;65 years suggest a similar efficacy for both age groups with slightly lower values for the higher age group (HR for OS 0.64 [95% CI 0.519, 0.790] vs. 0.73 [95%CI 0.545, 0.989]). Data in patients ≥75 year old were too limited to draw any conclusion, this is reflected in section 4.8 of the SmPC. Medicinal product no longer authorised

## Wording of the indication

As tislelizumab would be the 4 th  PD-(L)1 inhibitor in this setting, the following statement was added to the indication in line with Tecentriq and Keytruda: Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tizveni.

It is acknowledged that the pivotal Study 303 only excluded patients with known EGFR and ALK mutations. However, since the initiation of Study 303, the treatment landscape has changed and several ROS-targeted therapies have been approved for patients with ROS1 rearrangements that are recommended prior to treatment with immune- or chemotherapy (please refer to ESMO clinical

<div style=\"page-break-after: always\"></div>

practice guidelines). Therefore, the indication wording could lack reference to patients with mutations (as proposed by the applicant and as done for Opdivo). Nevertheless, for consistency reasons and to adequately reflect the inclusion criteria of study 303, a statement regarding EGFR and ALK mutations was added.

In consideration of heterogeneity of patients with locally advanced disease, which could be treated with Tizveni after progression to (neo)adjuvant chemotherapy, chemoradiation therapy or 1L metastatic chemotherapy -platinum-based in all four scenarios -, d eleting 'chemo' is endorsed to encompass both chemoradiation and chemotherapy.

Final indication statement: Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab. Tislelizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the 1L treatment of squamous NSCLC Design and conduct of clinical studies The pivotal study supporting the sought indication is the ongoing Study 307, a phase III randomised, open-label trial with tislelizumab in combination with carboplatin-paclitaxel/nab-paclitaxel (T+(n)PC) compared to carboplatin-paclitaxel (PC) in first line locally advanced (stage IIIB) or metastatic (stage IV) squamous NSCLC. No Scientific Advice to CHMP was requested on this study. Tislelizumab 200 mg Q3W was administered in combination with carboplatin AUC5 + paclitaxel 175 mg/m 2  or nab-paclitaxel 100 mg/m 2  for a total of 4 to 6 cycles, followed by tislelizumab until progression. Carboplatin with either paclitaxel or nab-paclitaxel is one of the accepted standard treatment options for 1 st  line squamous cell lung cancer. Cisplatin, although indicated and used in squamous disease, was not included in this study. Therefore, no data are available for tislelizumab in combination with cisplatin-based chemotherapy in squamous histology, contrary to non-squamous NSCLC (Study 304) where both cisplatin and carboplatin (with pemetrexed) have been tested (see section 2.6.6.4 below). The sought indication for tislelizumab in squamous NSCLC is ultimately in combination with carboplatin and either paclitaxel or nab-paclitaxel.  International guidelines recommend the use of 4 to 6 cycles of treatment for chemotherapy, Investigators choice of number of cycles (up to six) is therefore supported. Of note, lower doses for paclitaxel and carboplatin were applied in Study 307 compared to the recommended standard doses in European guidelines. However, literature data suggested that the dose reductions would likely not have a relevant impact on the efficacy results. Statistical methods Medicinal product no longer authorised

The sample size, power considerations and randomisation methods are acceptable. The primary PFS analysis for Study 307 by means of a stratified log-rank test using stratification factors with actual values as recorded in the EDC at randomisation is in principle supported. The hazard ratio was calculated using a Cox proportional hazard model with treatment arm as factor and stratified by the actual value of the stratification factors. This is endorsed. No estimand was defined. A one-sided significance level of α=0.025 is acceptable, and the use of the proposed sequential hypothesis testing procedure (Arm A vs C followed by Arm B vs C) as well as the use of the spending function approach to account for multiple analyses is also endorsed. The prespecified p-value boundaries per Lan-DeMets O Brien-Fleming approximation spending function were updated as 0.0115 for 136 events and 0.0103 for

<div style=\"page-break-after: always\"></div>

132 events, this is supported. Censoring rules for OS are acceptable. However, for PFS the censoring rules were not in line with the relevant EMA guideline (EMA/CHMP/27994/2008/Rev.1) but reflected FDA censoring rules. A sensitivity analysis based on EMA censoring rules was provided. Overall, this is acceptable.

Originally, it was planned to assign an alpha of 0.0125 and 0.0125 to the primary hypothesis testing of PFS of A versus C and PFS of B versus C, combined with an alpha passing to the other comparison in case any of the two comparisons would be statistically significant at the initial assigned alpha of 0.0125. In Amendment 3 this was changed to a hierarchical approach: Hypothesis testing for the primary endpoint of PFS was planned to be carried out sequentially (Arm A vs C followed by Arm B vs C), each at a one-sided alpha of 0.025, until the first non-rejection. Additionally, it was originally planned to perform the interim analysis when approximately 109 PFS events (67% of the targeted number of events, slightly corrected to 103 PFS events in Amendment 1) would have been observed. In Amendment 3 this was changed to 130 PFS events (75% of the now targeted number of 173 PFS events, based on an updated sample size calculation with a now assumed HR of 0.65 in Arm A as well as Arm B). Since this is an open-label trial, such late changes in the timing of the interim analysis (4 months before data cut-off) raise uncertainties. Upon request, the Applicant clarified that a delayed treatment effect was not expected during the initial planning but was suggested by results from other studies that were finalised during the conduct of this study. This led to the changes of the study. Although some uncertainty remains, e.g. due to the openlabel study design, this explanation seems reasonable. Further, results based on the original plan with 103 events in Arms T+PC and PC and Arms T+nPC and PC provide reassurance. Recruitment and conduct of the study In the ITT Analysis Set, a total of 360 patients were randomised 1:1:1 to receive T+PC, T+nPC or PC. More patients in the control arm as compared to the T+(n)PC arms were randomised but not treated or withdrew from the study (14.9% vs. 4.2%). Baseline characteristics The 307 study population was predominantly male (91.7%), had a median age of 62.0 years and 16% never smoker were included. Patients were enrolled in 43 centres in China. Some imbalances could be detected in the T+nPC arm compared to control (and T+PC). There are only 6% female and 10% never smoker in this arm. Overall, only Asian patients were included, the median age of 62 years is considered low (expected 69 years) and 8% female patients only are not considered representative for a European patient population, this raises concerns about the external validity of the trial. Medicinal product no longer authorised

Both intrinsic and extrinsic ethnic factors are of influence in the presented data for both trials. The magnitude of the differences in the intrinsic factors of age and gender distribution and the extrinsic factor of smoking status distribution between the 2 cohorts of study 304 and 307 and a European corresponding patient population, is notable and of importance. In studies 304/307, the median age was 61/62 years, the female fraction was 26%/8.3% and the never-smoker fraction was 36.2%/16.4%. In the European population of patients with mNSCLC, the median age at diagnosis is ~70 years, the distribution of females /males is ~35-50%/50-65% and the fraction of never-smokers is ~5-10%. However, this fraction of never-smokers is lower when patients with driver mutations are excluded, which is the situation in the cohorts of study 304 and 307. This fact makes the high frequency of never-smokers in study 304 and 307 even more striking.

It is reasonable to believe, that the efficacy and safety profile of a population of relatively younger patients, primarily male and far more frequent never-smokers, not impacted by the comorbidity that comes with smoking, could differ significantly from that of a population of older patients, a different gender distribution, and with the far majority being smoker/previous smokers (with the concomitant

<div style=\"page-break-after: always\"></div>

comorbidities smoking entails). Conversely, it is not justifiable to assume that there are no or only neglectable differences in the outcome of efficacy and toxicity profile between two patient populations with such distinct differences in characteristics.

The pattern of distribution of these intrinsic and extrinsic factors is consistent across the 2 trials; 304 and 307, verifying the fact, that the Chinese mNSCLC patient population presents inherent and distinct differences from that of the European population.

To generate reliable data -upon which an assessment of benefits and risks can be based -in a patient population that differs markedly from the one the medication was investigated in, a clinical trial, e.g., a bridging study, in the population of the new region (in this case Europe) is needed. This is clearly reflected in the ICH E5 guideline on Ethnic factors in the acceptability of foreign clinical data. External validity of the outcome data from study 304 and 307 was questioned, however considering that results could be regarded as comparable to other studies with PD-L1 inhibitors in NSCLC this issue was not further pursued.

Inclusion was limited to ECOG PS 0-1 and the inclusion was restricted to participants younger than 75 years which cannot be followed and is suboptimal, as it hampers the comparability with the real-world setting. Patients with sensitizing EGFR mutation or ALK translocation were not eligible. As consequence, this could result in exclusion of patients with EGFR and ALK mutations in the indication wording. However, compared with lung adenocarcinoma, evidence about the efficacy of EGFR TKIs and treatment progress in patients with lung squamous cell carcinoma (SCC) is limited and controversial. Activation of EGFR mutations are rare in patients with SCC (&lt;3%); the lack of reported mutations may limit the use of EGFR-TKIs in lung cancer patients with SCC. In addition, ALK and ROS1 rearrangements in lung squamous cell carcinoma are very rare (Zhao et al. Lung cancer 2016), so not considered relevant in real world setting. Overall, there are no meaningful imbalances in patients' baseline characteristics between the treatment arms T+PC and PC. Efficacy data and additional analyses A statistically significant and clinically meaningful improvement in PFS assessed by the IRC per RECIST v1.1 was shown for both treatment arms (T+PC and T+nPC vs PC alone) at the interim analysis. With a total of 191 PFS events (53% of the overall population), the stratified HR was 0.48 (95% CI: 0.34, 0.69) for T+PC vs PC and 0.45 (95% CI: 0.32, 0.64) for T+nPC vs PC. The median PFS was 7.6 months (95% CI: 5.9, 9.8) in Arm T+PC and 7.6 months (95% CI: 5.8, 11.0) in Arm T+nPC vs 5.4 months (95% CI: 4.2, 5.6) in Arm PC. In the final analysis, the stratified PFS HR was 0.45 (95% CI: 0.32, 0.62) for T+PC vs PC and 0.43 (95% CI: 0.31, 0.62) for T+nPC vs PC. At the data cutoff date for the final analysis (30 September 2020), the median follow-up time was 16.7 months in the ITT. Results from PFS sensitivity analysis 1, representing the preferred PFS analysis by EMA, and PFS based on investigator assessment were consistent with the primary analysis. Medicinal product no longer authorised

OS results showed a beneficial trend at the final PFS analysis with OS HRs of 0.68 (95% CI 0.46, 1.01) and 0.75 (95% CI 0.50, 1.12) in favour of T+PC and T+nPC vs PC, respectively. Median OS was 22.8 months in Arm T+PC, not reached in Arm T+nPC, and 20.2 months in Arm PC. However, taking the KM curves into consideration, the clinical relevance of the OS improvement appears less obvious. The maturity level of OS is only 41% at this analysis and OS KM curves are hardly interpretable after month 9 due to the high rate of censoring.

<div style=\"page-break-after: always\"></div>

In Study 307, statistical testing was only planned for PFS, but not for OS which is seen as a shortcoming in the study design. Overall survival is considered the clinically most relevant endpoint and generally also the preferred endpoint in oncology clinical trials when it can be reasonably assessed.

Since crossover to tislelizumab treatment (in 55% of patients in the control arm) could have hampered the chance to show meaningful OS results, two supplementary OS analyses (both not pre-specified) were performed to adjust for the crossover effect of tislelizumab. Both analyses suggested potentially more favourable OS benefit in Arm T+PC and Arm T+nPC compared with Arm PC, but the 95% confidence intervals for the HR's for both comparisons in both sensitivity analyses still include 1 and especially the difference between the point estimates based on the classical analysis and compared to the RPSFT model-based estimate is small. Furthermore, the differences in the results of the two sensitivity analyses raise uncertainties about the robustness of these analyses.

An advantage of T+(n)PC over PC alone is seen regarding response rates (confirmed ORR assessed by the IRC: 61.7% and 62.2% vs 37.2%). Median DOR (for unconfirmed responses) was also longer for T+PC and T+nPC vs PC (8.4 and 8.6 vs 4.3 months). Overall, the PFS advantage of T+(n)PC appears to be maintained in most of the subgroups analysed. It has been noted, that no meaningful benefit was observed for patients with ECOG-PS 0, however, numbers are too small and no biological rationale could support this finding. Only 1.7% of patients with brain metastasis were included, therefore the evidence does not allow to conclude on the treatment effect in patients with brain metastasis. During the procedure, updated PFS and OS data were provided based on a data cutoff date of 15-July2022, with a median follow up of 20.5 months. In literature, a trend for a better outcome with checkpoint inhibitor chemo combination with higher PD-L1 score has been observed also in squamous NSCLC. This trend was also evident in the updated PFS and OS data provided for Study 307. However, PFS and OS data indicate a meaningful benefit in the PD-L1 negative subgroup (T+PC vs PC: TC&lt;1% (HR: 0.57, 95% CI: 0.34, 0.93); and T+nPC vs PC: TC&lt;1% (HR: 0.73, 95% CI: 0.46, 1.17)) supporting an indication regardless of PD-L1 expression. Wording of the indication Overall, patients' selection criteria are considered reflective of the target population in the indication. The inclusion of patients with locally advanced stage in the indication wording for the first line treatment of both squamous NSCLC is accepted with the clarification that these patients were not candidates to platinum-based chemoradiation.  Therefore, the indication was updated as follows: Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the firstline treatment of adult patients with squamous NSCLC who have: · locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or · metastatic NSCLC. Medicinal product no longer authorised

Tislelizumab in combination with platinum and pemetrexed for the first line treatment of metastatic nonsquamous NSCLC

## Design and conduct of clinical studies

The pivotal study supporting the sought indication is the ongoing Study 304, a phase III randomised, open-label trial with tislelizumab in combination with cisplatin or carboplatin and pemetrexed (T+PP) compared to cisplatin or carboplatin and pemetrexed (PP) in first line metastatic (stage IIIB/ IV AJCC 7th edition) non-squamous NSCLC. No Scientific Advice to CHMP was requested on this study.

<div style=\"page-break-after: always\"></div>

Tislelizumab 200 mg Q3W was administered in combination with cisplatin 75 mg/m 2  or carboplatin AUC5 and pemetrexed 500 mg/m 2  for a total of 4 to 6 cycles, followed by tislelizumab in combination with pemetrexed 500 mg/m 2   Q3W until progression. A meta-analysis has supported the interchangeable use of carboplatin and cisplatin in combination with SOC antineoplastic agents and this is also reflected in the NCCN recommendations, nevertheless this is neither reflected in the ESMOGuideline for metastatic NSCLC (Ann Oncol (2016) 27 (suppl 5): v1-v27) nor it is clinical practice in Europe. Cisplatin doublets are currently recommended as the preferred choice and used in clinical practice in patients with no contraindications. Investigators choice for the platinum component is however considered acceptable. This refers also to the investigators' choice of number of cycles (up to six).

Statistical methods Please refer to the section above, discussion on Study 307. Recruitment and conduct of the study In the ITT Analysis Set, a total of 334 patients were randomised 2:1 to receive T+PP or PP. More patients in the control arm as compared to the T+PP arms withdrew from the study or treatment (22.5% vs. 11.2%) (see Table 75).  At the data cutoff date of 26 October 2020, the median follow-up time was 16.1 months for the ITT Analysis Set. Baseline characteristics The study population included in Study 304 was predominantly male (74.0%) and had a median age of 61.0 years. 36.2% of patients were never smoker. Patients were enrolled in 47 centres solely in China. Tumour tissue (either archival tissue or fresh biopsy) was required for enrolment in this study. Overall, patients' selection criteria are considered reflective of the target population in the indication; however, several limitations due to the inclusion of Chinese patients only should be taken into consideration. The median age of 61 years is considered low (expected 69 years) and the percentage of never smokers is significantly higher (36.2% vs. 10% in the European patient population). The percentage of female patients (26%) is rather low, but much more comparable to a European patient population than the proportion of women in Study 307 (10%). In addition, the considerably low percentage of patients with brain metastasis (ca. 5%) or liver metastasis (11%) indicates a highly selected patient population.  33% of the patients had tumour cell PDL1 expression ≥50%. The baseline characteristics for this study population were: median age 61 years (range: 25 to 75), 29% age 65 years or older; 74% male; 23.4% with ECOG PS of 0 and 76.6% with ECOG PS of 1; 18.3% with disease stage IIIB; 26.6% with unknown status for ALK rearrangement and 73.4% with negative ALK rearrangement; 36.2% never-smokers. The characteristics of age, sex, ECOG PS, stage, smoking status, PD-L1 TC score expression and prior anticancer treatments were balanced between the treatment arms. There were several imbalances in patients baseline characteristics between the treatment arms, e.g. patients ≥ 65 years (26.9% vs. 33.3%) and distant metastasis (including liver metastasis) (9.0% vs. 15.3% for T+PP vs. PP, respectively). Imbalances could also be detected regarding smoking status and sex. Medicinal product no longer authorised

The relatively young Asian patient population raised concerns regarding the external validity of the trial. However, the favourable OS could be regarded to be relevant to outweigh these uncertainties.

Inclusion was limited to ECOG PS 0-1. The inclusion was restricted to participants younger than 75 years which is not supported, as it hampers the comparability with the real-world setting. A statement was added in section 4.8 of the SmPC to highlight that data in patients aged 75 years and above are too limited to draw conclusions on this population.

<div style=\"page-break-after: always\"></div>

Patients with ROS rearrangements were not considered to be excluded in the indication wording, as they were not excluded in Study 304. At the time of study initiation the inclusion of these patients was acceptable. However, it is worth mentioning that in the meantime effective TKIs were approved for patients with ROS rearrangements. Crizotinib and entrectinib are both highly effective first line treatments for patients with ROS1 rearranged tumours, being entrectinib a preferred option in those patients with brain metastases.

## Efficacy data and additional analyses

A statistically significant improvement in PFS assessed by the IRC per RECIST v1.1 was observed in the overall patient population. The stratified HR of PFS was 0.632, indicating a 37% reduction in the risk of experiencing a PFS event of PD or death. The median PFS was 9.8 months (95% CI: 8.94, 11.70) in Arm T+PP and 7.6 months (95% CI: 5.55, 8.02) in Arm PP. The estimated 12-month PFS event-free rate was 39.9% (95% CI: 32.76, 46.84) in Arm T+PP and 20.1% (95% CI: 11.56, 30.22) in Arm PP. The median OS in Arm T+PP was 21.4 months (95% CI: 17.68, NE) compared to 21.3 months in Arm PP (95% CI: 15.64, NE) with a stratified HR of 0.90 (95% CI: 0.63, 1.28), being the OS comparable in the two arms. Taking the KM curves into consideration, the OS data is considered to be inconclusive. Maturity level of OS was 42% at this analysis and, due to the high rate of censoring, a late crossing of the curves cannot be excluded. The allowance of cross-over from the chemo arm (PP) to tislelizumab is presumably the reason for the unusually high OS in the chemo arm, what is confounding the OS data. In Study 304 statistical testing was only planned for PFS, but not for OS which is seen as a shortcoming in the study design. Overall survival is considered the clinically most relevant endpoint and generally also the preferred endpoint in oncology clinical trials when it can be reasonably assessed. As of the data cutoff date of 26 October 2020, 16 patients (7.2%) in Arm T+PP, 56 patients (50.5%) in Arm PP had received subsequent immunotherapy including 40 patients (36.0%) with in-study crossover. Since crossing over to tislelizumab treatment could have hampered the OS results, two supplementary OS analyses (both not pre-specified) were performed to adjust for the crossover effect of tislelizumab. Both analyses suggested a potentially more favourable OS benefit in Arm T+PP compared with Arm PP, but the 95% confidence intervals for the HR's for both comparisons in both sensitivity analyses still include 1 and especially the difference between the point estimates based on the classical analysis and compared to the RPSFT model-based estimate is small. Furthermore, the differences in the results of the two sensitivity analyses raise uncertainties about the robustness of these analyses. More mature OS results were provided (DCO 15 July 2022). In this updated analysis, the stratified HR for OS was 0.85 (95% CI: 0.63, 1.14) for Arm T+PP vs. Arm PP. Median OS was 21.6 months in Arm T+PP and 20.1 months in Arm PP. Medicinal product no longer authorised

An advantage of T+PP over PP alone is seen in the response rate (confirmed ORR assessed by the IRC: 50.7% vs 27.9%). Median DOR was also longer for T+PP (14.5 vs 8.4 months).

Overall, it appears that the PFS results are consistent in most subgroups analysed. Subgroups which had an unstratified PFS HR with 95% CI including 1.0 were females, ECOG PS 0, never smoker, and disease stage IIIB, which could be due to smaller sample size.

A strong benefit was demonstrated for patients with PD-L1 expression on ≥ 50% of the tumour cells, The unstratified PFS HR was 0.28 (95% CI: 0.16, 0.50) and OS HR 0.38 (95% CI: 0.21, 0.70). For patients with PD-L1 expression on &lt; 1% of TC, the unstratified PFS HR was 0.79 (95% CI: 0.51, 1.21) for T+PP vs PP, for patients with 1% - 49% TC the unstratified PFS HR was 0.90 (95% CI: 0.49, 1.63).

<div style=\"page-break-after: always\"></div>

OS data indicate a potential detrimental effect in these subgroups with HR 1.44 (95% CI: 0.83, 2.50) and HR 1.17 (95% CI: 0.54, 2.55), respectively.

Updated data for the 3 prespecified subgroups of PD-L1 expression negative, low and high (PD-L1 expression &lt;1%, 149%, ≥50%) substantiated the strong effect in PD -L1 highly positive patients but not in PD-L1 negative and low patients (&lt;1%, 1-49%) where the median PFS was the same for the tislelizumab+chemo combination as for chemotherapy alone. A shorter median OS was reported for the PD-L1 negative patients with PD-L1 &lt;1%: 17.1 months for the combination treatment vs 21.7 months for chemotherapy alone with a HR of 1.44(95% CI: 0.82, 2.50). A shorter median OS was also observed for patients with PD-L1 1-49%: 21.4 months vs NE, respectively with a HR of 1.17 (95% CI 0.54, 2.55).  Patients with missing PD-L1 status were wrongly included in the PD-L1 negative subgroup. When analyses were performed after excluding patients with missing PD-L1 status, the point estimate of the OS HR increased to 1.526 (95% CI 0.880, 2.645) in the PD-L1 &lt;1% population.

In both subgroups (PD-L1 negative and PD-L1 low), a small ORR treatment difference (16.7% and 17.9% respectively), a borderline PFS benefit (HR 0.78; 95% CI 0.51, 1.2 and HR  0.90; 95% CI 0.49, 1.63, respectively) and a detrimental OS could be observed. It is acknowledged that crossover to tislelizumab was almost 40% within the trial and 14.5% of the patients received IO outside the trial; however, similarly high crossover rates to IO were observed in KEYNOTE-189 (41.3%) and in IMpower130 (59.2%). Demonstration of benefit for the addition of tislelizumab to chemotherapy in 1L nsq NSCLC is based on the comparatively rather small pivotal Study 304 with PFS as primary endpoint. Efficacy results for patients with PD-L1 &lt;1% or PD-L1 1-49% do not show a clinically meaningful improvement in PFS and indicate a clearly detrimental effect on overall survival in a sufficiently mature dataset. It is acknowledged that uncertainties remain regarding inconsistent results in small PD-L1 subgroups of the comparator arm that might have negatively impacted the relative treatment effect of tislelizumab. It is also accepted that the study was not powered for demonstration of an overall survival benefit. However, the given deficiencies in the study design cannot be used as an argument to disregard the data. A lower treatment effect in PD-L1 low expression subgroups is considered biologically plausible and supported by external evidence. Thus, the detrimental OS effect for patients with PD-L1 expression cannot be ignored considering the additional toxicity in the combination treatment setting. Wording of the indication The benefit of tislelizumab in non-squamous NSCLC can therefore not be considered established neither in PD-L1 negative patients, nor in PD-L1 low patients. As a result, the indication was restricted to patients whose tumours express PD-L1 in ≥ 50%. Patients with locally advanced NSCLC were included in the indication but further characterised to reflect that these patients were not candidates for platinum-based chemoradiation, or metastatic NSCLC. Patients with known EGFR/ALK mutations were excluded. This resulted in exclusion of patients with EGFR and ALK mutations from the wording of the indication. Medicinal product no longer authorised

The final indication wording was agreed as follows:

Tizveni in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutatio ns and who have:

- locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or
- metastatic NSCLC.

<div style=\"page-break-after: always\"></div>

## 2.5.7. Conclusions on the clinical efficacy

A clinically meaningful benefit in overall survival was demonstrated for tislelizumab as monotherapy in patients with locally advanced or metastatic NSCLC after prior chemotherapy.

A clinically meaningful benefit in PFS assessed by IRC was demonstrated for tislelizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in the intended target population of patients with locally advanced or metastatic squamous NSCLC.

A benefit in PFS assessed by IRC could be shown for tislelizumab in combination with  pemetrexed and platinum containing chemotherapy in the intended target population of patients with locally advanced or metastatic non-squamous NSCLC in the ITT. However, the benefit in the PD-L1 negative/low patients is not considered established and the indication was restricted to patients whose tumour express PDL1 in ≥ 50% of tumour cells.

|                             | 303 Study                          | 303 Study               | 2L+ NSCLC           | 200 mg Q3W All Indications b (N=1534) n (%)   |
|-----------------------------|------------------------------------|-------------------------|---------------------|-----------------------------------------------|
|                             | Tislelizumab (N=534) n (%) product | Docetaxel (N=258) n (%) | All a (N=636) n (%) |                                               |
| Tislelizumab Regimen, n (%) |                                    |                         |                     |                                               |
| 200 mg Q3W                  | 534 (100.0)                        | NA                      | 589 (92.6)          | 1534 (100.0)                                  |
| 5.0 mg/kg Q3W               | 0 (0.0)                            | NA                      | 47 (7.4)            | 0 (0.0)                                       |

- pooling of squamous+non-squamous data (pivotal study 307, pivotal study 304 and supportive study 206): Full NSCLC Combination Therapy Safety Analysis Set

2.5.8. Clinical safety Tislelizumab safety data are provided for the treatment of NSCLC as monotherapy or in combination with chemotherapy. The safety of tislelizumab monotherapy in second-/third-line treatment of patients with previously treated locally advanced or metastatic NSCLC ('2L+' used as abbreviation in the following) is supported by safety data from the · the pivotal Study 303 · the previously treated NSCLC-specific pool and · the 200 mg Q3W All Indications pool: Table 91: Studies providing safety data for tislelizumab monotherapy The safety of tislelizumab with chemotherapy combinations in first-line treatment of patients with locally advanced or metastatic squamous and nonsquamous NSCLC is supported by safety data from · the pivotal Study 307 in squamous NSCLC, · the pivotal Study 304 in nonsquamous NSCLC, and from Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 92: Studies providing safety data for tislelizumab with chemotherapy combinations

|                    | SquamousNscLc   | SquamousNscLc   | SquamousNscLc   | Nonsquamous NSCLC   | Nonsquamous NSCLC   | NSCLC               | NSCLC           |
|--------------------|-----------------|-----------------|-----------------|---------------------|---------------------|---------------------|-----------------|
| Studies            | Study307        | Study307        | Study307        | Study 304           | Study 304           | Studies 307+304+206 | Studies 307+304 |
|                    | Arm T+PC        | Arm T+nPC       | Arm PC          | Arm T+PP            | Arm PP              | T+chemo*            | Chemo**         |
|                    | n               | n               | n               | n                   | n                   | n                   | n               |
| Safetyanalysis set | 120             | 118             | 117             | 222                 | 110                 | 497                 | 227             |

<!-- image -->

At the time of submission, the pivotal studies were ongoing; applied cutoff dates were 10 Aug 2020 for Study 303 (2L+ NSCLC), 30-Sep 2020 for Study 307 (1L sq NSCLC), and 26-Oct-2020 for Study 304 (1L non-sq NSCLC). For the monotherapy Study 303, the median follow-up was 11.9 months (13.4 vs 10.3 months for tislelizumab vs docetaxel); 20.2% and 4.7% of patients were still on study treatment at the cutoff date. For the 1L combination studies 307 and 304, the median follow-up time was 16.9 months for tislelizumab + chemotherapy groups and 15.6 months for the chemotherapy groups (16.2 months in squamous and 15.3 months in non-squamous patients); 24%-29% of patients in the tislelizumab + chemotherapy groups were still on study treatment compared to 0% with squamous and 5.5% with non-squamous patients in the chemotherapy groups. Study 303 recruited patients from 109 centres in China, Eastern Europe, Turkey and other regions (Brazil, Mexico, and New Zealand). Studies 307 and 304 were conducted in 46 and 47 centres in China. Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 93: Studies providing supportive safety data for tislelizumab

|    |        | authorised   |
|----|--------|--------------|
|    | longer |              |
| no |        |              |

|                                      | 303 Study                  | 303 Study               | 2L+ NSCLC           | 200 mg Q3W All Indications b (N=1534)   |
|--------------------------------------|----------------------------|-------------------------|---------------------|-----------------------------------------|
|                                      | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All a (N=636) n (%) | n (%)                                   |
| Duration of Exposure (Months)        |                            |                         |                     |                                         |
| N                                    | 534                        | 258                     | 636                 | 1534                                    |
| Mean (SD)                            | 7.49 (6.831)               | 3.34 (3.182)            | 7.77 (7.726)        | 7.24 (7.285)                            |
| Median                               | 5.36                       | 2.10                    | 4.83                | 4.16                                    |
| Q1, Q3                               | 2.10, 10.48                | 1.41, 4.17              | 2.10, 10.48         | 2.07, 10.38                             |
| Min, Max                             | 0.3, 32.2                  | 0.2, 24.3               | 0.2, 45.5           | 0.2, 41.0                               |
| Duration of Exposure (Months), n (%) |                            |                         |                     |                                         |

Patient exposure Exposure monotherapy 2L+ Table 94: Extent of treatment exposure Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                    | 303 Study                  | 303 Study               | 2L+ NSCLC           |                                             |
|------------------------------------|----------------------------|-------------------------|---------------------|---------------------------------------------|
|                                    | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All a (N=636) n (%) | 200 mg Q3W All Indications b (N=1534) n (%) |
| >= 6 Months                        | 244 (45.7)                 | 36 (14.0)               | 279 (43.9)          | 615 (40.1)                                  |
| >= 12 Months                       | 114 (21.3)                 | 6 (2.3)                 | 139 (21.9)          | 340 (22.2)                                  |
| >= 18 Months                       | 52 (9.7)                   | 2 (0.8)                 | 70 (11.0)           | 155 (10.1)                                  |
| >= 24 Months                       | 19 (3.6)                   | 1 (0.4)                 | 35 (5.5)            | 65 (4.2)                                    |
| >= 30 Months                       | 6 (1.1)                    | 0 (0.0)                 | 17 (2.7)            | 26 (1.7)                                    |
| Number of Cycle Received, n (%)    |                            |                         |                     |                                             |
| 1 -< 4 Cycles                      | 164 (30.7)                 | 150 (58.1)              | 199 (31.3)          | 514 (33.5)                                  |
| 4 -< 8 Cycles                      | 103 (19.3)                 | 69 (26.7)               | 133 (20.9)          | 360 (23.5)                                  |
| 8 -< 12 Cycles                     | 85 (15.9)                  | 18 (7.0)                | 91 (14.3)           | 180 (11.7)                                  |
| 12 -< 18 Cycles                    | 72 (13.5)                  | 14 (5.4)                | 78 (12.3)           | 153 (10.0)                                  |
| 18 -< 36 Cycles                    | 96 (18.0)                  | 7 (2.7)                 | 107 (16.8)          | 278 (18.1)                                  |
| >= 36 Cycles                       | 14 (2.6)                   | 0 (0.0)                 | 28 (4.4)            | 49 (3.2)                                    |
| Relative Dose Intensity (RDI)(%) d |                            |                         |                     | authorised                                  |
| Mean (SD)                          | 97.28 (5.350)              | 93.89 (8.978)           | 97.17 (5.855)       | 97.16 (6.374)                               |
| Median                             | 99.51                      | 98.44                   | 99.60               | 100.00                                      |
| Q1, Q3                             | 96.43, 100.00              | 89.08, 100.00           | 96.43,              | 96.92, 100.00                               |
| Min, Max                           | 60.4, 106.8                | 61.8, 106.8             | 53.8, 106.8         | 46.2, 107.7                                 |

<!-- image -->

|                                         | SQ-NSCLC                         | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|-----------------------------------------|----------------------------------|---------------------------|--------------------------|---------------------------------------|
|                                         | 307 T+PC (N = 120) n (%) product | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Number of Treatment Cycles              |                                  |                           |                          |                                       |
| Mean (SD)                               | 14.0 (8.71)                      | 14.1 (9.02)               | 13.0 (8.78)              | 13.7 (9.19)                           |
| Median                                  | 13.0                             | 13.0                      | 10.5                     | 12.0                                  |
| Q1, Q3                                  | 8.0, 20.5                        | 7.0, 22.0                 | 6.0, 21.0                | 6.0, 21.0                             |
| Min, Max                                | 1, 32                            | 1, 32                     | 1, 37                    | 1, 40                                 |
| Duration of Exposure (Months) Medicinal |                                  |                           |                          |                                       |
| Mean (SD)                               | 10.47 (6.631)                    | 11.03 (6.850)             | 9.94 (6.631)             | 10.47 (6.881)                         |
| Median                                  | 9.25                             | 10.17                     | 7.85                     | 9.00                                  |
| Q1, Q3                                  | 5.49, 16.64                      | 5.29, 16.79               | 4.44, 16.36              | 4.99, 16.56                           |
| Min, Max                                | 0.7, 23.2                        | 0.7, 24.1                 | 0.7, 27.1                | 0.7, 28.3                             |
| Duration of Exposure, n (%)             |                                  |                           |                          |                                       |
| < 1 months                              | 6 (5.0)                          | 6 (5.1)                   | 14 (6.3)                 | 28 (5.6)                              |
| 1 - <3 months                           | 16 (13.3)                        | 11 (9.3)                  | 24 (10.8)                | 55 (11.1)                             |
| 3 - <6 months                           | 15 (12.5)                        | 25 (21.2)                 | 39 (17.6)                | 87 (17.5)                             |
| 6 - <12 months                          | 37 (30.8)                        | 29 (24.6)                 | 65 (29.3)                | 139 (28.0)                            |
| 12 - <18 months                         | 24 (20.0)                        | 23 (19.5)                 | 49 (22.1)                | 101 (20.3)                            |
| 18 - <24 months                         | 22 (18.3)                        | 22 (18.6)                 | 29 (13.1)                | 76 (15.3)                             |
| ≥ 24 months                             | 0 (0.0)                          | 2 (1.7)                   | 2 (0.9)                  | 11 (2.2)                              |
| Duration of Exposure, n (%)             |                                  |                           |                          |                                       |
| ≥ 6 months                              | 83 (69.2)                        | 76 (64.4)                 | 145 (65.3)               | 327 (65.8)                            |
| ≥ 12 months                             | 46 (38.3)                        | 47 (39.8)                 | 80 (36.0)                | 188 (37.8)                            |
| ≥ 18 months                             | 22 (18.3)                        | 24 (20.3)                 | 31 (14.0)                | 87 (17.5)                             |

Exposure combination therapy 1L Exposure to tislelizumab Table 95: Extent of treatment exposure to tislelizumab (1L NSCLC Safety Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                 | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|---------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
|                                 | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| ≥ 24 months                     | 0 (0.0)                  | 2 (1.7)                   | 2 (0.9)                  | 11 (2.2)                              |
| ≥ 30 months                     | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 0 (0.0)                               |
| Number of Cycle Received, n (%) |                          |                           |                          |                                       |
| 1 - <4 cycles                   | 20 (16.7)                | 16 (13.6)                 | 27 (12.2)                | 66 (13.3)                             |
| 4 - <8 cycles                   | 9 (7.5)                  | 21 (17.8)                 | 44 (19.8)                | 82 (16.5)                             |
| 8 - <12 cycles                  | 24 (20.0)                | 16 (13.6)                 | 48 (21.6)                | 95 (19.1)                             |
| 12 - <18 cycles                 | 27 (22.5)                | 23 (19.5)                 | 35 (15.8)                | 90 (18.1)                             |
| 18 - <36 cycles                 | 40 (33.3)                | 42 (35.6)                 | 67 (30.2)                | 160 (32.2)                            |
| ≥ 36 cycles                     | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 4 (0.8)                               |
| Relative Dose Intensity (%) a   |                          |                           |                          |                                       |
| n                               | 120                      | 118                       | 222                      | 497                                   |
| Mean (SD)                       | 93.17 (8.125)            | 88.20 (9.619)             | 91.36 (8.626)            | 91.18 (8.843) authorised              |
| Median                          | 96.18                    | 90.98                     | 93.75                    | 93.75                                 |
| Q1, Q3                          | 89.18, 99.24             | 82.89, 94.65              | 86.30, 98.91             | 86.84, 97.95                          |
| Min, Max                        | 62.7, 107.7              | 54.5, 100.0               | 57.1, 103.3              | 54.5, 107.7                           |

|                                         | no            | SQ-NSCLC       | 307 PC (N = 117) n (%)   |
|-----------------------------------------|---------------|----------------|--------------------------|
| Number of Treatment Cycles              | product       |                |                          |
| n                                       | 120           | 118            | 117                      |
| Mean (SD)                               | 4.6 (1.56)    | 4.0 (1.38)     | 4.5 (1.47)               |
| Median                                  | 4.5           | 4.0            | 4.0                      |
| Q1, Q3                                  | 4.0, 6.0      | 3.0, 5.0       | 4.0, 6.0                 |
| Min, Max                                | 1, 6          | 1, 6           | 1, 6                     |
| Duration of Exposure (Months) Medicinal |               |                |                          |
| n                                       | 120           | 118            | 117                      |
| Mean (SD)                               | 3.36 (1.196)  | 3.24 (1.191)   | 3.22 (1.131)             |
| Median                                  | 3.47          | 3.22           | 3.09                     |
| Q1, Q3                                  | 2.76, 4.22    | 2.76, 3.94     | 2.76, 4.17               |
| Min, Max                                | 0.7, 5.6      | 0.7, 5.7       | 0.1, 5.2                 |
| Number of Cycle Received, n (%)         |               |                |                          |
| 1 - <4 cycles                           | 21 (17.5)     | 32 (27.1)      | 22 (18.8)                |
| 4 - <8 cycles                           | 99 (82.5)     | 86 (72.9)      | 95 (81.2)                |
| ≥ 8 cycles                              | 0 (0.0)       | 0 (0.0)        | 0 (0.0)                  |
| Relative Dose Intensity (%) a           |               |                |                          |
| Mean (SD)                               | 91.39 (9.700) | 59.93 (16.360) | 93.22 (8.572)            |
| Median                                  | 94.83         | 60.79          | 97.67                    |
| Q1, Q3                                  | 85.69, 99.37  | 47.73, 70.00   | 88.11, 100.00            |
| Min, Max                                | 62.2, 104.2   | 23.3, 100.0    | 62.1, 105.5              |

a  Relative dose intensity (%) was defined as the ratio of the actual dose intensity (mg/cycle) versus the planned dose intensity (mg/cycle). Exposure to chemotherapy Table 96: Extent of treatment exposure to paclitaxel/nab-paclitaxel (1L NSCLC Safety Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| authorised   |
|--------------|

Table 97: Extent of treatment exposure to cisplatin/carboplatin (1L NSCLC Safety Analysis Set)

|                                        | 303 Study                  | 303 Study               | 2L+ NSCLC All (N=636)   | 200 mg Q3W All Indications (N=1534) n (%)   |
|----------------------------------------|----------------------------|-------------------------|-------------------------|---------------------------------------------|
|                                        | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | n (%)                   |                                             |
| Patients with at least one TEAE        | 509 (95.3)                 | 254 (98.4)              | 610 (95.9)              | 1468 (95.7)                                 |
| Treatment-related TEAE                 | 390 (73.0)                 | 242 (93.8)              | 457 (71.9)              | 1125 (73.3)                                 |
| TEAE with Grade 3 or Higher            | 206 (38.6)                 | 193 (74.8)              | 256 (40.3)              | 669 (43.6)                                  |
| Treatment- related TEAE with ≥ Grade 3 | 77 (14.4)                  | 171 (66.3)              | 93 (14.6)               | 250 (16.3)                                  |
| Serious TEAE                           | 174 (32.6)                 | 83 (32.2)               | 213 (33.5)              | 516 (33.6)                                  |
| Treatment-related Serious TEAE         | 67 (12.5)                  | 59 (22.9)               | 78 (12.3)               | 175 (11.4)                                  |
| TEAE Leading to Death                  | 32 (6.0)                   | 11 (4.3)                | 37 (5.8)                | 127 (8.3)                                   |

Adverse events Analysis of adverse events Treatment emergent adverse events (TEAE) were summarised by MedDRA system organ class (SOC) and preferred term (PT) using MedDRA version 23.0. AEs were graded by the investigators using NCI CTCAE v4.03 for Studies 303 and  206 and NCI CTCAE v5.0 for Studies 304 and 307. In the pivotal Studies 303, 304 and 307, all AEs were reported until either 30 days after the last dose of study drug or initiation of new anticancer therapy; all imAEs were reported until 90 days after the last dose of tislelizumab, regardless of whether or not the patient started a new anticancer therapy. A patient reporting the same AE more than once is counted only once when calculating the incidence. · Monotherapy 2L+ The following tables are provided for the 2/3L NSCLC Safety Analysis Set as described above. Summary of AEs Table 98: Overall summary of treatment-emergent adverse events Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                             | 303 Study                  | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All             |
|---------------------------------------------|----------------------------|-------------------------|-------------------|----------------------------|
|                                             | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | Indications (N=1534) n (%) |
| Treatment-related TEAE Leading to Death     | 8 (1.5)                    | 4 (1.6)                 | 9 (1.4)           | 20 (1.3)                   |
| TEAE Leading to Treatment Discontinuation   | 56 (10.5)                  | 32 (12.4)               | 69 (10.8)         | 190 (12.4)                 |
| Treatment-related TEAE Leading to Treatment | 32 (6.0)                   | 25 (9.7)                | 40 (6.3)          | 85 (5.5)                   |
| Discont.                                    |                            |                         |                   |                            |
| TEAE Leading to Dose Modification           | 119 (22.3)                 | 89 (34.5)               | 152 (23.9)        | 398 (25.9)                 |
| Treatment-related TEAE Leading to Dose      | 68 (12.7)                  | 77 (29.8)               | 83 (13.1)         | 235 (15.3)                 |
| Modification                                |                            |                         |                   |                            |
| Immune-mediated TEAE                        | 104 (19.5)                 | NA                      | 126 (19.8)        | 276 (18.0)                 |
| Immune- mediated TEAE with ≥ Grade 3        | 35 (6.6)                   | NA                      | 43 (6.8)          | 81 (5.3)                   |
| Serious Immune-mediated TEAE                | 40 (7.5)                   | NA                      | 44 (6.9)          | 90 (5.9)                   |
| Immune-mediated TEAE Leading to Death       | 2 (0.4)                    | NA                      | 3 (0.5)           | 6 (0.4)                    |
| Infusion-related Reaction                   | 5 (0.9)                    | 9 (3.5)                 | 7 (1.1)           | 54 (3.5)                   |
| Infusion- related Reaction with ≥ Grade 3   | 0 (0.0)                    | 0 (0.0)                 | 0 (0.0)           | 4 (0.3)                    |

|                                                           | 303 Study                     | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All Indications (N=1534)   |
|-----------------------------------------------------------|-------------------------------|-------------------------|-------------------|---------------------------------------|
| System Organ Class Preferred Term                         | Tislelizumab (N=534) n (%) no | Docetaxel (N=258) n (%) | All (N=636) n (%) | n (%)                                 |
| Patients with at least one TEAE                           | 509 (95.3)                    | 254 (98.4)              | 610 (95.9)        | 1468 (95.7)                           |
| Investigations                                            | 311 (58.2)                    | 174 (67.4)              | 365 (57.4)        | 901 (58.7)                            |
| Alanine aminotransferase increased                        | 106 (19.9)                    | 38 (14.7)               | 121 (19.0)        | 295 (19.2)                            |
| Aspartate aminotransferase increased product              | 101 (18.9)                    | 31 (12.0)               | 121 (19.0)        | 320 (20.9)                            |
| Weight decreased                                          | 81 (15.2)                     | 26 (10.1)               | 104 (16.4)        | 216 (14.1)                            |
| White blood cell count decreased                          | 20 (3.7)                      | 74 (28.7)               | 25 (3.9)          | 101 (6.6)                             |
| Neutrophil count decreased                                | 15 (2.8)                      | 95 (36.8)               | 17 (2.7)          | 65 (4.2)                              |
| Respiratory, thoracic and mediastinal disorders Medicinal | 253 (47.4)                    | 111 (43.0)              | 304 (47.8)        | 558 (36.4)                            |
| Cough                                                     | 104 (19.5)                    | 40 (15.5)               | 122 (19.2)        | 237 (15.4)                            |
| Dyspnoea                                                  | 61 (11.4)                     | 32 (12.4)               | 73 (11.5)         | 113 (7.4)                             |
| Haemoptysis                                               | 57 (10.7)                     | 22 (8.5)                | 66 (10.4)         | 88 (5.7)                              |
| Metabolism and nutrition disorders                        | 252 (47.2)                    | 118 (45.7)              | 298 (46.9)        | 659 (43.0)                            |
| Decreased appetite                                        | 82 (15.4)                     | 59 (22.9)               | 99 (15.6)         | 221 (14.4)                            |
| Hypoalbuminaemia                                          | 70 (13.1)                     | 41 (15.9)               | 87 (13.7)         | 174 (11.3)                            |
| Hyperglycaemia                                            | 56 (10.5)                     | 29 (11.2)               | 60 (9.4)          | 111 (7.2)                             |
| Hyponatraemia                                             | 49 (9.2)                      | 29 (11.2)               | 55 (8.6)          | 130 (8.5)                             |
| General disorders and administration site conditions      | 215 (40.3)                    | 132 (51.2)              | 254 (39.9)        | 646 (42.1)                            |
| Asthenia                                                  | 67 (12.5)                     | 56 (21.7)               | 68 (10.7)         | 152 (9.9)                             |
| Pyrexia                                                   | 56 (10.5)                     | 26 (10.1)               | 70 (11.0)         | 236 (15.4)                            |
| Gastrointestinal disorders                                | 194 (36.3)                    | 127 (49.2)              | 245 (38.5)        | 683 (44.5)                            |
| Constipation                                              | 65 (12.2)                     | 42 (16.3)               | 84 (13.2)         | 181 (11.8)                            |
| Nausea                                                    | 59 (11.0)                     | 41 (15.9)               | 76 (11.9)         | 151 (9.8)                             |
| Diarrhoea                                                 | 35 (6.6)                      | 35 (13.6)               | 45 (7.1)          | 136 (8.9)                             |
| Blood and lymphatic system disorders                      | 179 (33.5)                    | 174 (67.4)              | 208 (32.7)        | 509 (33.2)                            |
| Anaemia                                                   | 152 (28.5)                    | 112 (43.4)              | 178 (28.0)        | 422 (27.5)                            |

For Tisle, TEAE leading to the dose modification is defined as a TEAE with action taken \"Dose delay\", \"Dose delayed\", \"Drug interrupted\", \"Dose interrupted\", \"Dose held/interrupted\" or \"Infusion rate decrease\" by investigator; for Docetaxel, as a TEAE with action taken \"Dose delay\", \"Dose interrupted\", \"Infusion rate decrease\" or \"Dose Reduction\" by investigator. For each row category, a pt with multiple AEs in that category is counted only once. Most common AEs Table 99: Most common TEAEs by SOC and PT (≥ 10% patients in any group) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                        | 303 Study                  | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All (N=1534) n (%)   |
|----------------------------------------|----------------------------|-------------------------|-------------------|---------------------------------|
| System Organ Class Preferred Term      | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | Indications                     |
| Leukopenia                             | 15 (2.8)                   | 69 (26.7)               | 17 (2.7)          | 44 (2.9)                        |
| Neutropenia                            | 9 (1.7)                    | 81 (31.4)               | 11 (1.7)          | 25 (1.6)                        |
| Febrile neutropenia                    | 0 (0.0)                    | 33 (12.8)               | 0 (0.0)           | 0 (0.0)                         |
| Infections and infestations            | 151 (28.3)                 | 77 (29.8)               | 191 (30.0)        | 472 (30.8)                      |
| Pneumonia                              | 61 (11.4)                  | 36 (14.0)               | 72 (11.3)         | 142 (9.3)                       |
| Upper respiratory tract infection      | 47 (8.8)                   | 25 (9.7)                | 64 (10.1)         | 131 (8.5)                       |
| Skin and subcutaneous tissue disorders | 102 (19.1)                 | 135 (52.3)              | 135 (21.2)        | 370 (24.1)                      |
| Pruritus                               | 37 (6.9)                   | 5 (1.9)                 | 49 (7.7)          | 154 (10.0)                      |
| Alopecia                               | 5 (0.9)                    | 122 (47.3)              | 8 (1.3)           | 6 (0.4)                         |
| Endocrine disorders                    | 79 (14.8)                  | 2 (0.8)                 | 95 (14.9)         | 243 (15.8)                      |
| Hypothyroidism                         | 57 (10.7)                  | 2 (0.8)                 | 68 (10.7)         | 184 (12.0)                      |

|                                                              | 303 Study                  | 303 Study                      | 2L+ NSCLC All (N=636) n (%)   | 200 mg Q3W All Indications (N=1534) n (%)   |
|--------------------------------------------------------------|----------------------------|--------------------------------|-------------------------------|---------------------------------------------|
| System Organ Class Preferred Term                            | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) longer | 2L+ NSCLC All (N=636) n (%)   | 200 mg Q3W All Indications (N=1534) n (%)   |
| Patients with at least one Treatment-related TEAE            | 390 (73.0)                 | 242 (93.8)                     | 457 (71.9)                    | 1125 (73.3)                                 |
| Investigations                                               | 224 (41.9)                 | 151 (58.5)                     | 257 (40.4)                    | 598 (39.0)                                  |
| Alanine aminotransferase increased                           | 86 (16.1)                  | 33 (12.8)                      | 101 (15.9)                    | 220 (14.3)                                  |
| Aspartate aminotransferase increased                         | 77 (14.4) no               | 29 (11.2)                      | 94 (14.8)                     | 228 (14.9)                                  |
| White blood cell count decreased                             | 12 (2.2)                   | 73 (28.3)                      | 13 (2.0)                      | 72 (4.7)                                    |
| Neutrophil count decreased                                   | 8 (1.5)                    | 93 (36.0)                      | 9 (1.4)                       | 44 (2.9)                                    |
| General disorders and administration site conditions product | 105 (19.7)                 | 97 (37.6)                      | 118 (18.6)                    | 325 (21.2)                                  |
| Asthenia                                                     | 39 (7.3)                   | 44 (17.1)                      | 40 (6.3)                      | 84 (5.5)                                    |
| Metabolism and nutrition disorders                           | 92 (17.2)                  | 80 (31.0)                      | 99 (15.6)                     | 238 (15.5)                                  |
| Decreased appetite                                           | 33 (6.2)                   | 48 (18.6)                      | 36 (5.7)                      | 91 (5.9)                                    |
| Skin and subcutaneous tissue disorders                       | 80 (15.0)                  | 129 (50.0)                     | 103 (16.2)                    | 281 (18.3)                                  |
| Alopecia                                                     | 4 (0.7)                    | 119 (46.1)                     | 7 (1.1)                       | 5 (0.3)                                     |
| Endocrine disorders                                          | 78 (14.6)                  | 0 (0.0)                        | 93 (14.6)                     | 223 (14.5)                                  |
| Hypothyroidism                                               | 57 (10.7)                  | 0 (0.0)                        | 68 (10.7)                     | 171 (11.1)                                  |
| Blood and lymphatic system disorders Medicinal               | 76 (14.2)                  | 161 (62.4)                     | 82 (12.9)                     | 212 (13.8)                                  |
| Anaemia                                                      | 59 (11.0)                  | 98 (38.0)                      | 64 (10.1)                     | 156 (10.2)                                  |
| Leukopenia                                                   | 11 (2.1)                   | 67 (26.0)                      | 13 (2.0)                      | 34 (2.2)                                    |
| Neutropenia                                                  | 5 (0.9)                    | 78 (30.2)                      | 7 (1.1)                       | 20 (1.3)                                    |
| Febrile neutropenia                                          | 0 (0.0)                    | 33 (12.8)                      | 0 (0.0)                       | 0 (0.0)                                     |
| Gastrointestinal disorders                                   | 69 (12.9)                  | 96 (37.2)                      | 84 (13.2)                     | 226 (14.7)                                  |
| Nausea                                                       | 28 (5.2)                   | 33 (12.8)                      | 34 (5.3)                      | 62 (4.0)                                    |
| Diarrhoea                                                    | 18 (3.4)                   | 29 (11.2)                      | 22 (3.5)                      | 70 (4.6)                                    |
| Constipation                                                 | 12 (2.2)                   | 27 (10.5)                      | 14 (2.2)                      | 28 (1.8)                                    |

Most common related AEs Table 100: Most common treatment-related TEAEs by SOC and PT (&gt;= 10% patients in any group) Medicinal product no longer authorised

Table 101: Examples of all-cause and related PTs, Study 303

<div style=\"page-break-after: always\"></div>

| Preferred Term     | All-cause                    | All-cause                 | Related                      | Related                   |
|--------------------|------------------------------|---------------------------|------------------------------|---------------------------|
|                    | Tislelizumab (N = 534) n (%) | Docetaxel (N = 258) n (%) | Tislelizumab (N = 534) n (%) | Docetaxel (N = 534) n (%) |
| Anaemia            | 152 (28.5)                   | 112 (43.4)                | 59 (11.0)                    | 98 (38.0)                 |
| Decreased appetite | 82 (15.4)                    | 59 (22.9)                 | 33 (6.2)                     | 48 (18.6)                 |
| Weight decreased   | 81 (15.2)                    | 26 (10.1)                 | 13 (2.4)                     | 18 (7.0)                  |
| Fatigue            | 28 (5.2)                     | 25 (9.7)                  | 16 (3.0)                     | 22 (8.5)                  |
| Nausea             | 59 (11.0)                    | 41 (15.9)                 | 28 (5.2)                     | 33 (12.8)                 |
| Diarrhoea          | 35 (6.6)                     | 35 (13.6)                 | 18 (3.4)                     | 29 (11.2)                 |
| Pneumonia          | 61 (11.4)                    | 36 (14.0)                 | 7 (1.3)                      | 16 (6.2)                  |

|                                                   | 303 Study                         | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All (N=1534)   |
|---------------------------------------------------|-----------------------------------|-------------------------|-------------------|---------------------------|
| System Organ Class Preferred Term                 | Tislelizumab (N=534) n (%) longer | Docetaxel (N=258) n (%) | All (N=636) n (%) | Indications n (%)         |
| Patients with at least one Grade 3 or Higher TEAE | 206 (38.6)                        | 193 (74.8)              | 256 (40.3)        | 669 (43.6)                |
| Respiratory, thoracic and mediastinal disorders   | 58 (10.9)                         | 19 (7.4)                | 65 (10.2)         | 105 (6.8)                 |
| Dyspnoea                                          | 9 (1.7)                           | 6 (2.3)                 | 10 (1.6)          | 19 (1.2)                  |
| Pneumonitis                                       | 9 (1.7)                           | 0 (0.0)                 | 11 (1.7)          | 16 (1.0)                  |
| Haemoptysis                                       | 6 (1.1)                           | 3 (1.2)                 | 6 (0.9)           | 7 (0.5)                   |
| Interstitial lung disease                         | 6 (1.1)                           | 0 (0.0)                 | 6 (0.9)           | 9 (0.6)                   |
| Respiratory failure                               | 5 (0.9) no                        | 3 (1.2)                 | 7 (1.1)           | 10 (0.7)                  |
| Infections and infestations                       | 47 (8.8)                          | 38 (14.7)               | 58 (9.1)          | 125 (8.1)                 |
| Pneumonia                                         | 38 (7.1)                          | 24 (9.3)                | 45 (7.1)          | 72 (4.7)                  |
| Upper respiratory tract infection                 | 5 (0.9)                           | 10 (3.9)                | 5 (0.8)           | 11 (0.7)                  |
| Investigations                                    | 40 (7.5)                          | 82 (31.8)               | 51 (8.0)          | 174 (11.3)                |
| Lymphocyte count decreased                        | 8 (1.5)                           | 8 (3.1)                 | 9 (1.4)           | 16 (1.0)                  |
| Gamma-glutamyltransferase increased product       | 6 (1.1)                           | 1 (0.4)                 | 8 (1.3)           | 32 (2.1)                  |
| Aspartate aminotransferase increased              | 5 (0.9)                           | 1 (0.4)                 | 9 (1.4)           | 40 (2.6)                  |
| Blood alkaline phosphatase increased              | 5 (0.9)                           | 0 (0.0)                 | 5 (0.8)           | 17 (1.1)                  |
| Alanine aminotransferase increased                | 4 (0.7)                           | 0 (0.0)                 | 7 (1.1)           | 22 (1.4)                  |
| Blood bilirubin increased                         | 4 (0.7)                           | 1 (0.4)                 | 4 (0.6)           | 21 (1.4)                  |
| Weight decreased                                  | 4 (0.7)                           | 0 (0.0)                 | 7 (1.1)           | 10 (0.7)                  |
| Neutrophil count decreased                        | 3 (0.6)                           | 71 (27.5)               | 4 (0.6)           | 11 (0.7)                  |
| White blood cell count decreased Medicinal        | 1 (0.2)                           | 47 (18.2)               | 1 (0.2)           | 8 (0.5)                   |
| Metabolism and nutrition disorders                | 37 (6.9)                          | 27 (10.5)               | 47 (7.4)          | 129 (8.4)                 |
| Hyperglycaemia                                    | 8 (1.5)                           | 3 (1.2)                 | 9 (1.4)           | 16 (1.0)                  |
| Hyponatraemia                                     | 8 (1.5)                           | 11 (4.3)                | 8 (1.3)           | 39 (2.5)                  |
| Hypokalaemia                                      | 7 (1.3)                           | 6 (2.3)                 | 9 (1.4)           | 23 (1.5)                  |
| Decreased appetite                                | 5 (0.9)                           | 3 (1.2)                 | 5 (0.8)           | 15 (1.0)                  |
| Hypercalcaemia                                    | 5 (0.9)                           | 1 (0.4)                 | 9 (1.4)           | 14 (0.9)                  |
| Hypochloraemia                                    | 1 (0.2)                           | 3 (1.2)                 | 1 (0.2)           | 3 (0.2)                   |
| Hypophosphataemia                                 | 0 (0.0)                           | 3 (1.2)                 | 0 (0.0)           | 5 (0.3)                   |
| Blood and lymphatic system disorders              | 26 (4.9)                          | 111 (43.0)              | 30 (4.7)          | 96 (6.3)                  |
| Anaemia                                           | 18 (3.4)                          | 16 (6.2)                | 21 (3.3)          | 75 (4.9)                  |
| Neutropenia                                       | 3 (0.6)                           | 72 (27.9)               | 4 (0.6)           | 8 (0.5)                   |
| Thrombocytopenia                                  | 2 (0.4)                           | 3 (1.2)                 | 2 (0.3)           | 5 (0.3)                   |
| Leukopenia                                        | 1 (0.2)                           | 41 (15.9)               | 2 (0.3)           | 3 (0.2)                   |

<div style=\"page-break-after: always\"></div>

|                                                 | 303 Study                  | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All             |
|-------------------------------------------------|----------------------------|-------------------------|-------------------|----------------------------|
| System Organ Class Preferred Term               | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | Indications (N=1534) n (%) |
| Febrile neutropenia                             | 0 (0.0)                    | 33 (12.8)               | 0 (0.0)           | 0 (0.0)                    |
| General disorders and administration site       | 24 (4.5)                   | 28 (10.9)               | 26 (4.1)          | 77 (5.0)                   |
| conditions                                      |                            |                         |                   |                            |
| Asthenia                                        | 6 (1.1)                    | 14 (5.4)                | 6 (0.9)           | 13 (0.8)                   |
| Fatigue                                         | 3 (0.6)                    | 8 (3.1)                 | 3 (0.5)           | 10 (0.7)                   |
| Cardiac disorders                               | 17 (3.2)                   | 6 (2.3)                 | 20 (3.1)          | 30 (2.0)                   |
| Pericardial effusion                            | 6 (1.1)                    | 1 (0.4)                 | 6 (0.9)           | 8 (0.5)                    |
| Vascular disorders                              | 14 (2.6)                   | 3 (1.2)                 | 17 (2.7)          | 40 (2.6)                   |
| Hypertension                                    | 13 (2.4)                   | 1 (0.4)                 | 15 (2.4)          | 28 (1.8)                   |
| Gastrointestinal disorders                      | 12 (2.2)                   | 11 (4.3)                | 18 (2.8)          | 115 (7.5) authorised       |
| Diarrhoea                                       | 4 (0.7)                    | 5 (1.9)                 | 4 (0.6)           | 12 (0.8)                   |
| Dysphagia                                       | 1 (0.2)                    | 0 (0.0)                 | 2 (0.3)           | 21 (1.4)                   |
| Ascites                                         | 0 (0.0)                    | 0 (0.0)                 | 0 (0.0)           | 18 (1.2)                   |
| Musculoskeletal and connective tissue disorders | 10 (1.9)                   | 4 (1.6)                 | 13 (2.0)          | 32 (2.1)                   |
| Pain in extremity                               | 1 (0.2)                    | 3 (1.2)                 | 2 (0.3)           | 3 (0.2)                    |

|                                                                             | 303 Study                     | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All Indications (N=1534)   |
|-----------------------------------------------------------------------------|-------------------------------|-------------------------|-------------------|---------------------------------------|
| System Organ Class Preferred Term                                           | Tislelizumab (N=534) n (%) no | Docetaxel (N=258) n (%) | All (N=636) n (%) | n (%)                                 |
| Patients with at least one Grade 3 or Higher Treatment-related TEAE product | 77 (14.4)                     | 171 (66.3)              | 93 (14.6)         | 250 (16.3)                            |
| Respiratory, thoracic and mediastinal disorders                             | 28 (5.2)                      | 6 (2.3)                 | 30 (4.7)          | 44 (2.9)                              |
| Pneumonitis                                                                 | 9 (1.7)                       | 0 (0.0)                 | 11 (1.7)          | 16 (1.0)                              |
| Interstitial lung disease                                                   | 6 (1.1)                       | 0 (0.0)                 | 6 (0.9)           | 9 (0.6)                               |
| Investigations                                                              | 19 (3.6)                      | 79 (30.6)               | 24 (3.8)          | 79 (5.1)                              |
| Alanine aminotransferase increased                                          | 4 (0.7)                       | 0 (0.0)                 | 7 (1.1)           | 15 (1.0)                              |
| Aspartate aminotransferase increased Medicinal                              | 4 (0.7)                       | 1 (0.4)                 | 8 (1.3)           | 22 (1.4)                              |
| Lymphocyte count decreased                                                  | 3 (0.6)                       | 8 (3.1)                 | 3 (0.5)           | 8 (0.5)                               |
| Neutrophil count decreased                                                  | 1 (0.2)                       | 70 (27.1)               | 1 (0.2)           | 6 (0.4)                               |
| White blood cell count decreased                                            | 1 (0.2)                       | 46 (17.8)               | 1 (0.2)           | 4 (0.3)                               |
| Blood and lymphatic system disorders                                        | 6 (1.1)                       | 106 (41.1)              | 7 (1.1)           | 30 (2.0)                              |
| Anaemia                                                                     | 5 (0.9)                       | 12 (4.7)                | 5 (0.8)           | 21 (1.4)                              |
| Thrombocytopenia                                                            | 1 (0.2)                       | 3 (1.2)                 | 1 (0.2)           | 2 (0.1)                               |
| Febrile neutropenia                                                         | 0 (0.0)                       | 33 (12.8)               | 0 (0.0)           | 0 (0.0)                               |
| Leukopenia                                                                  | 0 (0.0)                       | 40 (15.5)               | 1 (0.2)           | 2 (0.1)                               |
| Neutropenia                                                                 | 0 (0.0)                       | 70 (27.1)               | 1 (0.2)           | 5 (0.3)                               |
| General disorders and administration site conditions                        | 6 (1.1)                       | 21 (8.1)                | 6 (0.9)           | 15 (1.0)                              |
| Asthenia                                                                    | 1 (0.2)                       | 10 (3.9)                | 1 (0.2)           | 1 (0.1)                               |
| Fatigue                                                                     | 0 (0.0)                       | 7 (2.7)                 | 0 (0.0)           | 3 (0.2)                               |
| Metabolism and nutrition disorders                                          | 6 (1.1)                       | 13 (5.0)                | 7 (1.1)           | 27 (1.8)                              |
| Hyponatraemia                                                               | 1 (0.2)                       | 6 (2.3)                 | 1 (0.2)           | 8 (0.5)                               |
| Infections and infestations                                                 | 5 (0.9)                       | 19 (7.4)                | 7 (1.1)           | 18 (1.2)                              |
| Pneumonia                                                                   | 5 (0.9)                       | 14 (5.4)                | 6 (0.9)           | 13 (0.8)                              |
| Gastrointestinal disorders                                                  | 4 (0.7)                       | 9 (3.5)                 | 7 (1.1)           | 23 (1.5)                              |

Grade ≥3 AEs (related) Table 103: Treatmentrelated CTCAE Grade ≥ 3 TEAEs by SOC and PT (≥1% patients in any group) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                   | 303 Study                  | 303 Study               | 2L+ NSCLC         | 200 mg Q3W (N=1534) n (%)   |
|-----------------------------------|----------------------------|-------------------------|-------------------|-----------------------------|
| System Organ Class Preferred Term | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | All Indications             |
| Diarrhoea                         | 2 (0.4)                    | 5 (1.9)                 | 2 (0.3)           | 6 (0.4)                     |

## · Combination therapy 1L

The following tables are provided for the 1L NSCLC Safety Analysis Set as described above.

## Summary of AEs

|                                                      | SQ-NSCLC                     | SQ-NSCLC                     | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|------------------------------------------------------|------------------------------|------------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
|                                                      | 307 T+PC (N = 120) n (%)     | 307 T+nPC (N = 118) n (%)    | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Patients With at Least One TEAE                      | 120 (100.0)                  | 117 (99.2)                   | 117 (100.0)            | 222 (100.0)              | 109 (99.1)             | 496 (99.8)                            | 226 (99.6)                       |
| Treatment-Related                                    | 119 (99.2)                   | 117 (99.2)                   | 117 (100.0)            | 222 (100.0) longer       | 107 (97.3)             | 495 (99.6)                            | 224 (98.7)                       |
| Tislelizumab-Related                                 | 105 (87.5)                   | 105 (89.0)                   | NA                     | 190 (85.6)               | NA                     | 431 (86.7)                            | NA                               |
| Chemotherapy-Related                                 | 119 (99.2)                   | 117 (99.2)                   | 117 (100.0)            | 221 (99.5)               | 107 (97.3)             | 492 (99.0)                            | 224 (98.7)                       |
| ≥ Grade 3 TEAEs                                      | 107 (89.2)                   | 103 (87.3)                   | 99 (84.6) no           | 154 (69.4)62             | (56.4)                 | 394 (79.3)                            | 161 (70.9)                       |
| Treatment-Related                                    | 104 (86.7) 99 (83.9) product | 104 (86.7) 99 (83.9) product | 94 (80.3)              | 143 (64.4)51             | (46.4)                 | 372 (74.8)                            | 145 (63.9)                       |
| Tislelizumab-Related                                 | 46 (38.3) 51 (43.2)          | 46 (38.3) 51 (43.2)          | NA                     | 74 (33.3)                | NA                     | 177 (35.6)                            | NA                               |
| Chemotherapy-Related                                 | 102 (85.0) 97 (82.2)         | 102 (85.0) 97 (82.2)         | 94 (80.3)              | 137 (61.7)51             | (46.4)                 | 359 (72.2)                            | 145 (63.9)                       |
| Serious TEAEs                                        | 52 (43.3)                    | 50 (42.4)                    | 29 (24.8)              | 87 (39.2)                | 25 (22.7)              | 199 (40.0)                            | 54 (23.8)                        |
| Treatment-Related                                    | 31 (25.8)                    | 31 (26.3)                    | 17 (14.5)              | 52 (23.4)                | 15 (13.6)              | 123 (24.7)                            | 32 (14.1)                        |
| Tislelizumab-Related                                 | 25 (20.8)                    | 22 (18.6)                    | NA                     | 41 (18.5)                | NA                     | 95 (19.1)                             | NA                               |
| Chemotherapy-Related                                 | 18 (15.0)                    | 25 (21.2)                    | 17 (14.5)              | 36 (16.2)                | 15 (13.6)              | 82 (16.5)                             | 32 (14.1)                        |
| TEAEs Led to Death                                   | 4 (3.3)                      | 7 (5.9)                      | 5 (4.3)                | 9 (4.1)                  | 2 (1.8)                | 21 (4.2)                              | 7 (3.1)                          |
| Treatment-Related                                    | 1 (0.8)                      | 2 (1.7)                      | 3 (2.6)                | 4 (1.8)                  | 1 (0.9)                | 8 (1.6)                               | 4 (1.8)                          |
| Tislelizumab-Related                                 | 1 (0.8)                      | 2 (1.7)                      | NA                     | 4 (1.8)                  | NA                     | 8 (1.6)                               | NA                               |
| Chemotherapy-Related                                 | 1 (0.8)                      | 2 (1.7)                      | 3 (2.6)                | 1 (0.5)                  | 1 (0.9)                | 4 (0.8)                               | 4 (1.8)                          |
| TEAEs Led to Any Treatment Discontinuation Medicinal | 21 (17.5)                    | 38 (32.2)                    | 18 (15.4)              | 68 (30.6)                | 11 (10.0)              | 141 (28.4)                            | 29 (12.8)                        |
| Led to Tislelizumab Discontinuation                  | 17 (14.2)                    | 15 (12.7)                    | NA                     | 32 (14.4)                | NA                     | 71 (14.3)                             | NA                               |
| Led to Chemotherapy Discontinuation                  | 11 (9.2)                     | 31 (26.3)                    | 18 (15.4)              | 58 (26.1)                | 11 (10.0)              | 111 (22.3)                            | 29 (12.8)                        |
| TEAEs Led to Any Treatment Modification a            | 77 (64.2)                    | 109 (92.4)                   | 51 (43.6)              | 158 (71.2)57             | (51.8)                 | 366 (73.6)                            | 108 (47.6)                       |
| Led to Tislelizumab Modification                     | 57 (47.5)                    | 94 (79.7)                    | NA                     | 142 (64.0)               | NA                     | 312 (62.8)                            | NA                               |
| Led to Chemotherapy Modification                     | 65 (54.2)                    | 108 (91.5)                   | 49 (41.9)              | 148 (66.7)57             | (51.8)                 | 339 (68.2)                            | 106 (46.7)                       |
| Infusion-Related Reaction                            | 5 (4.2)                      | 5 (4.2)                      | 4 (3.4)                | 2 (0.9)                  | 1 (0.9)                | 14 (2.8)                              | 5 (2.2)                          |
| Immune-mediated TEAEs                                | 36 (30.0)                    | 30 (25.4)                    | NA                     | 55 (24.8)                | NA                     | 127 (25.6)                            | NA                               |
| ≥ Grade 3                                            | 13 (10.8)                    | 12 (10.2)                    | NA                     | 24 (10.8)                | NA                     | 52 (10.5)                             | NA                               |
| Led to Death                                         | 0 (0.0)                      | 1 (0.8)                      | NA                     | 4 (1.8)                  | NA                     | 6 (1.2)                               | NA                               |
| Serious                                              | 13 (10.8)                    | 14 (11.9)                    | NA                     | 23 (10.4)                | NA                     | 54 (10.9)                             | NA                               |

<div style=\"page-break-after: always\"></div>

|                                                                         | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|-------------------------------------------------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
|                                                                         | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Led to Tislelizumab Discontinuation                                     | 8 (6.7)                  | 8 (6.8)                   | NA                     | 18 (8.1)                 | NA                     | 38 (7.6)                              | NA                               |
| Led to Tislelizumab Modification                                        | 14 (11.7)                | 18 (15.3)                 | NA                     | 27 (12.2)                | NA                     | 62 (12.5)                             | NA                               |
| Treated With Systemic Corticosteroids/Immunosuppr.                      | 22 (18.3)                | 22 (18.6)                 | NA                     | 39 (17.6)                | NA                     | 88 (17.7)                             | NA                               |
| Treated with hormone treatment for selected endocrinopathies categories | 18 (15.0)                | 11 (9.3)                  | NA                     | 22 (9.9)                 | NA                     | 53 (10.7)                             | NA                               |

|                                                                         | 307&206 T+chemo * (N = 259) n (%) longer   | 304&206 T+PP (N = 238) n (%)   |
|-------------------------------------------------------------------------|--------------------------------------------|--------------------------------|
| Patients With at Least One TEAE                                         | 258 (99.6)                                 | 238 (100.0)                    |
| Treatment-Related                                                       | 257 (99.2)                                 | 238 (100.0)                    |
| Tislelizumab-Related                                                    | 228 (88.0)                                 | 203 (85.3)                     |
| Chemotherapy-Related                                                    | 256 (98.8)                                 | 236 (99.2)                     |
| ≥ Grade 3 TEAEs                                                         | 228 (88.0)                                 | 166 (69.7)                     |
| Treatment-Related                                                       | 218 (84.2)                                 | 154 (64.7)                     |
| Tislelizumab-Related                                                    | 101 (39.0) no                              | 76 (31.9)                      |
| Chemotherapy-Related                                                    | 213 (82.2)                                 | 146 (61.3)                     |
| Serious TEAEs                                                           | 108 (41.7)                                 | 91 (38.2)                      |
| Treatment-Related                                                       | 68 (26.3)                                  | 55 (23.1)                      |
| Tislelizumab-Related product                                            | 52 (20.1)                                  | 43 (18.1)                      |
| Chemotherapy-Related                                                    | 45 (17.4)                                  | 37 (15.5)                      |
| TEAEs Led to Death                                                      | 12 (4.6)                                   | 9 (3.8)                        |
| Treatment-Related                                                       | 4 (1.5)                                    | 4 (1.7)                        |
| Tislelizumab-Related                                                    | 4 (1.5)                                    | 4 (1.7)                        |
| Chemotherapy-Related                                                    | 3 (1.2)                                    | 1 (0.4)                        |
| TEAEs Led to Any Treatment Discontinuation                              | 70 (27.0)                                  | 71 (29.8)                      |
| Led to Tislelizumab Discontinuation                                     | 38 (14.7)                                  | 33 (13.9)                      |
| Led to Chemotherapy Discontinuation Medicinal                           | 51 (19.7)                                  | 60 (25.2)                      |
| TEAEs Led to Any Treatment Modification                                 | 197 (76.1)                                 | 169 (71.0)                     |
| Led to Tislelizumab Modification                                        | 159 (61.4)                                 | 153 (64.3)                     |
| Led to Chemotherapy Modification                                        | 183 (70.7)                                 | 156 (65.5)                     |
| Infusion-Related Reaction                                               | 12 (4.6)                                   | 2 (0.8)                        |
| Immune-mediated TEAEs                                                   | 71 (27.4)                                  | 56 (23.5)                      |
| ≥ Grade 3                                                               | 27 (10.4)                                  | 25 (10.5)                      |
| Led to Death                                                            | 2 (0.8)                                    | 4 (1.7)                        |
| Serious                                                                 | 30 (11.6)                                  | 24 (10.1)                      |
| Led to Tislelizumab Discontinuation                                     | 20 (7.7)                                   | 18 (7.6)                       |
| Led to Treatment Modification of Tislelizumab                           | 34 (13.1)                                  | 28 (11.8)                      |
| Treated With Systemic Corticosteroids/Immunosuppressive Drugs           | 48 (18.5)                                  | 40 (16.8)                      |
| Treated with hormone treatment for selected endocrinopathies categories | 31 (12.0)                                  | 22 (9.2)                       |

a  Treatment modification included dose interruption, dose delay, infusion rate decreased and dose modification (only for chemotherapy). Table 105: Overall summary of TEAEs, squamous vs non-squamous Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Most common AEs Table 106: Most common AE s by PT (≥10.0% pat.

## In NSCLC T+Chemo group)

|                                       | SQ-NSCLC                                         | SQ-NSCLC                                     | SQ-NSCLC                                     | NSQ-NSCLC                                    | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|---------------------------------------|--------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------|---------------------------------------|----------------------------------|
| Preferred Term                        | 307 T+PC (N = 120) n (%)                         | 307 T+nPC (N = 118) n (%)                    | 307 PC (N = 117) n (%)                       | 304 T+PP (N = 222) n (%)                     | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Patients With at Least One TEAE       | 120 (100.0)                                      | 117 (99.2)                                   | 117 (100.0)                                  | 222 (100.0)                                  | 109 (99.1)             | 496 (99.8)                            | 226 (99.6)                       |
| Anaemia                               | 107 (89.2)                                       | 111 (94.1)                                   | 94 (80.3)                                    | 186 (83.8)                                   | 85 (77.3)              | 433 (87.1)                            | 179 (78.9)                       |
| Neutrophil count decreased            | 78 (65.0)72 (61.0)68 (58.1)                      | 78 (65.0)72 (61.0)68 (58.1)                  | 78 (65.0)72 (61.0)68 (58.1)                  | 146 (65.8)                                   | 55 (50.0)              | 323 (65.0)                            | 123 (54.2)                       |
| White blood cell count decreased      | 67 (55.8)68 (57.6)62 (53.0)                      | 67 (55.8)68 (57.6)62 (53.0)                  | 67 (55.8)68 (57.6)62 (53.0)                  | 158 (71.2)                                   | 62 (56.4)              | 320 (64.4) authorised                 | 124 (54.6)                       |
| Platelet count decreased              | 44 (36.7)52 (44.1)29 (24.8)                      | 44 (36.7)52 (44.1)29 (24.8)                  | 44 (36.7)52 (44.1)29 (24.8)                  | 121 (54.5)                                   | 46 (41.8)              | 233 (46.9)                            | 75 (33.0)                        |
| Alanine aminotransferase increased    | 56 (46.7)43 (36.4)27 (23.1)                      | 56 (46.7)43 (36.4)27 (23.1)                  | 56 (46.7)43 (36.4)27 (23.1)                  | 115 (51.8)                                   | 50 (45.5)              | 229 (46.1)                            | 77 (33.9)                        |
| Aspartate aminotransferase increased  | 49 (40.8)42 (35.6)14 (12.0)                      | 49 (40.8)42 (35.6)14 (12.0)                  | 49 (40.8)42 (35.6)14 (12.0)                  | 102 (45.9)                                   | 51 (46.4)              | 210 (42.3)                            | 65 (28.6)                        |
| Nausea                                | 37 (30.8)54 (45.8)35 (29.9)                      | 37 (30.8)54 (45.8)35 (29.9)                  | 37 (30.8)54 (45.8)35 (29.9)                  | 101 (45.5)                                   | 46 (41.8)              | 206 (41.4)                            | 81 (35.7)                        |
| Decreased appetite                    | 54 (45.0)55 (46.6)37 (31.6)79                    | 54 (45.0)55 (46.6)37 (31.6)79                | 54 (45.0)55 (46.6)37 (31.6)79                | (35.6)                                       | 36 (32.7)              | 202 (40.6)                            | 73 (32.2)                        |
| Leukopenia                            | 58 (48.3)66 (55.9)57 (48.7)65 (29.3) longer      | 58 (48.3)66 (55.9)57 (48.7)65 (29.3) longer  | 58 (48.3)66 (55.9)57 (48.7)65 (29.3) longer  | 58 (48.3)66 (55.9)57 (48.7)65 (29.3) longer  | 32 (29.1)              | 191 (38.4)                            | 89 (39.2)                        |
| Neutropenia                           | 53 (44.2)50 (42.4)56 (47.9)84 (37.8) no          | 53 (44.2)50 (42.4)56 (47.9)84 (37.8) no      | 53 (44.2)50 (42.4)56 (47.9)84 (37.8) no      | 53 (44.2)50 (42.4)56 (47.9)84 (37.8) no      | 39 (35.5)              | 190 (38.2)                            | 95 (41.9)                        |
| Alopecia                              |                                                  |                                              |                                              |                                              | 7 (6.4)                | 188 (37.8)                            | 79 (34.8)                        |
| Thrombocytopenia                      | 78 (65.0)82 (69.5)72 (61.5) 20 (9.0) 35 (29.2)49 | (41.5)33                                     | (28.2)66                                     | (29.7)                                       | 33 (30.0)              | 157 (31.6)                            | 66 (29.1)                        |
| Constipation                          | 40 (33.3)36 (30.5)27 (23.1)54 (24.3)             | 40 (33.3)36 (30.5)27 (23.1)54 (24.3)         | 40 (33.3)36 (30.5)27 (23.1)54 (24.3)         | 40 (33.3)36 (30.5)27 (23.1)54 (24.3)         | 26 (23.6)              | 136 (27.4)                            | 53 (23.3)                        |
| Vomiting                              | 28 (23.3)27 (22.9)20 (17.1)61 (27.5) product     | 28 (23.3)27 (22.9)20 (17.1)61 (27.5) product | 28 (23.3)27 (22.9)20 (17.1)61 (27.5) product | 28 (23.3)27 (22.9)20 (17.1)61 (27.5) product | 26 (23.6)              | 121 (24.3)                            | 46 (20.3)                        |
| Asthenia                              | 30 (25.0)24 (20.3)24 (20.5)43 (19.4)             | 30 (25.0)24 (20.3)24 (20.5)43 (19.4)         | 30 (25.0)24 (20.3)24 (20.5)43 (19.4)         | 30 (25.0)24 (20.3)24 (20.5)43 (19.4)         | 17 (15.5)              | 117 (23.5)                            | 41 (18.1)                        |
| Hypoalbuminaemia Medicinal            | 30 (25.0)25 (21.2)19 (16.2)39 (17.6)             | 30 (25.0)25 (21.2)19 (16.2)39 (17.6)         | 30 (25.0)25 (21.2)19 (16.2)39 (17.6)         | 30 (25.0)25 (21.2)19 (16.2)39 (17.6)         | 11 (10.0)              | 98 (19.7)                             | 30 (13.2)                        |
| Pyrexia                               | 25 (20.8)24 (20.3)18 (15.4)42 (18.9)             | 25 (20.8)24 (20.3)18 (15.4)42 (18.9)         | 25 (20.8)24 (20.3)18 (15.4)42 (18.9)         | 25 (20.8)24 (20.3)18 (15.4)42 (18.9)         | 13 (11.8)              | 97 (19.5)                             | 31 (13.7)                        |
| Rash                                  | 26 (21.7)28 (23.7) 4 (3.4) 36 (16.2)             | 26 (21.7)28 (23.7) 4 (3.4) 36 (16.2)         | 26 (21.7)28 (23.7) 4 (3.4) 36 (16.2)         | 26 (21.7)28 (23.7) 4 (3.4) 36 (16.2)         | 13 (11.8)              | 96 (19.3)                             | 17 (7.5)                         |
| Hyponatraemia                         | 26 (21.7)25 (21.2)20 (17.1)33 (14.9)             | 26 (21.7)25 (21.2)20 (17.1)33 (14.9)         | 26 (21.7)25 (21.2)20 (17.1)33 (14.9)         | 26 (21.7)25 (21.2)20 (17.1)33 (14.9)         | 14 (12.7)              | 89 (17.9)                             | 34 (15.0)                        |
| Malaise                               | 24 (20.0)19 (16.1)19 (16.2)42 (18.9)             | 24 (20.0)19 (16.1)19 (16.2)42 (18.9)         | 24 (20.0)19 (16.1)19 (16.2)42 (18.9)         | 24 (20.0)19 (16.1)19 (16.2)42 (18.9)         | 23 (20.9)              | 88 (17.7)                             | 42 (18.5)                        |
| Blood lactate dehydrogenase increased | 22 (18.3)16 (13.6)13 (11.1)41 (18.5)             | 22 (18.3)16 (13.6)13 (11.1)41 (18.5)         | 22 (18.3)16 (13.6)13 (11.1)41 (18.5)         | 22 (18.3)16 (13.6)13 (11.1)41 (18.5)         | 16 (14.5)              | 83 (16.7)                             | 29 (12.8)                        |
| Blood bilirubin increased             | 30 (25.0)18 (15.3)15 (12.8)29 (13.1)             | 30 (25.0)18 (15.3)15 (12.8)29 (13.1)         | 30 (25.0)18 (15.3)15 (12.8)29 (13.1)         | 30 (25.0)18 (15.3)15 (12.8)29 (13.1)         | 10 (9.1)               | 80 (16.1)                             | 25 (11.0)                        |
| Pain in extremity                     | 40 (33.3)18 (15.3)27 (23.1) 17 (7.7)             | 40 (33.3)18 (15.3)27 (23.1) 17 (7.7)         | 40 (33.3)18 (15.3)27 (23.1) 17 (7.7)         | 40 (33.3)18 (15.3)27 (23.1) 17 (7.7)         | 8 (7.3)                | 80 (16.1)                             | 35 (15.4)                        |
| Cough                                 | 19 (15.8)19 (16.1) 8 (6.8) 32 (14.4)             | 19 (15.8)19 (16.1) 8 (6.8) 32 (14.4)         | 19 (15.8)19 (16.1) 8 (6.8) 32 (14.4)         | 19 (15.8)19 (16.1) 8 (6.8) 32 (14.4)         | 11 (10.0)              | 76 (15.3)                             | 19 (8.4)                         |
| Pneumonia                             | 26 (21.7)19 (16.1)13 (11.1)27 (12.2)             | 26 (21.7)19 (16.1)13 (11.1)27 (12.2)         | 26 (21.7)19 (16.1)13 (11.1)27 (12.2)         | 26 (21.7)19 (16.1)13 (11.1)27 (12.2)         | 14 (12.7)              | 75 (15.1)                             | 27 (11.9)                        |
| Hypokalaemia                          | 26 (21.7)20 (16.9)16 (13.7)26 (11.7)             | 26 (21.7)20 (16.9)16 (13.7)26 (11.7)         | 26 (21.7)20 (16.9)16 (13.7)26 (11.7)         | 26 (21.7)20 (16.9)16 (13.7)26 (11.7)         | 5 (4.5)                | 74 (14.9)                             | 21 (9.3)                         |
|                                       | 21 (17.5)23 (19.5) 8 (6.8) 29 (13.1)             | 21 (17.5)23 (19.5) 8 (6.8) 29 (13.1)         | 21 (17.5)23 (19.5) 8 (6.8) 29 (13.1)         | 21 (17.5)23 (19.5) 8 (6.8) 29 (13.1)         |                        |                                       |                                  |
| Diarrhoea                             |                                                  |                                              |                                              |                                              | 15 (13.6)              | 73 (14.7)                             | 23 (10.1)                        |

<div style=\"page-break-after: always\"></div>

|                                        | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|----------------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
| Preferred Term                         | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Gamma-glutamyltransferase increased    | 21 (17.5)17              | (14.4)15                  | (12.8)33               | (14.9)                   | 18 (16.4)              | 71 (14.3)                             | 33 (14.5)                        |
| Lymphocyte count decreased             | 15 (12.5)22              | (18.6)16                  | (13.7)29               | (13.1)                   | 6 (5.5)                | 67 (13.5)                             | 22 (9.7)                         |
| Hyperglycaemia                         | 21 (17.5)13              | (11.0)                    | 10 (8.5)               | 26 (11.7)                | 15 (13.6)              | 65 (13.1)                             | 25 (11.0)                        |
| Haemoptysis                            | 24 (20.0)20              | (16.9)13                  | (11.1)                 | 20 (9.0)                 | 9 (8.2)                | 64 (12.9)                             | 22 (9.7)                         |
| Hypothyroidism                         | 18 (15.0)16              | (13.6)                    | 0 (0.0)                | 26 (11.7)                | 1 (0.9)                | 64 (12.9)                             | 1 (0.4)                          |
| Blood creatinine increased             | 7 (5.8)                  | 9 (7.6)                   | 7 (6.0)                | 41 (18.5)                | 5 (4.5)                | 61 (12.3)                             | 12 (5.3)                         |
| Back pain                              | 13 (10.8)19              | (16.1)                    | 5 (4.3)                | 25 (11.3)                | 10 (9.1)               | 60 (12.1)                             | 15 (6.6)                         |
| Dyspnoea                               | 17 (14.2)13              | (11.0)                    | 11 (9.4)               | 29 (13.1)                | 7 (6.4)                | 60 (12.1)                             | 18 (7.9)                         |
| Weight decreased                       | 14 (11.7)17              | (14.4)                    | 7 (6.0)                | 26 (11.7)                | 12 (10.9) authorised   | 59 (11.9)                             | 19 (8.4)                         |
| Arthralgia                             | 26 (21.7)23              | (19.5)20                  | (17.1)                 | 6 (2.7)                  | 0 (0.0)                | 57 (11.5)                             | 20 (8.8)                         |
| Blood alkaline phosphatase increased   | 19 (15.8)12              | (10.2)                    | 11 (9.4)               | 24 (10.8)                | 13 (11.8)              | 55 (11.1)                             | 24 (10.6)                        |
| Upper respiratory tract infection      | 19 (15.8)14              | (11.9)                    | 11 (9.4)               | 17 (7.7)                 | 6 (5.5)                | 53 (10.7)                             | 17 (7.5)                         |
| Blood creatine phosphokinase increased | 20 (16.7)16              | (13.6)                    | 10 (8.5)               | 14 (6.3)                 | 5 (4.5)                | 52 (10.5)                             | 15 (6.6)                         |
| Hypoaesthesia                          | 27 (22.5)13              | (11.0)20                  | (17.1)                 | 6 (2.7)                  | 2 (1.8)                | 52 (10.5)                             | 22 (9.7)                         |

|                                                                                   | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|-----------------------------------------------------------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
| System Organ Class Preferred Term                                                 | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Patients With at Least One Treatment-related TEAE Related to Tislelizumab product | 105 (87.5)               | 105 (89.0)                | 190 (85.6)               | 431 (86.7)                            |
| Investigations                                                                    | 78 (65.0)                | 78 (66.1)                 | 127 (57.2)               | 295 (59.4)                            |
| Alanine aminotransferase increased                                                | 32 (26.7)                | 27 (22.9)                 | 64 (28.8)                | 126 (25.4)                            |
| Aspartate aminotransferase increased Medicinal                                    | 28 (23.3)                | 22 (18.6)                 | 59 (26.6)                | 112 (22.5)                            |
| White blood cell count decreased                                                  | 20 (16.7)                | 29 (24.6)                 | 45 (20.3)                | 95 (19.1)                             |
| Neutrophil count decreased                                                        | 24 (20.0)                | 32 (27.1)                 | 35 (15.8)                | 92 (18.5)                             |
| Platelet count decreased                                                          | 20 (16.7)                | 25 (21.2)                 | 46 (20.7)                | 92 (18.5)                             |
| Blood bilirubin increased                                                         | 25 (20.8)                | 15 (12.7)                 | 17 (7.7)                 | 58 (11.7)                             |
| Blood lactate dehydrogenase increased                                             | 15 (12.5)                | 13 (11.0)                 | 26 (11.7)                | 56 (11.3)                             |
| Blood creatine phosphokinase increased                                            | 17 (14.2)                | 16 (13.6)                 | 14 (6.3)                 | 49 (9.9)                              |
| Gamma-glutamyltransferase increased                                               | 9 (7.5)                  | 9 (7.6)                   | 22 (9.9)                 | 40 (8.0)                              |
| Blood thyroid stimulating hormone increased                                       | 9 (7.5)                  | 9 (7.6)                   | 11 (5.0)                 | 32 (6.4)                              |
| Blood creatinine increased                                                        | 4 (3.3)                  | 4 (3.4)                   | 22 (9.9)                 | 31 (6.2)                              |
| Blood alkaline phosphatase increased                                              | 12 (10.0)                | 6 (5.1)                   | 12 (5.4)                 | 30 (6.0)                              |
| Lymphocyte count decreased                                                        | 6 (5.0)                  | 11 (9.3)                  | 10 (4.5)                 | 27 (5.4)                              |
| Alpha hydroxybutyrate dehydrogenase increased                                     | 5 (4.2)                  | 2 (1.7)                   | 11 (5.0)                 | 20 (4.0)                              |
| Blood thyroid stimulating hormone decreased                                       | 4 (3.3)                  | 6 (5.1)                   | 4 (1.8)                  | 17 (3.4)                              |
| Blood and lymphatic system disorders                                              | 48 (40.0)                | 60 (50.8)                 | 74 (33.3)                | 184 (37.0)                            |
| Anaemia                                                                           | 43 (35.8)                | 47 (39.8)                 | 61 (27.5)                | 153 (30.8)                            |
| Leukopenia                                                                        | 22 (18.3)                | 27 (22.9)                 | 20 (9.0)                 | 69 (13.9)                             |
| Neutropenia                                                                       | 19 (15.8)                | 19 (16.1)                 | 28 (12.6)                | 66 (13.3)                             |

Most common related AEs Table 107: Most common treatmentrelated TEAEs to tislelizumab by SOC and PT (≥ 5.0% patients in any group) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 108: Most common treatmentrelated TEAEs to chemotherapy by SOC and PT (≥ 5.0% patients in any group)

|                                                         | SQ-NSCLC                 | SQ-NSCLC                    | NSQ-NSCLC                   | NSCLC                                 |
|---------------------------------------------------------|--------------------------|-----------------------------|-----------------------------|---------------------------------------|
| System Organ Class Preferred Term                       | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%)   | 304 T+PP (N = 222) n (%)    | 307&304&206 T+chemo * (N = 497) n (%) |
| Thrombocytopenia                                        | 19 (15.8)                | 24 (20.3)                   | 21 (9.5)                    | 64 (12.9)                             |
| Metabolism and nutrition disorders                      | 42 (35.0)                | 42 (35.6)                   | 66 (29.7)                   | 154 (31.0)                            |
| Decreased appetite                                      | 22 (18.3)                | 19 (16.1)                   | 29 (13.1)                   | 73 (14.7)                             |
| Hyperglycaemia                                          | 7 (5.8)                  | 8 (6.8)                     | 17 (7.7)                    | 32 (6.4)                              |
| Hypoalbuminaemia                                        | 9 (7.5)                  | 8 (6.8)                     | 11 (5.0)                    | 28 (5.6)                              |
| Hyponatraemia                                           | 7 (5.8)                  | 6 (5.1)                     | 13 (5.9)                    | 26 (5.2)                              |
| Hyperuricaemia                                          | 7 (5.8)                  | 7 (5.9)                     | 10 (4.5)                    | 24 (4.8)                              |
| Hypokalaemia                                            | 7 (5.8)                  | 9 (7.6)                     | 7 (3.2)                     | 23 (4.6)                              |
| Hypoproteinaemia                                        | 8 (6.7)                  | 3 (2.5)                     | 4 (1.8)                     | 15 (3.0)                              |
| Hypocalcaemia                                           | 6 (5.0)                  | 4 (3.4)                     | 3 (1.4)                     | 13 (2.6)                              |
| Skin and subcutaneous tissue disorders                  | 37 (30.8)                | 45 (38.1)                   | 46 (20.7)                   | 132 (26.6)                            |
| Rash                                                    | 22 (18.3)                | 26 (22.0)                   | 27 (12.2)                   | 77 (15.5)                             |
| Alopecia                                                | 11 (9.2)                 | 12 (10.2)                   | 2 (0.9)                     | 25 (5.0)                              |
| General disorders and administration site conditions    | 28 (23.3)                | 28 (23.7)                   | 58 (26.1)                   | 123 (24.7)                            |
| Asthenia                                                | 10 (8.3)                 | 8 (6.8) 19 (8.6) authorised | 8 (6.8) 19 (8.6) authorised | 45 (9.1)                              |
| Malaise                                                 | 8 (6.7)                  | 4 (3.4)                     | 24 (10.8)                   | 36 (7.2)                              |
| Pyrexia                                                 | 8 (6.7)                  | 8 (6.8)                     | 11 (5.0)                    | 28 (5.6)                              |
| Gastrointestinal disorders                              | 23 (19.2)                | 30 (25.4)                   | 56 (25.2)                   | 112 (22.5)                            |
| Nausea                                                  | 3 (2.5)                  | 12 (10.2) longer            | 27 (12.2)                   | 42 (8.5)                              |
| Vomiting                                                | 4 (3.3)                  | 7 (5.9)                     | 15 (6.8)                    | 26 (5.2)                              |
| Constipation                                            | 5 (4.2)                  | 4 (3.4)                     | 11 (5.0)                    | 20 (4.0)                              |
| Diarrhoea                                               | 7 (5.8)                  | 4 (3.4)                     | 5 (2.3)                     | 16 (3.2)                              |
| Respiratory, thoracic and mediastinal disorders         | 19 (15.8) no             | 19 (16.1)                   | 43 (19.4)                   | 87 (17.5)                             |
| Pneumonitis                                             | 7 (5.8)                  | 6 (5.1)                     | 28 (12.6)                   | 44 (8.9)                              |
| Endocrine disorders                                     | 23 (19.2)                | 17 (14.4)                   | 32 (14.4)                   | 76 (15.3)                             |
| Hypothyroidism                                          | 18 (15.0)                | 15 (12.7)                   | 26 (11.7)                   | 63 (12.7)                             |
| Hyperthyroidism                                         | 7 (5.8)                  | 2 (1.7)                     | 10 (4.5)                    | 20 (4.0)                              |
| Infections and infestations                             | 10 (8.3)                 | 17 (14.4)                   | 17 (7.7)                    | 46 (9.3)                              |
| Musculoskeletal and connective tissue disorders product | 17 (14.2)                | 17 (14.4)                   | 11 (5.0)                    | 46 (9.3)                              |
| Arthralgia                                              | 7 (5.8)                  | 8 (6.8)                     | 2 (0.9)                     | 17 (3.4)                              |
| Pain in extremity                                       | 9 (7.5)                  | 3 (2.5)                     | 3 (1.4)                     | 15 (3.0)                              |
| Cardiac disorders                                       | 8 (6.7)                  | 12 (10.2)                   | 19 (8.6)                    | 43 (8.7)                              |
| Nervous system disorders                                | 15 (12.5)                | 9 (7.6)                     | 16 (7.2)                    | 42 (8.5)                              |
| Hypoaesthesia                                           | 7 (5.8)                  | 4 (3.4)                     | 1 (0.5)                     | 13 (2.6)                              |
| Hepatobiliary disorders                                 | 6 (5.0)                  | 6 (5.1)                     | 4 (1.8)                     | 19 (3.8)                              |

<div style=\"page-break-after: always\"></div>

|                                                                   | SQ-NSCLC            | SQ-NSCLC                  | SQ-NSCLC                    | NSQ-NSCLC               | NSQ-NSCLC               | NSCLC                           | NSCLC                            |
|-------------------------------------------------------------------|---------------------|---------------------------|-----------------------------|-------------------------|-------------------------|---------------------------------|----------------------------------|
| System Organ Class                                                | 307 T+PC (N = 120)  | 307 T+nPC (N = 118)       | 307 PC (N = 117)            | 304 T+PP (N = 222)      | 304 PP (N = 110)        | 307&304&206 T+chemo * (N = 497) | 307&304 chemo ** (N = 227) n (%) |
| Preferred Term                                                    | n (%)               | n (%)                     | n (%)                       | n (%)                   | n (%)                   | n (%)                           |                                  |
| Patients With at Least One Treatment-                             | 119 (99.2)          | 117 (99.2)                | 117                         | 221 (99.5)              | 107 (97.3)              | 492 (99.0)                      | 224 (98.7)                       |
| related TEAE Related to Chemotherapy                              | 107 (89.2)          |                           | (100.0) 101                 |                         | 88 (80.0)               |                                 |                                  |
| Blood and lymphatic system disorders                              |                     | 111 (94.1)                | (86.3)                      | 197 (88.7)              |                         | 443 (89.1)                      | 189 (83.3)                       |
| Anaemia                                                           | 98 (81.7)           | 104 (88.1)                | 87 (74.4)                   | 177 (79.7)              | 75 (68.2)               | 407 (81.9)                      | 162 (71.4)                       |
| Leukopenia                                                        | 57 (47.5)           | 66 (55.9)                 | 57 (48.7)                   | 65 (29.3)               | 32 (29.1)               | 190 (38.2)                      | 89 (39.2)                        |
| Neutropenia                                                       | 52 (43.3)           | 50 (42.4)                 | 56 (47.9)                   | 84 (37.8)               | 39 (35.5)               | 189 (38.0)                      | 95 (41.9)                        |
| Thrombocytopenia                                                  | 34 (28.3)           | 47 (39.8)                 | 33 (28.2)                   | 66 (29.7)               | 33 (30.0)               | 153 (30.8)                      | 66 (29.1)                        |
| Investigations                                                    | 105 (87.5)          | 103 (87.3)                | 97 (82.9)                   | 202 (91.0)              | 95 (86.4)               | 441 (88.7)                      | 192 (84.6)                       |
| Neutrophil count decreased                                        | 77 (64.2)           | 72 (61.0)                 | 68 (58.1)                   | 145 (65.3)              | 55 (50.0)               | 320 (64.4)                      | 123 (54.2)                       |
| White blood cell count decreased                                  | 65 (54.2)           | 68 (57.6)                 | 62 (53.0)                   | 158 (71.2)              | 62 (56.4)               | 318 (64.0)                      | 124 (54.6)                       |
| Platelet count decreased                                          | 39 (32.5)           | 52 (44.1)                 | 29 (24.8)                   | 121 (54.5)              | 46 (41.8)               | 227 (45.7) authorised           | 75 (33.0)                        |
| Alanine aminotransferase increased                                | 47 (39.2)           | 38 (32.2)                 | 27 (23.1)                   | 106 (47.7)              | 48 (43.6)               | 204 (41.0)                      | 75 (33.0)                        |
| Aspartate aminotransferase increased                              | 38 (31.7)           | 39 (33.1)                 | 13 (11.1)                   | 96 (43.2)               | 49 (44.5)               | 187 (37.6)                      | 62 (27.3)                        |
| Blood bilirubin increased                                         | 23 (19.2)           | 12 (10.2)                 | 15 (12.8)                   | 26 (11.7)               | 8 (7.3)                 | 63 (12.7)                       | 23 (10.1)                        |
| Gamma-glutamyltransferase increased                               | 15 (12.5)           | 14 (11.9)                 | 14 (12.0)                   | 31 (14.0)               | 16 (14.5)               | 60 (12.1)                       | 30 (13.2)                        |
| Lymphocyte count decreased                                        | 13 (10.8)           | 21 (17.8)                 | 15 (12.8)                   | 26 (11.7)               | 6 (5.5)                 | 60 (12.1)                       | 21 (9.3)                         |
| Blood lactate dehydrogenase increased                             | 18 (15.0)           | 11 (9.3)                  | 9 (7.7)                     | 27 (12.2)               | 11 (10.0)               | 58 (11.7)                       | 20 (8.8)                         |
| Blood creatinine increased                                        | 4 (3.3)             | 6 (5.1)                   | 7 (6.0)                     | 34 (15.3)               | 5 (4.5)                 | 47 (9.5)                        | 12 (5.3)                         |
| Blood creatine phosphokinase increased Gastrointestinal disorders | 12 (10.0) 62 (51.7) | 7 (5.9) 69 (58.5)         | 8 (6.8) 54 (46.2)           | 7 (3.2) 135 (60.8)      | 4 (3.6) 60 (54.5)       | 28 (5.6) 279 (56.1)             | 12 (5.3) 114 (50.2)              |
| Nausea                                                            | 34 (28.3)           | 48 (40.7)                 | 29 (24.8)                   | 96 (43.2) longer        | 44 (40.0)               | 189 (38.0)                      | 73 (32.2)                        |
| Vomiting                                                          | 24 (20.0)           | 22 (18.6)                 | 15 (12.8)                   | 55 (24.8)               | 24 (21.8)               | 106 (21.3)                      | 39 (17.2)                        |
| Constipation                                                      | 22 (18.3)           | 12 (10.2)                 | 18 (15.4)                   | 31 (14.0)               | 15 (13.6)               | 66 (13.3)                       | 33 (14.5)                        |
| Diarrhoea                                                         | 12 (10.0)           | 7 (5.9)                   | 7 (6.0)                     | 10 (4.5)                | 10 (9.1)                | 29 (5.8)                        | 17 (7.5)                         |
| Abdominal distension                                              | 6 (5.0)             | 4 (3.4)                   |                             | 5 (2.3)                 | 2 (1.8)                 | 16 (3.2)                        | 4 (1.8)                          |
| Metabolism and nutrition disorders                                | 78 (65.0)           | no                        | 2 (1.7)                     | 109 (49.1)              | 53 (48.2)               | 274 (55.1)                      | 107 (47.1)                       |
|                                                                   | 48 (40.0)           | 72 (61.0)                 | 54 (46.2) 36 (30.8)         | 69 (31.1)               | 32 (29.1)               | 177 (35.6)                      | 68 (30.0)                        |
| Decreased appetite Hypoalbuminaemia                               | 17 (14.2)           | 48 (40.7) 11 (9.3)        | 13 (11.1)                   | 21 (9.5)                | 8 (7.3)                 | 50 (10.1)                       | 21 (9.3)                         |
| Hyponatraemia                                                     | 9 (7.5)             | 12 (10.2)                 | 12 (10.3)                   | 20 (9.0)                | 8 (7.3)                 | 41 (8.2)                        | 20 (8.8)                         |
| Hypokalaemia                                                      | 11 (9.2)            | 8 (6.8)                   | 5 (4.3)                     | 10 (4.5)                | 1 (0.9)                 | 29 (5.8)                        | 6 (2.6)                          |
| Hyperglycaemia                                                    | 6 (5.0)             | 6 (5.1)                   | 3 (2.6)                     | 14 (6.3)                | 4 (3.6)                 | 26 (5.2)                        | 7 (3.1)                          |
| Hyperuricaemia                                                    | 6 (5.0)             | 6 (5.1)                   | 4 (3.4)                     | 12 (5.4)                | 7 (6.4)                 | 24 (4.8)                        | 11 (4.8)                         |
| Hypoproteinaemia                                                  | 10 (8.3)            | 8 (6.8)                   | 8 (6.8)                     | 6 (2.7)                 | 2 (1.8)                 | 24 (4.8)                        | 10 (4.4)                         |
| Hypochloraemia                                                    | 5 (4.2)             | 5 (4.2)                   | 6 (5.1)                     | 9 (4.1)                 | 1 (0.9)                 | 20 (4.0)                        | 7 (3.1)                          |
| Hypocalcaemia                                                     | 8 (6.7)             | 3 (2.5)                   | 3 (2.6)                     | 5 (2.3)                 | 4 (3.6)                 | 16 (3.2)                        | 7 (3.1)                          |
| Skin and subcutaneous tissue disorders                            | 86 (71.7) product   | 89 (75.4)                 | 74 (63.2)                   | 55 (24.8)               | 17 (15.5)               | 242 (48.7)                      | 91 (40.1)                        |
| Alopecia                                                          | 78 (65.0)           | 81 (68.6)                 | 72 (61.5)                   | 19 (8.6)                | 4 (3.6)                 | 186 (37.4)                      | 76 (33.5)                        |
| Rash                                                              | 9 (7.5)             | 14 (11.9)                 | 4 (3.4)                     | 26 (11.7)               | 7 (6.4)                 | 53 (10.7)                       | 11 (4.8)                         |
| Pruritus                                                          | 3 (2.5)             | 6 (5.1)                   | 3 (2.6)                     | 9 (4.1)                 | 1 (0.9)                 | 22 (4.4)                        | 4 (1.8)                          |
| General disorders and administration Medicinal                    | 56 (46.7)           | 51 (43.2)                 | 49 (41.9)                   | 84 (37.8)               | 41 (37.3)               | 212 (42.7)                      | 90 (39.6)                        |
| Asthenia                                                          | 24 (20.0)           | 20 (16.9)                 | 23 (19.7)                   | 35 (15.8)               | 16 (14.5)               | 98 (19.7)                       | 39 (17.2)                        |
| Malaise                                                           | 17 (14.2)           | 17 (14.4)                 | 17 (14.5)                   | 37 (16.7)               | 19 (17.3)               | 73 (14.7)                       | 36 (15.9)                        |
| Pyrexia                                                           | 11 (9.2)            | 11 (9.3)                  | 6 (5.1)                     | 9 (4.1)                 | 4 (3.6)                 | 32 (6.4)                        | 10 (4.4)                         |
| Nervous system disorders                                          | 58 (48.3)           | 21 (17.8)                 | 41 (35.0)                   | 20 (9.0)                | 6 (5.5)                 | 109 (21.9)                      | 47 (20.7)                        |
| Hypoaesthesia                                                     | 25 (20.8)           | 10 (8.5)                  | 19 (16.2)                   | 2 (0.9)                 | 1 (0.9)                 | 41 (8.2)                        | 20 (8.8)                         |
| Dizziness                                                         | 2 (1.7)             | 4 (3.4)                   | 3 (2.6)                     | 13 (5.9)                | 3 (2.7)                 | 22 (4.4)                        | 6 (2.6) 12 (5.3)                 |
| Neurotoxicity                                                     | 15 (12.5) 8 (6.7)   | 5 (4.2)                   | 12 (10.3)                   | 0 (0.0)                 | 0 (0.0)                 | 21 (4.2)                        | 5 (2.2)                          |
| Peripheral sensory neuropathy                                     | 52 (43.3)           | 0 (0.0)                   | 5 (4.3)                     | 1 (0.5)                 | 0 (0.0)                 | 10 (2.0)                        | 48                               |
| Musculoskeletal and connective tissue                             |                     | 35 (29.7)                 | 42 (35.9)                   | 12 (5.4)                | 6 (5.5)                 | 105 (21.1)                      | (21.1)                           |
| disorders                                                         |                     |                           |                             |                         |                         |                                 |                                  |
| Pain in extremity Arthralgia                                      | 31 (25.8) 21 (17.5) | 8 (6.8) 15 (12.7) 8 (6.8) | 24 (20.5) 17 (14.5) 5 (4.3) | 6 (2.7) 0 (0.0) 1 (0.5) | 4 (3.6) 0 (0.0) 0 (0.0) | 49 (9.9) 38 (7.6) 15 (3.0)      | 28 (12.3) 17 (7.5) 5 (2.2)       |
| Myalgia Respiratory, thoracic and mediastinal disorders           | 6 (5.0) 10 (8.3)    | 10 (8.5)                  | 9 (7.7)                     | 28 (12.6)               | 13 (11.8)               | 51 (10.3)                       | 22 (9.7)                         |
| Infections and infestations                                       | 6 (5.0)             | (12.7)                    | 8 (6.8)                     | 20 (9.0)                | 7 (6.4)                 | 42 (8.5)                        | 15 (6.6)                         |
|                                                                   |                     | 15                        |                             |                         |                         |                                 |                                  |

<div style=\"page-break-after: always\"></div>

|                                   | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|-----------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
| System Organ Class Preferred Term | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Cardiac disorders                 | 7 (5.8)                  | 14 (11.9)                 | 4 (3.4)                | 13 (5.9)                 | 3 (2.7)                | 36 (7.2)                              | 7 (3.1)                          |
| Hepatobiliary disorders           | 9 (7.5)                  | 5 (4.2)                   | 11 (9.4)               | 2 (0.9)                  | 0 (0.0)                | 18 (3.6)                              | 11 (4.8)                         |
| Hepatic function abnormal         | 7 (5.8)                  | 4 (3.4)                   | 10 (8.5)               | 0 (0.0)                  | 0 (0.0)                | 13 (2.6)                              | 10 (4.4)                         |
| Psychiatric disorders             | 3 (2.5)                  | 1 (0.8)                   | 5 (4.3)                | 8 (3.6)                  | 9 (8.2)                | 12 (2.4)                              | 14 (6.2)                         |
| Insomnia                          | 3 (2.5)                  | 1 (0.8)                   | 4 (3.4)                | 5 (2.3)                  | 9 (8.2)                | 9 (1.8)                               | 13 (5.7)                         |

|                                                           | TEAEs related to chemotherapy TEAEs related to tislelizumab   | TEAEs related to chemotherapy TEAEs related to tislelizumab   |
|-----------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| System Organ Class Preferred Term                         | NSCLC 307&304&206 T+chemo (N = 497)                           | NSCLC 307&304&206 T+chemo (N = 497)                           |
|                                                           | n (%)                                                         |                                                               |
|                                                           |                                                               | n (%)                                                         |
| Patients with at least one treatment-related TEAE         | 492 (99.0)                                                    | 431 (86.7)                                                    |
| Investigations                                            | 441 (88.7)                                                    | 295 (59.4)                                                    |
| Alanine aminotransferase increased                        | 204 (41.0)                                                    | 126 (25.4)                                                    |
| Aspartate aminotransferase increased                      | 187 (37.6)                                                    | 112 (22.5)                                                    |
| White blood cell count decreased                          | 318 (64.0)                                                    | 95 (19.1)                                                     |
| Neutrophil count decreased                                | 320 (64.4)                                                    | 92 (18.5)                                                     |
| Platelet count decreased                                  | 227 (45.7)                                                    | 92 (18.5)                                                     |
| Blood bilirubin increased                                 | 63 (12.7)                                                     | 58 (11.7)                                                     |
| Blood lactate dehydrogenase increased no                  | 58 (11.7)                                                     | 56 (11.3)                                                     |
| Gamma-glutamyltransferase increased                       | 60 (12.1)                                                     | 0                                                             |
| Lymphocyte count decreased                                | 60 (12.1)                                                     | 0                                                             |
| Blood and lymphatic system disorders                      | 443 (89.1)                                                    | 184 (37.0)                                                    |
| Anaemia                                                   | 407 (81.9)                                                    | 153 (30.8)                                                    |
| Leukopenia                                                | 190 (38.2)                                                    | 69 (13.9)                                                     |
| Neutropenia                                               | 189 (38.0)                                                    | 66 (13.3)                                                     |
| Thrombocytopenia                                          | 153 (30.8)                                                    | 64 (12.9)                                                     |
| Metabolism and nutrition disorders product                | 274 (55.1)                                                    | 154 (31.0)                                                    |
| Decreased appetite                                        | 177 (35.6)                                                    | 73 (14.7)                                                     |
| Hypoalbuminaemia                                          | 50 (10.1)                                                     | 0                                                             |
| Skin and subcutaneous tissue disorders Vomiting Medicinal | 242 (48.7) 106 (21.3)                                         | 132 (26.6) 0                                                  |
| Rash                                                      | 53 (10.7)                                                     | 77 (15.5)                                                     |
| Alopecia                                                  | 186 (37.4)                                                    | 0                                                             |
| Endocrine disorders                                       | 0                                                             | 76 (15.3)                                                     |
| Hypothyroidism                                            | 0                                                             | 63 (12.7)                                                     |
| Gastrointestinal disorders                                | 279 (56.1)                                                    | 0                                                             |
| Nausea                                                    | 189 (38.0)                                                    | 0                                                             |
| Constipation                                              | 66 (13.3)                                                     | 0                                                             |
| General disorders and administration site conditions      | 212 (42.7)                                                    | 0                                                             |
| Asthenia                                                  | 98 (19.7)                                                     | 0                                                             |
| Malaise                                                   | 73 (14.7)                                                     | 0                                                             |

## Grade ≥ 3 A Es (all-cause)

## Table 110: CTCAE Grade 3 or higher TEAEs by SOC and PT (≥1.0% patients in NSCLC T+Chemo group)

<div style=\"page-break-after: always\"></div>

|                                                                | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|----------------------------------------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
| System Organ Class Preferred Term                              | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Patients With at Least One TEAE with Grade ≥ 3                 | 107 (89.2)               | 103 (87.3)                | 99 (84.6)              | 154 (69.4)               | 62 (56.4)              | 394 (79.3)                            | 161 (70.9)                       |
| Investigations                                                 | 77 (64.2)                | 69 (58.5)                 | 58 (49.6)              | 85 (38.3)                | 22 (20.0)              | 254 (51.1)                            | 80 (35.2)                        |
| Neutrophil count decreased                                     | 64 (53.3)                | 54 (45.8)                 | 53 (45.3)              | 57 (25.7)                | 14 (12.7)              | 193 (38.8)                            | 67 (29.5)                        |
| White blood cell count decreased                               | 28 (23.3)                | 32 (27.1)                 | 28 (23.9)              | 30 (13.5)                | 5 (4.5)                | 96 (19.3)                             | 33 (14.5)                        |
| Platelet count decreased                                       | 6 (5.0)                  | 16 (13.6)                 | 2 (1.7)                | 19 (8.6)                 | 6 (5.5)                | 45 (9.1)                              | 8 (3.5)                          |
| Alanine aminotransferase increased                             | 3 (2.5)                  | 2 (1.7)                   | 0 (0.0)                | 8 (3.6)                  | 3 (2.7)                | 16 (3.2)                              | 3 (1.3)                          |
| Lymphocyte count decreased                                     | 3 (2.5)                  | 4 (3.4)                   | 4 (3.4)                | 6 (2.7)                  | 1 (0.9)                | 14 (2.8)                              | 5 (2.2)                          |
| Gamma-glutamyltransferase increased                            | 2 (1.7)                  | 3 (2.5)                   | 1 (0.9)                | 4 (1.8)                  | 3 (2.7)                | 9 (1.8)                               | 4 (1.8)                          |
| Aspartate aminotransferase increased                           | 2 (1.7)                  | 1 (0.8)                   | 0 (0.0)                | 4 (1.8)                  | 0 (0.0)                | 8 (1.6) authorised                    | 0 (0.0)                          |
| Weight decreased                                               | 2 (1.7)                  | 1 (0.8)                   | 0 (0.0)                | 2 (0.9)                  | 0 (0.0)                | 5 (1.0)                               | 0 (0.0)                          |
| Blood and lymphatic system disorders                           | 56 (46.7)                | 68 (57.6)                 | 63 (53.8)              | 87 (39.2)                | 38 (34.5)              | 218 (43.9)                            | 101 (44.5)                       |
| Neutropenia                                                    | 40 (33.3)                | 32 (27.1)                 | 47 (40.2)              | 53 (23.9)                | 25 (22.7)              | 126 (25.4)                            | 72 (31.7)                        |
| Anaemia                                                        | 12 (10.0)                | 27 (22.9)                 | 15 (12.8)              | 33 (14.9) longer         | 13 (11.8)              | 77 (15.5)                             | 28 (12.3)                        |
| Leukopenia                                                     | 19 (15.8)                | 30 (25.4)                 | 22 (18.8)              | 24 (10.8)                | 12 (10.9)              | 73 (14.7)                             | 34 (15.0)                        |
| Thrombocytopenia                                               | 8 (6.7)                  | 15 (12.7)                 | 7 (6.0)                | 25 (11.3)                | 10 (9.1)               | 49 (9.9)                              | 17 (7.5)                         |
| Febrile neutropenia                                            | 5 (4.2)                  | 5 (4.2)                   | 3 (2.6)                | 2 (0.9)                  | 0 (0.0)                | 12 (2.4)                              | 3 (1.3)                          |
| Bone marrow failure                                            | 2 (1.7)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 1 (0.9)                | 5 (1.0)                               | 1 (0.4)                          |
| Infections and infestations                                    | 13 (10.8)                | 13 (11.0)                 | 6 (5.1) no             | 20 (9.0)                 | 9 (8.2)                | 46 (9.3)                              | 15 (6.6)                         |
| Pneumonia                                                      | 6 (5.0)                  | 6 (5.1)                   | 3 (2.6)                | 13 (5.9)                 | 8 (7.3)                | 25 (5.0)                              | 11 (4.8)                         |
| Upper respiratory tract infection                              | 5 (4.2)                  | 0 (0.0)                   | 1 (0.9)                | 2 (0.9)                  | 1 (0.9)                | 7 (1.4)                               | 2 (0.9)                          |
| Respiratory, thoracic and mediastinal disorders                | 9 (7.5)                  | 13 (11.0) product         | 3 (2.6)                | 20 (9.0)                 | 2 (1.8)                | 44 (8.9)                              | 5 (2.2)                          |
| Pneumonitis                                                    | 3 (2.5)                  | 3 (2.5)                   | 0 (0.0)                | 9 (4.1)                  | 1 (0.9)                | 15 (3.0)                              | 1 (0.4)                          |
| Haemoptysis                                                    | 2 (1.7)                  | 4 (3.4)                   | 0 (0.0)                | 4 (1.8)                  | 0 (0.0)                | 10 (2.0)                              | 0 (0.0)                          |
| Dyspnoea                                                       | 0 (0.0)                  | 1 (0.8)                   | 1 (0.9)                | 5 (2.3)                  | 0 (0.0)                | 7 (1.4)                               | 1 (0.4)                          |
| Metabolism and nutrition disorders                             | 11 (9.2)                 | 7 (5.9)                   | 8 (6.8)                | 17 (7.7)                 | 4 (3.6)                | 42 (8.5)                              | 12 (5.3)                         |
| Hypokalaemia                                                   | 3 (2.5)                  | 2 (1.7)                   | 2 (1.7)                | 2 (0.9)                  | 0 (0.0)                | 8 (1.6)                               | 2 (0.9)                          |
| Hyponatraemia                                                  | 2 (1.7)                  | 2 (1.7)                   | 3 (2.6)                | 3 (1.4)                  | 1 (0.9)                | 8 (1.6)                               | 4 (1.8)                          |
| Decreased appetite                                             | 2 (1.7)                  | 2 (1.7)                   | 1 (0.9)                | 3 (1.4)                  | 2 (1.8)                | 7 (1.4)                               | 3 (1.3)                          |
| Hypertriglyceridaemia                                          | 4 (3.3)                  | 1 (0.8)                   | 1 (0.9)                | 1 (0.5)                  | 0 (0.0)                | 7 (1.4)                               | 1 (0.4)                          |
| Hyperglycaemia                                                 | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 2 (0.9)                  | 1 (0.9)                | 5 (1.0)                               | 1 (0.4)                          |
| Gastrointestinal disorders                                     | 5 (4.2)                  | 2 (1.7)                   | 3 (2.6)                | 10 (4.5)                 | 1 (0.9)                | 18 (3.6)                              | 4 (1.8)                          |
| General disorders and administration site conditions Medicinal | 5 (4.2)                  | 3 (2.5)                   | 5 (4.3)                | 6 (2.7)                  | 6 (5.5)                | 17 (3.4)                              | 11 (4.8)                         |
| Malaise                                                        | 3 (2.5)                  | 1 (0.8)                   | 0 (0.0)                | 1 (0.5)                  | 3 (2.7)                | 6 (1.2)                               | 3 (1.3)                          |
| Nervous system disorders                                       | 7 (5.8)                  | 1 (0.8)                   | 2 (1.7)                | 6 (2.7)                  | 3 (2.7)                | 16 (3.2)                              | 5 (2.2)                          |
| Skin and subcutaneous tissue disorders                         | 6 (5.0)                  | 4 (3.4)                   | 0 (0.0)                | 3 (1.4)                  | 1 (0.9)                | 13 (2.6)                              | 1 (0.4)                          |
| Rash                                                           | 4 (3.3)                  | 2 (1.7)                   | 0 (0.0)                | 2 (0.9)                  | 0 (0.0)                | 8 (1.6)                               | 0 (0.0)                          |
| Hepatobiliary disorders                                        | 1 (0.8)                  | 3 (2.5)                   | 0 (0.0)                | 4 (1.8)                  | 0 (0.0)                | 10 (2.0)                              | 0 (0.0)                          |
| Cardiac disorders                                              | 0 (0.0)                  | 1 (0.8)                   | 1 (0.9)                | 7 (3.2)                  | 0 (0.0)                | 9 (1.8)                               | 1 (0.4)                          |
| Musculoskeletal and connective tissue disorders                | 5 (4.2)                  | 1 (0.8)                   | 1 (0.9)                | 1 (0.5)                  | 2 (1.8)                | 8 (1.6)                               | 3 (1.3)                          |
| Renal and urinary disorders Injury, poisoning and              | 0 (0.0)                  | 2 (1.7)                   | 0 (0.0)                | 4 (1.8)                  | 0 (0.0)                | 6 (1.2)                               | 0 (0.0)                          |
| procedural complications                                       | 2 (1.7)                  | 2 (1.7)                   | 1 (0.9)                | 1 (0.5)                  | 0 (0.0)                | 5 (1.0)                               | 1 (0.4)                          |

<div style=\"page-break-after: always\"></div>

## Grade ≥ 3 AEs (related)

In general, the most common drugrelated CTCAE Grade ≥ 3 TEAEs were similar to reported CTCAE Grade ≥ 3 TEAEs regardless of drug relatedness (data not shown). Drug -related Grade ≥3 AEs were higher for the combined tislelizumab vs the combined chemotherapy groups (74.8% vs 63.9%).

## Serious adverse event/deaths/other significant events

## · Monotherapy 2L+

|                                                 | 303 Study                  | 303 Study               | 2L+ NSCLC         | 2L+ NSCLC                                 |
|-------------------------------------------------|----------------------------|-------------------------|-------------------|-------------------------------------------|
| System Organ Class Preferred Term               | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | 200 mg Q3W All Indications (N=1534) n (%) |
| Patients with at least one Serious TEAE         | 174 (32.6)                 | 83 (32.2)               | 213 (33.5)        | 516 (33.6)                                |
| Respiratory, thoracic and mediastinal disorders | 71 (13.3)                  | 17 (6.6)                | 77 (12.1)         | 128 (8.3)                                 |
| Pneumonitis                                     | 15 (2.8)                   | 0 (0.0)                 | 17 (2.7)          | 24 (1.6)                                  |
| Haemoptysis                                     | 10 (1.9)                   | 4 (1.6)                 | 11 (1.7)          | 12 (0.8)                                  |
| Dyspnoea                                        | 8 (1.5)                    | 4 (1.6)                 | 8 (1.3)           | 16 (1.0)                                  |
| Pleural effusion                                | 8 (1.5)                    | 5 (1.9) longer          | 9 (1.4)           | 13 (0.8)                                  |
| Immune-mediated pneumonitis                     | 7 (1.3)                    | 0 (0.0)                 | 7 (1.1)           | 12 (0.8)                                  |
| Interstitial lung disease                       | 7 (1.3)                    | 0 (0.0)                 | 7 (1.1)           | 10 (0.7)                                  |
| Respiratory failure                             | 5 (0.9)                    | 3 (1.2)                 | 6 (0.9)           | 9 (0.6)                                   |
| Infections and infestations                     | 38 (7.1) no                | 25 (9.7)                | 48 (7.5)          | 112 (7.3)                                 |
| Pneumonia                                       | 35 (6.6)                   | 19 (7.4)                | 41 (6.4)          | 75 (4.9)                                  |
| Gastrointestinal disorders                      | 12 (2.2)                   | 4 (1.6)                 | 18 (2.8)          | 95 (6.2)                                  |
| Dysphagia                                       | 2 (0.4)                    | 0 (0.0)                 | 3 (0.5)           | 16 (1.0)                                  |
| Blood and lymphatic system disorders product    | 5 (0.9)                    | 36 (14.0)               | 5 (0.8)           | 11 (0.7)                                  |
| Anaemia                                         | 2 (0.4)                    | 5 (1.9)                 | 2 (0.3)           | 4 (0.3)                                   |
| Febrile neutropenia                             | 0 (0.0)                    | 21 (8.1)                | 0 (0.0)           | 0 (0.0)                                   |
| Leukopenia                                      | 0 (0.0)                    | 6 (2.3)                 | 0 (0.0)           | 0 (0.0)                                   |
| Neutropenia                                     | 0 (0.0)                    | 11 (4.3)                | 0 (0.0)           | 0 (0.0)                                   |
| Investigations                                  | 5 (0.9)                    | 11 (4.3)                | 6 (0.9)           | 20 (1.3)                                  |
| Neutrophil count decreased                      | 0 (0.0)                    | 8 (3.1)                 | 0 (0.0)           | 0 (0.0)                                   |
| White blood cell count decreased                | 0 (0.0)                    | 4 (1.6)                 | 0 (0.0)           | 0 (0.0)                                   |

SAEs Table 111: Serious TEAEs by SOC and PT (≥ 1% patients in any group ) Table 112: Treatmentrelated SAEs by SOC and PT (≥1% pat ents in any group) Medicinal product no longer authorised

<!-- image -->

|                                                           | 303 Study                  | 303 Study               | 2L+ NSCLC All (N=636)   | 200 mg Q3W All (N=1534) n (%)   |
|-----------------------------------------------------------|----------------------------|-------------------------|-------------------------|---------------------------------|
| System Organ Class Preferred Term                         | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | n (%)                   | Indications                     |
| Patients with at least one Treatment-related Serious TEAE | 67 (12.5)                  | 59 (22.9)               | 78 (12.3)               | 175 (11.4)                      |
| Respiratory, thoracic and mediastinal disorders           | 36 (6.7)                   | 3 (1.2)                 | 38 (6.0)                | 61 (4.0)                        |
| Pneumonitis                                               | 14 (2.6)                   | 0 (0.0)                 | 16 (2.5)                | 23 (1.5)                        |
| Immune-mediated pneumonitis                               | 7 (1.3)                    | 0 (0.0)                 | 7 (1.1)                 | 12 (0.8)                        |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                      | 303 Study                  | 303 Study               | 2L+ NSCLC         | 200 mg Q3W All (N=1534)   |
|--------------------------------------|----------------------------|-------------------------|-------------------|---------------------------|
| System Organ Class Preferred Term    | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | Indications n (%)         |
| Interstitial lung disease            | 7 (1.3)                    | 0 (0.0)                 | 7 (1.1)           | 10 (0.7)                  |
| Infections and infestations          | 4 (0.7)                    | 13 (5.0)                | 6 (0.9)           | 18 (1.2)                  |
| Pneumonia                            | 4 (0.7)                    | 11 (4.3)                | 5 (0.8)           | 16 (1.0)                  |
| Investigations                       | 4 (0.7)                    | 11 (4.3)                | 5 (0.8)           | 13 (0.8)                  |
| Neutrophil count decreased           | 0 (0.0)                    | 8 (3.1)                 | 0 (0.0)           | 0 (0.0)                   |
| White blood cell count decreased     | 0 (0.0)                    | 4 (1.6)                 | 0 (0.0)           | 0 (0.0)                   |
| Blood and lymphatic system disorders | 3 (0.6)                    | 36 (14.0)               | 3 (0.5)           | 6 (0.4)                   |
| Anaemia                              | 1 (0.2)                    | 5 (1.9)                 | 1 (0.2)           | 2 (0.1)                   |
| Febrile neutropenia                  | 0 (0.0)                    | 21 (8.1)                | 0 (0.0)           | 0 (0.0)                   |
| Leukopenia                           | 0 (0.0)                    | 6 (2.3)                 | 0 (0.0)           | 0 (0.0)                   |
| Neutropenia                          | 0 (0.0)                    | 11 (4.3)                | 0 (0.0)           | 0 (0.0)                   |

|                                                                | Study 303                                                                                                                   | Study 303                                                                                                                   | Study 303                                                                                                                   | Study 303                                                                                                                   |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| System Organ Class Preferred Term                              | Tislelizumab (N = 534) n (%)                                                                                                | Docetaxel (N = 258) n (%)                                                                                                   | Tislelizumab (N=534) n (%)                                                                                                  | Docetaxel (N=258) n (%)                                                                                                     |
|                                                                | Patients with at least one TEAE leading to death Patients with at least one treatment- related TEAE leading to death longer | Patients with at least one TEAE leading to death Patients with at least one treatment- related TEAE leading to death longer | Patients with at least one TEAE leading to death Patients with at least one treatment- related TEAE leading to death longer | Patients with at least one TEAE leading to death Patients with at least one treatment- related TEAE leading to death longer |
|                                                                | 32 (6.0)                                                                                                                    | 11 (4.3)                                                                                                                    | 8 (1.5)                                                                                                                     | 4 (1.6)                                                                                                                     |
| Respiratory, thoracic and mediastinal disorders                | 12 (2.2) no                                                                                                                 | 3 (1.2)                                                                                                                     | 3 (0.6)                                                                                                                     |                                                                                                                             |
| Respiratory failure                                            | 5 (0.9)                                                                                                                     | 0 (0.0)                                                                                                                     | 2 (0.4)                                                                                                                     |                                                                                                                             |
| Acute respiratory failure                                      | 2 (0.4)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Pleural effusion                                               | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Pneumonitis                                                    | 1 (0.2) product                                                                                                             | 0 (0.0)                                                                                                                     | 1 (0.2)                                                                                                                     |                                                                                                                             |
| Pulmonary haemorrhage                                          | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Pulmonary thrombosis                                           | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Tracheal stenosis                                              | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Dyspnoea                                                       | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Haemoptysis                                                    | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Hypoxia                                                        | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| General disorders and administration site conditions Medicinal | 6 (1.1)                                                                                                                     | 3 (1.2)                                                                                                                     | 3 (0.6)                                                                                                                     | 1 (0.4)                                                                                                                     |
| Death                                                          | 5 (0.9)                                                                                                                     | 2 (0.8)                                                                                                                     | 2 (0.4)                                                                                                                     | 1 (0.4)                                                                                                                     |
| Multiple organ dysfunction syndrome                            | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     | 1 (0.2)                                                                                                                     |                                                                                                                             |
| General physical health deterioration                          | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Infections and infestations                                    | 6 (1.1)                                                                                                                     | 3 (1.2)                                                                                                                     | 2 (0.4)                                                                                                                     | 2 (0.8)                                                                                                                     |
| Pneumonia                                                      | 6 (1.1)                                                                                                                     | 2 (0.8)                                                                                                                     | 2 (0.4)                                                                                                                     | 1 (0.4)                                                                                                                     |
| Septic shock                                                   | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             | 1 (0.4)                                                                                                                     |
| Cardiac disorders                                              | 4 (0.7)                                                                                                                     | 2 (0.8)                                                                                                                     |                                                                                                                             | 1 (0.4)                                                                                                                     |
| Acute myocardial infarction                                    | 2 (0.4)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Cardiac tamponade                                              | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Pericardial effusion                                           | 1 (0.2)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Acute left ventricular failure                                 | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Cardiogenic shock                                              | 0 (0.0)                                                                                                                     | 1 (0.4)                                                                                                                     |                                                                                                                             | 1 (0.4)                                                                                                                     |
| Nervous system disorders                                       | 3 (0.6)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |
| Cerebral infarction                                            | 2 (0.4)                                                                                                                     | 0 (0.0)                                                                                                                     |                                                                                                                             |                                                                                                                             |

Deaths Table 113: TEAEs leading to death by SOC and PT; all-cause and related (Study 303) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                   | Study 303                    | Study 303                 | Study 303                  |                         |
|-----------------------------------|------------------------------|---------------------------|----------------------------|-------------------------|
| System Organ Class Preferred Term | Tislelizumab (N = 534) n (%) | Docetaxel (N = 258) n (%) | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) |
| Cerebral artery occlusion         | 1 (0.2)                      | 0 (0.0)                   |                            |                         |
| Hepatobiliary disorders           | 2 (0.4)                      | 0 (0.0)                   | 1 (0.2)                    |                         |
| Acute hepatic failure             | 1 (0.2)                      | 0 (0.0)                   |                            |                         |
| Hepatic function abnormal         | 1 (0.2)                      | 0 (0.0)                   | 1 (0.2)                    |                         |
| Psychiatric disorders             | 1 (0.2)                      | 0 (0.0)                   |                            |                         |
| Depression                        | 1 (0.2)                      | 0 (0.0)                   |                            |                         |

<!-- image -->

Immune-related AEs Process for the identification of immune-mediated TEAEs All reported immune-mediated treatment-emergent adverse events (imAEs) in Study 303 were confirmed. The process of identification of confirmed imAE followed a 2-step process: · Step 1: Generation of Potential imAE List Potential imAEs were identified using a predefined list of MedDRA preferred terms ('Look -Up List') based on imAE terms from other approved checkpoint inhibitors and published literature. TEAEs in the tislelizumab arm with a coded MedDRA PT of the Look-Up List are forwarded for medical review provided the following criteria were met: o The TEAE started on or after the date in which the first dose of tislelizumab was administered. o The TEAE was linked with treatment with systemic corticosteroids, endocrine therapy, or other immunosuppressants recorded on the concomitant medications eCRF page. o The systemic corticosteroids, endocrine therapy, or other immunosuppressants linked to the TEAE, must have started on or after the start date, and no later than the end date for the TEAE. With the exception of TEAEs of hyperthyroidism and hypothyroidism, systemic corticosteroids must have started within 30 days of the TEAE start date. · Step 2: Medical Evaluation of Potential imAE All potential imAEs are reviewed by two medical reviewers, or individuals with appropriate training and experience in performing medical review. The medical review is performed to rule out clear alternative aetiologies of potential imAE cases identified in Step 1. The two reviewers evaluate potential imAE cases independently. They considered use of systematic steroid or immunosuppressive therapy, outcome of rechallenge, existence of alternative explanation and the investigator´s assessment of the immune-related check box. If there were discrepancies between the 2 reviewers, adjudication was to be made by a third qualified medical reviewer. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Frequency of immune-mediated TEAEs -Study 303

Note : In the following confirmed immune-mediated events (imAEs) are presented.

Table 114: Overall summary of immune-mediated TEAEs

| Category CTCAE Grade                                      | 303 Study Tislelizumab (N=534) n (%)   | 2L+ NSCLC All (N=636) n (%)   | 200 mg Q3W All Indications (N=1534) n (%)   |
|-----------------------------------------------------------|----------------------------------------|-------------------------------|---------------------------------------------|
| Patients with at least one Immune-mediated TEAE           | 104 (19.5)                             | 126 (19.8)                    | 276 (18.0)                                  |
| Immune-mediated TEAE with Grade 3 or Higher               | 35 (6.6)                               | 43 (6.8)                      | 81 (5.3)                                    |
| Serious Immune-mediated TEAE                              | 40 (7.5)                               | 44 (6.9)                      | 90 (5.9)                                    |
| Immune-mediated TEAE Leading to Treatment Modification    | 28 (5.2)                               | 34 (5.3) authorised           | 89 (5.8)                                    |
| Immune-mediated TEAE Leading to Treatment Discontinuation | 23 (4.3)                               | 29 (4.6)                      | 53 (3.5)                                    |
| Immune-mediated TEAE Leading to Death                     | 2 (0.4)                                | 3 (0.5)                       | 6 (0.4)                                     |
| Immune-mediated TEAE Treated with Systemic Steroids       | 63 (11.8)                              | 78 (12.3)                     | 161 (10.5)                                  |
| Immune-mediated TEAE Treated with Immunosuppressants      | 4 (0.7)                                | 4 (0.6)                       | 5 (0.3)                                     |
| Immune-mediated TEAE Treated with Hormone Therapy         | 48 (9.0) longer                        | 56 (8.8)                      | 132 (8.6)                                   |

| Category Preferred Term                                                     | 303 Study Tislelizumab (N=534) n (%)   | 2L+ NSCLC All (N=636)   | 200 mg Q3W All Indications (N=1534) n (%)   |
|-----------------------------------------------------------------------------|----------------------------------------|-------------------------|---------------------------------------------|
| Patients with at least one Immune-mediated TEAE Medicinal product           | 104 (19.5)                             | n (%) 126 (19.8)        | 276 (18.0)                                  |
| Immune-mediated hypothyroidism                                              | 42 (7.9)                               | 49 (7.7)                | 116 (7.6)                                   |
| Immune-mediated pneumonitis                                                 | 33 (6.2)                               | 38 (6.0)                | 66 (4.3)                                    |
| Immune-mediated skin adverse reaction                                       | 8 (1.5)                                | 12 (1.9)                | 27 (1.8)                                    |
| Immune-mediated hepatitis                                                   | 7 (1.3)                                | 11 (1.7)                | 26 (1.7)                                    |
| Immune-mediated myositis/rhabdomyolysis                                     | 7 (1.3)                                | 7 (1.1)                 | 14 (0.9)                                    |
| Immune-mediated thyroiditis                                                 | 6 (1.1)                                | 6 (0.9)                 | 12 (0.8)                                    |
| Immune-mediated nephritis and renal dysfunction                             | 5 (0.9)                                | 5 (0.8)                 | 10 (0.7)                                    |
| Immune-mediated colitis                                                     | 4 (0.7)                                | 5 (0.8)                 | 11 (0.7)                                    |
| Other immune-mediated reactions (Arthritis, imArthritis, Pericarditis, PMR) | 3 (0.6)                                | 4 (0.6)                 | 4 (0.3)                                     |
| Immune-mediated adrenal insufficiency                                       | 2 (0.4)                                | 2 (0.3)                 | 4 (0.3)                                     |
| Immune-mediated myocarditis                                                 | 2 (0.4)                                | 3 (0.5)                 | 7 (0.5)                                     |
| Immune-mediated type 1 diabetes mellitus                                    | 2 (0.4)                                | 2 (0.3)                 | 6 (0.4)                                     |
| Immune-mediated hyperthyroidism                                             | 1 (0.2)                                | 4 (0.6)                 | 5 (0.3)                                     |
| Immune-mediated pancreatitis                                                | 0 (0.0)                                | 0 (0.0)                 | 1 (0.1)                                     |
| Immune-mediated pituitary dysfunction                                       | 0 (0.0)                                | 0 (0.0)                 | 1 (0.1)                                     |

Table 115: ImAEs by category Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 116: Grade ≥ 3 imAEs by category and maximum severity

| Category CTCAE Grade                               | 303 Study      | 2L+ NSCLC All (N=636)   | 200 mg Q3W All Indications (N=1534) n (%)   |
|----------------------------------------------------|----------------|-------------------------|---------------------------------------------|
| Patients with at least one Immune-mediated TEAE    | 104 (19.5)     | 126 (19.8)              | 276 (18.0)                                  |
| Immune-mediated hypothyroidism                     | 42 (7.9)       | 49 (7.7)                | 116 (7.6)                                   |
| Grade 3                                            | 0 (0.0)        | 0 (0.0)                 | 0 (0.0)                                     |
| Grade 4                                            | 0 (0.0)        | 0 (0.0)                 | 1 (0.1)                                     |
| Immune-mediated pneumonitis                        | 33 (6.2)       | 38 (6.0)                | 66 (4.3) authorised                         |
| Grade 3                                            | 13 (2.4)       | 14 (2.2)                | 23 (1.5)                                    |
| Grade 4                                            | 5 (0.9)        | 5 (0.8)                 | 5 (0.3)                                     |
| Grade 5                                            | 2 (0.4)        | 3 (0.5)                 | 3 (0.2)                                     |
| Immune-mediated skin adverse reaction              | 8 (1.5)        | 12 (1.9)                | 27 (1.8)                                    |
| Grade 3                                            | 2 (0.4)        | 4 (0.6)                 | 5 (0.3)                                     |
| Grade 4                                            | 1 (0.2)        | 1 (0.2)                 | 4 (0.3)                                     |
| Immune-mediated hepatitis                          | 7 (1.3) longer | 11 (1.7)                | 26 (1.7)                                    |
| Grade 3                                            | 3 (0.6)        | 5 (0.8)                 | 14 (0.9)                                    |
| Grade 4                                            | 1 (0.2)        | 1 (0.2)                 | 1 (0.1)                                     |
| Grade 5                                            | 0 (0.0)        | 0 (0.0)                 | 2 (0.1)                                     |
| Immune-mediated myositis/rhabdomyolysis            | 7 (1.3) no     | 7 (1.1)                 | 14 (0.9)                                    |
| Grade 3                                            | 2 (0.4)        | 2 (0.3)                 | 5 (0.3)                                     |
| Grade 4                                            | 0 (0.0)        | 0 (0.0)                 | 1 (0.1)                                     |
| Immune-mediated nephritis and renal dysfunction    | 5 (0.9)        | 5 (0.8)                 | 10 (0.7)                                    |
| Grade 3                                            | 1 (0.2)        | 1 (0.2)                 | 3 (0.2)                                     |
| Grade 4                                            | 2 (0.4)        | 2 (0.3)                 | 2 (0.1)                                     |
| Grade 5                                            | 0 (0.0)        | 0 (0.0)                 | 1 (0.1)                                     |
| Immune-mediated colitis                            | 4 (0.7)        | 5 (0.8)                 | 11 (0.7)                                    |
| Grade 3                                            | 1 (0.2)        | 2 (0.3)                 | 2 (0.1)                                     |
| Immune-mediated adrenal insufficiency product      | 2 (0.4)        | 2 (0.3)                 | 4 (0.3)                                     |
| Grade 3                                            | 1 (0.2)        | 1 (0.2)                 | 1 (0.1)                                     |
| Grade 4                                            | 1 (0.2)        | 1 (0.2)                 | 1 (0.1)                                     |
| Immune-mediated myocarditis                        | 2 (0.4)        | 3 (0.5)                 | 7 (0.5)                                     |
| Grade 3                                            | 0 (0.0)        | 1 (0.2)                 | 3 (0.2)                                     |
| Grade 4                                            | 1 (0.2)        | 1 (0.2)                 | 1 (0.1)                                     |
| Immune-mediated type 1 diabetes mellitus Medicinal | 2 (0.4)        | 2 (0.3)                 | 6 (0.4)                                     |
| Grade 3                                            | 2 (0.4)        | 2 (0.3)                 | 5 (0.3)                                     |
| Immune-mediated pancreatitis                       | 0 (0.0)        | 0 (0.0)                 | 1 (0.1)                                     |
| Grade 3                                            | 0 (0.0)        | 0 (0.0)                 | 1 (0.1)                                     |

Patients with multiple events for a given category are counted only once at the worst toxicity grade for the category.

<div style=\"page-break-after: always\"></div>

| imAEcategory                            | Number of events in category   | <3months Events (%)   | 3to<6months Events (%)   | 6 to<9 months Events (%)   | 9 to < 12 months Events (%)   | ≥12 months Events (%)   |
|-----------------------------------------|--------------------------------|-----------------------|--------------------------|----------------------------|-------------------------------|-------------------------|
| Immune-mediated hypothyroidism          | 54                             | 15 (27.8)             | 22 (40.7)                | 4 (7.4)                    | 0                             | 13 (24.1)               |
| Immune-mediatedpneumonitis              | 34                             | 12 (35.3)             | 9 (26.5)                 | 7 (20.6)                   | 3 (8.8)                       | 3 (8.8)                 |
| Immune-mediatedhepatitis                | 7                              | 6 (85.7)              | 1 (14.3)                 | 0                          | 0                             | 0                       |
| Immune-mediated myositis/rhabdomyolysis | 7                              | 3 (42.9)              | 1 (14.3)                 | 2 (28.6)                   | 0                             | 1 (14.3)                |
| Immune-mediated thyroiditis             | 10                             | 4 (40.0)              | 0                        | 1(10.0)                    | 2 (20.0)                      | 3 (30.0)                |
|                                         |                                |                       |                          |                            |                               | 0                       |
|                                         |                                |                       |                          |                            |                               | 0                       |
|                                         |                                |                       |                          |                            |                               | 0                       |
|                                         |                                |                       |                          |                            |                               | 1 (25.0)                |
|                                         |                                |                       |                          |                            |                               | 0                       |
|                                         |                                |                       |                          |                            |                               | 0                       |
|                                         |                                |                       |                          |                            |                               | 1(100)                  |
|                                         |                                |                       |                          |                            |                               | 0                       |

Table 117: Time-to-onset of imTEAEs in tislelizumab arm (Study 303)

|                                                           | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   |
|-----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                           | Patient-based analysis                               | Patient-based analysis                               | Event-based analysis                                 | Event-based analysis                                 | Event-based analysis                                 |
| imAE category                                             | n                                                    | Resolved a                                           | n                                                    | Resolved b (%)                                       | Resolving b (%)                                      |
| Immune-mediated pancreatitis                              | 1                                                    | 1 (100.0) no                                         | 1                                                    | 1 (100.0)                                            | 0                                                    |
| Immune-mediated colitis                                   | 11                                                   | 9 (81.8)                                             | 11                                                   | 9 (81.8)                                             | 1 (9.1)                                              |
| Immune-mediated hyperthyroidism                           | 5                                                    | 4 (80.0)                                             | 5                                                    | 4 (80.0)                                             | 0                                                    |
| Immune-mediated myositis/rhabdomyolysis                   | 14                                                   | 8 (57.1)                                             | 16                                                   | 10 (62.5)                                            | 0                                                    |
| Immune-mediated myocarditis                               | 7                                                    | 4 (57.1)                                             | 7                                                    | 4 (57.1)                                             | 1 (14.3)                                             |
| Immune-mediated skin adverse reaction product             | 27                                                   | 14 (51.9)                                            | 31                                                   | 16 (51.6)                                            | 6 (19.4)                                             |
| Immune-mediated nephritis and renal dysfunction Medicinal | 10                                                   | 5 (50.0)                                             | 10                                                   | 5 (50.0)                                             | 3 (30.0)                                             |
| Immune-mediated hepatitis                                 | 26                                                   | 13 (50.0)                                            | 40                                                   | 25 (62.5)                                            | 5 (12.5)                                             |
| Immune-mediated pneumonitis                               | 66                                                   | 30 (45.5)                                            | 68                                                   | 32 (47.1)                                            | 15 (22.1)                                            |
| Immune-mediated hypothyroidism                            | 116                                                  | 37 (31.9)                                            | 138                                                  | 59 (42.8)                                            | 25 (18.1)                                            |
| Immune-mediated adrenal insufficiency                     | 4                                                    | 1 (25.0)                                             | 4                                                    | 1 (25.0)                                             | 1 (25.0)                                             |
| Immune-mediated thyroiditis                               | 12                                                   | 2 (16.7)                                             | 17                                                   | 6 (35.3)                                             | 3 (17.6)                                             |
| Immune-mediated type 1 diabetes mellitus                  | 6                                                    | 1 (16.7)                                             | 7                                                    | 2 (28.6)                                             | 2 (28.6)                                             |
| Immune-mediated pituitary dysfunction                     | 1                                                    | 0                                                    | 1                                                    | 0                                                    | 0                                                    |
| Other immune-mediated reactions                           | 4                                                    | 2 (50.0)                                             | 4                                                    | 2 (50.0)                                             | 0                                                    |

Table 118: Percentage of imAE events resolved and resolving by imAE category (Tislelizumab 200 mg Q3W, All indications, Safety Analysis Set) Medicinal product no longer authorised

Resolved includes both 'Recovered/resolved' and 'Recovered/resolved with sequelae' in the CRF.

a A patient was considered as resolved in a category if, and only if, all events in the category from this patient were resolved. Percentage was based on the number of patients with at least one immune-mediated adverse event in the category.

b  Percentages were based on the number of immune-mediated adverse events in the category.

<div style=\"page-break-after: always\"></div>

## Potential immune-mediated TEAEs

Step 2 of the imAE adjudication process, the medical review of each imAE candidate, was applied only to the tislelizumab arm due to the open-label of the study design. Thus, a direct comparison of imAEs between the tislelizumab and docetaxel arms is not possible.

However, to allow an indirect comparison between the two treatment arms, data were provided for potential imAEs (selected in Step 1) in both arms of Study 303 following targeted re-adjudication.

Table 119: Overall summary of potential immune-mediated TEAEs (Study 303)

| Category                                                  | Tislelizumab (N = 534) n (%)   | Docetaxel (N = 258) n (%) authorised   |
|-----------------------------------------------------------|--------------------------------|----------------------------------------|
| Patients with at least one Immune-mediated TEAE           | 126 (23.6)                     | 11 (4.3)                               |
| Immune-mediated TEAE with Grade 3 or higher               | 48 (9.0)                       | 9 (3.5)                                |
| Serious Immune-mediated TEAE                              | 55 (10.3)                      | 6 (2.3)                                |
| Immune-mediated TEAE leading to treatment modification    | 33 (6.2)                       | 4 (1.6)                                |
| Immune-mediated TEAE leading to treatment discontinuation | 30 (5.6)                       | 1 (0.4)                                |
| Immune-mediated TEAE leading to death                     | 9 (1.7)                        | 2 (0.8)                                |
| Immune-mediated TEAE treated with systemic steroids       | 77 (14.4)                      | 8 (3.1)                                |
| Immune-mediated TEAE treated with immunosuppressant       | 4 (0.7)                        | 0 (0.0)                                |
| Immune-mediated TEAE treated with hormone therapy         | 55 (10.3)                      | 3 (1.2)                                |

|                                          | Study 303                    | Study 303                 | 2L+NSCLC            | 2L+NSCLC                                    |
|------------------------------------------|------------------------------|---------------------------|---------------------|---------------------------------------------|
| Category                                 | Tislelizumab (N = 534) n (%) | Docetaxel (N = 258) n (%) | All (N = 636) n (%) | 200 mg Q3W All Indications (N = 1534) n (%) |
| Patients with at least one IRR           | 5 (0.9)                      | 9 (3.5)                   | 7 (1.1)             | 54 (3.5)                                    |
| IRR on with Grade ≥3                     | 0 (0.0)                      | 0 (0.0)                   | 0 (0.0)             | 4 (0.3)                                     |
| - Grade 3                                | 0 (0.0)                      | 0 (0.0)                   | 0 (0.0)             | 4 (0.3)                                     |
| Serious IRR                              | 0 (0.0)                      | 0 (0.0)                   | 0 (0.0)             | 3 (0.2)                                     |
| IRR leading to treatment modification    | 4 (0.7)                      | 5 (1.9)                   | 5 (0.8)             | 7 (0.5)                                     |
| IRR leading to treatment discontinuation | 0 (0.0)                      | 1 (0.4)                   | 0 (0.0)             | 2 (0.1)                                     |
| IRR leading to death                     | 0 (0.0)                      | 0 (0.0)                   | 0 (0.0)             | 0 (0.0)                                     |
| Resolved IRR a                           | 5 (0.9)                      | 8 (3.1)                   | 7 (1.1)             | 51 (3.3)                                    |

The most commonly reported potential imAEs by PT in the tislelizumab arm were hypothyroidism (42 patients, 7.9% vs. 1 patient, 0.4% in the docetaxel arm) and pneumonitis (18 patients, 3.4% vs. 0 patients in the docetaxel arm). The most common potential imAE in the docetaxel arm was pneumonia (16 patients, 3% in the tislelizumab arm vs. 9 patients, 3.5% in the docetaxel arm). The only other potential imAEs reported in the docetaxel arm were hyperglycaemia and hypothyroidism in 1 patient each. Infusion-related reactions Table 120: Overall summary of infusion-related reactions (IRR) Medicinal product no longer authorised a A patient was considered as resolved if all the events were resolved.

<div style=\"page-break-after: always\"></div>

## · Combination therapy 1L

SAEs Table 121: SAES by SOC and PT (≥1% patients in NSCLC T+Chemo group therapy group))

## (combination

|                                                                | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                          | NSCLC                         |
|----------------------------------------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|------------------------------------------------|-------------------------------|
| System Organ Class Preferred Term                              | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo (N = 497) n (%) authorised | 307&304 chemo (N = 227) n (%) |
| Patients With at Least One Serious TEAE                        | 52 (43.3)                | 50 (42.4)                 | 29 (24.8)87            | (39.2)                   | 25 (22.7)              | 199 (40.0)                                     | 54 (23.8)                     |
| Respiratory, thoracic and mediastinal disorders                | 14 (11.7)                | 16 (13.6)                 | 4 (3.4)                | 30 (13.5)                | 3 (2.7)                | 64 (12.9)                                      | 7 (3.1)                       |
| Pneumonitis                                                    | 6 (5.0)                  | 5 (4.2)                   | 0 (0.0)                | 15 (6.8)                 | 1 (0.9)                | 28 (5.6)                                       | 1 (0.4)                       |
| Haemoptysis                                                    | 4 (3.3)                  | 4 (3.4)                   | 1 (0.9)                | 4 (1.8)                  | 0 (0.0)                | 12 (2.4)                                       | 1 (0.4)                       |
| Dyspnoea                                                       | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                | 5 (2.3)                  | 0 (0.0)                | 7 (1.4)                                        | 0 (0.0)                       |
| Infections and infestations                                    | 14 (11.7)                | 12 (10.2)                 | 7 (6.0)                | 16 (7.2) longer          | 6 (5.5)                | 42 (8.5)                                       | 13 (5.7)                      |
| Pneumonia                                                      | 12 (10.0)                | 6 (5.1)                   | 5 (4.3)                | 12 (5.4)                 | 6 (5.5)                | 30 (6.0)                                       | 11 (4.8)                      |
| Blood and lymphatic system disorders                           | 8 (6.7)                  | 10 (8.5)                  | 6 (5.1)                | 12 (5.4)                 | 6 (5.5)                | 32 (6.4)                                       | 12 (5.3)                      |
| Thrombocytopenia                                               | 2 (1.7)                  | 1 (0.8)                   | 3 (2.6)                | 7 (3.2)                  | 3 (2.7)                | 10 (2.0)                                       | 6 (2.6)                       |
| Febrile neutropenia                                            | 2 (1.7)                  | 4 (3.4)                   | 1 (0.9) no             | 1 (0.5)                  | 0 (0.0)                | 7 (1.4)                                        | 1 (0.4)                       |
| Anaemia                                                        | 1 (0.8)                  | 1 (0.8)                   | 2 (1.7)                | 3 (1.4)                  | 2 (1.8)                | 5 (1.0)                                        | 4 (1.8)                       |
| Investigations                                                 | 7 (5.8)                  | 8 (6.8)                   | 3 (2.6)                | 11 (5.0)                 | 4 (3.6)                | 28 (5.6)                                       | 7 (3.1)                       |
| Neutrophil count decreased                                     | 4 (3.3)                  | 4 (3.4)                   | 2 (1.7)                | 2 (0.9)                  | 0 (0.0)                | 10 (2.0)                                       | 2 (0.9)                       |
| Platelet count decreased                                       | 1 (0.8)                  | 2 (1.7)                   | 0 (0.0)                | 5 (2.3)                  | 2 (1.8)                | 10 (2.0)                                       | 2 (0.9)                       |
| Aspartate aminotransferase increased                           | 2 (1.7) product          | 0 (0.0)                   | 0 (0.0)                | 3 (1.4)                  | 1 (0.9)                | 5 (1.0)                                        | 1 (0.4)                       |
| Gastrointestinal disorders                                     | 3 (2.5)                  | 4 (3.4)                   | 2 (1.7)                | 12 (5.4)                 | 1 (0.9)                | 20 (4.0)                                       | 3 (1.3)                       |
| General disorders and administration site conditions Medicinal | 7 (5.8)                  | 3 (2.5)                   | 7 (6.0)                | 9 (4.1)                  | 4 (3.6)                | 19 (3.8)                                       | 11 (4.8)                      |
| Pyrexia                                                        | 2 (1.7)                  | 1 (0.8)                   | 2 (1.7)                | 5 (2.3)                  | 3 (2.7)                | 8 (1.6)                                        | 5 (2.2)                       |
| Nervous system disorders                                       | 5 (4.2)                  | 1 (0.8)                   | 0 (0.0)                | 8 (3.6)                  | 2 (1.8)                | 15 (3.0)                                       | 2 (0.9)                       |
| Cerebral infarction                                            | 1 (0.8)                  | 1 (0.8)                   | 0 (0.0)                | 2 (0.9)                  | 0 (0.0)                | 5 (1.0)                                        | 0 (0.0)                       |
| Metabolism and nutrition disorders                             | 1 (0.8)                  | 4 (3.4)                   | 0 (0.0)                | 7 (3.2)                  | 0 (0.0)                | 12 (2.4)                                       | 0 (0.0)                       |
| Cardiac disorders                                              | 1 (0.8)                  | 2 (1.7)                   | 2 (1.7)                | 7 (3.2)                  | 0 (0.0)                | 11 (2.2)                                       | 2 (0.9)                       |
| Hepatobiliary disorders                                        | 1 (0.8)                  | 3 (2.5)                   | 1 (0.9)                | 3 (1.4)                  | 0 (0.0)                | 9 (1.8)                                        | 1 (0.4)                       |
| Injury, poisoning and procedural complications                 | 2 (1.7)                  | 3 (2.5)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 6 (1.2)                                        | 0 (0.0)                       |
| Renal and urinary disorders                                    | 0 (0.0)                  | 2 (1.7)                   | 0 (0.0)                | 4 (1.8)                  | 0 (0.0)                | 6 (1.2)                                        | 0 (0.0)                       |
| Skin and subcutaneous tissue disorders                         | 4 (3.3)                  | 1 (0.8)                   | 1 (0.9)                | 0 (0.0)                  | 0 (0.0)                | 5 (1.0)                                        | 1 (0.4)                       |

<div style=\"page-break-after: always\"></div>

## Treatment-related SAEs

Table 122: SAES related to tislelizumab by SOC and PT

|                                                                 | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|-----------------------------------------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
| System Organ Class Preferred Term                               | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Patients With at Least One Serious TEAE Related to Tislelizumab | 25 (20.8)                | 22 (18.6)                 | 41 (18.5)                | 95 (19.1)                             |
| Respiratory, thoracic and mediastinal disorders                 | 8 (6.7)                  | 8 (6.8)                   | 15 (6.8)                 | 35 (7.0) authorised                   |
| Pneumonitis                                                     | 5 (4.2)                  | 4 (3.4)                   | 15 (6.8)                 | 26 (5.2)                              |
| Immune-mediated pneumonitis                                     | 1 (0.8)                  | 2 (1.7)                   | 0 (0.0)                  | 4 (0.8)                               |
| Interstitial lung disease                                       | 1 (0.8)                  | 2 (1.7)                   | 0 (0.0)                  | 3 (0.6)                               |
| Dyspnoea                                                        | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Pleural effusion                                                | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Pneumothorax                                                    | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Blood and lymphatic system disorders                            | 4 (3.3)                  | 3 (2.5)                   | 6 (2.7)                  | 14 (2.8)                              |
| Thrombocytopenia                                                | 2 (1.7)                  | 1 (0.8)                   | 2 (0.9)                  | 5 (1.0)                               |
| Anaemia                                                         | 1 (0.8)                  | 0 (0.0)                   | 2 (0.9)                  | 3 (0.6)                               |
| Bone marrow failure                                             | 1 (0.8)                  | 1 (0.8)                   | 0 (0.0) longer           | 2 (0.4)                               |
| Febrile neutropenia                                             | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Hypofibrinogenaemia                                             | 0 (0.0)                  | 1 (0.8) no                | 0 (0.0)                  | 1 (0.2)                               |
| Immune-mediated pancytopenia                                    | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Leukopenia                                                      | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Lymphadenitis                                                   | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Pancytopenia                                                    | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Investigations                                                  | 4 (3.3)                  | 3 (2.5)                   | 7 (3.2)                  | 14 (2.8)                              |
| Aspartate aminotransferase increased                            | 2 (1.7)                  | 0 (0.0)                   | 3 (1.4)                  | 5 (1.0)                               |
| Alanine aminotransferase increased                              | 1 (0.8) product          | 0 (0.0)                   | 3 (1.4)                  | 4 (0.8)                               |
| Neutrophil count decreased                                      | 2 (1.7)                  | 1 (0.8)                   | 0 (0.0)                  | 3 (0.6)                               |
| Platelet count decreased                                        | 0 (0.0)                  | 0 (0.0)                   | 3 (1.4)                  | 3 (0.6)                               |
| Blood creatine phosphokinase increased Medicinal                | 0 (0.0)                  | 2 (1.7)                   | 0 (0.0)                  | 2 (0.4)                               |
| Electrocardiogram ST-T segment abnormal                         | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Gamma-glutamyltransferase increased                             | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Infections and infestations                                     | 3 (2.5)                  | 2 (1.7)                   | 5 (2.3)                  | 10 (2.0)                              |
| Pneumonia                                                       | 2 (1.7)                  | 1 (0.8)                   | 3 (1.4)                  | 6 (1.2)                               |
| Infection                                                       | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Lymph gland infection                                           | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Pyelonephritis acute                                            | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2)                               |
| Rash pustular                                                   | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Gastrointestinal disorders                                      | 1 (0.8)                  | 2 (1.7)                   | 5 (2.3)                  | 9 (1.8)                               |
| Immune-mediated enterocolitis                                   | 0 (0.0)                  | 0 (0.0)                   | 3 (1.4)                  | 3 (0.6)                               |
| Ascites                                                         | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2)                               |
| Chronic gastritis                                               | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Colitis                                                         | 0 (0.0) 1 (0.8)          | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2) 1 (0.2)                       |
| Diarrhoea                                                       |                          | 0 (0.0)                   | 0 (0.0)                  |                                       |

<div style=\"page-break-after: always\"></div>

|                                                           | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|-----------------------------------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
| System Organ Class Preferred Term                         | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Stomatitis                                                | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Vomiting                                                  | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Cardiac disorders                                         | 1 (0.8)                  | 1 (0.8)                   | 4 (1.8)                  | 7 (1.4)                               |
| Myocarditis                                               | 0 (0.0)                  | 1 (0.8)                   | 2 (0.9)                  | 4 (0.8)                               |
| Immune-mediated myocarditis                               | 1 (0.8)                  | 0 (0.0)                   | 1 (0.5)                  | 2 (0.4)                               |
| Right ventricular failure                                 | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| General disorders and administration site conditions      | 4 (3.3)                  | 1 (0.8)                   | 2 (0.9)                  | 7 (1.4)                               |
| Pyrexia                                                   | 2 (1.7)                  | 0 (0.0)                   | 1 (0.5)                  | 3 (0.6) authorised                    |
| Chest discomfort                                          | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Death                                                     | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2)                               |
| Malaise                                                   | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Non-cardiac chest pain                                    | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Metabolism and nutrition disorders                        | 1 (0.8)                  | 3 (2.5)                   | 2 (0.9)                  | 6 (1.2)                               |
| Decreased appetite                                        | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2)                               |
| Diabetes mellitus                                         | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Hyperkalaemia                                             | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Hypoalbuminaemia                                          | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Hypoproteinaemia                                          | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                  | 1 (0.2)                               |
| Type 1 diabetes mellitus                                  | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0) longer           | 1 (0.2)                               |
| Hepatobiliary disorders                                   | 0 (0.0)                  | 2 (1.7)                   | 1 (0.5)                  | 5 (1.0)                               |
| Immune-mediated hepatitis                                 | 0 (0.0)                  | 1 (0.8)                   | 1 (0.5)                  | 3 (0.6)                               |
| Hepatic failure                                           | 0 (0.0)                  | 1 (0.8) no                | 0 (0.0)                  | 1 (0.2)                               |
| Hepatic function abnormal                                 | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Nervous system disorders                                  | 2 (1.7)                  | 0 (0.0)                   | 2 (0.9)                  | 4 (0.8)                               |
| Guillain-Barre syndrome                                   | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Hydrocephalus                                             | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Immune-mediated encephalitis                              | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Neuralgia                                                 | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Skin and subcutaneous tissue disorders                    | 4 (3.3) product          | 0 (0.0)                   | 0 (0.0)                  | 4 (0.8)                               |
| Rash                                                      | 2 (1.7)                  | 0 (0.0)                   | 0 (0.0)                  | 2 (0.4)                               |
| Drug eruption                                             | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Rash erythematous                                         | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Renal and urinary disorders                               | 0 (0.0)                  | 1 (0.8)                   | 2 (0.9)                  | 3 (0.6)                               |
| Acute kidney injury                                       | 0 (0.0)                  | 1 (0.8)                   | 1 (0.5)                  | 2 (0.4)                               |
| Tubulointerstitial nephritis                              | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Musculoskeletal and connective tissue disorders Medicinal | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 2 (0.4)                               |
| Myositis                                                  | 0 (0.0)                  | 0 (0.0)                   | 1 (0.5)                  | 1 (0.2)                               |
| Rhabdomyolysis                                            | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                  | 1 (0.2)                               |
| Autoimmune thyroiditis                                    | 1 (0.8)                  | (0.0)                     | 0                        | 1                                     |
|                                                           |                          | 0                         | (0.0)                    | (0.2)                                 |

<div style=\"page-break-after: always\"></div>

Deaths

Table 123: TEAEs leading to death by SOC and PT

|                                                      | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                 | NSCLC                            |
|------------------------------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|---------------------------------------|----------------------------------|
| System Organ Class Preferred Term                    | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&206 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Patients With at Least One TEAE Leading to Death     | 4 (3.3)                  | 7 (5.9)                   | 5 (4.3)                | 9 (4.1)                  | 2 (1.8)                | 21 (4.2)                              | 7 (3.1)                          |
| Respiratory, thoracic and mediastinal disorders      | 2 (1.7)                  | 2 (1.7)                   | 0 (0.0)                | 5 (2.3)                  | 1 (0.9)                | 10 (2.0) authorised                   | 1 (0.4)                          |
| Pneumonitis                                          | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 3 (1.4)                  | 1 (0.9)                | 3 (0.6)                               | 1 (0.4)                          |
| Dyspnoea                                             | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 2 (0.4)                               | 0 (0.0)                          |
| Haemoptysis                                          | 1 (0.8)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 2 (0.4)                               | 0 (0.0)                          |
| Respiratory failure                                  | 1 (0.8)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 2 (0.4)                               | 0 (0.0)                          |
| Asphyxia                                             | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Cardiac disorders                                    | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 2 (0.9)                  | 0 (0.0)                | 3 (0.6)                               | 0 (0.0)                          |
| Myocarditis                                          | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 2 (0.4)                               | 0 (0.0)                          |
| Atrial fibrillation                                  | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| General disorders and administration site conditions | 0 (0.0)                  | 2 (1.7)                   | 3 (2.6)                | 1 (0.5) longer           | 0 (0.0)                | 3 (0.6)                               | 3 (1.3)                          |
| Death                                                | 0 (0.0)                  | 2 (1.7)                   | 2 (1.7)                | 1 (0.5)                  | 0 (0.0)                | 3 (0.6)                               | 2 (0.9)                          |
| Multiple organ dysfunction syndrome                  | 0 (0.0)                  | 0 (0.0)                   | 1 (0.9) no             | 0 (0.0)                  | 0 (0.0)                | 0 (0.0)                               | 1 (0.4)                          |
| Nervous system disorders                             | 2 (1.7)                  | 0 (0.0)                   | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 3 (0.6)                               | 0 (0.0)                          |
| Cerebellar haemorrhage                               | 0 (0.0)                  | 0 (0.0) product           | 0 (0.0)                | 1 (0.5)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Cerebrovascular accident                             | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Hydrocephalus                                        | 1 (0.8)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Hepatobiliary disorders                              | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Hepatic failure                                      | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Infections and infestations                          | 0 (0.0)                  | 1 (0.8)                   | 2 (1.7)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 2 (0.9)                          |
| Pneumonia                                            | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Septic shock                                         | 0 (0.0)                  | 0 (0.0)                   | 2 (1.7)                | 0 (0.0)                  | 0 (0.0)                | 0 (0.0)                               | 2 (0.9)                          |
| Metabolism and nutrition disorders Medicinal         | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Hypokalaemia                                         | 0 (0.0)                  | 1 (0.8)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Musculoskeletal and connective tissue disorders      | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Rhabdomyolysis                                       | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                               | 0 (0.0)                          |
| Vascular disorders                                   | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 1 (0.9)                | 0 (0.0)                               | 1 (0.4)                          |
| Embolism                                             | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 1 (0.9)                | 0 (0.0)                               | 1 (0.4)                          |

## Related AEs leading to death

TEAEs leading to death that were considered to be related to tislelizumab were reported for a total of 8 patients (1.6%), including 4 patients in the Study 304 T+PP group (3 with pneumonitis and 1 patient with myocarditis), 2 patients in the Study 307 T+nPC group (1 each with death with no cause given and hepatic failure), 1 patient in the Study 307 T+PC group (hydrocephalus) and 1 patient in the Study 206 T+chemo group (dyspnoea and myocarditis).

<div style=\"page-break-after: always\"></div>

TEAEs leading to death that were considered to be related to chemotherapy were reported for a total of 4 patients (0.8%) in the NSCLC T+chemo group (1 patient each with death with no cause given, hepatic failure, hydrocephalus and pneumonitis) and 4 patients (1.8%) in the NSCLC chemo group (2 patients with septic shock and 1 patient each with death with no cause given and pneumonitis).

## Immune-related AEs

## Frequency of immune-mediated TEAEs

Note : In the following confirmed immune-mediated events (imAEs) for the 1L combination treatment are presented. The methodology of identifying imAEs is presented and discussed subsequently.

|                                                     | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC NSCLC          | NSQ-NSCLC NSCLC                       |
|-----------------------------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
|                                                     | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Patients With at Least One imAE                     | 36 (30.0)                | 30 (25.4)                 | 55 (24.8)                | 127 (25.6)                            |
| imAE with Grade ≥ 3 Discontinuation of tislelizumab | 13 (10.8)                | 12 (10.2) longer          | 24 (10.8)                | 52 (10.5)                             |
| Serious imAE                                        | 13 (10.8)                | 14 (11.9)                 | 23 (10.4)                | 54 (10.9)                             |
| imAE Leading to Permanent                           | 8 (6.7)                  | 8 (6.8)                   | 18 (8.1)                 | 38 (7.6)                              |
| imAE Leading to tislelizumab Modification           | 14 (11.7)                | 18 (15.3)                 | 27 (12.2)                | 62 (12.5)                             |
| imAE Leading to Death                               | 0 (0.0) no               | 1 (0.8)                   | 4 (1.8)                  | 6 (1.2)                               |
| imAE Treated with Systemic Steroids                 | 22 (18.3)                | 22 (18.6)                 | 38 (17.1)                | 87 (17.5)                             |
| imAE Treated with Immunosuppressants                | 1 (0.8)                  | 1 (0.8)                   | 4 (1.8)                  | 6 (1.2)                               |
| imAE Treated with Hormone Therapy                   | 18 (15.0)                | 11 (9.3)                  | 22 (9.9)                 | 53 (10.7)                             |

|                                                 | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|-------------------------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
| imAE Category Preferred Term Medicinal          | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Patients With at Least One imAE                 | 36 (30.0)                | 30 (25.4)                 | 55 (24.8)                | 127 (25.6)                            |
| Immune-Mediated Hypothyroidism                  | 15 (12.5)                | 9 (7.6)                   | 19 (8.6)                 | 45 (9.1)                              |
| Immune-Mediated Pneumonitis                     | 9 (7.5)                  | 12 (10.2)                 | 21 (9.5)                 | 45 (9.1)                              |
| Immune-Mediated Skin Adverse Reaction           | 7 (5.8)                  | 5 (4.2)                   | 7 (3.2)                  | 19 (3.8)                              |
| Immune-Mediated Hepatitis                       | 1 (0.8)                  | 3 (2.5)                   | 3 (1.4)                  | 8 (1.6)                               |
| Immune-Mediated Colitis                         | 2 (1.7)                  | 1 (0.8)                   | 4 (1.8)                  | 7 (1.4)                               |
| Immune-Mediated Myocarditis                     | 1 (0.8)                  | 2 (1.7)                   | 3 (1.4)                  | 7 (1.4)                               |
| Immune-Mediated Myositis/Rhabdomyolysis         | 1 (0.8)                  | 3 (2.5)                   | 1 (0.5)                  | 6 (1.2)                               |
| Immune-Mediated Nephritis And Renal Dysfunction | 0 (0.0)                  | 3 (2.5)                   | 2 (0.9)                  | 5 (1.0)                               |
| Immune-Mediated Type 1 Diabetes Mellitus        | 0 (0.0)                  | 1 (0.8)                   | 4 (1.8)                  | 5 (1.0)                               |
| Immune-Mediated Hyperthyroidism                 | 0 (0.0)                  | 1 (0.8)                   | 2 (0.9)                  | 3 (0.6)                               |
| Immune-Mediated Nervous System Disorder         | 1 (0.8)                  | 0 (0.0)                   | 1 (0.5)                  | 2 (0.4)                               |

Table 124: Overall summary of immune-mediated TEAEs Table 125: ImAEs by category Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                              | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                 |
|------------------------------|--------------------------|---------------------------|--------------------------|---------------------------------------|
| imAE Category Preferred Term | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo * (N = 497) n (%) |
| Immune-Mediated Thyroiditis  | 2 (1.7)                  | 0 (0.0)                   | 0 (0.0)                  | 2 (0.4)                               |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 126: Grade ≥ 3 imAEs by category and maximum grade

|                                                            | SQ-NSCLC               | SQ-NSCLC                | NSQ-NSCLC              | NSCLC                               |
|------------------------------------------------------------|------------------------|-------------------------|------------------------|-------------------------------------|
| imAE Category Maximum Grade                                | 307 T+PC (N=120) n (%) | 307 T+nPC (N=118) n (%) | 304 T+PP (N=222) n (%) | 307&304&20 6 T+chemo* (N=497) n (%) |
| Patients With at Least One imAE                            | 36 (30.0)              | 30 (25.4)               | 55 (24.8)              | 127 (25.6)                          |
| Immune-Mediated Pneumonitis                                | 9 (7.5)                | 12 (10.2)               | 21 (9.5)               | 45 (9.1)                            |
| Grade 3                                                    | 4 (3.3)                | 5 (4.2)                 | 5 (2.3)                | 15 (3.0)                            |
| Grade 4                                                    | 0 (0.0)                | 1 (0.8)                 | 1 (0.5)                | 2 (0.4)                             |
| Grade 5                                                    | 0 (0.0)                | 0 (0.0)                 | 3 (1.4)                | 3 (0.6)                             |
| Immune-Mediated Skin Adverse Reaction                      | 7 (5.8)                | 5 (4.2)                 | 7 (3.2)                | 19 (3.8) authorised                 |
| Grade 3                                                    | 5 (4.2)                | 2 (1.7)                 | 4 (1.8)                | 11 (2.2)                            |
| Immune-Mediated Hepatitis                                  | 1 (0.8)                | 3 (2.5)                 | 3 (1.4)                | 8 (1.6)                             |
| Grade 3                                                    | 1 (0.8)                | 1 (0.8)                 | 3 (1.4)                | 6 (1.2)                             |
| Grade 5                                                    | 0 (0.0)                | 1 (0.8)                 | 0 (0.0)                | 1 (0.2)                             |
| Immune-Mediated Colitis                                    | 2 (1.7)                | 1 (0.8)                 | 4 (1.8)                | 7 (1.4)                             |
| Grade 3                                                    | 0 (0.0)                | 1 (0.8) longer          | 2 (0.9)                | 3 (0.6)                             |
| Grade 4                                                    | 0 (0.0)                | 0 (0.0)                 | 0 (0.0)                | 0 (0.0)                             |
| Immune-Mediated Myocarditis                                | 1 (0.8)                | 2 (1.7)                 | 3 (1.4)                | 7 (1.4)                             |
| Grade 3                                                    | 0 (0.0)                | 0 (0.0)                 | 1 (0.5)                | 1 (0.2)                             |
| Grade 4                                                    | 0 (0.0)                | 0 (0.0)                 | 1 (0.5)                | 1 (0.2)                             |
| Grade 5                                                    | 0 (0.0)                | 0 (0.0)                 | 1 (0.5)                | 2 (0.4)                             |
| Immune-Mediated                                            | 1 (0.8) no             | 3 (2.5)                 | 1 (0.5)                | 6 (1.2)                             |
| Myositis/Rhabdomyolysis Grade 3                            | 1 (0.8)                | 1 (0.8)                 | 1 (0.5)                | 3 (0.6)                             |
| Grade 4                                                    | 0 (0.0)                | 1 (0.8)                 | 0 (0.0)                | 1 (0.2)                             |
| Grade 5                                                    | 0 (0.0)                | 0 (0.0)                 | 0 (0.0)                | 1 (0.2)                             |
| Immune-Mediated Nephritis And Renal                        | 0 (0.0)                | 3 (2.5)                 | 2 (0.9)                | 5 (1.0)                             |
| Dysfunction Grade 3                                        | 0 (0.0)                | 1 (0.8)                 | 1 (0.5)                | 2 (0.4)                             |
| Immune-Mediated Type 1 Diabetes Mellitus Medicinal product | 0 (0.0)                | 1 (0.8)                 | 4 (1.8)                | 5 (1.0)                             |
| Grade 3                                                    | 0 (0.0)                | 0 (0.0)                 | 3 (1.4)                | 3 (0.6)                             |
| Grade 4                                                    | 0 (0.0)                | 1 (0.8)                 | 1 (0.5)                | 2 (0.4)                             |
| Immune-Mediated Nervous System                             | 1 (0.8)                | 0 (0.0)                 | 1 (0.5)                | 2 (0.4)                             |
| Disorder Grade 3                                           | 1 (0.8)                | 0 (0.0)                 | 1 (0.5)                | 2 (0.4)                             |
| Immune-Mediated Thyroiditis                                | 2 (1.7)                | 0 (0.0)                 | 0 (0.0)                | 2 (0.4)                             |
| Grade 3                                                    | 1 (0.8)                | 0 (0.0)                 | 0 (0.0)                | 1 (0.2)                             |

<div style=\"page-break-after: always\"></div>

Table 127: ImAEs leading to permanent discontinuation of tislelizumab

|                                                                                             | SQ-NSCLC                 | SQ-NSCLC                  | NSQ-NSCLC                | NSCLC                                |
|---------------------------------------------------------------------------------------------|--------------------------|---------------------------|--------------------------|--------------------------------------|
| imAECategory PreferredTerm                                                                  | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 304 T+PP (N = 222) n (%) | 307&304&206 T+chemo* (N = 497) n (%) |
| PatientswithatleastoneImmune-mediated TEAELeadingtoPermanent Discontinuation ofTislelizumab | 8 (6.7)                  | 8 (6.8)                   | 18 (8.1)                 | 38 (7.6)                             |
| Immune-MediatedPneumonitis                                                                  | 5 (4.2)                  | 4 (3.4)                   | 9 (4.1)                  | 20 (4.0)                             |
|                                                                                             |                          |                           |                          | 6 (1.2)                              |
|                                                                                             |                          |                           |                          | 5 (1.0)                              |
|                                                                                             |                          |                           |                          | 4 (0.8)                              |
|                                                                                             |                          |                           |                          | 3 (0.6)                              |
|                                                                                             |                          |                           |                          | 3 (0.6)                              |
|                                                                                             |                          |                           |                          | 2 (0.4)                              |
|                                                                                             |                          |                           |                          | 1 (0.2)                              |

|           |    | longer   |
|-----------|----|----------|
|           | no |          |
| product   |    |          |
| Medicinal |    |          |

Table 128: ImAEs by outcome and category in combined T+chemo group and monotherapy Medicinal product no longer authorised

## Potential immune-mediated TEAEs

Please refer to the 'Process for the identification of immune -mediated TEAEs' above.

<div style=\"page-break-after: always\"></div>

Table 129: Potential immune-mediated TEAEs in combination therapy studies

| Category                               | 307 T+PC N=120 n (%)   | 307 T+nPC N=118 n (%)   | 307 PC N=117 n (%)   | 304 T+PP N=222 n (%)   | 304 PP N=11 0 n (%)   | 307,304 & 206 T+chemo *N=497 n (%)   | 307&304 T+chemo* * N=460 n (%)   |
|----------------------------------------|------------------------|-------------------------|----------------------|------------------------|-----------------------|--------------------------------------|----------------------------------|
| Patients with at least one im TEAE     | 43 (35.8)              | 37 (31.4)               | 3 (2.6)              | 62 (27.9)              | 3 (2.7)               | 148 (29.8)                           | 142 (30.9)                       |
| Im TEAE ≥ Grade 3                      | 14 (11.7)              | 13 (11.0)               | 1 (0.9)              | 29 (13.1)              | 3 (2.7)               | 59 (11.9)                            | 56 (12.2)                        |
| Serious im TEAE                        | 16 (13.3)              | 14 (11.9)               | 3 (2.6)              | 28 (12.6)              | 2 (1.8)               | 62 (12.5)                            | 58 (12.6)                        |
| Im TEAE leading to modification        | 14 (11.7)              | 19 (16.1)               | 0 (0.0)              | 30 (13.3)              | 0 (0.0)               | 66 (13.3) authorised                 | 63 (13.7)                        |
| Im TEAE leading to discontinuation     | 9 (7.5)                | 9 (7.6)                 | 0 (0.0)              | 19 (8.6)               | 0 (0.0)               | 41 (8.2)                             | 37 (8.0)                         |
| Im TEAE leading to death               | 0 (0.0)                | 2 (1.7)                 | 0 (0.0)              | 4 (1.8)                | 1 (0.9)               | 7 (1.4)                              | 6 (1.3)                          |
| Im TEAE treated with systemic steroids | 26 (21.7)              | 27 (22.9)               | 3 (2.6)              | 44 (19.8)              | 2 (1.8)               | 102 (20.5)                           | 97 (21.1)                        |
| Im TEAE treated with immunosuppressant | 1 (0.8)                | 1 (0.8)                 | 0 (0.0)              | 4 (1.8)                | 1 (0.9)               | 6 (1.2)                              | 6 (1.3)                          |
| s ImTEAE treated with hormone therapy  | 21 (17.5)              | 14 (11.9)               | 0 (0.0)              | 24 (10.8) longer       | 1 (0.9)               | 61 (12.3)                            | 59 (12.8)                        |

|                                  | SQ-NSCLC                 | SQ-NSCLC                  | SQ-NSCLC               | NSQ-NSCLC                | NSQ-NSCLC              | NSCLC                                  | NSCLC                            |
|----------------------------------|--------------------------|---------------------------|------------------------|--------------------------|------------------------|----------------------------------------|----------------------------------|
|                                  | 307 T+PC (N = 120) n (%) | 307 T+nPC (N = 118) n (%) | 307 PC (N = 117) n (%) | 304 T+PP (N = 222) n (%) | 304 PP (N = 110) n (%) | 307&304&2 06 T+chemo * (N = 497) n (%) | 307&304 chemo ** (N = 227) n (%) |
| Patient with at least one IRR    | 5 (4.2)                  | 5 (4.2)                   | 4 (3.4)                | 2 (0.9)                  | 1 (0.9)                | 14 (2.8)                               | 5 (2.2)                          |
| IRR with Grade ≥ 3               | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)                | 0 (0.0)                                | 0 (0.0)                          |
| IRR leading to discontinuation   | 0 (0.0)                  | 0 (0.0)                   | 1 (0.9)                | 0 (0.0)                  | 0 (0.0)                | 1 (0.2)                                | 1 (0.4)                          |
| IRR leading to dose modification | 3 (2.5)                  | 0 (0.0)                   | 3 (2.6)                | 2 (0.9)                  | 1 (0.9)                | 6 (1.2)                                | 4 (1.8)                          |

The most commonly reported PTs in the chemotherapy control arm for Studies 304 and 307 were immune-mediated pneumonitis (1.8% and 1.7%, respectively). Other potential imAE reported in the chemotherapy control arms of Study 304 were Type 1 diabetes Mellitus (0.9%), and rash maculopapular (0.9%) in the chemotherapy control arm of Study 307. Infusion-related reactions Table 130: Overall summary of infusion-related reactions Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Adverse drugs reactions

## Selection of ADRs

The clinical database of the studies where tislelizumab was administered either as monotherapy or combination therapy were screened for ADR candidates using an ADR screening tool. ADR candidates included two types of events namely pre-qualified ADR candidates and ADR candidates identified through numerical screening rules.

## Pre-qualified ADR candidates

Pre-qualified ADR candidates were events that are associated with the drug based on current knowledge. Pre-qualified ADR candidates were identified using the eCRS and Excel files produced by the Statistical programming and quantitative Safety groups. Numerical screening rule to identify other non-pre-qualified ADR candidates Other ADR candidates were events for which an excess (based on medical review) versus comparator is observed or for which reasonable frequency is observed under tislelizumab. These were identified using a numerical screening rule (i.e. algorithmically), based on all TEAEs. Within the randomised period subset of each pivotal study at MedDRA HLT and PT level the following selection criteria were applied: · AEs with &gt;2% higher incidence for tislelizumab vs. respective comparator arm · AEs with lower bound of relative risk (between tislelizumab arm and comparator arm) 95% confidence interval &gt;1.0. · SAEs with &gt;0.5% difference in incidence for tislelizumab vs. respective comparator arm. · Drug-related AEs (any drug component) with &gt;0.5% difference in incidence for tislelizumab vs. respective comparator arm. In addition, based on the respective monotherapy and the combination therapy safety pools, the following rules were applied to flag potential ADR candidates: · AEs with &gt;2% incidence · AEs leading to tislelizumab discontinuation with &gt;0.5% incidence. A medical assessment was also made on the laboratory toxicities from the laboratory data. All identified ADR candidates underwent medical review using the Bradford Hill criteria to assess the plausibility of a causal association between tislelizumab and these candidate ADRs. Event severity, relationship, pharmacological action, and the safety profile of other drugs with similar mechanism of action where all considered in relation to the Bradford Hill Criteria. Once a causal association has been medically established, the eCRS (case retrieval strategy) was updated with the proposed ADRs and an ADR table generated. Medicinal product no longer authorised

ADRs identified with tislelizumab in the monotherapy and combination therapy pools are shown in the following table.

<div style=\"page-break-after: always\"></div>

Table 131: Frequency and frequency category of ADRs with tislelizumab by SOC and ADR

|                                                  | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab combination N = 497   | Tislelizumab combination N = 497   | Tislelizumab combination N = 497   |
|--------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Adverse drug reactions                           | All grades n (%)                               | Grades 3-4 n (%)                               | Frequency category (All Grades)                | All grades n (%)                   | Grades 3-4 n (%)                   | Frequency category (All Grades)    |
| Infections and infestations Pneumonia            | 148 (9.6)                                      | 64 (4.2)                                       | Common                                         | 77 (15.5)                          | 25 (5.0)                           | Very common                        |
| Blood and lymphatic system disorders             |                                                |                                                |                                                |                                    |                                    |                                    |
| Anaemia                                          | 448 (29.2)                                     | 77 (5.0)                                       | Very common                                    | 439 (88.3)                         | 78 (15.7)                          | Very common authorised             |
| Thrombocytopenia                                 | 136 (8.9)                                      | 16 (1.0)                                       | Common                                         | 333 (67.0)                         | 91 (18.3)                          | Very common                        |
| Neutropenia                                      | 85 (5.5)                                       | 19 (1.2)                                       | Common                                         | 430 (86.5)                         | 291 (58.6)                         | Very common                        |
| Lymphopenia                                      | 69 (4.5)                                       | 17 (1.1)                                       | Common                                         | 68 (13.7)                          | 14 (2.8)                           | Very common                        |
| Endocrine disorders                              |                                                |                                                |                                                |                                    |                                    |                                    |
| Hypothyroidism                                   | 204 (13.3)                                     | 1 (0.07)                                       | Very common                                    | 77 (15.5)                          | 0                                  | Very common                        |
| Hyperthyroidism                                  | 85 (5.5)                                       | 0                                              | Common                                         | 54 (10.9)                          | 0                                  | Very common                        |
| Thyroiditis                                      | 17 (1.1)                                       | 0                                              | Common                                         | 3 (0.6)                            | 1 (0.2)                            | Uncommon                           |
| Adrenal insufficiency                            | 7 (0.5)                                        | 3 (0.2)                                        | Uncommon                                       | 0                                  | 0                                  | -                                  |
| Hypophysitis                                     | 1 (0.07)                                       | 0                                              | Rare                                           | 0                                  | 0                                  | -                                  |
| Metabolism and nutrition disorders               |                                                | no                                             | longer                                         |                                    |                                    |                                    |
| Hyperglycaemia                                   | 143 (9.3)                                      | 23 (1.5)                                       | Common                                         | 81 (16.3)                          | 7 (1.4)                            | Very common                        |
| Hyponatraemia                                    | 140 (9.1)                                      | 42 (2.7)                                       | Common                                         | 94 (18.9)                          | 8 (1.6)                            | Very common                        |
| Hypokalaemia                                     | 113 (7.4)                                      | 23 (1.5)                                       | Common                                         | 79 (15.9)                          | 8 (1.6)                            | Very common                        |
| Diabetes mellitus                                | 11 (0.7)                                       | 5 (0.3)                                        | Uncommon                                       | 6 (1.2)                            | 4 (0.8)                            | Common                             |
| Nervous system disorders Guillain-Barre syndrome | 0 product                                      | 0                                              | -                                              | 1 (0.2)                            | 1 (0.2)                            | Uncommon                           |
| Eye disorders Uveitis                            | 4 (0.3)                                        | 0                                              | Uncommon                                       | 0                                  | 0                                  | -                                  |
| Cardiac disorders                                |                                                |                                                |                                                |                                    |                                    |                                    |
| Myocarditis                                      | 12 (0.8)                                       | 4 (0.3)                                        | Uncommon                                       | 9 (1.8)                            | 2 (0.4)                            | Common                             |
| Pericarditis                                     | 1 (0.07)                                       | 0                                              | Rare                                           | 0                                  | 0                                  | -                                  |
| Vascular disorders Medicinal                     |                                                |                                                |                                                |                                    |                                    |                                    |
| Hypertension                                     | 73 (4.8)                                       | 29 (1.9)                                       | Common                                         | 25 (5.0)                           | 4 (0.8)                            | Common                             |
| Respiratory, thoracic and mediastinal disorders  |                                                |                                                |                                                |                                    |                                    |                                    |
| Cough                                            | 237 (15.4)                                     | 5 (0.3)                                        | Very common                                    | 76 (15.3)                          | 2 (0.4)                            | Very common                        |
| Dyspnoea                                         | 113 (7.4)                                      | 18 (1.2)                                       | Common                                         | 60 (12.1)                          | 5 (1.0)                            | Very common                        |
| Pneumonitis                                      | 80 (5.2)                                       | 31 (2.0)                                       | Common                                         | 60 (12.1)                          | 17 (3.4)                           | Very common                        |
| Gastrointestinal disorders                       |                                                |                                                |                                                |                                    |                                    |                                    |
| Nausea                                           | 151 (9.8)                                      | 3 (0.2)                                        | Common                                         | 206 (41.4)                         | 2 (0.4)                            | Very common                        |
| Diarrhoea                                        | 137 (8.9)                                      | 12 (0.8)                                       | Common                                         | 73 (14.7)                          | 3 (0.6)                            | Very common                        |
| Stomatitis Pancreatitis                          | 46 (3.0) 15 (1.0)                              | 5 (0.3) 8 (0.5)                                | Common Uncommon                                | 29 (5.8) 1 (0.2)                   | 2 (0.4) 0                          | Common Uncommon                    |
| Colitis                                          | 5 (0.3)                                        | 0                                              | Uncommon                                       | 6 (1.2)                            | 3 (0.6)                            | Common                             |
| Hepatobiliary disorders                          |                                                |                                                |                                                |                                    |                                    |                                    |
| Hepatitis                                        | 40 (2.6)                                       | 18 (1.2)                                       | Common                                         | 21 (4.2)                           | 7 (1.4)                            | Common                             |

<div style=\"page-break-after: always\"></div>

|                                                      | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab monotherapy 200 mg Q3W N = 1534   | Tislelizumab combination therapy N = 497   | Tislelizumab combination therapy N = 497   | Tislelizumab combination therapy N = 497   |
|------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Adverse drug reactions                               | All grades n (%)                               | Grades 3-4 n (%)                               | Frequency category (All Grades)                | All grades n (%)                           | Grades 3-4 n (%)                           | Frequency category (All Grades)            |
| Skin and subcutaneous tissue disorders               |                                                |                                                |                                                |                                            |                                            |                                            |
| Rash                                                 | 221 (14.4)                                     | 15 (1.0)                                       | Very common                                    | 131 (26.4)                                 | 13 (2.6)                                   | Very common                                |
| Pruritus                                             | 154 (10.0)                                     | 0                                              | Very common                                    | 34 (6.8)                                   | 1 (0.2)                                    | Common                                     |
| Severe skin reaction                                 | 1 (0.07)                                       | 0                                              | Rare                                           | 0                                          | 0                                          | -                                          |
| Musculoskeletal and connective tissue disorders      |                                                |                                                |                                                |                                            |                                            | authorised                                 |
| Arthralgia                                           | 132 (8.6)                                      | 4 (0.3)                                        | Common                                         | 78 (15.7)                                  | 0                                          | Very common                                |
| Myalgia                                              | 24 (1.6)                                       | 0                                              | Common                                         | 19 (3.8)                                   | 0                                          | Common                                     |
| Myositis                                             | 14 (0.9)                                       | 4 (0.3)                                        | Uncommon                                       | 1 (0.2)                                    | 1 (0.2)                                    | Uncommon                                   |
| Arthritis                                            | 6 (0.4)                                        | 0                                              | Uncommon                                       | 5 (1.0)                                    | 0                                          | Common                                     |
| Renal and urinary disorders                          |                                                |                                                |                                                |                                            |                                            |                                            |
| Nephritis                                            | 3 (0.2)                                        | 1 (0.07)                                       | Uncommon                                       | 2 (0.4)                                    | 0                                          | Uncommon                                   |
| General disorders and administration site conditions |                                                |                                                | longer                                         |                                            |                                            |                                            |
| Fatigue                                              | 352 (22.9)                                     | 30 (2.0)                                       | Very common                                    | 214 (43.1)                                 | 11 (2.2)                                   | Very common                                |
| Decreased appetite                                   | 221 (14.4)                                     | 14 (0.9)                                       | Very common                                    | 202 (40.6)                                 | 7 (1.4)                                    | Very common                                |
| Investigations                                       |                                                | no                                             |                                                |                                            |                                            |                                            |
| Aspartate aminotransferase increased                 | 320 (20.9)                                     | 40 (2.6)                                       | Very common                                    | 210 (42.3)                                 | 8 (1.6)                                    | Very common                                |
| Alanine aminotransferase increased                   | 295 (19.2)                                     | 22 (1.4)                                       | Very common                                    | 229 (46.1)                                 | 16 (3.2)                                   | Very common                                |
| Blood bilirubin increased                            | 183 (11.9) product                             | 30 (2.0)                                       | Very common                                    | 90 (18.1)                                  | 2 (0.4)                                    | Very common                                |
| Blood alkaline phosphatase increased                 | 111 (7.2)                                      | 17 (1.1)                                       | Common                                         | 55 (11.1)                                  | 2 (0.4)                                    | Very common                                |
| Blood creatinine increased                           | 79 (5.1)                                       | 2 (0.1)                                        | Common                                         | 61 (12.3)                                  | 0                                          | Very common                                |
| Injury, poisoning and procedural complications       |                                                |                                                |                                                |                                            |                                            |                                            |
| Infusion related reaction                            | 3 (0.2)                                        | 1 (0.07)                                       | Uncommon                                       | 12 (2.4)                                   | 0                                          | Common                                     |

## Laboratory findings

Laboratory abnormalities worsening from baseline with tislelizumab as monotherapy (N=1534) and in combination with chemotherapy (N=497) are summarised in the following table. This table also serves as the basis to support the presentation of 'laboratory abnormalities' in section 4.8. of the SmPC, where the proportions of patients who experienced a shift from baseline to a grade 3 or 4 laboratory abnormality are reported.

<div style=\"page-break-after: always\"></div>

Table 132:  Laboratory abnormalities worsening from baseline with tislelizumab as monotherapy and in combination with chemotherapy

|                                  | Tislelizumab monotherapy N =1534   | Tislelizumab monotherapy N =1534   | Tislelizumab monotherapy N =1534   | Tislelizumab combination therapy N = 497 ‡   | Tislelizumab combination therapy N = 497 ‡   | Tislelizumab combination therapy N = 497 ‡   |
|----------------------------------|------------------------------------|------------------------------------|------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
| Laboratory abnormality parameter | All grades n/m (%)                 | Grades 3- 4 n/m (%)                | Frequency category (All Grades)    | All grades n/m (%)                           | Grades 3- 4 n/m (%)                          | Frequency category (All Grades)              |
| Haematology                      |                                    |                                    |                                    |                                              |                                              |                                              |
| Haemoglobin increased            | 56/14941911 (3.7)                  | 2/1494 (0.1)                       | Common                             | 8/495 (1.6)                                  | 0/495 (0.0)                                  | Common                                       |
| Haemoglobin decreased            | 563/1494 (37.7)                    | 66/1494 (4.4)                      | Very common                        | 460/495 (92.9)                               | 80/495 (16.2)                                | Very common authorised                       |
| Leukocytes decreased             | 216/494 (14.3)                     | 14/1494 (0.9)                      | Very common                        | 439/495 (88.7)                               | 163/495 (32.9)                               | Very common                                  |
| Lymphocytes increased            | 23/1475(1.6)                       | -                                  | Common                             | -                                            | -                                            | -                                            |
| Lymphocytes decreased            | 577/1475(39.1)                     | 126/1475 (8.5)                     | Very common                        | -                                            | -                                            | -                                            |
| Neutrophils decreased            | 163/1476 (11.0)                    | 25/1476 (1.7)                      | Very common                        | 445/494 (90.1)                               | 302/494 (61.1)                               | Very common                                  |
| Platelets decreased              | 248/1910 (13.0)                    | 17/1495 (1.1)                      | Very common                        | 365/495 (73.7)                               | 94/495 (19.0)                                | Very common                                  |
| Biochemistry                     |                                    |                                    |                                    |                                              |                                              |                                              |
| ALT increased                    | 434/1491 (29.1)                    | 30/1491 (2.0)                      | Very common longer                 | 278/495 (56.2.4)                             | 23/495 (4.6)                                 | Very common                                  |
| Albumin decreased                | 625/1908 (32.8)                    | 6/1491 (0.4)                       | Very common                        | -                                            | -                                            | -                                            |
| Alkaline phosphatase increased   | 465/1491 (31.2)                    | 56/1907 (2.9) no                   | Very common                        | 164/494 (33.2)                               | 4/494 (0.8)                                  | Very common                                  |
| AST increased                    | 471/1491 (31.6)                    | 48/1491 (3.2)                      | Very common                        | 265/495 (53.5)                               | 13/495 (2.6)                                 | Very common                                  |
| Bilirubin increased              | 280/1486 (18.8)                    | 32/1486 (2.2)                      | Very common                        | 141/495 (28.5)                               | 8/495 (1.6)                                  | Very common                                  |
| Creatine kinase increased        | 165/894 (18.5) product             | 18/894 (2.0)                       | Very common                        | 102/457 (22.3)                               | 7/457 (1.5)                                  | Very common                                  |
| Creatinine increased             | 180/1491 (12.1)                    | 13/1491 (0.9)                      | Very common                        | 94/495 (19.0)                                | 12/495 (2.4)                                 | Very common                                  |
| Potassium increased              | 143/1486 (9.6)                     | 13/1486 (0.9)                      | Common                             | 55/495 (11.1)                                | 10/495 (2.0)                                 | Very common                                  |
| Potassium decreased              | 210/1486 (14.1)                    | 33/1486 (2.2)                      | Very common                        | 146/495 (29.5)                               | 31/495 (6.3)                                 | Very common                                  |
| Sodium increased                 | 99/1486 (6.7)                      | 1/1486 (0.1)                       | Common                             | 39/495 (7.9)                                 | 1/495 (0.2)                                  | Common                                       |
| Sodium decreased                 | 494/1486 (33.2)                    | 84/486 (5.7)                       | Very common                        | 289/495 (58.4)                               | 55/495 (11.1)                                | Very common                                  |

Patients who crossed over from the chemotherapy control arms in studies 304 and 307 to Tislelizumab monotherapy were not included. SCLC patients from Study 206 are not included.

n is the number of patient with worsen toxicity grade compared with baseline. m is the number of patients with both baseline and post-baseline laboratory test assessments.

## In vitro biomarker test for patient selection for safety

Not applicable.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Safety by age

Table 133: Overview of controlled and non-controlled studies by age group in tislelizumab treated patients (200 mg Q3W)

|                        | Age 65 - 74 years n (%)   | Age 75 - 84 years n (%)   | Age ≥ 85 years n (%)   |
|------------------------|---------------------------|---------------------------|------------------------|
| Controlled studies     |                           |                           |                        |
| Study 302 (N= 255)     | 85 (33.3)                 | 13 (5.1)                  | 0 (0.0)                |
| Study 303 (N= 534)     | 155 (29.0)                | 14 (2.6)                  | 1 (0.1)                |
| Study 304 (N=222)      | 56 (25.2)                 | 3 (1.4)                   | 0 (0.0)                |
| Study 307 (N= 238)     | 91 (38.2)                 | 0 (0.0)                   | 0 (0.0)                |
| Non-controlled studies |                           |                           | authorised             |
| Study 102 (N=300)      | 72 (24.0)                 | 5 (1.7)                   | 0 (0.0)                |
| Study 001 (N=13)       | 6 (46.2)                  | 1 (7.7)                   | 0 (0.0)                |
| Study 208 (N=249)      | 75 (30.1)                 | 24 (9.6)                  | 1 (0.4)                |
| Study 204 (N=113)      | 38 (33.6)                 | 6 (5.3)                   | 0 (0.0)                |
| Study 203 (N=70)       | 4 (5.7)                   | 0 (0.0)                   | 0 (0.0)                |
| Study 206 (N=37)       | 11 (29.7)                 | 1 (2.7)                   | 0 (0.0)                |

<!-- image -->

|           | product   |
|-----------|-----------|
| Medicinal |           |

N= number of patients in tislelizumab-containing arms · Monotherapy Table 134: Summary of TEAEs by age group (&lt; 65, ≥65 -&lt;75, ≥75 years) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 135: Safety by age in Study 303 and 200 mg Q3W;  all indications

|                                                                     | 303 Tislelizumab N=534     | 303 Tislelizumab N=534        | 303 Tislelizumab N=534   | 200 mg Q3W all indications   | 200 mg Q3W all indications    | 200 mg Q3W all indications   |
|---------------------------------------------------------------------|----------------------------|-------------------------------|--------------------------|------------------------------|-------------------------------|------------------------------|
| MedDRA terms                                                        | Age < 65 years N=364 n (%) | Age 65- <75 years N=155 n (%) | Age ≥75 years N=15 n (%) | Age < 65 years N=1034 n (%)  | Age 65- <75 years N=435 n (%) | Age ≥75 years N=65 n (%)     |
| Total AEs                                                           | 348 (95.6)                 | 146 (94.2)                    | 15 (100.0)               | 991 (95.8)                   | 413 (94.9)                    | 64                           |
| Grade >= 3 AEs                                                      | 136 (37.4)                 | 63 (40.6)                     | 7 (46.7)                 | 428 (41.4)                   | 211 (48.5) authorised         | (98.5) 30 (46.2)             |
| Serious AEs - total                                                 | 113 (31.0)                 | 55 (35.5)                     | 6 (40.0)                 | 331 (32.0)                   | 160 (36.8)                    | 25 (38.5)                    |
| Fatal                                                               | 19 (5.2)                   | 12 (7.7)                      | 1 (6.7)                  | 80 (7.7)                     | 42 (9.7)                      | 5 (7.7)                      |
| Hospitalisation/prolong existing hospitalisation                    | 109 (29.9)                 | 53 (34.2)                     | 5 (33.3)                 | 308 (29.8)                   | 150 (34.5)                    | 21 (32.3)                    |
| Life-threatening                                                    | 9 (2.5)                    | 6 (3.9)                       | 0 (0.0)                  | 31 (3.0)                     | 16 (3.7)                      | 0 (0.0)                      |
| Disability/incapacity                                               | 1 (0.3)                    | 1 (0.6)                       | 0 (0.0)                  | 2 (0.2)                      | 2 (0.5)                       | 0 (0.0)                      |
| Other (medically significant)                                       | 0 (0.0)                    | 2 (1.3)                       | 1 (6.7)                  | 11 (1.1)                     | 9 (2.1)                       | 3 (4.6)                      |
| AE leading to treatment discontinuation                             | 30 (8.2)                   | 24 (15.5)                     | 2 (13.3)                 | 113 (10.9)                   | 68 (15.6)                     | 9 (13.8)                     |
| Blood and lymphatic system disorders                                | 119 (32.7)                 | 52 (33.5) longer              | 8 (53.3)                 | 345 (33.4)                   | 148 (34.0)                    | 16 (24.6)                    |
| Cardiac disorders                                                   | 39 (10.7)                  | 23 (14.8)                     | 0 (0.0)                  | 92 (8.9)                     | 49 (11.3)                     | 2 (3.1)                      |
| Ear and labyrinth disorders                                         | 5 (1.4)                    | 0 (0.0)                       | 1 (6.7)                  | 19 (1.8)                     | 4 (0.9)                       | 1 (1.5)                      |
| Endocrine disorders                                                 | 60 (16.5) no               | 18 (11.6)                     | 1 (6.7)                  | 177 (17.1)                   | 58 (13.3)                     | 8 (12.3)                     |
| Eye disorders                                                       | 28 (7.7) product           | 16 (10.3)                     | 2 (13.3)                 | 72 (7.0)                     | 38 (8.7)                      | 6 (9.2)                      |
| Gastrointestinal disorders                                          | 133 (36.5)                 | 56 (36.1)                     | 5 (33.3)                 | 448 (43.3)                   | 206 (47.4)                    | 29 (44.6)                    |
| General disorders and administration site conditions                | 156 (42.9)                 | 51 (32.9)                     | 8 (53.3)                 | 428 (41.4)                   | 184 (42.3)                    | 34 (52.3)                    |
| Hepatobiliary disorders                                             | 14 (3.8)                   | 4 (2.6)                       | 2 (13.3)                 | 60 (5.8)                     | 34 (7.8)                      | 9 (13.8)                     |
| Immune system disorders                                             | 2 (0.5)                    | 1 (0.6)                       | 0 (0.0)                  | 9 (0.9)                      | 5 (1.1)                       | 0 (0.0)                      |
| Infections and infestations                                         | 105 (28.8)                 | 44 (28.4)                     | 2 (13.3)                 | 332 (32.1)                   | 122 (28.0)                    | 18 (27.7)                    |
| Injury, poisoning and procedural complications Medicinal            | 12 (3.3)                   | 10 (6.5)                      | 0 (0.0)                  | 42 (4.1)                     | 27 (6.2)                      | 2 (3.1)                      |
| Investigations                                                      | 213 (58.5)                 | 92 (59.4)                     | 6 (40.0)                 | 633 (61.2)                   | 240 (55.2)                    | 28 (43.1)                    |
| Metabolism and nutrition disorders                                  | 169 (46.4)                 | 78 (50.3)                     | 5 (33.3)                 | 426 (41.2)                   | 211 (48.5)                    | 22 (33.8)                    |
| Musculoskeletal and connective tissue disorders                     | 109 (29.9)                 | 46 (29.7)                     | 2 (13.3)                 | 276 (26.7)                   | 114 (26.2)                    | 18 (27.7)                    |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 26 (7.1)                   | 9 (5.8)                       | 0 (0.0)                  | 66 (6.4)                     | 22 (5.1)                      | 5 (7.7)                      |
| Nervous system disorders                                            | 40 (11.0)                  | 26 (16.8)                     | 1 (6.7)                  | 125 (12.1)                   | 65 (14.9)                     | 14 (21.5)                    |
| Product issues                                                      | 0 (0.0)                    | 0 (0.0)                       | 0 (0.0)                  | 2 (0.2)                      | 0 (0.0)                       | 0 (0.0)                      |
| Psychiatric disorders                                               | 25 (6.9)                   | 13 (8.4)                      | 0 (0.0)                  | 74 (7.2)                     | 40 (9.2)                      | 4 (6.2)                      |

<div style=\"page-break-after: always\"></div>

|                                                                                           | 303 Tislelizumab N=534     | 303 Tislelizumab N=534        | 303 Tislelizumab N=534   | 200 mg Q3W all indications N=1534   | 200 mg Q3W all indications N=1534   | 200 mg Q3W all indications N=1534   |
|-------------------------------------------------------------------------------------------|----------------------------|-------------------------------|--------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| MedDRA terms                                                                              | Age < 65 years N=364 n (%) | Age 65- <75 years N=155 n (%) | Age ≥75 years N=15 n (%) | Age < 65 years N=1034 n (%)         | Age 65- <75 years N=435 n (%)       | Age ≥75 years N=65 n (%)            |
| Renal and urinary disorders                                                               | 19 (5.2)                   | 16 (10.3)                     | 1 (6.7)                  | 100 (9.7)                           | 55 (12.6)                           | 4 (6.2)                             |
| Reproductive system and breast disorders                                                  | 5 (1.4)                    | 3 (1.9)                       | 0 (0.0)                  | 20 (1.9)                            | 7 (1.6)                             | 1 (1.5)                             |
| Respiratory, thoracic and mediastinal disorders                                           | 179 (49.2)                 | 70 (45.2)                     | 4 (26.7)                 | 379 (36.7)                          | 161 (37.0)                          | 18 (27.7)                           |
| Skin and subcutaneous tissue disorders                                                    | 69 (19.0)                  | 32 (20.6)                     | 1 (6.7)                  | 231 (22.3)                          | 114 (26.2)                          | 25 (38.5)                           |
| Vascular disorders                                                                        | 23 (6.3)                   | 10 (6.5)                      | 0 (0.0)                  | 65 (6.3)                            | 45 (10.3)                           | 3 (4.6)                             |
| CMQ sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 44 (12.1)                  | 22 (14.2)                     | 0 (0.0)                  | 103 (10.0) authorised               | 67 (15.4)                           | 10 (15.4)                           |

|                                             | NSCLC                                | NSCLC                       | NSCLC                             | NSCLC                      |
|---------------------------------------------|--------------------------------------|-----------------------------|-----------------------------------|----------------------------|
|                                             | <65 years                            | <65 years                   | >=65 years                        | >=65 years                 |
| product                                     | 307&304&206 T+chemo (N=335) n (%) no | 307&304 chemo (N=156) n (%) | 307&304&206 T+chemo (N=162) n (%) | 307&304 chemo (N=71) n (%) |
| Patients With at Least One TEAE             | 334 (99.7)                           | 155 (99.4)                  | 162 (100)                         | 71 (100)                   |
| Treatment-Related                           | 334 (99.7)                           | 154 (98.7)                  | 161 (99.4)                        | 70 (98.6)                  |
| ≥ Grade 3 TEAEs                             | 259 (77.3)                           | 110 (70.5)                  | 135 (83.3)                        | 51 (71.8)                  |
| Treatment-Related                           | 243 (72.5)                           | 100 (64.1)                  | 129 (79.6)                        | 45 (63.4)                  |
| Serious TEAEs                               | 120 (35.8)                           | 34 (21.8)                   | 79 (48.8)                         | 20 (28.2)                  |
| Treatment-Related                           | 66 (19.7)                            | 20 (12.8)                   | 57 (35.2)                         | 12 (16.9)                  |
| TEAEs Led to Death                          | 14 (4.2)                             | 4 (2.6)                     | 7 (4.3)                           | 3 (4.2)                    |
| Treatment-Related                           | 6 (1.8)                              | 2 (1.3)                     | 2 (1.2)                           | 2 (2.8)                    |
| TEAEs Led to Any Treatment Medicinal        | 85 (25.4)                            | 15 (9.6)                    | 56 (34.6)                         | 14 (19.7)                  |
| Discontinuation                             |                                      |                             |                                   |                            |
| Led to Tislelizumab Discontinuation         | 39 (11.6)                            | NA                          | 32 (19.8)                         | NA                         |
| Led to Chemotherapy Discontinuation         | 67 (20.0)                            | 15 (9.6)                    | 44 (27.2)                         | 14 (19.7)                  |
| TEAEs Led to Any Treatment Modification (a) | 244 (72.8)                           | 65 (41.7)                   | 122 (75.3)                        | 43 (60.6)                  |
| Led to Tislelizumab Modification            | 210 (62.7)                           | NA                          | 102 (63.0)                        | NA                         |
| Led to Chemotherapy Modification            | 222 (66.3)                           | 63 (40.4)                   | 117 (72.2)                        | 43 (60.6)                  |
| Infusion-Related Reaction                   | 9 (2.7)                              | 4 (2.6)                     | 5 (3.1)                           | 1 (1.4)                    |
| Immune-mediated TEAEs                       | 73 (21.8)                            | NA                          | 54 (33.3)                         | NA                         |
| ≥ Grade 3                                   | 27 (8.1)                             | NA                          | 25 (15.4)                         | NA                         |

· Combination therapy 1L Table 136: Summary of TEAEs by age (pooled 1L NSCLC data) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                     | NSCLC                             | NSCLC                       | NSCLC                             | NSCLC                      |
|-------------------------------------|-----------------------------------|-----------------------------|-----------------------------------|----------------------------|
|                                     | <65 years                         | <65 years                   | >=65 years                        | >=65 years                 |
|                                     | 307&304&206 T+chemo (N=335) n (%) | 307&304 chemo (N=156) n (%) | 307&304&206 T+chemo (N=162) n (%) | 307&304 chemo (N=71) n (%) |
| Led to Death                        | 5 (1.5)                           | NA                          | 1 (0.6)                           | NA                         |
| Serious                             | 27 (8.1)                          | NA                          | 27 (16.7)                         | NA                         |
| Led to Tislelizumab Discontinuation | 18 (5.4)                          | NA                          | 20 (12.3)                         | NA                         |

(a) Treatment modification included dose interruption, dose delay, infusion rate decreased and dose modification (only for chemotherapy).

|                                                                | NSCLC 307&304&206 T+chemo   | NSCLC 307&304&206 T+chemo           | 307&304 Chemo N=227        | 307&304 Chemo N=227         |
|----------------------------------------------------------------|-----------------------------|-------------------------------------|----------------------------|-----------------------------|
| MedDRA terms                                                   | Age < 65 years N=335 n (%)  | Age 65-<75 years N=158 n (%) longer | Age < 65 years N=156 n (%) | Age 65-<75 years N=71 n (%) |
| Total AEs                                                      | 334 (99.7)                  | 158 (100.0)                         | 155 (99.4)                 | 71 (100.0)                  |
| Grade >= 3 AEs                                                 | 259 (77.3)                  | 133 (84.2)                          | 110 (70.5)                 | 51 (71.8)                   |
| Serious AEs - total                                            | 120 (35.8)                  | 77 (48.7)                           | 34 (21.8)                  | 20 (28.2)                   |
| Fatal                                                          | 14 (4.2)                    | 7 (4.4)                             | 4 (2.6)                    | 3 (4.2)                     |
| Hospitalisation/prolong existing hospitalisation               | 116 (34.6)                  | 73 (46.2) no                        | 31 (19.9)                  | 18 (25.4)                   |
| Life-threatening                                               | 5 (1.5)                     | 7 (4.4)                             | 1 (0.6)                    | 0 (0.0)                     |
| Disability/incapacity                                          | 0 (0.0)                     | 0 (0.0)                             | 1 (0.6)                    | 0 (0.0)                     |
| Other (medically significant)                                  | 1 (0.3)                     | 2 (1.3)                             | 1 (0.6)                    | 0 (0.0)                     |
| AE leading to Tislelizumab discontinuation                     | 39 (11.6) product           | 31 (19.6)                           | 0 (0.0)                    | 0 (0.0)                     |
| AEs by SOC                                                     |                             |                                     |                            |                             |
| Blood and lymphatic system disorders                           | 303 (90.4)                  | 150 (94.9)                          | 138 (88.5)                 | 65 (91.5)                   |
| Cardiac disorders                                              | 48 (14.3)                   | 25 (15.8)                           | 14 (9.0)                   | 2 (2.8)                     |
| Ear and labyrinth disorders                                    | 6 (1.8)                     | 2 (1.3)                             | 3 (1.9)                    | 2 (2.8)                     |
| Endocrine disorders                                            | 56 (16.7)                   | 24 (15.2)                           | 2 (1.3)                    | 1 (1.4)                     |
| Eye disorders                                                  | 15 (4.5)                    | 8 (5.1)                             | 2 (1.3)                    | 3 (4.2)                     |
| Gastrointestinal disorders                                     | 231 (69.0)                  | 109 (69.0)                          | 87 (55.8)                  | 47 (66.2)                   |
| General disorders and administration site conditions Medicinal | 197 (58.8)                  | 107 (67.7)                          | 78 (50.0)                  | 43 (60.6)                   |
| Hepatobiliary disorders                                        | 25 (7.5)                    | 7 (4.4)                             | 12 (7.7)                   | 2 (2.8)                     |
| Immune system disorders                                        | 2 (0.6)                     | 3 (1.9)                             | 4 (2.6)                    | 0 (0.0)                     |
| Infections and infestations                                    | 112 (33.4)                  | 62 (39.2)                           | 36 (23.1)                  | 17 (23.9)                   |
| Injury, poisoning and procedural complications                 | 29 (8.7)                    | 10 (6.3)                            | 6 (3.8)                    | 1 (1.4)                     |
| Investigations                                                 | 311 (92.8)                  | 150 (94.9)                          | 139 (89.1)                 | 63 (88.7)                   |
| Metabolism and nutrition disorders                             | 225 (67.2)                  | 125 (79.1)                          | 89 (57.1)                  | 48 (67.6)                   |
| Musculoskeletal and connective tissue disorders                | 150 (44.8)                  | 67 (42.4)                           | 52 (33.3)                  | 23 (32.4)                   |

<div style=\"page-break-after: always\"></div>

|                                                                                           | NSCLC                      | NSCLC                        | NSCLC                      | NSCLC                       |
|-------------------------------------------------------------------------------------------|----------------------------|------------------------------|----------------------------|-----------------------------|
|                                                                                           | 307&304&206 T+chemo N=497  | 307&304&206 T+chemo N=497    | 307&304 Chemo N=227        | 307&304 Chemo N=227         |
| MedDRA terms                                                                              | Age < 65 years N=335 n (%) | Age 65-<75 years N=158 n (%) | Age < 65 years N=156 n (%) | Age 65-<75 years N=71 n (%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)                       | 22 (6.6)                   | 12 (7.6)                     | 13 (8.3)                   | 7 (9.9)                     |
| Nervous system disorders                                                                  | 111 (33.1)                 | 59 (37.3)                    | 46 (29.5)                  | 18 (25.4)                   |
| Product issues                                                                            | 2 (0.6)                    | 0 (0.0)                      | 0 (0.0)                    | 0 (0.0)                     |
| Psychiatric disorders                                                                     | 45 (13.4)                  | 16 (10.1)                    | 21 (13.5)                  | 14 (19.7)                   |
| Renal and urinary disorders                                                               | 28 (8.4)                   | 13 (8.2)                     | 4 (2.6)                    | 1 (1.4)                     |
| Reproductive system and breast disorders                                                  | 5 (1.5)                    | 3 (1.9)                      | 2 (1.3)                    | 2 (2.8)                     |
| Respiratory, thoracic and mediastinal disorders                                           | 167 (49.9)                 | 85 (53.8)                    | 50 (32.1)                  | 27 (38.0)                   |
| Skin and subcutaneous tissue disorders                                                    | 178 (53.1)                 | 92 (58.2)                    | 69 (44.2) authorised       | 34 (47.9)                   |
| Vascular disorders                                                                        | 26 (7.8)                   | 15 (9.5)                     | 14 (9.0)                   | 2 (2.8)                     |
| CMQ sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 88 (26.3)                  | 48 (30.4)                    | 34 (21.8)                  | 20 (28.2)                   |

|                                                          | Normal Study             | Normal Study                    | Normal Study                              | Impairment 303 Study      | Impairment 303 Study   | Impairment 303 Study                     |
|----------------------------------------------------------|--------------------------|---------------------------------|-------------------------------------------|---------------------------|------------------------|------------------------------------------|
| System Organ Class                                       | 303 Tislelizumab (N=494) | Docetaxel (N=236) n (%) product | 200 mg Q3W All Indications (N=1243) n (%) | Tislelizumab (N=40) n (%) | Docetaxel (N=22) n (%) | 200 mg Q3W All Indications (N=285) n (%) |
| Preferred Term Patients with at least one TEAE Medicinal | n (%) 470 (95.1)         | 233 (98.7)                      | 1188 (95.6)                               | 39 (97.5)                 | 21 (95.5)              | 274 (96.1)                               |
| Treatment-related TEAE                                   | 362 (73.3)               | 222 (94.1)                      | 932 (75.0)                                | 28 (70.0)                 | 20 (90.9)              | 189 (66.3)                               |
| TEAE ≥ Grade 3                                           | 189 (38.3)               | 174 (73.7)                      | 521 (41.9)                                | 17 (42.5)                 | 19 (86.4)              | 145 (50.9)                               |
| Related TEAE ≥ Grade 3                                   | 69 (14.0)                | 152 (64.4)                      | 199 (16.0)                                | 8 (20.0)                  | 19 (86.4)              | 50 (17.5)                                |
| Serious TEAE                                             | 157 (31.8)               | 79 (33.5)                       | 404 (32.5)                                | 17 (42.5)                 | 4 (18.2)               | 110 (38.6)                               |
| Treatment-related SAEs                                   | 61 (12.3)                | 55 (23.3)                       | 143 (11.5)                                | 6 (15.0)                  | 4 (18.2)               | 31 (10.9)                                |
| TEAE Leading to Death                                    | 26 (5.3)                 | 11 (4.7)                        | 85 (6.8)                                  | 6 (15.0)                  | 0 (0.0)                | 41 (14.4)                                |
| Related TEAE Leading to Death                            | 7 (1.4)                  | 4 (1.7)                         | 13 (1.0)                                  | 1 (2.5)                   | 0 (0.0)                | 6 (2.1)                                  |
| TEAE Leading to Discontinuation                          | 51 (10.3)                | 29 (12.3)                       | 152 (12.2)                                | 5 (12.5)                  | 3 (13.6)               | 35 (12.3)                                |
| Related TEAE Leading to Treatment Discontinuation        | 31 (6.3)                 | 22 (9.3)                        | 75 (6.0)                                  | 1 (2.5)                   | 3 (13.6)               | 9 (3.2)                                  |
| TEAE Leading to Dose Modification                        | 113 (22.9)               | 82 (34.7)                       | 306 (24.6)                                | 6 (15.0)                  | 7 (31.8)               | 90 (31.6)                                |
| Treatment-related TEAE Leading to Dose Modification      | 66 (13.4)                | 71 (30.1)                       | 186 (15.0)                                | 2 (5.0)                   | 6 (27.3)               | 48 (16.8)                                |
| Immune-mediated TEAE                                     | 100 (20.2)               | NA                              | 234 (18.8)                                | 4 (10.0)                  | NA                     | 41 (14.4)                                |

Hepatic impairment : Table 138: Overall summary of TEAEs by baseline hepatic impairment Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                   | Normal 303 Study           | Normal 303 Study        | Normal 303 Study                          | Impairment 303 Study      | Impairment 303 Study   | Impairment 303 Study                     |
|-----------------------------------|----------------------------|-------------------------|-------------------------------------------|---------------------------|------------------------|------------------------------------------|
| System Organ Class Preferred Term | Tislelizumab (N=494) n (%) | Docetaxel (N=236) n (%) | 200 mg Q3W All Indications (N=1243) n (%) | Tislelizumab (N=40) n (%) | Docetaxel (N=22) n (%) | 200 mg Q3W All Indications (N=285) n (%) |
| Immune-mediated TEAE              | 34 (6.9)                   | NA                      | 70 (5.6)                                  | 1 (2.5)                   | NA                     | 11 (3.9)                                 |

with Grade 3 or Higher

<!-- image -->

Safety by gender Overall, no clinically meaningful differences in the AE profile between male and female subgroups were observed in the tislelizumab monotherapy treatment groups (apart from a higher incidence of weight decreased in the male population in the tislelizumab treatment arm of Study 303 [15.4% vs 9.5%]). In the pooled tislelizumab + chemotherapy group, SAEs (41.5% vs. 32.9%) and immune-mediated TEAEs (25.5% vs 18.8%) were reported at higher incidences (≥ 5% difference) for male patients compared to females. Safety by race As the 1L combination therapy Studies 304 and 307 were conducted exclusively in China, analyses by race and region were only performed in the monotherapy setting. In Study 303, 80% of the study population was Asian and 17% White; in the 200 mg Q3W All Indications group, 80% of patients were Asian, 17% White and 3% other race types. The following tables focus on results for Asian and White to improve readability and due to the only small proportion of other race types [other: n=17 and 7 in treatment arms of Study 303 and n=47 in the 200 mg Q3W All Indications group]. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 139: Overall summary of TEAEs by race (Asian and White [without other], Study 303 and All Doses and All Indications)

|                                           | Asian Study 303                | Asian Study 303             | Asian Study 303                               | White Study 303               | White Study 303            | White Study 303                                 |
|-------------------------------------------|--------------------------------|-----------------------------|-----------------------------------------------|-------------------------------|----------------------------|-------------------------------------------------|
|                                           | Tisleli- zumab (N = 423) n (%) | Doce- taxel (N = 210) n (%) | 200 mg Q3W All Indica- tions (N = 1234) n (%) | Tisleli- zumab (N = 94) n (%) | Doce- taxel (N = 41) n (%) | All Doses and All Indica- tions (N = 253) n (%) |
| Patients with at least one TEAE           | 409 (96.7)207                  | (98.6)                      | 1184 (95.9)                                   | 84 (89.4)40                   | (97.6)                     | 238 (94.1)) authorised                          |
| Treatment-related TEAE                    | 321 (75.9)196                  | (93.3)                      | 934 (75.7)                                    | 60 (63.8)39                   | (95.1)163                  | (64.4)                                          |
| Grade 3 or higher TEAE                    | 165 (39.0)158                  | (75.2)                      | 527 (42.7)                                    | 34 (36.2)28                   | (68.3)119                  | (47.0)                                          |
| Grade ≥ 3 related TEAE                    | 64 (15.1)                      | 141 (67.1)                  | 216 (17.5)                                    | 11 (11.7)23                   | (56.1)                     | 29 (11.5)                                       |
| Serious TEAE                              | 144 (34.0)                     | 66 (31.4)                   | 416 (33.7)                                    | 24 (25.5)13                   | (31.7)                     | 82 (32.4)                                       |
| Treatment-related SAE                     | 59 (13.9)                      | 47 (22.4)                   | 157 (12.7)                                    | 7 (7.4)                       | 10 (24.4)                  | 16 (6.3)                                        |
| TEAE leading to death                     | 22 (5.2)                       | 9 (4.3)                     | 90 (7.3)                                      | 7 (7.4)                       | 2 (4.9)                    | 29 (11.5)                                       |
| TEAE leading to treatment discontinuation | 41 (9.7)                       | 26 (12.4)                   | 152 (12.3) longer                             | 13 (13.8)                     | 5 (12.2)                   | 31 (12.3)                                       |
| TEAE leading to dose modification         | 89 (21.0)                      | 66 (31.4)                   | 310 (25.1)                                    | 25 (26.6)18                   | (43.9)                     | 75 (29.6)                                       |
| Immune-mediated TEAE                      | 78 (18.4)                      | NA                          | 227 (18.4)                                    | 15 (16.0)                     | NA                         | 42 (16.6)                                       |
| Grade 3 or higher                         | 25 (5.9)                       | NA                          | 66 (5.3)                                      | 5 (5.3)                       | NA                         | 12 (4.7)                                        |

|                                           | Asian                                  | Asian                       | Asian                                         | White                         | White                      | White                                        |
|-------------------------------------------|----------------------------------------|-----------------------------|-----------------------------------------------|-------------------------------|----------------------------|----------------------------------------------|
|                                           | Study 303                              | Study 303                   | Study 303                                     | Study 303                     | Study 303                  | Study 303                                    |
| System Organ Class Preferred Term         | Tisleli- zumab (N = 423) n (%) product | Doce- taxel (N = 210) n (%) | 200 mg Q3W All Indica- tions (N = 1234) n (%) | Tisleli- zumab (N = 94) n (%) | Doce- taxel (N = 41) n (%) | 200 mg Q3W All Indica- tions (N = 253) n (%) |
| Patients with at least one TEAE Medicinal | 409 (96.7)                             | 207 (98.6)                  | 1184 (95.9)                                   | 84 (89.4)                     | 40 (97.6)                  | 238 (94.1)                                   |
| Investigations                            | 276 (65.2)                             | 157 (74.8)                  | 813 (65.9)                                    | 31 (33.0)                     | 15 (36.6)                  | 73 (28.9)                                    |
| ALT increased                             | 98 (23.2)                              | 38 (18.1)                   | 271 (22.0)                                    | 8 (8.5)                       | 0 (0.0)                    | 22 (8.7)                                     |
| AST increased                             | 92 (21.7)                              | 30 (14.3)                   | 286 (23.2)                                    | 8 (8.5)                       | 1 (2.4)                    | 26 (10.3)                                    |
| Weight decreased                          | 77 (18.2)                              | 21 (10.0)                   | 205 (16.6)                                    | 4 (4.3)                       | 5 (12.2)                   | 9 (3.6)                                      |
| Blood bilirubin increased                 | 27 (6.4)                               | 14 (6.7)                    | 143 (11.6)                                    | 0 (0.0)                       | 1 (2.4)                    | 7 (2.8)                                      |
| White blood cell count decr.              | 20 (4.7)                               | 72 (34.3)                   | 101 (8.2)                                     | 0 (0.0)                       | 2 (4.9)                    | 0 (0.0)                                      |
| Neutrophil count decreased                | 15 (3.5)                               | 91 (43.3)                   | 64 (5.2)                                      | 0 (0.0)                       | 4 (9.8)                    | 1 (0.4)                                      |

Table 140: TEAEs with incidence ≥ 10% by race, SOC and PT (Asian and White, Study 303 and 200 mg Q3W All Indications) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                      | Asian                          | Asian                       | Asian                                         | White                         | White                      | White                                        |
|------------------------------------------------------|--------------------------------|-----------------------------|-----------------------------------------------|-------------------------------|----------------------------|----------------------------------------------|
|                                                      | Study 303                      | Study 303                   |                                               | Study 303                     | Study 303                  |                                              |
| System Organ Class Preferred Term                    | Tisleli- zumab (N = 423) n (%) | Doce- taxel (N = 210) n (%) | 200 mg Q3W All Indica- tions (N = 1234) n (%) | Tisleli- zumab (N = 94) n (%) | Doce- taxel (N = 41) n (%) | 200 mg Q3W All Indica- tions (N = 253) n (%) |
| Metabolism and nutrition disorders                   | 215 (50.8)                     | 100 (47.6)                  | 557 (45.1)                                    | 31 (33.0)                     | 84 (33.2)15 (36.6)         |                                              |
| Decreased appetite                                   | 69 (16.3)                      | 46 (21.9)                   | 168 (13.6)                                    | 11 (11.7)                     | 11 (26.8)                  | 42 (16.6)                                    |
| Hypoalbuminaemia                                     | 66 (15.6)                      | 37 (17.6)                   | 163 (13.2)                                    | 4 (4.3)                       | 4 (9.8) authorised         | 11 (4.3)                                     |
| Hyperglycaemia                                       | 50 (11.8)                      | 26 (12.4)                   | 99 (8.0)                                      | 4 (4.3)                       | 2 (4.9)                    | 10 (4.0)                                     |
| Hyponatraemia                                        | 44 (10.4)                      | 28 (13.3)                   | 121 (9.8)                                     | 3 (3.2)                       | 0 (0.0)                    | 5 (2.0)                                      |
| Hypokalaemia                                         | 42 (9.9)                       | 12 (5.7)                    | 99 (8.0)                                      | 1 (1.1)                       | 1 (2.4)                    | 6 (2.4)                                      |
| Respiratory, thoracic and mediastinal disorders      | 214 (50.6)                     | 91 (43.3)                   | 452 (36.6)                                    | 34 (36.2)                     | 15 (36.6)                  | 90 (35.6)                                    |
| Cough                                                | 93 (22.0)                      | 36 (17.1)                   | 202 (16.4) longer                             | 10 (10.6)                     | 3 (7.3)                    | 31 (12.3)                                    |
| Haemoptysis                                          | 51 (12.1)                      | 21 (10.0)                   | 78 (6.3)                                      | 3 (3.2)                       | 1 (2.4)                    | 7 (2.8)                                      |
| Dyspnoea                                             | 45 (10.6)                      | 22 (10.5)                   | 82 (6.6)                                      | 15 (16.0)                     | 8 (19.5)                   | 26 (10.3)                                    |
| General disorders and administration site conditions | 169 (40.0)                     | 106 (50.5) no               | 489 (39.6)                                    | 40 (42.6)                     | 22 (53.7)                  | 136 (53.8)                                   |
| Asthenia                                             | 54 (12.8)                      | 46 (21.9)                   | 92 (7.5)                                      | 12 (12.8)                     | 9 (22.0)                   | 52 (20.6)                                    |
| Pyrexia                                              | 49 (11.6) product              | 25 (11.9)                   | 202 (16.4)                                    | 7 (7.4)                       | 1 (2.4)                    | 28 (11.1)                                    |
| Fatigue                                              | 10 (2.4)                       | 12 (5.7)                    | 67 (5.4)                                      | 14 (14.9)                     | 11 (26.8)                  | 48 (19.0)                                    |
| Blood and lymphatic system disorders Medicinal       | 155 (36.6)                     | 144 (68.6)                  | 448 (36.3)                                    | 20 (21.3)                     | 26 (63.4)                  | 51 (20.2)                                    |
| Anaemia                                              | 132 (31.2)                     | 98 (46.7)                   | 373 (30.2)                                    | 16 (17.0)                     | 12 (29.3)                  | 43 (17.0)                                    |
| Leukopenia                                           | 14 (3.3)                       | 60 (28.6)                   | 43 (3.5)                                      | 1 (1.1)                       | 9 (22.0)                   | 1 (0.4)                                      |
| Neutropenia                                          | 7 (1.7)                        | 57 (27.1)                   | 23 (1.9)                                      | 2 (2.1)                       | 20 (48.8)                  | 2 (0.8)                                      |
| Febrile neutropenia                                  | 0 (0.0)                        | 25 (11.9)                   | 0 (0.0)                                       | 0 (0.0)                       | 7 (17.1)                   | 0 (0.0)                                      |
| Gastrointestinal disorders                           | 155 (36.6)                     | 99 (47.1)                   | 521 (42.2)                                    | 30 (31.9)                     | 21 (51.2)                  | 135 (53.4)                                   |
| Constipation                                         | 55 (13.0)                      | 38 (18.1)                   | 147 (11.9)                                    | 6 (6.4)                       | 3 (7.3)                    | 26 (10.3)                                    |
| Nausea                                               | 41 (9.7)                       | 30 (14.3)                   | 108 (8.8)                                     | 16 (17.0)                     | 8 (19.5)                   | 39 (15.4)                                    |
| Vomiting                                             | 30 (7.1)                       | 15 (7.1)                    | 95 (7.7)                                      | 3 (3.2)                       | 3 (7.3)                    | 17 (6.7)                                     |
| Diarrhoea                                            | 27 (6.4)                       | 24 (11.4)                   | 94 (7.6)                                      | 5 (5.3)                       | 6 (14.6)                   | 35 (13.8)                                    |

<div style=\"page-break-after: always\"></div>

|                                        | Asian                          | Asian                       | Asian                                         | White                         | White                      | White                                        |
|----------------------------------------|--------------------------------|-----------------------------|-----------------------------------------------|-------------------------------|----------------------------|----------------------------------------------|
|                                        | Study 303                      | Study 303                   |                                               | Study 303                     | Study 303                  | Study 303                                    |
| System Organ Class Preferred Term      | Tisleli- zumab (N = 423) n (%) | Doce- taxel (N = 210) n (%) | 200 mg Q3W All Indica- tions (N = 1234) n (%) | Tisleli- zumab (N = 94) n (%) | Doce- taxel (N = 41) n (%) | 200 mg Q3W All Indica- tions (N = 253) n (%) |
| Abdominal pain                         | 8 (1.9)                        | 6 (2.9)                     | 52 (4.2)                                      | 2 (2.1)                       | 1 (2.4)                    | 20 (7.9)                                     |
| Infections and infestations            | 122 (28.8)                     | 60 (28.6)                   | 379 (30.7)                                    | 25 (26.6)                     | 14 (34.1)                  | 75 (29.6)                                    |
| Pneumonia                              | 47 (11.1)                      | 29 (13.8)                   | 118 (9.6)                                     | 13 (13.8)                     | 6 (14.6)                   | 20 (7.9)                                     |
| Upper respiratory tract infection      | 44 (10.4)                      | 23 (11.0)                   | 125 (10.1)                                    | 3 (3.2)                       | 2 (4.9)                    | 6 (2.4)                                      |
| Skin and subcutaneous tissue disorders | 86 (20.3)                      | 115 (54.8)                  | 282 (22.9)                                    | 12 (12.8) (43.9)              | 18                         | 74 (29.2)                                    |
| Pruritus                               | 31 (7.3)                       | 4 (1.9)                     | 116 (9.4)                                     | 4 (4.3)                       | 0 (0.0)                    | 31 (12.3)                                    |
| Alopecia                               | 4 (0.9)                        | 107 (51.0)                  | 4 (0.3)                                       | 0 (0.0) authorised            | 13 (31.7)                  | 0 (0.0)                                      |
| Endocrine disorders                    | 64 (15.1)                      | 0 (0.0)                     | 205 (16.6)                                    | 14 (14.9)                     | 1 (2.4)                    | 35 (13.8)                                    |
| Hypothyroidism                         | 46 (10.9)                      | 0 (0.0)                     | 157 (12.7)                                    | 10 (10.6)                     | 1 (2.4)                    | 25 (9.9)                                     |
| Nervous system disorders               | 51 (12.1)                      | 31 (14.8)                   | 144 (11.7) longer                             | 10 (10.6)                     | 15 (36.6)                  | 46 (18.2)                                    |
| Headache                               | 13 (3.1)                       | 6 (2.9)                     | 28 (2.3)                                      | 4 (4.3)                       | 5 (12.2)                   | 14 (5.5)                                     |
| Psychiatric disorders                  | 35 (8.3)                       | 28 (13.3)                   | 91 (7.4)                                      | 2 (2.1)                       | 3 (7.3)                    | 23 (9.1)                                     |
| Insomnia                               | 27 (6.4)                       | 23 (11.0) no                | 75 (6.1)                                      | 1 (1.1)                       | 1 (2.4)                    | 14 (5.5)                                     |

Immunological events For tislelizumab monotherapy, 18.3% of patients were tested positive for treatment emergent antidrug antibodies (ADA), and neutralising antibodies (NAb) were detected in 0.9% of patients of 1,916 ADA evaluable patients treated at the recommended dose of 200 mg Q3W. For tislelizumab combination therapy, ADA was detected in 24.0% of 492 evaluable patients and NAb in 1.4% of patients. Please see section 2.6.2.2 pharmacodynamics for a detailed assessment of immunogenicity. Safety related to drug-drug interactions and other interactions Formal pharmacokinetic interaction studies have not been conducted. As tislelizumab is a monoclonal antibody that is cleared from the circulation through catabolism and not metabolised by cytochrome P450 (CYP) enzymes or other drug metabolizing enzymes, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of tislelizumab. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## · Monotherapy 2L+

Table 141: TEAEs leading to treatment discontinuation by SOC and PT (≥ 1% patients in any group)

|                                                                      | 303 Study                  | 303 Study               | 2L+ NSCLC         |                                                      |
|----------------------------------------------------------------------|----------------------------|-------------------------|-------------------|------------------------------------------------------|
| System Organ Class Preferred Term                                    | Tislelizumab (N=534) n (%) | Docetaxel (N=258) n (%) | All (N=636) n (%) | 200 mg Q3W All Indications (N=1534) n (%) authorised |
| Patients with at least one TEAE Leading to Treatment Discontinuation | 56 (10.5)                  | 32 (12.4)               | 69 (10.8)         | 190 (12.4)                                           |
| Respiratory, thoracic and mediastinal disorders                      | 28 (5.2)                   | 3 (1.2)                 | 32 (5.0)          | 53 (3.5)                                             |
| Pneumonitis                                                          | 9 (1.7)                    | 0 (0.0)                 | 12 (1.9)          | 15 (1.0)                                             |
| Interstitial lung disease                                            | 6 (1.1)                    | 0 (0.0)                 | 6 (0.9)           | 7 (0.5)                                              |
| Infections and infestations                                          | 7 (1.3)                    | 5 (1.9)                 | 8 (1.3)           | 20 (1.3)                                             |
| Pneumonia                                                            | 7 (1.3)                    | 4 (1.6)                 | 8 (1.3)           | 18 (1.2)                                             |
| Investigations                                                       | 0 (0.0)                    | 3 (1.2)                 | 1 (0.2)           | 5 (0.3)                                              |
| Neutrophil count decreased                                           | 0 (0.0)                    | 3 (1.2)                 | 0 (0.0)           | 0 (0.0)                                              |

|                                                                                      | SQ-NSCLC                | SQ-NSCLC                 | SQ-NSCLC              | NSQ-NSCLC               | NSQ-NSCLC             | NSCLC                              | NSCLC                        |
|--------------------------------------------------------------------------------------|-------------------------|--------------------------|-----------------------|-------------------------|-----------------------|------------------------------------|------------------------------|
| System Organ Class Preferred Term                                                    | 307 T+PC (N=120 ) n (%) | 307 T+nPC (N=118 ) n (%) | 307 PC (N=117 ) n (%) | 304 T+PP (N=222 ) n (%) | 304 PP (N=110 ) n (%) | 307&304&20 6 T+chemo (N=497) n (%) | 307&30 4 chemo (N=227) n (%) |
| Patients With at Least One TEAE Event Leading to Treatment Discontinuation Medicinal | 21 (17.5)               | 38 (32.2)                | 18 (15.4)             | 68 (30.6)               | 11 (10.0)             | 141 (28.4)                         | 29 (12.8)                    |
| Blood and lymphatic system disorders                                                 | 3 (2.5)                 | 15 (12.7)                | 5 (4.3)               | 17 (7.7)                | 3 (2.7)               | 39 (7.8)                           | 8 (3.5)                      |
| Anaemia                                                                              | 1 (0.8)                 | 9 (7.6)                  | 3 (2.6)               | 11 (5.0)                | 1 (0.9)               | 25 (5.0)                           | 4 (1.8)                      |
|                                                                                      | 3 (2.5)                 | 2 (1.7)                  | 3 (2.6)               | 6 (2.7)                 | 0 (0.0)               | 13 (2.6)                           | 3 (1.3)                      |
| Thrombocytopeni a                                                                    |                         |                          |                       |                         |                       |                                    |                              |
| Neutropenia                                                                          | 1 (0.8)                 | 2 (1.7)                  | 0 (0.0)               | 2 (0.9)                 | 2 (1.8)               | 5 (1.0)                            | 2 (0.9)                      |
| Investigations                                                                       | 4 (3.3)                 | 15 (12.7)                | 6 (5.1)               | 15 (6.8)                | 3 (2.7)               | 36 (7.2)                           | 9 (4.0)                      |
| Blood creatinine increased                                                           | 0 (0.0)                 | 2 (1.7)                  | 0 (0.0)               | 10 (4.5)                | 0 (0.0)               | 12 (2.4)                           | 0 (0.0)                      |
| Neutrophil count decreased                                                           | 1 (0.8)                 | 6 (5.1)                  | 4 (3.4)               | 1 (0.5)                 | 0 (0.0)               | 8 (1.6)                            | 4 (1.8)                      |

· Combination therapy 1L Table 142: TEAEs leading to treatment discontinuation by SOC and PT (≥ 1% patients in combined+chemo or chemo group) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                      | SQ-NSCLC                | SQ-NSCLC                 | SQ-NSCLC              | NSQ-NSCLC               | NSQ-NSCLC             | NSCLC                              | NSCLC                        |
|------------------------------------------------------|-------------------------|--------------------------|-----------------------|-------------------------|-----------------------|------------------------------------|------------------------------|
| System Organ Class Preferred Term                    | 307 T+PC (N=120 ) n (%) | 307 T+nPC (N=118 ) n (%) | 307 PC (N=117 ) n (%) | 304 T+PP (N=222 ) n (%) | 304 PP (N=110 ) n (%) | 307&304&20 6 T+chemo (N=497) n (%) | 307&30 4 chemo (N=227) n (%) |
| Platelet count decreased                             | 0 (0.0)                 | 5 (4.2)                  | 1 (0.9)               | 1 (0.5)                 | 1 (0.9)               | 7 (1.4)                            | 2 (0.9)                      |
| White blood cell count decreased                     | 1 (0.8)                 | 4 (3.4)                  | 2 (1.7)               | 2 (0.9)                 | 0 (0.0)               | 7 (1.4)                            | 2 (0.9)                      |
| Respiratory, thoracic and mediastinal disorders      | 8 (6.7)                 | 6 (5.1)                  | 0 (0.0)               | 11 (5.0)                | 0 (0.0)               | 28 (5.6)                           | 0 (0.0)                      |
| Pneumonitis                                          | 3 (2.5)                 | 1 (0.8)                  | 0 (0.0)               | 11 (5.0)                | 0 (0.0)               | 17 (3.4)                           | 0 (0.0)                      |
| Immune- mediated pneumonitis                         | 1 (0.8)                 | 2 (1.7)                  | 0 (0.0)               | 0 (0.0)                 | 0 (0.0)               | 3 (0.6) authorised                 | 0 (0.0)                      |
| Gastrointestinal disorders                           | 2 (1.7)                 | 1 (0.8)                  | 1 (0.9)               | 9 (4.1)                 | 1 (0.9)               | 14 (2.8)                           | 2 (0.9)                      |
| General disorders and administration site conditions | 0 (0.0)                 | 2 (1.7)                  | 3 (2.6)               | 7 (3.2)                 | 3 (2.7) longer        | 10 (2.0)                           | 6 (2.6)                      |
| Cardiac disorders                                    | 1 (0.8)                 | 3 (2.5)                  | 0 (0.0)               | 4 (1.8)                 | 0 (0.0)               | 9 (1.8)                            | 0 (0.0)                      |
| Myocarditis                                          | 0 (0.0)                 | 3 (2.5)                  | 0 (0.0)               | 1 (0.5)                 | 0 (0.0)               | 5 (1.0)                            | 0 (0.0)                      |
| Immune- mediated myocarditis                         | 1 (0.8)                 | 0 (0.0)                  | 0 (0.0) no            | 1 (0.5)                 | 0 (0.0)               | 2 (0.4)                            | 0 (0.0)                      |
| Infections and infestations                          | 2 (1.7)                 | 3 (2.5)                  | 1 (0.9)               | 3 (1.4)                 | 2 (1.8)               | 8 (1.6)                            | 3 (1.3)                      |
| Pneumonia                                            | 2 (1.7)                 | 2 (1.7)                  | 0 (0.0)               | 1 (0.5)                 | 2 (1.8)               | 5 (1.0)                            | 2 (0.9)                      |
| Metabolism and nutrition disorders                   | 0 (0.0)                 | 2 (1.7) product          | 0 (0.0)               | 6 (2.7)                 | 0 (0.0)               | 8 (1.6)                            | 0 (0.0)                      |
| Nervous system disorders                             | 3 (2.5)                 | 1 (0.8)                  | 0 (0.0)               | 2 (0.9)                 | 0 (0.0)               | 8 (1.6)                            | 0 (0.0)                      |

|                                         | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   |
|-----------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                         | Patient-based analysis                               | Patient-based analysis                               | Event-based analysis                                 | Event-based analysis                                 | Event-based analysis                                 |
| imAE category                           | n                                                    | Resolved a                                           | n                                                    | Resolved b (%)                                       | Resolving b (%)                                      |
| Immune-mediated pancreatitis            | 1                                                    | 1 (100.0)                                            | 1                                                    | 1 (100.0)                                            | 0                                                    |
| Immune-mediated colitis                 | 11                                                   | 9 (81.8)                                             | 11                                                   | 9 (81.8)                                             | 1 (9.1)                                              |
| Immune-mediated hyperthyroidism         | 5                                                    | 4 (80.0)                                             | 5                                                    | 4 (80.0)                                             | 0                                                    |
| Immune-mediated myositis/rhabdomyolysis | 14                                                   | 8 (57.1)                                             | 16                                                   | 10 (62.5)                                            | 0                                                    |
| Immune-mediated myocarditis             | 7                                                    | 4 (57.1)                                             | 7                                                    | 4 (57.1)                                             | 1 (14.3)                                             |

Table 143: Percentage of imAE events resolved and resolving by imAE category (Tislelizumab 200 mg Q3W, All indications, Safety Analysis Set) Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                 | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   | Tislelizumab 200 mg Q3W - All Indications N = 1534   |
|-------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                 | Patient-based analysis                               | Patient-based analysis                               | Event-based analysis                                 | Event-based analysis                                 | Event-based analysis                                 |
| imAE category                                   | n                                                    | Resolved a                                           | n                                                    | Resolved b (%)                                       | Resolving b (%)                                      |
| Immune-mediated skin adverse reaction           | 27                                                   | 14 (51.9)                                            | 31                                                   | 16 (51.6)                                            | 6 (19.4)                                             |
| Immune-mediated nephritis and renal dysfunction | 10                                                   | 5 (50.0)                                             | 10                                                   | 5 (50.0)                                             | 3 (30.0)                                             |
| Immune-mediated hepatitis                       | 26                                                   | 13 (50.0)                                            | 40                                                   | 25 (62.5)                                            | 5 (12.5)                                             |
| Immune-mediated pneumonitis                     | 66                                                   | 30 (45.5)                                            | 68                                                   | 32 (47.1)                                            | 15 (22.1)                                            |
| Immune-mediated hypothyroidism                  | 116                                                  | 37 (31.9)                                            | 138                                                  | 59 (42.8)                                            | 25 (18.1)                                            |
| Immune-mediated adrenal insufficiency           | 4                                                    | 1 (25.0)                                             | 4                                                    | 1 (25.0) authorised                                  | 1 (25.0)                                             |
| Immune-mediated thyroiditis                     | 12                                                   | 2 (16.7)                                             | 17                                                   | 6 (35.3)                                             | 3 (17.6)                                             |
| Immune-mediated type 1 diabetes mellitus        | 6                                                    | 1 (16.7)                                             | 7                                                    | 2 (28.6)                                             | 2 (28.6)                                             |
| Immune-mediated pituitary dysfunction           | 1                                                    | 0                                                    | 1                                                    | 0                                                    | 0                                                    |
| Other immune-mediated reactions                 | 4                                                    | 2 (50.0)                                             | 4                                                    | 2 (50.0)                                             | 0                                                    |

Source: 1L/2L NSCLC Response to CHMP Day 180 LoOIs Appendix 2-EU\\_D180\\_Table\\_ 2.7.4.2.2.7 Data cutoff: 001-26AUG2020, 102-31MAY2020, 203-26NOV2018, 204-16SEP2019, 208-27FEB2020, 303-10AUG2020, 302-01DEC2020. Data extraction: 001-26AUG2020, 102-30JUN2020, 20315JAN2019, 204-16OCT2019, 208-15APR2020, 303-27OCT2020, 302-15JAN2021. Resolved includes both 'Recovered/resolved' and 'Recovered/resolved with sequelae' in the CRF. a  A patient was considered as resolved in a category if, and only if, all events in the category from this patient were resolved. Percentage was based on the number of patients with at least one immune-mediated adverse event in the category. b  Percentages were based on the number of immune-mediated adverse events in the category. Adverse events were coded using MedDRA version 23.0. Post marketing experience Tislelizumab is registered in China for the treatment of several cancers. The first marketing authorisation for tislelizumab was granted in China on 26-Dec-2019 for rrHL, followed by indications in 2L+ urothelial carcinoma, 1L squamous and non-squamous NSCLC, 2L/3L HCC and 2L/3L NSCLC. Tislelizumab is also registered in the European union as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. The marketing authorisation for Tevimbra (EMEA/H/C/005919) was granted on 15/09/2023. Medicinal product no longer authorised

## 2.5.9. Discussion on clinical safety

The safety of tislelizumab monotherapy in the 2L NSCLC setting is supported by Study 303, by data from 102 previously treated NSCLC patients from two phase 1/2 studies (n=636 2L+ NSCLC in total), and a pooled safety dataset from patients treated with 200 mg Q3W tislelizumab monotherapy across different indications (n=1534; including NSCLC, ESCC, HCC, UC und r/r cHL).

<div style=\"page-break-after: always\"></div>

The safety of tislelizumab in combination with chemotherapy in the 1L NSCLC setting is supported by Study 304 in non-squamous NSCLC and Study 307 in squamous NSCLC. In addition, 1L NSCLC safety data were pooled across histologies and adding 54 patients from the phase II Study 206 (in total n=497 in the combined NSCLC T+chemo group).

Median follow-up for tislelizumab monotherapy in Study 303 was 13.4 months and about 16.9 months for the 1L combination Studies 304 and 307.

This amount of safety data can be considered adequate to describe the toxicity profile of tislelizumab. It is however noted that the pivotal 1L Studies 304 and 307 were conducted exclusively in China Study 303 recruited only about 20% of patients from other regions than China (mainly Eastern Europe) and did not enrol patients with more than 2 prior lines of systemic chemotherapy (whereas the proposed 2L+ NSCLC indication refers to patients after prior chemotherapy without restricting the use of tislelizumab to 2L or 3L).

The most commonly reported events (≥ 40%) in the combined NSCLC T+chemo group (Studies 304, 307 and 206) were anaemia, neutrophil count, white blood cell count and platelet count decreased, ALT and AST increased, nausea, and decreased appetite. These are known toxicities associated with chemotherapy; however, for all of these events higher incidences were observed in the combined tislelizumab + chemotherapy group than in the combined chemotherapy group (≥ 10% difference for neutrophil count decreased [+10.8%], platelet count decreased [+13.9%], ALT increased [+12.2%], and AST increased [+13.7%]).

Median exposure to tislelizumab as monotherapy in Study 303 was longer than exposure to docetaxel (5.4 months vs. 2.1 months). Median exposure to tislelizumab in the tislelizumab + chemotherapy combinations was slightly higher for patients with squamous NSCLC in Study 307 compared to patients with non-squamous NSCLC in Study 304 (about 9.7 vs 7.9 months). Platinum-based combination chemotherapy was planned to be given for 4-6 treatment cycles and patients received a median number of 4.0 cycles across treatment arms of both 1L studies. For non-squamous NSCLC, pemetrexed was allowed as maintenance treatment; median duration of exposure to pemetrexed was 7.5 months for the T+PP combination and 4.9 month for the PP group. In the squamous NSCLC Study 307, the median relative dose intensity (RDI) of chemotherapy was lower in the nab-paclitaxel arm (T+nPC arm) compared to the T+PC arm and the PC arm [RDI for nabpaclitaxel was 61% vs 95-98% for paclitaxel; RDI for platinum compound was 83% in T+nPC arm vs 95% in paclitaxel arms]. Higher rates of treatment discontinuations (32% vs 18%) and dose modifications (92% vs 64%) were observed in the T+nPC group compared to the T+PC arm. Weekly administration of nab-paclitaxel was new to most of the Chinese investigators in this open-label study; as a result, it may have led to a more cautious toxicity assessment and an increased chance of dose modifications in the nab-paclitaxel treatment arm. Most common AEs in the tislelizumab monotherapy group of Study 303 (≥ 15%) were anaemia (28.5%), ALT increased (19.9%) and AST increased (18.9%), cough (19.5%), decreased appetite (15.4%), and weight loss (15.2%). As expected, lower rates of haematological toxicities and alopecia were observed for tislelizumab compared to docetaxel. The safety profile was overall comparable between the tislelizumab monotherapy groups (in Study 303, the 2L+ NSCLC pool and the 200 mg Q3W All Indications pool). However, some differences were notable in the All Indications dataset, reflecting the mix of tumour types in this pool (e.g., lower rates of respiratory and metabolism disorders, but higher rates of gastrointestinal, skin and hepatobiliary disorders in the pooled dataset compared to the tislelizumab group of Study 303). Medicinal product no longer authorised

In Study 303, Grade ≥ 3 AEs were reported at lower incidences for tislelizumab monotherapy than for docetaxel (49% vs 75%), mainly driven by lower rates of haematological toxicities. Most common

<div style=\"page-break-after: always\"></div>

severe events (≥ 2% of patients in the tislelizumab arm) were: pneumonia (7.1% vs 9.3%), anaemia (3.4% vs 6.2%), and hypertension (2.4% vs 0.4% for tislelizumab vs docetaxel, respectively).

In the 1L studies, Grade ≥ 3 AEs were more common in the tislelizumab + chemotherapy groups than for the chemotherapy groups for both squamous and non-squamous NSCLC patients (79% vs 71% for combined T+chemo vs chemo). This difference was mainly driven by higher incidences of haematological toxicities; but higher incidences of Grade ≥ 3 AEs in the tislelizumab arms (though with smaller differences) were also observed for the SOC infections (9.3% vs 6.6%) and for the PTs pneumonitis, haemoptysis and rash.

Regarding the comparison for squamous vs non-squamous patients, similar incidences were reported for most categories of AEs apart from Grade ≥ 3 AEs that were more frequent in patients with squamous histology. The higher rate of Grade ≥ 3 AEs in squamous NSCLC is more likely due to the different backbone chemotherapy regimens than to histology, since this difference was similarly observed for the control arms of Studies 304 and 307. All grade AEs with higher rates (≥ 10.0%) in squamous vs non-squamous NSCLC patients were e.g. alopecia, arthralgia, hypoaesthesia and pain in extremity, reflecting the safety profiles of the individual chemotherapies. In Study 303, about one third of patients experienced a serious adverse event in both treatment arms. In the docetaxel group, higher incidences were mainly reported for serious haematological events (in the SOCs of blood disorders [14.0% vs. 0.9%], and investigation [4.3% vs. 0.9% for docetaxel vs tislelizumab, respectively]). For tislelizumab, incidences were higher for respiratory disorders (13.3% vs 6.6 for docetaxel), with pneumonitis/ILD driving this difference (together 5.4% for tislelizumab vs 0% for docetaxel). For some other SOCs, smaller, but numerically higher incidences were reported in the tislelizumab compared to the docetaxel arm, as e.g. for cardiac disorders (3.0% vs. 1.6%), nervous system (2.4% vs. 0.4%), musculoskeletal (2.1% vs. 0.4%), metabolism (1.9% vs. 0.4%), hepatobiliary (1.5% vs. 0.8%), renal (1.1% vs 0.4%) and endocrine disorders (0.6% vs. 0.0%). In the 1L studies, the overall incidence of serious TEAEs was higher for the combined NSCLC T+chemo group (40.0%) than for the combined chemo group (23.8%). The largest difference was observed in the SOC of respiratory disorders, where higher incidences were reported for serious pneumonitis, haemoptysis und dyspnoea in the tislelizumab treatment arms. Moreover, higher rates of serious pneumonia, febrile neutropenia and decreased neutrophil counts were observed in the tislelizumab than the chemotherapy only groups. In Study 303, similar percentages of patients discontinued study treatment for TEAEs in the tislelizumab and docetaxel groups (10.5% and 12.4%). In the tislelizumab group, the most common (≥ 1%) reasons for treatment discontinuation were pneumonitis (1.7%), interstitial lung disease (1.1%), and pneumonia (1.3%). Dose modifications occurred in 22% in the tislelizumab and 35% in the docetaxel arm. Medicinal product no longer authorised

In the 1L studies, AEs that led to discontinuation were more common in the combined NSCLC T+chemo group than for the combined chemotherapy group (28.4% vs 12.8%). Most common AEs leading to treatment discontinuations and contributing to differences between the tislelizumab and the control arms were seen for haematological abnormalities, pneumonitis (4%), and myocarditis (1.4%).

TEAE leading to death were reported for 6% of patients (n=32) in the tislelizumab group in Study 303 and for 4.3% of patients in the docetaxel arm. Grade 5 AEs reported in ≥ 2 patients included pneumonia (1.1%), respiratory failure (0.9%), death (0.9%), acute respiratory failure (0.4%), acute myocardial infarction (0.4%), and cerebral infarction (0.4%). The slightly higher proportion of AEs leading to death in the tislelizumab arm were mainly driven by events in the SOC of respiratory disorders.

<div style=\"page-break-after: always\"></div>

In the 1L studies, a total of 21 patients (4.2%) in the combined NSCLC T+chemo group and 7 patients (3.1%) in the combined chemo group had TEAEs which led to death. The most common TEAEs which led to death in the NSCLC T+chemo group were AEs in the SOC respiratory, thoracic and mediastinal disorders. They were reported more frequently for T+chemo patients vs chemo patients in both the squamous and non-squamous NSCLC groups (2.0% vs 0.4% in the combined chemotherapy group). Pneumonitis, dyspnoea, haemoptysis and respiratory failure were observed in ≥ 2 patients in the combined T+chemo group. Of note, 3 patients died to pneumonitis (0.6%), 2 patients died due to myocarditis (0.4%) and 1 patient died due to hepatitis (0.2%) resulting in a rate of 1.2% of (at least possibly) immune-associated fatal events in the combined T+chemo group.

The incidences of related AEs are lower in the tislelizumab group of Study 303 compared to docetaxel across all categories (with the exception of AEs leading to death that were reported with similar rates). Overall, tislelizumab related AEs in Study 303 reflected the AEs that were observed regardless of treatment relationship. In the 1L studies, treatment related AEs were reported for nearly all patients (≥99%) with higher incidences for related Grade ≥ 3 and serious AEs in the combined T+chemo group than the combined chemo group (75% vs 64% and 25% vs 14%, respectively). The overall profile of most common related TEAEs was similar to the most frequently reported TEAEs regardless of treatment relationship. All grade chemotherapy-related haematological toxicities, elevation of liver parameters and nausea were reported with higher incidences in the tislelizumab +chemotherapy groups vs. the chemotherapy control groups. There appeared to be a trend for investigators to consider AEs to be more frequently related to chemotherapy as opposed to tislelizumab in Study 303. A similar imbalance regarding causality assessment was noted in the 1L combination studies. Knowledge about incidences of ADRs that were more frequently reported for chemotherapy than for checkpoint inhibitors likely impacted the causality assessment of specific AEs. Examples from other studies with checkpoint inhibitors confirmed a similar pattern. The above description of safety data focuses on the presentation of adverse events that were reported in the pivotal studies (Study 303 for tislelizumab monotherapy and Studies 304 and 307 for the combination of tislelizumab with chemotherapy), since for these datasets comparative safety with a control group were available within the pivotal studies. However, the comparison of the tislelizumab treatment arms of the pivotal studies with the respective pooled datasets for monotherapy and combination arms did not show any meaningful differences . Adverse drug reactions (ADRs) for tislelizumab monotherapy that are included in section 4.8 of the SmPC are based on the '200 mg Q3W All Indications dataset' (N=1534). This dataset also includes indications for which no approval is currently foreseen in the EU. Nonetheless, given the similar posology of tislelizumab, a pooled analysis across suitable studies is considered to provide the best estimate of frequency and thus, this approach is considered acceptable. Medicinal product no longer authorised

The combined 1L NSCLC tislelizumab + chemotherapy pool (n=497) is considered adequate to determine the ADRs for the combination treatment.

The methodology to determine ADRs is considered acceptable.

For tislelizumab monotherapy, the most common adverse reaction was anaemia (29.2%). The most common grade 3/4 adverse reactions were anaemia (5.0%) and pneumonia (4.2%). 1.2% of patients experienced adverse reactions leading to death. The adverse reactions leading to death were pneumonia (0.78%), hepatitis (0.13%), pneumonitis (0.07%), dyspnoea (0.07%), decreased appetite (0.07%) and thrombocytopenia (0.07%). Among the 1 534 patients, 40.1% were exposed to tislelizumab for longer than 6 months, and 22.2% were exposed for longer than 12 months.

<div style=\"page-break-after: always\"></div>

For tislelizumab given in combination with chemotherapy, the most common adverse reactions were anaemia (88.3%), neutropenia (86.5%), thrombocytopenia (67.0%), alanine aminotransferase increased (46.1%), fatigue (43.1%), aspartate aminotransferase increased (42.3%), nausea (41.4%), decreased appetite (40.6%) and rash (26.4%). The most common grade 3/4 adverse reactions were neutropenia (58.6%), thrombocytopenia (18.3%), anaemia (15.7%), pneumonia (5.0%), pneumonitis (3.4%), alanine aminotransferase increased (3.2%), lymphopenia (2.8%), rash (2.6%) and fatigue (2.2%). 1.6% of patients experienced adverse reactions leading to death. The adverse reactions leading to death were pneumonitis (0.60%), dyspnoea (0.40%), myocarditis (0.40%), pneumonia (0.20%) and hypokalaemia (0.20%). Among the 497 patients, 65.8% were exposed to tislelizumab for longer than 6 months, and 37.8% were exposed for longer than 12 months.

In the 1L studies, 25.6% of patients had immune-mediated TEAEs in the combined NSCLC T+chemo group. Overall, incidences were similar for both squamous and non-squamous NSCLC. Most common imAEs were observed for pneumonitis (9.1%), hypothyroidism (9.1%) and skin adverse reactions (3.8%). Grade ≥ 3 events were reported in 10.5% of patients, the most common were pneumonitis (4.0%), skin adverse reaction (2.2%), hepatitis (1.4%) myositis/rhabdomyolysis (1.0%), type 1 diabetes (1.0%) and myocarditis (0.8%). Most of these were Grade 3 events; however, Grade 4 imAEs occurred for pneumonitis, type 1 diabetes, myocarditis, and myositis/rhabdomyolysis. Immunemediated TEAEs were fatal for 3 patients with pneumonitis (0.6%), 2 patients with myocarditis (0.4%) and 1 patient each with hepatitis (hepatic failure) and myositis/rhabdomyolysis (0.2%). 10.9% of patients experienced serious imAE ImAEs led to discontinuation of tislelizumab in 7.6% of patients, the most common were pneumonitis (4.0%), myocarditis (1.2%) and myositis/rhabdomyolysis (1.0%).

As severe infusion-related reactions (grade 3 or higher) have been reported for tislelizumab monotherapy and in combination, a warning to monitor for signs and symptoms of infusion-related reactions, as well as dose recommendation have been included in section 4.4 and 4.2 of the SmPC. In general, laboratory findings in Study 303 reflected the known safety profiles of each drug; haematological toxicities were reported more frequently for docetaxel treated patients, while increases in liver enzymes (AST, ALT, ALP) and CK were more common for tislelizumab treated patients. In addition, an increase in creatinine was slightly more pronounced in the tislelizumab treatment group compared to the docetaxel group. In the combined NSCLC T+chemo group, laboratory data indicate a worsening of haematologic toxicities and a more pronounced increase of liver parameters and creatinine by the addition of tislelizumab to chemotherapy. This is reflected accordingly in section 4.8 of the SmPC. Immune-related AEs Incidences of imAE 19.5% of patients in the tislelizumab group in Study 303 had an immune-mediated TEAE (18.0% in the pooled dataset across indications). Most common imAEs (≥ 2%) in the tislelizumab arm were hypothyroidism (7.9%) and pneumonitis (6.2%). 6.6% of patients experienced Grade ≥ 3 imAEs, the most common was pneumonitis (3.7% including 0.4% of fatal events); other Grade ≥ 3 imAEs were hepatitis (0.7%), nephritis and skin ADRs (0.6% each), adrenal insufficiency, type 1 diabetes mellitus and myositis/rhabdomyolysis (0.4% each) as well as myocarditis and colitis (0.2% each). For 7.5% of patients imAEs were serious. ImAEs led to discontinuation of tislelizumab in 23 patients (4.3%), most commonly due to pneumonitis (n=18); further reasons were hepatitis (n=2), myocarditis, nephritis/renal failure, skin adverse reactions and type 1 diabetes mellitus (n=1 each). For 38.4% of patients in the pooled monotherapy dataset imAEs were resolved; endocrine events resolved at lower rates, e.g. hypothyroidism in 31.9%, adrenal insufficiency in 25% and thyroiditis and type 1 diabetes mellitus in 16.7% of patients. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Overall, imAEs resolved during the study in approximately half of NSCLC patients (53.5% across both pivotal studies).

In order to mitigate the safety concern around immune mediated adverse reactions, a patient card will be distributed to the patients in order to increase the awareness of patients on the signs and symptoms relevant to the early recognition/identification of the potential immune-related ARs and prompt them about when to seek medical attention (see RMP and Annex II).

In section 4.4 of the SmPC it has been clarified that the majority of these events improved with interruption of tislelizumab, administration of corticosteroids and/or supportive care. Immune-related adverse reactions have also been reported after the last dose of tislelizumab. Immune-related adverse reactions affecting more than one body system can occur simultaneously.

Age : Generally, an increase of AE rates is expected with increasing age and a trend towards a more unfavourable safety profile was observed in the ≥ 65 years old subgroup compared to younger patients also in the tislelizumab studies; in Study 303, for tislelizumab monotherapy, this was similarly reported in both treatment arms, whereas increases of Grade ≥ 3 AEs and SAEs in elderly were more pronounced in the tislelizumab and chemotherapy combination arms compared to patients treated with chemotherapy only. The safety data for tislelizumab in patients ≥ 75 years are limited (n=4 in the chemotherapy combinations arms). This limited data for patients beyond 75 years of age is reflected in sections 4.2 and 4.8 of the SmPC.

Warnings and recommendations about immune-related pneumonitis (including fatal cases) , immunerelated hepatitis (including fatal cases), immune-related skin rash or dermatitis (including cases of severe cutaneous adverse reactions (SCARs)), immune-related colitis, immune-related endocrinopathies (including thyroid disorders, adrenal insufficiency, hypophysitis and type 1 diabetes mellitus), immune-related nephritis with renal dysfunction and other clinically important immunerelated adverse reactions (myositis, myocarditis, arthritis, polymyalgia rheumatica, pericarditis and Guillain-Barre syndrome) were included in section 4.4 of the SmPC. Treatment modifications recommendation have also been included in section 4.2 of the SmPC for all these immune-related adverse reactions. As solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-(L)1 inhibitors a warning that treatment with tislelizumab may increase the risk of rejection in solid organ transplant recipients has been included in section 4.4 of the SmPC. Safety in special populations Overall, no consistent, clinically meaningful differences could be observed by analyses of subgroups across histology, disease stage, body weight, ECOG status and mild/moderate renal impairment. Approximately 20% of patients had mild or moderate hepatic impairment at study baseline in the pooled monotherapy population across indications with a numerical trend towards more severe and serious AEs and higher incidences of dose modifications in the hepatic impairment subgroup. In the combination treatment setting, data are too limited to draw conclusions (17 and 12 patients with mild or moderate hepatic dysfunction in the tislelizumab arms of Studies 304 and 307).  Regarding gender, the toxicity profile did not show meaningful differences for tislelizumab monotherapy and is difficult to interpret in the 1L NSCLC combination treatment setting due to the low proportion of female patients (17%). Regarding smoking history, for some categories a slightly worse safety profile was reported for current/previous smokers versus never smokers; however, similar differences were also observed in the control groups. Medicinal product no longer authorised

Race and region : As the 1L combination therapy Studies 304 and 307 were conducted exclusively in China, an analysis by race and region was only performed in the monotherapy setting, where the majority of patients was also Asian (80% in Study 303 and 69% in the All Doses and All Indications

<div style=\"page-break-after: always\"></div>

Group). Higher incidences of laboratory-related adverse events were reported in the Asian subgroup than in the White subgroup in the tislelizumab arm of Study 303. A similar trend was observed in patients treated with chemotherapy and in the pooled dataset across indications. However, no significant differences in the 'more objective' laboratory safety evaluations were detected despite the lower frequency of laboratory abnormalities reported as AEs in White patients vs. Asian patients. Therefore, the apparent discrepancies observed are more likely explained by regional differences in interpretation of the clinical relevance of laboratory abnormalities and data do not sustain a different pattern of tolerability in different races. It is considered reassuring that, for example, incidences of leukopenia and neutropenia, which were reported with a notably lower frequency in the White subgroup compared to the Asian subgroup, were consistent between the pooled monotherapy population and a meta-analysis of studies with PD-1 inhibitors as monotherapy. Frequency of AEs, other than laboratory abnormalities, was generally similar across regions which is not suggestive of a general pattern of underreporting in study sites enrolling White patients. Overall, the totality of the reported safety data does not further support concerns that the results mainly derived from Asian patients would not be applicable to European patients.

| Important identified risks   | • Immune-mediated adverse reactions       |
|------------------------------|-------------------------------------------|
| Important potential risks    | • Reproductive and developmental toxicity |
| Missing information          | • None                                    |

2.5.10. Conclusions on the clinical safety Safety data for tislelizumab for the treatment of NSCLC generally reflect the known toxicity profile of checkpoint inhibitors as monotherapy and the additional toxicities in combination with chemotherapy. No new safety issues have been identified compared to already authorised checkpoint inhibitors. 2.6. Risk Management Plan Safety concerns Important identified risks Immune-mediated adverse reactions Important potential risks Reproductive and developmental toxicity Missing information Pharmacovigilance plan No additional pharmacovigilance activities. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 144: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

<!-- image -->

| Safety Concern                          | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                        |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risk               | Important Identified Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Important Identified Risk                                                                                                                                                           |
| Immune-mediated Adverse Reactions       | Routine Risk Minimisation Measures: SmPC Section 4.2 where guidelines for withholding or permanent discontinuation of treatment are provided. SmPC Section 4.4 where advice is provided regarding monitoring and management of immune- mediated adverse reactions. SmPC Section 4.8 where the adverse drug reactions of immune-mediated adverse reactions are listed. PL Section 2 and PL Section 4 where guidance on how to early identify signs and symptoms and seek medical attention is included. Additional Risk Minimisation Measures: Patient Card Legal Status: Restricted medical prescription                                            | Routine Pharmacovigilance Activities Beyond Adverse Reactions Reporting and Signal Detection: Targeted follow-up checklist Additional Pharmacovigilance Activities: None authorised |
| Important Potential Risk                | Important Potential Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                     |
| Reproductive and Developmental Toxicity | Routine Risk Minimisation Measures: SmPC Section 4.6 where advice is provided regarding the need for women of childbearing potential to avoid getting pregnant and for lactating women to avoid breastfeeding infants while taking tislelizumab and that, women of childbearing potential should use effective contraception during treatment with tislelizumab and for 4 months after the last dose. SmPC Section 5.3. PL Section 2 where guidance on how to early identify signs and symptoms and seek medical attention is included. Additional Risk Minimisation Measures: None Legal status: Restricted medical prescription product no longer | Routine Pharmacovigilance Activities Beyond Adverse Reactions Reporting and Signal Detection: Targeted follow-up checklist Additional Pharmacovigilance Activities: None            |
| Missing Information                     | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Missing Information                                                                                                                                                                 |
| None                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                     |

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.7. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the

<div style=\"page-break-after: always\"></div>

requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.8. Product information

<!-- image -->

<!-- image -->

User consultation The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use. Additional monitoring Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Tizveni (tislelizumab) is included in the additional monitoring list as: -it is a biological product that is not covered by the previous category and authorised after 1 January 2011. Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle. Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Approved indication:

Tizveni in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PDL1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: · locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or · metastatic NSCLC. Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the firstline treatment of adult patients with squamous non-small cell lung cancer who have: · locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or · metastatic NSCLC. Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab. 3.1.2. Available therapies and unmet medical need Second-/third-line treatment options for advanced or metastatic NSCLC without oncogenic driver mutations Before ICI therapy was available, there were 2 established chemotherapeutic agents available globally for the treatment of locally advanced or metastatic NSCLC with no actionable oncogenic driver after prior chemotherapy: docetaxel for patients with either non-squamous or squamous NSCLC and pemetrexed for patients with non-squamous NSCLC who did not receive pemetrexed as first-line treatment (Planchard et al 2018, Ettinger et al 2019). Erlotinib can also be considered for patients who cannot receive cytotoxic chemotherapy due to poor performance status (Tarceva USPI 2010, Planchard et al 2018). Overall, the therapeutic benefit of these further lines of treatment has been restricted by limited improvements in survival, low response rates, and significant toxicities (Stinchcombe and Socinski 2008, Al-Farsi and Ellis 2014, Nadler et al 2018). Presently, pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are approved in the US and EU for the second-line treatment of metastatic NSCLC (Keytruda USPI 2021, Keytruda SmPC 2021, Opdivo SmPC 2021, Opdivo USPI 2021, Tecentriq SmPC 2021, Tecentriq USPI 2021). Medicinal product no longer authorised

First-line treatment options for advanced or metastatic NSCLC without oncogenic driver aberrations

Multiple regimens for the 1L treatment of patients with metastatic oncogenic-driver-negative NSCLC regardless of PD-L1 expression are approved and recommendable across Europe, most of them containing one or more immune checkpoint inhibitors and histology-selected platinum-based chemotherapy:

<div style=\"page-break-after: always\"></div>

- -Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel for squamous histology 1
- Pembrolizumab + carboplatin + pemetrexed for non-squamous histology 1
- Atezolizumab + bevacizumab + carboplatin + paclitaxel for non-squamous histology 2
- Atezolizumab + carboplatin + nab-paclitaxel for non-squamous histology 2
- Nivolumab + ipilimumab + 2 cycles of platinum-doublet, regardless of histology 3

Additionally, pembrolizumab 1 , atezolizumab 2  and cemiplimab 4  as monotherapy are approved for the subgroup of patients with high PDL1 expression (≥50%). ( 1  Keytruda SmPC, 2  Tecentriq SmPC, 3 Opdivo SmPC, 4  Libtayo SmPC) Concerning patients with locally advanced (stage IIIB) disease that are not candidates for platinum-based chemoradiation, the usual approach is the same as for patients with metastatic disease.

3.1.3. Main clinical studies The open-label study BGB-A317-303 randomly assigned 805 patients with locally advanced or metastatic NSCLC in a 2:1 ratio to receive either tislelizumab or docetaxel. All patients had received 1 platinum-based chemotherapy regimen ( 2 nd  line NSCLC ). The open-label study BGB-A317-307 randomly assigned 360 patients with locally advanced or metastatic squamous NSCLC in a 1:1:1 ratio to receive either tislelizumab combined with paclitaxel plus carboplatin or tislelizumab combined with nab-paclitaxel plus carboplatin or paclitaxel plus carboplatin as first-line treatment . The open-label study BGB-A317-304 randomly assigned 334 patients with locally advanced or metastatic non-squamous NSCLC in a 2:1 ratio to receive either tislelizumab combined with carboplatin or cisplatin plus pemetrexed or carboplatin/cisplatin plus pemetrexed as first-line treatment. 3.2. Favourable effects Results from primary analyses: Monotherapy 2L+ NSCLC Efficacy in ITT analysis set · OS (primary endpoint): HR 0.66 (95% CI: 0.56, 0.79) · PFS (per investigator; secondary endpoint): HR 0.63 (95% CI: 0.53, 0.75) Efficacy in PDL1 positive analysis set (TC ≥ 25%) · OS (primary endpoint): HR 0.54 (95% CI: 0.41, 0.71) Medicinal product no longer authorised

- PFS (per investigator; secondary endpoint):

HR 0.38 (95% CI: 0.29, 0.50)

## Combination therapy 1 st  line squamous NSCLC

Efficacy in ITT analysis set

## Arm T+PC vs PC

- PFS (per IRC; primary endpoint):

HR 0.45 (95% CI: 0.33, 0.62)

- OS (secondary endpoint):

HR 0.68 (95% CI: 0.45, 1.01

)

<div style=\"page-break-after: always\"></div>

## Arm T+nPC vs PC

- PFS (per IRC; primary endpoint):

HR 0.43 (95% CI: 0.31, 0.60)

- OS (secondary endpoint):

HR 0.75 (95% CI: 0.50, 1.12 )

## Combination therapy 1 st  line non-squamous NSCLC

## Efficacy in ITT analysis set

- PFS (per IRC; primary  endpoint):

HR 0.63 (95% CI: 0.47, 0.86)

- OS (secondary endpoint): HR 0.90 (95% CI: 0.63, 1.28 ) Efficacy in the PD-L1 TC&gt;=50% population · PFS (per IRC; primary  endpoint): HR 0.31 (95% CI: 0.18, 0.55) · OS (secondary endpoint): HR 0.39 (95% CI: 0.22, 0.71) 3.3. Uncertainties and limitations about favourable effects Monotherapy 2L+ NSCLC · 30% of patients were never smokers, 55% non-squamous and only 20% were female, which is not considered fully representative of an EU NSCLC patient population. 80% of the patients were enrolled in China. Nonetheless, the totality of efficacy results do not raise concerns that these differences in baseline characteristics have a relevant impact on the study outcome. Combination therapy 1 st  line (squamous NSCLC  and non-squamous) · Only Asian patients were included, the median age of 62 years (for squamous) and 61 years for non-squamous) is considered low (expected 69 years), 8 % female patients only (for squamous) and 36% never smoker (for non-squamous) are not considered fully representative of an European patient population. However, the overall study results support that the observed differences in baseline characteristics do not have a meaningful impact on the efficacy outcome. Therefore, the conclusions based on these pivotal studies can be considered also relevant for a European patient population. · No data are available for patients older than 75. This is reflected in section 4.8 of the SmPC. 3.4. Unfavourable effect Monotherapy 2L+ NSCLC Medicinal product no longer authorised
- The incidences of treatment-related AEs (73% vs 93.8%), all cause and treatment-related Grade ≥ 3 AEs (38.6% vs 74.8% and 14.4% vs. 66.3%), treatment -related SAEs (12.5% vs 22.9%) and AEs leading to dose modification (22.3% vs 34.5%) were less frequent in the tislelizumab arm of Study 303 than in the docetaxel arm. Similar frequencies in both treatment arms were reported for all cause SAEs (32.6% vs 32.2%), AEs leading to death (6% vs 4.3%) and AEs leading to treatment discontinuation (10.5% vs 12.4%).
- Most common AEs in the tislelizumab group of Study 303 (≥ 15%) were anaemia (28.5%), ALT increased (19.9%) and AST increased (18.9%), cough (19.5%), decreased appetite (15.4%), and weight loss (15.2%).

<div style=\"page-break-after: always\"></div>

- 19.5% of patients in the tislelizumab group in Study 303 had an immune-mediated TEAE. The most common imAEs (≥ 2%) in the tislelizumab arm were hypothyroidism (7.9%) and pneumonitis (6.2%). 6.6% of patients experienced Grade ≥ 3 imAEs, the most common was pneumonitis (3.7% including 0.4% of fatal events); other Grade ≥ 3 imAEs were hepatitis (0.7%), nephritis and skin ADRs (0.6% each), adrenal insufficiency, type 1 diabetes mellitus and myositis/rhabdomyolysis (0.4% each) as well as myocarditis and colitis (0.2% each). For 7.5% of patients imAEs were serious. ImAEs led to discontinuation of tislelizumab in 4.3% of patients. For 38.4% of patients in the pooled monotherapy dataset imAEs were resolved; endocrine events resolved at lower rates, e.g. hypothyroidism in 31.9%, adrenal insufficiency in 25% and thyroiditis and type 1 diabetes mellitus in only 16.7% of patients.
- No safety data are available for tislelizumab in patients with ECOG PS &gt;1 and after more than 2 prior lines of therapy; this is reflected in section 4.4 and 5.1 of the SmPC.
- Combination therapy 1L NSCLC · The incidences of all cause and treatmentrelated Grade ≥ 3 AEs (79.3% vs 70.9% and 74.8% vs 63.9%), all cause and treatment-related SAEs (40% vs 23.8% and 24.7% vs 14.1%), treatment  discontinuations due to AEs (28.4% vs 12.8%) and dose modifications due to AEs (73.6% vs. 47.6%) were all more frequent in the combined tislelizumab + chemotherapy group compared to the combined chemotherapy control. · The most commonly reported events in the combined NSCLC T+chemo group (≥ 40%) were anaemia, neutrophil count, white blood cell count and platelet count decreased, ALT and AST increased, nausea, and decreased appetite. For all these events, higher incidences were observed in the combined T+chemo group than in the combined chemotherapy group (≥ 10% difference for neutrophil count decreased [+10.8%], platelet count decreased [+13.9%], ALT increased [+12.2%], and AST increased [+13.7%]). · 25.6% of patients in the combined NSCLC T+chemo group had immune-mediated AEs; most common imAEs were pneumonitis (9.1%), hypothyroidism (9.1%) and skin adverse reactions (3.8%). Grade ≥ 3 events were reported in 10.5% of patients, the most frequent were pneumonitis (4.0%), skin adverse reaction (2.2%), hepatitis (1.4%), myositis/rhabdomyolysis (1.0%), type 1 diabetes mellitus (1.0) and myocarditis (0.8%). Fatal imAEs occurred for pneumonitis (0.6%), myocarditis (0.4%) as well as hepatitis and myositis/rhabdomyolysis (0.2% each). 10.9% of patients experienced serious imAE , and imAEs led to discontinuation of tislelizumab in 7.6% of patients. Overall, imAEs resolved during the study in approximately half of NSCLC patients (53.5% across both pivotal studies). 3.5. Uncertainties and limitations about unfavourable effects Monotherapy 2L+ NSCLC Medicinal product no longer authorised
- There are only limited safety data in patients with ≥ 75 years; this is reflected in section 4.8 of the SmPC.

## Combination therapy 1L NSCLC

- Studies in 1L NSCLC were conducted exclusively in China with the possible impact of regional differences regarding clinical practice or baseline/disease characteristics on safety data; however, subgroup analysis of race in the 2L monotherapy setting and the results of the

<div style=\"page-break-after: always\"></div>

inspection reports including on-site inspections in China did not further support concerns that the Asian patients derived safety data would not be applicable to European patients.

- The evaluation of the safety profile in females is hampered by the low proportion of enrolled females (17% of study population). However, no clinically meaningful differences in the AE profile between male and female subgroups were observed in the tislelizumab monotherapy treatment groups.

<!-- image -->

| Effect                                                                                                                   | Short Description                                                                                                        | Unit                                                                                                                     | Tislelizumab 200 mg Q3W        | Docetaxel                      | Uncertainties/ Strength of evidence                                                               |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Favourable Effects longer                                                                                                | Favourable Effects longer                                                                                                | Favourable Effects longer                                                                                                | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer                                                                         | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      | Favourable Effects longer      |
| OS median                                                                                                                | Time from randomisation until death                                                                                      | months                                                                                                                   | 16.9 no                        | 11.9                           | Impact of high rate of dropouts in docetaxel population Uncertainties regarding external validity |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| OS median                                                                                                                | Time from randomisation until death                                                                                      | HR, 95% CI                                                                                                               | 0.66 (0.56,                    | 0.79)                          |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| PFS median                                                                                                               | Time from the date of randomisation to first tumour progression or death                                                 | months HR, 95% CI product                                                                                                | 4.2 0.63 (0.53,                | 2.6 0.75)                      |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Unfavourable Effects                                                                                                     | Unfavourable Effects                                                                                                     | Unfavourable Effects                                                                                                     | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects                                                                              | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects           |
| Tolerability                                                                                                             | Tolerability                                                                                                             | Tolerability                                                                                                             | Tolerability                   | Tolerability                   | Tolerability                                                                                      | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   | Tolerability                   |
|                                                                                                                          |                                                                                                                          |                                                                                                                          | 39                             |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Grade ≥3 AE • drug related % Serious AE %                                                                                | Grade ≥3 AE • drug related % Serious AE %                                                                                | Grade ≥3 AE • drug related % Serious AE %                                                                                |                                |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| • drug related AE leading to death • drug related % AE leading to discont. • drug related % Immune-mediated AE Medicinal | • drug related AE leading to death • drug related % AE leading to discont. • drug related % Immune-mediated AE Medicinal | • drug related AE leading to death • drug related % AE leading to discont. • drug related % Immune-mediated AE Medicinal |                                |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| All cause imAE %                                                                                                         | All cause imAE %                                                                                                         | All cause imAE %                                                                                                         | 19.5                           |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| • Grade ≥ 3 • serious                                                                                                    | • Grade ≥ 3 • serious                                                                                                    | • Grade ≥ 3 • serious                                                                                                    | 7.5                            |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| frequent imAE (≥1%)                                                                                                      | frequent imAE (≥1%)                                                                                                      | frequent imAE (≥1%)                                                                                                      |                                |                                |                                                                                                   |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Hypothyroidism % 7.9 NR                                                                                                  | Hypothyroidism % 7.9 NR                                                                                                  | Hypothyroidism % 7.9 NR                                                                                                  | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR                                                                           | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        | Hypothyroidism % 7.9 NR        |
| Pneumonitis % 6.2 NR                                                                                                     | Pneumonitis % 6.2 NR                                                                                                     | Pneumonitis % 6.2 NR                                                                                                     | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR                                                                              | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           | Pneumonitis % 6.2 NR           |
| Skin adverse reaction % 1.5 NR                                                                                           | Skin adverse reaction % 1.5 NR                                                                                           | Skin adverse reaction % 1.5 NR                                                                                           | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR                                                                    | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR | Skin adverse reaction % 1.5 NR |
| Hepatitis % 1.3 NR                                                                                                       | Hepatitis % 1.3 NR                                                                                                       | Hepatitis % 1.3 NR                                                                                                       | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR                                                                                | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             | Hepatitis % 1.3 NR             |

3.6. Effects Table Table 145: Effects table for Tizveni as monotherapy for the treatment of advanced / metastatic NSCLC after prior chemotherapy (Study 303; data cut-off: 15 Jul-2021)] Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect   | Short Description                   | Unit   | Tislelizumab 200 mg Q3W   | Docetaxel   | Uncertainties/ Strength of evidence   |
|----------|-------------------------------------|--------|---------------------------|-------------|---------------------------------------|
|          | Myositis/rhabdomyolysis Thyroiditis | % %    | 1.3 1.1                   | NR NR       |                                       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 146: Effects table for Tizveni in combination with chemotherapy for the 1L treatment of advanced/metastatic NSCLC (data cut-off for non-squamous Study 304: 26-Oct-2020; data cut-off for squamous Study 307: 30-Sep 2020)

<!-- image -->

| Effect                                                    | Short Description                                            | Unit                                                      | Treatment                                                 | Control                                                   | Uncertainties/ Strength of evidence                                                            | Referen ces                                                                                    |
|-----------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Favourable Effects 1L squamous NSCLC                      | Favourable Effects 1L squamous NSCLC                         | Favourable Effects 1L squamous NSCLC                      | Favourable Effects 1L squamous NSCLC                      | Favourable Effects 1L squamous NSCLC                      | Favourable Effects 1L squamous NSCLC                                                           | Favourable Effects 1L squamous NSCLC                                                           |
| Arm T+PC vs PC                                            | Arm T+PC vs PC                                               | Arm T+PC vs PC                                            | Arm T+PC vs PC                                            | Arm T+PC vs PC                                            | Arm T+PC vs PC                                                                                 | Arm T+PC vs PC                                                                                 |
| PFS median                                                | Time from randomisation to first tumour progression or death | months HR, 95% CI                                         | 7.7 0.45 (0.33,                                           | 5.5 0.62)                                                 | Only Asian patients were included No data are available for patients older than 75. authorised | Only Asian patients were included No data are available for patients older than 75. authorised |
| OS median                                                 | Time from the date of randomisation until death              | months HR, 95% CI                                         | 22.8 0.68 (0.45, 1.01)                                    | 20.2                                                      |                                                                                                |                                                                                                |
| Arm T+nPC vs PC                                           | Arm T+nPC vs PC                                              | Arm T+nPC vs PC                                           | Arm T+nPC vs PC                                           | Arm T+nPC vs PC                                           | Arm T+nPC vs PC                                                                                | Arm T+nPC vs PC                                                                                |
| PFS median                                                | Time from randomisation to first tumour progression or death | months HR, 95% CI                                         | 9.6 (0.31,                                                | 5.5 0.43 0.60) longer                                     |                                                                                                |                                                                                                |
| OS median                                                 | Time from the date of randomisation until death              | months HR, 95% CI                                         | NE 0.75 (0.50, no                                         | 20.2 1.12)                                                |                                                                                                |                                                                                                |
| Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%) | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%)    | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%) | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%) | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%) | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%)                                      | Favourable Effects 1L non-squamous NSCLC (TC PD-L1 >=50%)                                      |
| PFS median                                                | Time from randomisation to first tumour progression or death | months HR, 95% CI product                                 | 14.6 0.31 (0.18,                                          | 4.6 0.55)                                                 | Only Asian patients were included. No data are available for patients older than 75.           | Only Asian patients were included. No data are available for patients older than 75.           |
| OS median                                                 | Time from the date of randomisation until death Medicinal    | months HR, 95% CI                                         | NE 0.39 (0.22,                                            | 13.1 0.71)                                                |                                                                                                |                                                                                                |
| Effect                                                    | Short Description                                            | Unit                                                      | Pooled T+chemo (Studies 307 + 304+206)                    | Pooled chemo (Studies 307 + 304+206)                      | Uncertainties/ Strength of evidence                                                            | Referen ces                                                                                    |
| Unfavourable Effects                                      | Unfavourable Effects                                         | Unfavourable Effects                                      | Unfavourable Effects                                      | Unfavourable Effects                                      | Unfavourable Effects                                                                           | Unfavourable Effects                                                                           |
| Tolerability                                              | Tolerability                                                 | Tolerability                                              | Tolerability                                              | Tolerability                                              | Tolerability                                                                                   | Tolerability                                                                                   |
| •                                                         | Grade ≥3 AE drug related Serious AE drug related             | %                                                         | 79.3 74.8 40.0                                            | 70.9 63.9 23.8 14.1                                       | Studies in 1L NSCLC conducted exclusively in China;                                            | clinical AR, CSR, SCS                                                                          |
| •                                                         |                                                              | %                                                         | 24.7                                                      |                                                           |                                                                                                |                                                                                                |
| AE •                                                      | leading to death drug related                                | %                                                         | 4.2 1.6                                                   | 3.1 1.8                                                   |                                                                                                |                                                                                                |

<div style=\"page-break-after: always\"></div>

|                          | AE leading to discont.               | %   | 28.4           | 12.8   |
|--------------------------|--------------------------------------|-----|----------------|--------|
| Immune-mediated AE       | Immune-mediated AE                   |     |                |        |
|                          | All cause imAE • Grade ≥ 3 • serious | %   | 25.6 10.5 10.9 | NR     |
| Most frequent imAE (≥1%) | Most frequent imAE (≥1%)             |     |                |        |
|                          | Hypothyroidism                       | %   | 9.1            | NR     |
|                          | Pneumonitis                          | %   | 9.1            | NR     |
|                          | Skin adverse reaction                | %   | 3.8            | NR     |
|                          | Hepatitis                            | %   | 1.6            | NR     |
|                          | Colitis                              | %   | 1.4            | NR     |
|                          | Myocarditis                          | %   | 1.4            | NR     |
|                          | Myositis/rhabdomyolys is             | %   | 1.2            | NR     |
|                          | Nephritis                            | %   | 1.0            | NR     |
|                          | Type 1 diabetes mell.                | %   | 1.0            | NR     |

<!-- image -->

Abbreviations: drug-related: related to tislelizumab and/or chemotherapy; NR: not reported; CSR: clinical study report, SCS: summary of clinical safety, T+nPC: Tislelizumab + nab-paclitaxel 3.7. Benefit-risk assessment and discussion 3.7.1. Importance of favourable and unfavourable effects Monotherapy 2L+ NSCLC A clinically meaningful benefit in overall survival was demonstrated in patients with locally advanced or metastatic NSCLC after prior chemotherapy. The described safety profile of tislelizumab monotherapy in the sought indication was as expected for PD-1 inhibitors without new safety concerns. Combination therapy 1L NSCLC A clinically meaningful benefit in PFS was demonstrated for the addition of tislelizumab to combination chemotherapy in patients with locally advanced or metastatic squamous NSCLC; a positive trend in OS can be considered supportive. In patients with non-squamous NSCLC, a benefit in PFS was also shown in the overall study population; however, the treatment effect was driven by the subgroup of patients whose tumour express PDL1 in ≥ 50% of tumour cells. The safety profile of tislelizumab in combination with chemotherapy reflects the added toxicities of the single components, as already observed for other PD-(L)1 /chemotherapy combinations treatments in this setting. 3.7.2. Balance of benefits and risks Medicinal product no longer authorised

## Monotherapy 2L+ NSCLC

In view of the relevant improvement in overall survival, the benefit of treatment with tislelizumab is considered to outweigh its associated risks.

## Combination therapy 1L NSCLC

For squamous NSCLC, the clinically meaningful benefit in PFS is acknowledged and is considered to outweigh the observed added toxicities.

<div style=\"page-break-after: always\"></div>

For non-squamous NSCLC, a clinically meaningful benefit in PFS is considered established for the addition of tislelizumab in the patients whose tumour express PDL1 in ≥ 50% of tumour cells and is considered to outweigh the observed added toxicities.

## 3.8. Conclusions

The overall benefit/risk balance of Tizveni is positive, subject to the conditions stated in section 'Recommendations' .

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Tizveni is favourable in the following indication(s):

-in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutatio ns and who have:

o locally advanced NSCLC and are not candidates for surgical resection or platinumbased chemoradiation, or o metastatic NSCLC. -in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous non-small cell lung cancer who have: o locally advanced NSCLC and are not candidates for surgical resection or platinumbased chemoradiation, or o metastatic NSCLC. -as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab. The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions: Conditions or restrictions regarding supply and use Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). Other conditions and requirements of the marketing authorisation · Periodic Safety Update Reports The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. Conditions or restrictions with regard to the safe and effective use of the medicinal product · Risk Management Plan (RMP) The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP. Medicinal product no longer authorised

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## · Additional risk minimisation measures

Prior to the launch of Tizveni in each Member State, the MAH must agree about the content and format of the Patient Card, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The Patient Card is aimed at increasing the awareness of patients on the signs and symptoms relevant to the early recognition/identification of the potential immune-related ARs and prompt them about when to seek medical attention. It also contains prompts to enter the contact details of the physician and to alert other physicians that the patient is being treated with Tizveni. The Patient Card is designed to be carried by the patient at all times and presented to any healthcare professional who may help them.

Based on the review of available data, it is considered that tislelizumab is not a new active substance, as it is a constituent of a medicinal product previously authorised within the European Union. Tislelizumab is contained in the marketing authorisation Tevimbra which was authorised in the Union on 15/09/2023.

The MAH shall ensure that in each Member State where Tizveni is marketed, all healthcare professionals and patients/carers who are expected to prescribe and use Tizveni have access to/are provided with the Patient Card disseminated through healthcare professionals. The Patient Card shall contain the following key elements: · Description of the main signs or symptoms of the immune-related ARs (pneumonitis, colitis, hepatitis, endocrinopathies, immune-mediated skin adverse reactions, nephritis and other immune-related ARs) and infusion-related reactions, and the importance of notifying their treating physician immediately if symptoms occur. · The importance of not attempting to self-treat any symptoms without consulting their healthcare professional first. · The importance of carrying the Patient Card at all times and to show it at all medical visits to healthcare professionals other than the prescriber (e.g. emergency healthcare professionals). · A warning message to inform healthcare professionals treating the patient at any time, including in emergency conditions, that the patient is being treated with Tizveni. · A reminder that all known or suspected adverse drug reactions (ADRs) can also be reported to local regulatory authorities. · The contact details of their Tizveni prescriber. The Patient Card reminds patients about key symptoms that need to be reported immediately to the physician. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States Not applicable. New Active Substance Status Medicinal product no longer authorised